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Preface 
 
Multiprotein complexes play a crucial role in living cells by catalyzing and mediating 
virtually all essential cellular activities. However, many of these essential machines 
exist in very low endogenous amount in cells, in particular for eukaryotic complexes. 
This is refractory to large-scale extraction from native source material, severely 
impeding the elucidation of their structure and function. In order to make multiprotein 
complexes accessible by means of recombinant production, the Berger laboratory has 
developed an array of advanced expression systems tailor-made for overproducing 
multiprotein complexes in various host organisms including E. coli, insect cells and 
mammalian cells. Those systems, in particular the MultiBac baculovirus/insect cell 
system have already greatly contributed to studying the structural and functional 
assemblies of numerous important multiprotein complexes in molecular and atomic 
detail. Notably, this includes also the human general transcription factor TFIID, a 
~1.5 MDa complex, which is the research focus of the Berger laboratory. My 
contributions to the expression technology development and to the structural 
elucidation of human TFIID complexes are discussed in details in this thesis. 
In the introduction section (chapter 1), two expression systems specifically 
designed for overpexpressing multiprotein complexes in E. coli (ACEMBL) and 
insect cells (MultiBac) are described (chapter 1.1 and 1.2). Details of the current state-
of-the-art of multiprotein complex research, and the new baculovirus expression 
vector systems developed in the Berger laboratory are presented in Publications 1 and 
2. This presentation of expression system technology is then followed by an overview 
of our current knowledge of the human TFIID complex (chapter 1.3). 
In chapter 2, I describe my contributions in developing the ACEMBL system, 
the first fully automatable expression system for multiprotein complex production in a 
prokaryotic host (E. coli), in Publications 3 and 4. 
In chapter 3, I describe my efforts towards elucidating the structure of a 1.3 
MDa TFIID subcomplex we termed ‘9TAF’, which consists of a subset of TAFs 
(TAF2, 3, 4, 5, 6, 8, 9, 10, 12), and its function in holo-TFIID assembly, including the 
role of the TFIID subunit TAF3 in stabilizing the holo-TFIID complex (chapter 3.1). 
9TAF has been produced recombinantly and analyzed by single-particle EM methods 
   
   
     III 
(chapter 3.2). Also, design and production of TAF3 truncation variants, which are 
essential to localize the TAF3 domain(s) that may be crucial for holo-TFIID 
assembly, are discussed in chapter 3.3. 
In chapter 4, I present the recombinant production and single-particle EM 
analysis of complete human TFIID holo-complex containing a full complement of 
TAFs and TBP. 
In chapter 5, I present the materials and methods that I used for this work, 
among which in particular the DNA methods are summarized in Publication 5. 
In the appendix, I present Publication 6, which reviews structural and functional 
analysis of components of the eukaryotic basal and activated transcription machinery, 
including TFIID. 
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Préface 
 
Les complexes multi-protéiques jouent un rôle crucial dans les cellules vivantes en 
catalysant et servant d’intermédiaires entre pratiquement toutes les activités 
cellulaires essentielles. Cependant, un grand nombre de ces machines se trouvent en 
très faibles quantités dans les cellules en particulier en ce qui concernent les 
complexes eucaryotes. Ceci est réfractaire à leur extraction à grande échelle et 
empêche sévèrement l’élucidation de leur structure et fonction. Dans le but de rendre 
les complexes multi protéiques accessibles par la voie de production recombinante, le 
groupe Berger a mis au point un ensemble de systèmes d’expression sur mesure pour 
la surproduction de complexes multi protéiques dans différents organismes hôtes 
incluant E. coli, les cellules d’insectes et les cellules de mammifères. Ces systèmes et 
en particulier le système MultiBac baculovirus/cellules d’insecte ont d’ors et déjà 
grandement contribués à l’étude de l’assemblage structural et fonctionnel à l’échelle 
moléculaire et atomique de nombreux complexes multi protéiques importants. Cela 
inclut en particulier le facteur général humain de transcription TFIID, un complexe de 
~1.5 MDa qui constitue le sujet de recherche du laboratoire Berger. Mes contributions 
dans le développement de la technologie pour la production et dans l’élucidation des 
complexes TFIID humains sont discutées en détails dans cette thèse. 
Dans la section d’introduction (chapitre 1), deux systèmes d’expression 
spécifiquement conçus pour la surexpression de complexes multi protéiques dans E. 
coli (ACEMBL) et les cellules d’insectes (MultiBac) sont décrits (chapitre 1.1 et 1.2). 
Les détails sur l’état de l’art de la recherche actuelle sur les complexes multi 
protéiques, ainsi que les nouveaux systèmes de vecteurs d’expression développés dans 
le laboratoire Berger sont présentés dans les publications 1 et 2. Cette présentation de 
la technologie de system d’expression et ensuite suivie par une revue de la 
connaissance actuelle sur le complexe humain TFIID (chapitre 1.3). 
Dans le chapitre 2, je décris mes contributions dans le développement du 
système ACEMBL, le premier système d’expression complètement automatisable 
pour la production de complexe protéiques dans les procaryotes (E. coli), voir les 
publications 3 et 4. 
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Dans le chapitre 3, je décris mes efforts vis-à-vis de l’élucidation de la structure 
d’un sous-complexe de TFIID de 1.3 MDa que l’on appelle 9TAF qui consiste en un 
sous ensemble de TAFs (TAF2, 3, 4, 5, 6, 8, 9, 10, 12) ainsi que sa fonction dans 
l’assemblage du holo-TFIID, incluant le rôle de la sous unité TAF3 de TFIID dans la 
stabilisation du holo-TFIID complexe (chapitre 3.1). 9TAF a été produit de manière 
recombinante et analysé par des méthodes de microscopie électronique à particules 
uniques (chapitre 3.2). De plus, la conception et la production de variants tronqués de 
TAF3 qui sont essentiels à la localisation du/des domaine(s) pouvant être crucial pour 
l’assemblage du holo-TFIID sont discutés dans le chapitre 3.3. 
Dans le chapitre 4, je présente la production de manière recombinante et 
l’analyse par microscopie électronique à particules uniques du holo complexe TFIID 
complet contenant tous les TAFs et TBP. 
Dans le chapitre 5, je présente les matériels et méthodes que j’ai utilisé pour ce 
travail, parmi lesquelles les méthodes sur l’ADN qui sont résumées dans la 
publication 5. 
Dans l’appendice, je présente la présentation 6 qui passe en revue l’analyse 
structurale et fonctionnelle des composants de la machinerie de transcription basale et 
activée incluant TFIID. 
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Chapter 1: Introduction 
 
Abstract 
 
In this chapter I introduce a current bottleneck of multiprotein complex research 
brought about by insufficient quantity and quality of endogenous samples, which 
characterizes most essential multiprotein machines in the cell (chapter 1.1). Two 
advanced expression systems, which have been specifically designed to overcome this 
imposing bottleneck of sample provision, are then described in chapter 1.2 for 
overproducing multiprotein complexes in E. coli (ACEMBL) or in insect cells 
(MultiBac), respectively. Those expression systems were instrumental for structural 
and functional elucidation of essential multiprotein assemblies including TFIID, a 
large ~1.5 MDa general transcription factor which is crucial for initiating mRNA 
transcription in eukaryotes. The current knowledge of subunit architecture and 
biological function of TFIID are summarized in chapter 1.3. 
 
Résumé 
 
Dans ce premier chapitre, une limite actuelle liée à la qualité et à la quantité 
insuffisante des échantillons endogènes, de la recherche sur les complexes 
multiprotéiques est présentée. Cette dernière caractérise les machineries protéiques 
cellulaires les plus essentielles (chapitre 1.1). Deux systèmes d’expression 
perfectionnés ont été spécialement développés pour produire des complexes 
multiprotéiques dans E. coli (ACEMBL) ou en cellules d’insecte (MultiBac) et ainsi 
surmonter cette limite imposée concernant les quantités d’échantillon disponible. Ces 
systèmes d’expression, décris dans le chapitre 1.2, ont été cruciaux dans l’élucidation 
structurale et fonctionnelle de nombreux assemblages multiprotéiques incluant TFIID, 
un important facteur de transcription d’environ 1.5 MDa qui est primordial dans 
l’initiation de la transcription des ARNm chez les eucaryotes. Les connaissances 
actuelles de l’organisation des sous-unités au sein du complexe ainsi que les fonctions 
biologiques de TFIID sont discutés dans le chapitre 1.3. 
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1.1 Tackle the bottleneck of producing multiprotein 
complexes for structural and functional analysis 
 
Our knowledge of cellular processes have significantly advanced thanks to an array of 
recent technological developments, notably in affinity purification, DNA sequencing, 
mass spectroscopy, yeast two-hybrid screens, and computational approaches (Puig et 
al., 2001; Gavin et al., 2002, 2006; Y Nie, C Viola, et al., 2009). These technological 
developments compellingly underpinned Bruce Albert’s proposal 15 years ago: 
virtually all essential cellular processes (DNA replication, transcription, translation, 
cell cycle regulation, intermediary metabolism, etc) are maintained by a highly 
coordinated network of protein-protein interactions (PPIs), in which most proteins 
collaborate and function in the context of multiprotein complexes (Alberts, 1998). A 
summary of the current state-of-the-art of multiprotein complex research and the 
associated challenges and solutions can be found in Publication 1 in this thesis. 
Detailed structural analysis is indispensable for elucidating the biological 
functions of PPIs, which are normally first identified from biochemical or genetic 
screens. A structure of the interacting surfaces at high resolution is crucial to confirm 
the physical interactions between subunits and illustrate the interaction mechanisms, 
which are invaluable for designing strategies to modulate or inhibit these interactions. 
However, despite the rapid data accumulation of PPIs in a genome-wide scale, 
structural details of the interacting surfaces at near-atomic level are available for only 
a small percentage of many thousands known PPIs. This remarkable disparity arises 
to a large part from the current technical bottlenecks of producing multiprotein 
complexes for structural analysis. First, most multiprotein complexes exist in very 
low endogenous amount and hence difficult to be purified in sufficient quantity and 
quality directly from their native hosts. The sample paucity often hinders structural 
determination already in the case of single-particle electron microscopy (EM) analysis, 
which generally requires much less sample comparing to X-ray crystallography and 
nuclear magnetic resonance (NMR) (Frank, 2006). In addition, some multiprotein 
complexes, such as general transcription factor IID (TFIID), an essential complex 
which is a focus of this thesis, could exist as various isoforms in the cells (Müller and 
Tora, 2004), which further complicates their purifications and subsequent structural 
determination. 
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In order to increase the yield and homogeneity of multiprotein complexes of 
interest, recombinant overproduction remains to date the only practically useful 
method. A few expression systems have been designed for expressing multiprotein 
complexes in Escherichia coli (E. coli) by co-expression from polycistrons on a single 
plasmid, or co-transformation and co-expression from two or more plasmids (Tan et 
al., 2005; Busso et al., 2011; Diebold et al., 2011).  However, the overexpression of 
many eukaryotic multiprotein complexes is not efficient in these prokaryotic 
expression systems. Many multiprotein complexes contain very large subunits, which 
cannot be efficiently processed by prokaryotic transcriptional and translational 
machinery. In addition, overproduction of active eukaryotic multiprotein complexes 
often requires proper posttranslational modifications (such as phosphorylation, 
acetylation, glycosylation, etc) and specific chaperone systems, which are not 
available in E. coli. 
Although these processing limitations in prokaryotic hosts could be resolved by 
switching to eukaryotic expression systems utilizing insect cells or mammalian cells, 
rapid and flexible modifications of genes of interest, which are essential for sample 
optimization, remains a major challenge for many existing prokaryotic and eukaryotic 
expression systems. For example in protein X-ray crystallography, it is often already 
labor intensive to optimize the production of an individual protein, where alterations 
(e.g. homologs from several species) and iterative modifications of the genes 
(mutation, truncation/extension, purification tags, etc) and expression regulatory 
elements (promoters, terminators), are frequently required before well-diffracting 
protein crystals can be obtained. For crystallization of multiprotein complexes, the 
work load required for implementing such modifications grows exponentially as the 
number of protein subunits increases, Conventional serial subcloning methods (one 
gene inserted or modified at a time), cannot support this, in particular not in high 
throughput (HT), but integration into an automated HT robotic setup would be 
desirable to overcome the challenges. 
Last but not least, when multiprotein complexes are produced by co-expressing 
each subunit from individual expression cassettes, the overall yield of the full 
complex could occasionally be reduced by certain subunits expressed at much lower 
level comparing to others. This substoichiometric co-expression problem, in the 
baculovirus/insect cell system which was mainly used in this thesis, appears to affect 
subunits of higher molecular weight (more than 100 kDa). 
Thesis  Chapter 1 
Yan NIE  Introduction 
     4 
The successful overproduction of multiprotein complexes amenable to high-
resolution structural and functional analysis calls urgently for new expression 
methodologies. In the following chapters of this thesis, I describe novel expression 
approaches developed in the Berger laboratory, which are tailor-made to tackle and 
overcome the technical difficulties for overproducing multiprotein complexes. 
Detailed information about this work and the systems developed are reviewed in 
Publications 1 and 2 in this thesis. 
 
1.2 Streamline recombinant production of multiprotein 
complexes 
 
We developed a new concept denoted ‘tandem recombineering (TR)’ for the 
development of new expression systems for streamlining the recombinant production 
of multiprotein complexes. TR is the combination of sequence and ligation 
independent cloning (SLIC) (Li and Elledge, 2007) and subsequent multigene vector 
concatamerization mediated by Cre-LoxP recombination (Vijayachandran et al., 
2011). Since each step of TR only requires one enzyme (DNA polymerases or Cre 
recombinase) and one reaction protocol at a time, the experimental procedure of 
generating multigene expressing vectors is greatly simplified, and has been 
successfully integrated into a high-throughput robotic liquid-handling pipeline we call 
ACEMBL (Bieniossek et al., 2009; Y Nie et al., 2009), which is instrumental for 
tackling ambitious and challenging structural biology projects aiming at large 
multiprotein complexes with many subunits, including human TFIID. We 
implemented the ACEMBL system originally implemented for multigene expression 
in E. coli for technical reasons, as this prokaryotic system allowed us to assay protein 
production from the constructs generated by TR rapidly. Later, as outlined below and 
described in detail in Publications 1 and 2 of this thesis, we have extended the 
ACEMBL technology concept successfully to multiprotein production also in 
eukaryotic hosts (baculovirus/insect cell system, mammalian expression). 
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1.2.1 ACEMBL, an automated recombineering expression system for 
multiprotein complex production in E. coli 
 
1.2.1.1 The ACEMBL synopsis 
 
The ACEMBL system utilizes a series of specifically-designed vectors (called 
acceptor or donor, respectively) for multigene vector generation catalyzed by Cre-
LoxP recombination (Fitzgerald et al., 2006). All ACEMBL vectors are custom-
designed, synthetic, small plasmids (2-3 kbp). Our acceptor and donor plasmids 
possess only the DNA elements required for protein expression and plasmid 
propagation, and DNA elements required for our TR approach. In contrast to currently 
available expression plasmids including commercial plasmids, these elements are 
directly juxtaposed, without intervening sequences without functionality, giving rise 
to the smallest possible DNA molecules that propagate and can be used for multigene 
expression (Fig. 1.1). 
 
Figure 1.1: A schematic view of ACEMBL vectors (adapted from Bieniossek et 
al., 2009). 
Thesis  Chapter 1 
Yan NIE  Introduction 
     6 
 
All ACEMBL vectors contain common plasmid modules such as 
promoter/terminator and resistance marker. The Multiple Integration Element (MIE) 
(Fig. 1.2), is adapted from a previously published polylinker (Tan et al., 2005), is 
tailor-made for single/multiple gene insertions via either automatable SLIC or 
conventional restriction/ligation methods. In addition, complementary homing 
endonuclease (HE)/BstXI sites are introduced for theoretically unlimited iterative 
gene insertions. Once the gene insertions are done, the acceptor and donor vectors can 
be fused together (concatamerization) for multigene co-expression in a rapid and 
flexible fashion, by utilizing LoxP imperfect inverted repeats (LoxP sites) and the Cre 
recombinase. There are two origins of replication, acceptors contain a common E. coli 
origin or replication (BR322) and donors contain a conditional origin of replication 
derived from phage R6Kγ. All plasmids contain a different resistance marker..  
 
 
Figure 1.2: A schematic view of the Multiple Integration Element (MIE) 
(adapted from Bieniossek et al., 2009. Supplementary Protocol), which is tailor-
made to facilitate multigene insertions. Restriction sites available for 
conventional restriction/ligation subcloning are indicated, flanked by homology 
regions for single/multiple gene insertions via SLIC. Since a ribosome binding 
site (rbs) is placed between the promoter and NdeI site, there is no need to 
introduce additional rbs sequences for single gene insertion. The entire expression 
cassette can be exchanged by utilizing the ClaI/PmeI restriction sites, in case a 
different promoter/terminator pair is desired. After gene insertions, the expression 
cassette can be transferred to another ACEMBL vector by utilizing the HE site (I-
CeuI/PI-SceI) and the complementary BstXI site (detailed protocols for gene 
insertions into MIE are available in the ‘Materials and Methods’ chapter). 
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1.2.1.2 Multigene expressing vectors from acceptor and donor vectors via Cre-LoxP 
recombination 
 
Each ACEMBL vector contains a single LoxP site, which facilitate the simultaneous 
concatamerizations of two or more vectors catalyzed by Cre recombinase. Cre 
recombinase is a member of the integrase family (Type I topoisomerase from 
bacteriophage P1). It catalyzes reversible recombination events between two 34 bp 
LoxP sites in the absence of accessory protein or auxiliary DNA sequence. A LoxP 
site is comprised of two 13 bp recombinase-binding elements arranged as inverted 
repeats, flanking an 8 bp central spacer which is not palindromic, thereby conferring 
the site orientation (Fig. 1.3), where cleavage and ligation reactions occur (Gopaul et 
al., 1998). 
 
 
 
Figure 1.3: The sequence of a LoxP imperfect inverted repeat (LoxP site) 
(adapted from Gopaul et al., 1998). The two thick arrows in grey indicate the two 
13 bp inverted repeats where Cre recombinase binds. The horizontal arrow in 
grey indicates the site orientation conferred by the 8 bp central spacer. The two 
vertical arrows in black indicate the cleavage positions on the DNA backbone. 
 
The site-specific recombination mediated by Cre recombinase involves the 
formation of a Holliday junction (HJ) by strand cleavages and exchanges (Fig. 1.4). 
The recombination events catalyzed by Cre recombinase are dependent on the 
locations and relative orientations of the LoxP sites. Two DNA molecules containing 
one single LoxP site each will be fused to give rise to one circular DNA molecule 
containing two LoxP sites. In contrast, in one DNA molecule containing two or more 
LoxP sites, DNA between directly repeated LoxP sites will be excised in circular form, 
while DNA between opposing LoxP sites will be inverted with respect to the external 
sequences. The Cre recombination is an equilibrium reaction and the excision and 
fusion reactions are competing, with overall 20-30% efficiency in assembling DNA 
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(www.neb.com). The Cre reaction is more favourable in disassembling a DNA 
molecule containing multiple LoxP sites rather than assembling separate DNA 
molecules with single LoxP sites. The detailed recombination pathway between two 
directly repeated LoxP sites in one DNA molecule is shown in Figure 1.4. 
 
 
Figure 1.4: The Cre-LoxP site-specific recombination pathway of two 
directly repeated LoxP sites in one DNA molecule (external DNA strands only 
shown in steps i and vi for simplicity) (adapted from Gopaul et al., 1998). During 
the recombination, two recombinases (grey ellipses) interact with one LoxP site 
at the two 13 bp inverted repeats flanking the central spacer (site orientations 
indicated by arrows between stands). Conserved tyrosine residues from two 
recombinases cleave the DNA backbones of the recombining segments to form 
transient 3’-phosphotyrosine linkages. The released 5’-hydroxyl ends of the 
cleaved DNA undergo intermolecular nucleophilic attack of the partner 
phosphotyrosine linkages to complete strand exchanges and form an intermediate 
HJ. After isomerisation, a second round of strand cleavages and exchanges by the 
other two recombinases ends the recombination process, generating two separate 
DNA molecules with single LoxP sites. The anti-parallel arrow pairs indicate that 
each recombination step is reversible. 
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When educt vectors containing single LoxP sites are subjected to Cre-LoxP 
recombination, only a small portion of educt vectors are combined together, while the 
rest remain separate and co-exist with the fusion products. 
Acceptor vectors (pACE and pACE2; ACE indicates acceptor) contain a regular 
origin of replication (BR322), which enables their replications in regular E. coli 
strains (TOP10, OmniMAX, BL21, etc). In contrast, donor vectors (pDC, pDK, pDS) 
contain a conditional origin of replication termed R6Kγ (the γ replication origin of the 
R6K plasmid) (Metcalf et al., 1994). The replication of donors containing this origin 
absolutely relies on the presence of the π protein (encoded by pir gene). Therefore, 
propagation and manipulation of all donor plasmids has to be carried out in specific E. 
coli strains, such as BW23473 (PirLC) and BW23474 (PirHC) which contain a pir 
knock-in in their genome. The PirLC strain carries a wild type pir gene in its 
chromosome, while the PirHC strain carries a mutated pir-116 gene, which leads to a 
higher copy number (Haldimann and Wanner, 2001). By switching between these two 
E. coli strains, the copy number of a donor vector can be modulated. We use these 
two variants owing to our observation that large plasmids (> 10 kbp) are significantly 
more stable when propagated at low copy numbers (i.e. in the PirLC strain). The 
amount of plasmid DNA that can be prepared is on the other hand higher when 
propagated in the PirHC strain. Therefore, we propagate plasmids that are stable 
(usually < 10 kb) in the PirHC strain. 
A donor vector cannot replicate in a regular E. coli strain, which does not 
contain the pir gene (i.e. pir-negative), unless fused with an acceptor vector with a 
regular origin of replication. Hence, the recombination between acceptor vectors and 
donor vectors is exploited for more specific selection of desired fusion products. For 
example, a regular E. coli strain (i.e. TOP10) co-transformed with separate pACE and 
pDC vectors cannot survive in LB medium containing both ampicillin and 
chloramphenicol, since pDC vector cannot replicate and confer chloramphenicol 
resistance in a pir-negative host. In this case the donor serves as a suicide vector. In 
contrast, a regular E. coli cell transformed by pACE-pDC fusion (desired product) is 
able to replicate and survive the ampicillin-chloramphenicol challenge (Fig 1.5). 
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Figure 1.5: Combination of acceptor and donor vectors helps to achieve 
more strict antibiotic selections. The combination of acceptor vector and donor 
vector helps to achieve more specific selection of desired Cre-LoxP fusion 
products in a pir-negative E. coli host upon antibiotic challenge. LoxP sites are 
shown as red circles, resistance markers and origins of replication are labelled. 
White and grey thick arrows stand for the entire expression cassette (promoter, 
MIE, and terminator). (a) A regular E. coli host (TOP10) co-transformed by one 
acceptor vector (pACE) and one donor vector (pDC) cannot survive the 
ampicillin and chloramphenicol challenges, since the pDC vector cannot replicate 
and confer chloramphenicol resistance in a regular (pir-negative) E. coli host. (b) 
In contrast, another regular E. coli host (TOP10) transformed by the acceptor-
donor fusion (pACE-pDC), which contains a regular origin of replication, is able 
to replicate and survive the double-antibiotic challenge. 
 
A single acceptor vector could be recombined in a single Cre-LoxP reaction 
with a theoretically unlimited number of donors, with one to several genes on each 
donor and acceptor. Pragmatically, we use one acceptor and up to three donor vectors 
to generate multigene expression vectors. Due to the equilibrium nature of the Cre-
LoxP reaction, the recombined products are a mixture of all possible fusions from two 
or more educt vectors, including acceptor-acceptor, acceptor-donor, and donor-donor 
fusions. Since fusion events are less favorable, fusion products containing increasing 
numbers of educt vectors are present in smaller amounts. All fusions and also the 
single plasmids are quasi bar-coded by the resistance marker combinations, since all 
plasmids of the system have a different resistance marker. After transformation into 
regular E. coli strains (pir-negative background), the desired acceptor-donor fusions 
are selected by challenging with corresponding combinations of antibiotics (Fig. 1.6). 
This enables the generation of multigene vectors expressing a complete protein 
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complex as well as subsets of its subunits in a single Cre-LoxP reaction. This 
combinatorial approach is very useful for investigating the hierarchical assembly of 
multiprotein complexes, the biological functions of specific subunit(s) or their 
combinations, as well as the integration of putative subunit isoforms into a 
multiprotein complex of choice (Vijayachandran et al., 2011). 
 
 
Figure 1.6: Dynamic assembly (Cre) and disassembly (De-Cre) of acceptor 
and donor vectors in a single Cre-LoxP reaction. Cre-mediated assembly and 
disassembly of pACE, pDK, and pDS vectors in a single reaction tube are shown 
schematically (left). LoxP sites are shown as red circles, resistance markers and 
origins of replication are labelled. White thick arrows stand for the entire 
expression cassette (promoter, MIE, and terminator) in the ACEMBL vectors. 
AD stands for acceptor-donor fusion. ADD stands for acceptor-donor-donor 
fusion. Not all possible fusion products are shown for clarity. Levels of 
multiresistance for vector selection are indicated (right). 
 
After the multiresistance challenge, we further verify the fusion plasmids by 
restriction digestions. For example, transformants might contain fusion products 
harboring more than one copy of a particular educt vectors. This may cause 
expression imbalance between subunits due to the increase in copy number of the 
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gene(s) present on that educt. On the other hand, this can also be used advantageously. 
When a certain gene of interest is expressed at lower level comparing to others in a 
multigene expression experiment, it can be helpful to incorporate an additional copy 
of the corresponding educt vector, or to place the same gene in several copies on one 
or more educt plasmids. 
When more than two educt vectors are subjected to Cre-LoxP recombination, 
their incorporations are stochastic and hence lead to sequence variations in the fusion 
plasmids depending on the assembling orders of educt vectors (Fig. 1.7). The number 
of possible fusion plasmids (Pn) containing n educt vectors (each as a single copy) is 
given by the formula of circular permutation: )!1( -= nPn  (Weisstein). For example, a 
fusion plasmid containing one acceptor and three donors (n=4) has 6!34 ==P possible 
variants (Fig. 1.7). Although it appears from our experiments that the assembling 
order of educt vectors in a multifusion plasmid is probably not influencing the success 
of the complex expression experiment, it is always good practice to verify the order of 
assembly of educt vectors in the multifusion plasmid as a quality control step, before 
moving on to protein complex expression experiments. Therefore, the exact DNA 
sequences of all possible fusion variants are required for verification and selection by 
restriction digestions. 
 
Figure 1.7: Possible fusion variants from two, three, and four ACEMBL 
vectors. Variants of possible fusion plasmids containing two (top row), three 
(middle row), or four (bottom row) educt vectors, each as a single copy, are 
shown. Colored squares indicate educt vectors (A represents acceptor, D1-3 
represent donor 1-3) in each fusion plasmid. The linear order (clockwise, A is 
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always at the beginning for simplicity) of educt vectors in each fusion plasmid is 
indicated below the corresponding plasmid map. The number of educt vectors 
and compositions are indicated (right). 
 
To facilitate the generation of DNA sequences of all possible fusion variants in 
silico, a software termed Cre-ACEMBLER was programmed (in Python) by Christian 
Becke, at EMBL Grenoble and Freie Universität Berlin (Becke, 2010). Cre-
ACEMBLER runs on Windows, Linux, and MacOS operating systems, and the DNA 
sequences can be processed in either FASTA or GenBank format. Since the copy 
number of each educt vector is defined by users, this software is very useful for 
generating sequences and interpreting restriction patterns of fusion plasmids with 
more than one copy of educt vectors. Cre-ACEMBLER can be downloaded from the 
Berger lab web page (http://www.embl.fr/multibac/multiexpression_technologies/). 
With the ACEMBL system, many multiprotein and protein-RNA complexes 
have been successfully expressed and purified both manually and in an automated 
robotic setup. One notable example is the successful production of the entire 
prokaryotic holotranslocon, a large transmembrane multiprotein complex containing 
six subunits expressed from a 16 kbp multifusion plasmid (Bieniossek et al., 2009). 
 
1.2.1.3 Extending the ACEMBL pipeline to eukaryotic expression systems 
 
The successful applications of the ACEMBL system for producing challenging 
multiprotein specimens in E. coli, we have expanded the ACEMBL pipeline to 
eukaryotic expression systems (Table 1.1) in order to produce functional eukaryotic 
protein complexes requiring the authentic processing and posttranslational machinery 
provided by eukaryotic hosts (Vijayachandran et al., 2011). Multifusion plasmids 
generated from Cre-LoxP reaction are utilized by the MultiMam system to facilitate 
simultaneous multigene introduction into mammalian cells (Kriz et al., 2010; 
Trowitzsch et al., 2011). The latest version of MultiBac system has been upgraded by 
introducing ACEMBL DNA modules (MIE and HE/BstXI sites) for automatable and 
theoretically unlimited multigene insertion into a baculoviral genome for protein co-
expression in insect cells (Vijayachandran et al., 2011; Bieniossek et al., 2012). The 
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MultiBac system is discussed in the next chapter (1.2.2) and presented in Publications 
1 and 2 of this thesis. 
 
Table 1.1: Prokaryotic and eukaryotic expression systems derived from 
ACEMBL technology for multiprotein co-expression (Vijayachandran et al., 
2011). Note that initially, ACEMBL referred to the E. coli system. We have now 
named the individual ACEMBL systems MultiColi for E.coli, MultiMam for 
mammalian and MultiBac for baculovirus/insect cell expression. See also 
http://www.embl.fr/multibac/multiexpression_technologies. 
 
 
 
1.2.2 MultiBac, an advanced baculovirus/insect cell expression system 
for producing recombinant multiprotein complexes 
1.2.2.1 Baculoviruses are versatile gene delivery vectors for recombinant protein 
production in insect cells  
 
Baculoviruses are rod-shaped viruses that infect various invertebrate hosts, such as 
Diptera, Hymenoptera, and Lepidoptera (Rohrmann, 2011). Although initially 
regarded as potential insecticides, they evolved as versatile gene delivery vectors for a 
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number of applications, notably for recombinant protein production in larvae and 
cultured insect cells. Baculovirus-mediated recombinant protein production in 
cultured insect cells was first accomplished almost 30 years ago (Smith et al., 1983). 
Since then, many thousands of recombinant cytosolic and membrane proteins have 
been successfully expressed in baculovirus-infected insect cells (Kost et al., 2005; 
Summers, 2006; Bieniossek et al., 2012). 
Several factors contribute to the popularity of the baculovirus-insect cell 
expression system. First, insect cells offer machineries essential for producing soluble 
and active recombinant eukaryotic proteins, such as posttranslational modifications, 
chaperone systems, and authentic transportation after protein synthesis. Furthermore, 
the large size (~130 kbp) of baculoviral genome enables the accommodation of large 
foreign DNA inserts encoding for proteins up to several hundred kDa (Murphy et al., 
2001). Finally, no specific safety measures are required for handling baculovirus since 
it is non-infectious to vertebrates; and baculoviral promoters have been shown to be 
inactive in most mammalian cells (Grabenhorst et al., 1993), which makes the 
baculovirus-insect cell expression system ideal for expressing oncogenic and 
potentially toxic proteins. 
In the following, I discuss important aspects of baculovirus life cycle and 
infection characteristics in the context of the expression technology we developed 
(MultiBac) and use in the laboratory. More details are provided in Publication 2 of the 
thesis. 
 
1.2.2.2 The baculovirus infection is chronologically regulated 
 
The most widely used baculovirus for baculovirus-insect cell expression is a lytic 
virus termed Autographa californica nuclear polyhedrosis virus (AcNPV), which 
infects arthropods (Doerfler and Böhmi, 1986). 
In nature, baculovirus normally exists in the form of an occlusion derived virus 
(ODV) for its survival outside of its insect hosts. In an ODV particle, up to hundreds 
of individual virions are embedded in a sturdy proteinaceous matrix, mainly 
composed of the polyhedrin protein. This protein matrix protects ODV from 
environmental stress until it is ingested by the next host which it will then infect. 
When the ingested ODV reaches the host’s midgut, polyhedrin dissolves in the 
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alkaline environment and baculoviral particles are released to infect the midgut 
epithelial cells. Shortly after entering the cell, the baculoviral DNA is replicated, 
followed by the assembly of baculoviral particles in the nuclei. At the late phase of 
infection, some baculoviral particles are budded out to infect neighboring host cells, 
leading to a systemic infection of the host. These budded baculoviral particles are 
called budded virus (BV). During the late and very late phase of infection, ODV 
particles start to accumulate massively in nuclei and are eventually released from the 
lysed host to the environment, ready for a new round of infection (Murphy et al., 
2001; Rohrmann, 2011) (Fig. 1.8). 
 
 
Figure 1.8: Baculovirus life cycle (Rohrmann, 2011). (A) ODV particles (blue 
hexagons) are ingested and dissolved in the midgut of an insect host, during 
which the embedded baculoviral particles are released to infect the midgut 
epithelial cells. (B) A BV particle buds out of the infected epithelial cell in a 
basal direction and initiates a systemic infection. The virogenic stroma (VS), a 
typical nuclear structure in infected cells, is indicated. (C) Early in the systemic 
infection more BV particles are produced, which spread the infection throughout 
the host. (D) Late in infection, many ODV particles are produced and eventually 
released from the lysed host for a new round of infection.
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During infection, AcNPV genes are expressed at different times in a tightly 
regulated manner. Based on the temporal order of expression, the baculoviral genes 
are divided into three distinct classes: early, late, and very late (Smith et al., 1983; 
Pennock et al., 1984). The early genes contain host-like promoters and hence can be 
transcribed by the host transcriptional machinery at the early phase of infection. The 
expression of late genes, driven by late promoters, starts after the replication of 
baculoviral DNA and requires the baculoviral transcriptional machinery. Very late 
genes, driven by very late promoters, are expressed at the very end of infection cycle 
(Miller, 1997; Passarelli and Guarino, 2007). 
Baculoviral genes driven by very late promoters are typically well or very well 
expressed (Roy et al., 1997). As a result, the commonly used baculoviral promoters, 
p10 and polyhedrin (polh), are both derived from very late genes. The p10 promoter 
regulates the expression of the p10 protein, which forms fibrillar structures and may 
be involved in the assembly of polyhedrin in ODV (Russell et al., 1991).  The 
polyhedrin promoter drives the expression of polyhedrin, which is the major structural 
protein that makes up the ODV (Rohrmann, 2011). 
Besides gene expression, the baculoviral DNA replication and packaging 
(during viral particle assembly) are also chronologically regulated (Fig. 1.9). The 
replication of baculoviral DNA starts ~6 hours postinfection, followed by viral 
particle assembly in nuclei. The BV particle starts budding out of the infected cell at 
~12 hours postinfection and its production peaks at ~20 hours postinfection. In 
contrast, the ODV particles appear in nuclei at ~18 hours postinfection and keep 
accumulating till at least 72 hours postinfection (Murphy et al., 2001). Interestingly, 
BV has been shown to infect cultured insect cells 1,000 fold more efficiently than 
ODV, while ODV infects midgut epithelial cells up to 10,000 fold more efficiently 
than BV (Volkman et al., 1976; Volkman and Summers, 1977). Further, due to high-
level replication, ODV genomes are prone to contain significantly more mutations and 
errors as compared to the BV genomes. This, in combination, makes BV the virion of 
choice for propagating baculovirus in cultured insect cells. 
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Figure 1.9: Overview of DNA replication and baculoviral particle production 
during an idealized AcNPV infection (adapted from Braunagel et al., 1998). 
The production kinetics of baculoviral DNA (thinner line), BV (thicker line), and 
ODV (thick dotted line) are normalized. BV is considered “good” virus for 
recombinant protein production, ODV has lower infectivity and exhibits 
significantly more genomic damage and is therefore considered “bad” virus for 
recombinant protein production. 
 
Taking advantage of the exact chronological regulation of baculovirus infection, 
standardized protocols were developed for efficiently propagating baculovirus (BV) 
and expressing recombinant proteins (controlled by baculoviral promoters) in cultured 
insect cell lines such as Sf21 cells, a continuous cell line derived from ovaries of the 
Fall Armyworm (Spodoptera frugiperda) (Vaughn et al., 1977). 
 
1.2.2.3 Two commonly used methods for generating recombinant baculovirus 
 
To express recombinant proteins in insect cells, recombinant baculoviruses are 
generated by incorporating genes of interest, which are flanked by baculoviral 
promoters (p10 or polh) and corresponding transcriptional termination signals (HSVtk 
or SV40) to ensure high expression level. Most, if not all, current baculovirus 
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expression vector systems (BEVSs) utilize homologous recombination or Tn7 
transposition for inserting foreign genes into baculovirus DNA. 
A popular method for inserting foreign genes by homologous recombination is 
to co-transfect cultured insect cells with a linearized baculovirus DNA (restriction 
digestion product from an engineered circular baculovirus DNA) and a transfer 
plasmid containing gene(s) of interest and homologous DNA sequences (Fig. 1.10). 
The circular baculovirus DNA (BacPAK6) is derived from wild type AcNPV and had 
the original polyhedrin gene replaced by a bacterial lacZ gene. BacPAK6 contains 
three Bsu36I restriction sites, one of which is placed in an essential gene called 
ORF1629 (Possee et al., 1991) downstream of the lacZ gene. During the restriction 
linearization, the ORF1629 gene is truncated and hence inactivated. As a result, the 
linearized BacPAK6 cannot replicate in insect cells, unless the missing piece of the 
ORF1629 gene is replenished from the transfer plasmid by homologous 
recombination, when the gene(s) of interest are also integrated. This recombination 
event results a re-circularized recombinant BacPAK6, capable of replicating and 
producing recombinant proteins (Kitts and Possee, 1993). This method greatly 
increases the efficiency (>90%) of recombinant baculovirus generation comparing to 
previous methods, which are also based on homologous recombination (Smith et al., 
1983; Kitts et al., 1990). However, plaque assay is still necessary for identifying and 
purifying productive recombinant baculoviruses, therefore complicates the subsequent 
handling. 
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Figure 1.10: Principle of integrating foreign gene into baculovirus DNA by 
homologous recombination (adapted from Kitts, 1996). Three Bsu36I restriction 
sites are present in the circular baculovirus DNA (BacPAK6) with their locations 
indicated. After restriction digestion, the BacPAK6 is linearized and the essential 
gene ORF1629 is truncated, which makes the linearized BacPAK6 inviable in 
insect cells. The viability of the linearized BAcPAK6 is restored by recombined 
with a transfer plasmid carrying homologous DNA sequences, which contain the 
entire ORF1629 gene. During the homologous recombination (indicated by black 
crosses), the truncated ORF1629 gene is regenerated; the gene of interest is also 
integrated into the recombinant BacPAK6, which is re-circularized and able to 
replicate in insect cells. 
 
A second method, originally developed by Luckow and coworkers (Luckow et 
al., 1993) uses Tn7 transposition for generating recombinant baculoviruses. The 
baculoviral DNA (usually also an AcNPV derivative) contains a resistance marker 
(kanamycin), a mini-F replicon (single-copy bacterial origin of replication), and a 
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lacZα gene with an internal Tn7 attachment site (att-Tn7) for selecting recombinant 
baculovirus by blue/white screen (Fig. 1.11). This baculovirus DNA can is maintained 
and propagated in an E. coli as a bacterial artificial chromosome (BAC), also called 
bacmid. The foreign gene is cloned into an expression cassette on a so-called transfer 
plasmid, flanked by Tn7L and Tn7R sequences, and inserted into the BAC at the Tn7 
attachment site, mediated by the Tn7 transposon enzyme complex which is expressed 
in the bacteria from a separate plasmid. The lacZα gene in the recombinant BAC is 
disrupted upon successful Tn7 transposition of the foreign gene, and the bacteria now 
harbouring recombinant BACs form white colonies in blue/white screen. 
Recombinant BAC is then purified used for transfecting cultured insect cells for 
baculovirus amplification and recombinant protein production (Luckow et al., 1993). 
This system has a very high efficiency (more than 95%) and is widely used by the 
community (Invitrogen, Bac-to-Bac; Airenne, 2003; Berger et al., 2004; Laitinen, 
2005). Our MultiBac system also utilizes this system for foreign gene integration. 
 
 
Figure 1.11: Principle of inserting foreign gene into a BAC (bacmid) by Tn7 
transposition (adapted from Kitts, 1996). The BAC contains a kanamycin (KnR) 
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resistance marker, a lacZα gene with an internal Tn7 attachment site (att-Tn7), 
and a mini-F replicon which enables replication of the BAC in a regular E. coli 
strain. In the transfer plasmid, a gentamicin (GnR) resistance marker and gene of 
interest (GOI) are flanked by Tn7L and Tn7R sequences. The DNA fragment 
between the Tn7L and Tn7R sequences are inserted into the att-Tn7 site via Tn7 
transposition, catalyzed by the Tn7 transposon enzyme complex encoded by a 
tetracycline (TcR) resistant helper plasmid. The lacZα gene is interrupted after the 
gene insertion and hence inactivated, which makes the bacteria colonies 
containing the recombinant BAC appears whitish during blue/white screen. The 
purified recombinant BAC from white bacteria colonies are then used for 
transfecting insect cells. 
 
1.2.2.4 Expressing recombinant multiprotein complexes with MultiBac system 
 
BEVSs were originally developed for expressing one single foreign protein, and are 
not designed for simultaneous integration of many genes of interest for multiprotein 
complex production. Although some BEVSs (Bac-to-Bac, Invitrogen; Belyaev and 
Roy, 1993) provide the possibilities for inserting two genes of interest into a single 
transfer plasmid, even this gene insertion is based on conventional serial subcloning 
methods and therefore impractical for gene manipulation after insertion. A surrogate 
is to co-infect cultured insect cells simultaneously with several recombinant 
baculoviruses. This co-infection method in principle offers a fast track to express 
several proteins simultaneously. However, co-infection often suffers from unbalanced 
expression of the proteins, as it is not straight-forward to titrate the individual viruses 
exactly. Further, especially if three or more baculoviruses are used, it cannot be 
guaranteed that all viruses enter all cells at the same level (Vijayachandran et al., 
2011). Therefore, the co-infection method is not efficient for co-producing many 
proteins, especially for large-scale protein production. For challenging structural 
biology projects, which require continuous supply of considerable amounts of 
recombinant multiprotein complexes of high quantity and quality, co-infection proved 
not to be a useful method. 
Co-expression of multiple genes from a single composite recombinant 
baculovirus turned out to be much more productive than co-infection as shown by 
previous studies (Miller, 1988; Roy et al., 1997; Bertolotti-Ciarlet et al., 2003). The 
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generation of a single multigene expressing baculovirus, in particular for structural 
studies, requires the rapid incorporation of many genes of interest into a single 
transfer plasmid. In addition, the alteration of genes of interest should also be flexible 
in case iterative gene modifications (purification tag replacement, truncation/insertion, 
etc) are required until optimal expression and purification results are achieved, an 
aspect which is crucial for structural biology. The MultiBac system was introduced by 
the Berger laboratory to specifically address these challenges. Since its inception 
(Berger et al., 2004), the MultiBac system has been optimized progressively over the 
last few years to simplify handling, standardize protocols and optimize production 
properties (Berger et al., 2004; Fitzgerald et al., 2006; Bieniossek et al., 2008; 
Vijayachandran et al., 2011). 
Comparing to previous BEVSs, the first generation of MultiBac system features 
an engineered BAC with two gene incorporation sites (att-Tn7 and LoxP), and two 
modular gene transfer plasmids (pFBDM and pUCDM) (Berger et al., 2004). The 
MultiBac BAC is derived from the Tn7-based AcNPV bacmid (Luckow et al., 1993). 
Besides the att-Tn7 site embedded in the lacZα gene, the MultiBac BAC also contains 
a LoxP site for gene integration catalyzed by in vivo Cre-LoxP recombination. During 
the introduction of the LoxP site by ET recombination, two of the wild type AcNPV 
genes (v-cath, encoding the protease V-CATH; chi-A, encoding a chitinase that 
activates V-CATH) were eliminated, resulting in additional benefits such as reduced 
proteolytic breakdown of recombinant proteins and prolongated life span of infected 
insect cells. The pFBDM is an acceptor vector designed for inserting foreign genes 
into the Tn7 attachment site, while the pUCDM is a donor vector for integrating 
foreign genes into the LoxP site. Both vectors contain the same dual expression 
cassettes (controlled by p10 and polh promoters, respectively) and a multiplication 
module for iterative incorporation of additional expression cassettes. The modular 
design of the first generation of MultiBac system makes it an ideal and pioneer system 
for multiprotein production in insect cell. 
The second generation of MultiBac system (Fitzgerald et al., 2006) was created 
to introduce further modular gene transfer plasmids (pFL and pKL as acceptor 
vectors, pSPL as donor vector), which all contain single LoxP sites and could be 
recombined to form a single fusion transfer plasmid by in vitro Cre-LoxP 
recombination, followed by simultaneous multigene integration into the att-Tn7 site. 
This strategy further facilitates the multiple gene assembly, validation, and integration 
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into MultiBac BAC. Notably, pKL is characterised by a medium to low-copy origin 
of replication (in contrast to pFL which has a high-copy origin of replication derived 
from pUC vector), which facilitates cloning of very large and inherently instable 
genes and the generation of multigene fusions. 
In the third generation of MultiBac system (Bieniossek et al., 2008), an 
enhanced yellow fluorescent protein (YFP) encoding gene was inserted into the LoxP 
site of the original MultiBac BAC, resulting in a new BAC named EMBacY. Since 
the YFP encoding gene is driven by a polh promoter, its expression is synchronized 
with other heterologous genes, which are also driven by very late promoters (p10 and 
polh). To take full advantage of the new EMBacY BAC, a fully standardized protocol 
for baculovirus amplification and recombinant protein production was established, in 
which the fluorescence signals of cell probes (1 × 106 cells/probe) taken at regular 
intervals (12-24 h) are used to evaluate viral infection status and heterologous protein 
production levels. In addition, an experimental routine for maintaining a low 
multiplicity of infection (MOI) during the viral amplification has also been integrated 
into the protocol, so as to prevent the accumulation of defective viral particles, which 
leads to reduced heterologous protein expression (Wickham et al., 1991; Fitzgerald et 
al., 2006). 
The latest (fourth and current) generation of MultiBac system (Vijayachandran 
et al., 2011) utilizes a series of novel acceptor and donor vectors (Fig. 1.12a), based 
on the ACEMBL concept for recombinant multiprotein complex production originally 
developed for E. coli as a host (Bieniossek et al., 2009; Nie et al., 2009). The new 
vectors (2-3 kbp) are considerably smaller than those from previous generations (3-5 
kbp) and lack all redundant and/or not functional DNA elements. Further, we 
introduced minimal cloning modules (MCS1/2 and HE/BstXI sites) from the original 
ACEMBL system into the new MultiBac plasmids which are tailor-made for 
automatable SLIC methods and allow for theoretically unlimited iterative integrations 
of expression cassettes. A simplified work flow of multiprotein complex production is 
shown in Figure 1.12b. 
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Figure 1.12: An overview of the current version of the MultiBac system 
(adapted from Bieniossek et al., 2012). (a) A schematic view of MultiBac vectors 
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with all essential DNA modules annotated. (b) A simplified work flow of 
multiprotein complex production with MultiBac system with each major step 
indicated. For simplicity, some DNA modules (resistance maker, MCS1/2, 
HE/BstXI pairs, etc) are not shown in the plasmid maps, and only the MultiBac 
BAC is shown. 
 
1.2.3 Polyproteins, a novel strategy for improving subunit stoichiometry 
of recombinant multiprotein complexes 
 
Many multiprotein complexes have been successfully produced with the MultiBac 
system in laboratories all around the world, often for the first time (Bieniossek et al., 
2012). High-resolution structure elucidation has been achieved with several of these 
recombinantly produced protein complexes, due to the superior sample quality and 
quantity (Trowitzsch et al., 2010; Bieniossek et al., 2012). 
For our own work including the study of TFIID, however, a further, new 
technology had to be implemented to catalyze success. We observed that in a 
multiprotein expression experiment, occasionally one of the subunits is expressed at a 
much lower level than the others, which can be utterly detrimental to overall yield of 
purified complex with all subunits. We believe, based on our results, protein subunits 
of large molecular weight (> 100 kDa) are more likely to be affected by this. On the 
other hand, we noticed that some very large proteins (> 500 kDa) can be produced 
efficiently with the MultiBac system, confirming that the insect cell transcriptional 
and translational machineries are capable of processing also very large open reading 
frames (ORFs) authentically in most cases. 
In order to restore the subunit stoichiometry of complexes impeded by 
imbalanced expression, we developed and implemented a novel expression strategy 
based on polyproteins. This approach is inspired by studies on the SARS coronavirus, 
which causes severe acute respiratory syndrome (SARS) (Peiris et al., 2003). The 
viral genes are arranged in two ORFs, from which two large polyproteins are 
produced by host translational machineries. Altogether 16 individual viral proteins are 
then liberated from the polyproteins by autoproteolysis catalyzed by viral proteases, 
which also reside in the polyproteins. Notably, one of the viral polyproteins is very 
large, 700 kDa (Gorbalenya et al., 2006). 
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In order to adapt the polyprotein approach in the MultiBac system, a fusion 
protein (CFPtcsYFP) has been created to evaluate the efficiency of proteolysis 
catalyzed by the protease N1A from tobacco etch virus (TEV). This fusion protein 
contains an N-terminal cyan fluorescent protein (CFP) and a C-terminal YFP, jointed 
by a linker containing a TEV cleavage site (tcs). When expressed alone, this fusion 
protein remained intact and resulted an overexpressed band at 50 kDa, as revealed by 
the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) method. 
When co-expressed with TEV protease, the fusion protein was cleaved completely, as 
confirmed by both SDS-PAGE and ﬂuorescent resonance energy transfer (FRET). 
Furthermore, this fusion protein can also be efficiently cleaved by adding purified 
TEV protease in cell lysate and incubating overnight (Vijayachandran et al., 2011). 
We have purified many protein complexes successfully by using the polyprotein 
strategy, which could not be obtained in high quantities before. One notable example 
is the restoration of subunit stoichiometry of a TFIID core complex named 3TAF, 
composed of three TBP associated factors (TAFs) 5, 6, and 9 (each present as two 
copies) (Fitzgerald et al., 2007). The 3TAF complex was first expressed from 
individual expression cassettes on a MultiBac BAC and purified by the immobilized 
metal ion affinity chromatography (IMAC) method, utilizing the C-terminal histidine 
tag (his-tag) on TAF9. The eluted sample contained much more TAF6/TAF9 dimers 
than TAF5, indicating that the TAF5 subunit (~ 100 kDa) was expressed at a much 
lower level and hence severely limited the overall production level of the 3TAF 
complex. In order to have a more balanced expression, the encoding genes of the 
3TAF subunits were subcloned into the same transfer plasmid as a single ORF, with a 
tcs in between each other. In addition, a TEV encoding gene succeeded by a tcs was 
introduced at the 5’ end of the ORF for liberating each subunit via autoproteolysis 
during translation. This new transfer plasmid was then subjected for expression and 
purification in the same way as previous case. As revealed by SDS-PAGE, the subunit 
stoichiometry was completely restored. Furthermore, the overall recombinant protein 
production level was not compromised by the elevated production of the TAF5 
subunit (Fig. 1.13). 
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Figure 1.13: The 3TAF complex was produced from single expression 
cassettes (SEc) and also a polyprotein (PP) (adapted from Vijayachandran et 
al., 2011). Annotated plasmid maps of the two DNA constructs are shown on the 
left. TAF5 contains an N-terminal calmodulin binding peptide (CBP) affinity tag; 
while TAF9 contains a C-terminal his-tag. TEV cleavage sites (tcs) connecting 
the polyprotein components are indicated. Sections from SDS–PAGE are shown 
on the right. Bands corresponding to each subunit are indicated. A band 
corresponding to a degradation product of TAF6 is marked with an asterisk. 
Expression from single expression cassettes resulted in unbalanced complex 
production in which TAF5 was produced at a significantly lower amount. In 
comparison, expression from a polyprotein resulted in stoichiometrically 
balanced sample and reduced degradation. In both cases, protein samples were 
puriﬁed from equivalent amounts of cells. 
 
To simplify application of the polyprotein strategy in the MultiBac system, we 
created a novel expression vector named pPBac for standardized polyprotein 
expressions (Fig. 1.14). The cloning site is flanked by a TEV protease encoding gene 
and a CFP encoding gene preceded with a tcs, so that every polyprotein produced 
from this vector contains an N-terminal TEV protease for autoproteolysis and a C-
terminal CFP for monitor protein expression level (Vijayachandran et al., 2011). 
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Figure 1.14: The pPBac plasmid for polyprotein expression with the 
MultiBac system (from Vijayachandran et al., 2011). 
 
1.3 The structure and function of human general transcription 
factor TFIID 
 
Transcription, the synthesis of RNA from DNA templates, is an essential step of gene 
regulation, converting the genetic information encoded by genotypes to phenotypes.  
Transcription of eukaryotic Class II (protein-encoding) genes is initiated by a highly 
coordinated and elaborate assembly of the preinitiation complex (PIC), which 
contains RNA polymerase II (pol II) and the general transcription factors (GTFs) 
TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH, together with the Mediator complex 
and various coactivators. 
TFIID (~1.5 MDa) is the largest GTF and plays a vital role during the initiation 
of eukaryotic transcription by recognizing the promoter and nucleating the PIC. The 
current knowledge of its biological functions and structural assembly are summarized 
in the following subchapters. 
 
1.3.1 A general overview of eukaryotic transcription initiation 
 
The Central Dogma states that genetic information is passed from DNA to RNA and 
finally to protein (Crick, 1958). This sequential view of genetic information flow has 
been further expanded by discovery of additional pathways, demonstrating that 
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genetic information could also flow from RNA to DNA (Baltimore, 1970; Temin and 
Mizutani, 1970). 
Transcription is the production of RNA from DNA templates catalyzed by RNA 
polymerases, whose enzymatic activity was first discovered from rat liver nuclei 
(Weiss and Gladstone, 1959) and later from E. coli as well (Hurwitz et al., 1960; 
Stevens, 1960; Chamberlin and Berg, 1962). So far, four RNA polymerases (I, II, III, 
and IV) have been discovered in higher eukaryotes, whereas only one RNA 
polymerase has been identified in prokaryotes and archaea (Thomas and Chiang, 
2006). 
In eukaryotes, RNA polymerase I is mainly transcribing ribosome RNA (18S 
and 28S); RNA polymerase II is responsible for transcribing mRNA, most snRNA 
(small nuclear RNA) and miRNA (microRNA); RNA polymerase III is primarily 
involved in the synthesis of tRNAs, cellular 5S rRNA, and adenovirus VA RNAs 
(Roeder and Rutter, 1970; Zylber and Penman, 1971; Weil and Blatti, 1976; 
Kornberg, 1999; Sims III et al., 2004). The recently identified RNA polymerase IV is 
responsible for the production of siRNA (small interfering RNA) in plants, mediating 
RNA-directed DNA methylation, transcriptional silencing, and heterochromatin 
formation (Herr et al., 2005; Kanno et al., 2005; Onodera et al., 2005). Although all 
the RNA polymerases share the common function of synthesizing RNA molecules 
from DNA templates, they cannot specifically recognize transcription start sites 
without the help of other accessory protein factors. For example, during the 
transcription of Class II genes, GTFs and general cofactors are required to recruit 
RNA polymerase II to transcription start sites in a site-specific manner (Thomas and 
Chiang, 2006). 
The importance of GTFs in site-specific transcription was first demonstrated by 
an in vitro transcription assay, in which accurate transcription of native adenovirus 
DNA template by purified RNA pol II was achieved by adding crude subcellular 
fractions (Weil et al., 1979). Subsequently, these crude subcelluar fractions were 
further fractionated with an ion exchange column (a Whatman P11 phosphocellulose 
ion exchange column), from which four fractions (A, B, C, D) with distinct enzymatic 
activities were eluted by buffers containing 0.1, 0.3, 0.5 (or 0.6), and 0.85 (or 1.0) M 
KCl (Fig. 1.15). Further studies showed that fractions A, C, and D are necessary for 
RNA pol II to accurately initiate transcription (Matsui et al., 1980; Samuels et al., 
1982). Consequently, the enzymatic components present in fractions A and D, which 
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are required for accurate transcription initiation catalyzed by RNA pol II, are named 
as TFIIA and TFIID. The enzymatic components in fraction C were further purified 
and identified as individual factors called TFIIB, TFIIE, TFIIF, and TFIIH (Sawadogo 
and Roeder, 1985; Reinberg and Roeder, 1987; Flores et al., 1989, 1992; Ge et al., 
1996). All these enzymatic components (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and 
TFIIH) are defined as GTFs and are named according to the following nomenclature: 
TF indicates Transcription Factor; the Roman number II indicates that these factors 
are involved in transcription mediated by RNA pol II; the Latin letters at the end 
indicate the corresponding fractions from which they are identified (Thomas and 
Chiang, 2006).  
 
 
Figure 1.15: Puriﬁcation scheme for partially puriﬁed GTFs (Thomas and 
Chiang, 2006). HeLa nuclear extract was fractionated with an ion exchange 
column (a Whatman P11 phosphocellulose ion exchange column) and the molar 
concentrations of KCl used for elutions are indicated in the ﬂow chart, except for 
the Phenyl Superose column where the molar concentrations of ammonium 
sulfate are shown. A thick horizontal line indicates that step elutions were used 
for protein fractionation, while a slant line represents that a linear gradient was 
used for fractionation. 
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With distinct biological functions (Table 1.2), individual GTFs function in 
a collective fashion to accurately recruit the RNA pol II to the promoter, which 
serves as a platform for formation of the PIC, an essential multiprotein assembly 
responsible for initiating transcription in eukaryotes. 
 
Table 1.2: Compositions and functions of PIC components (Thomas and 
Chiang, 2006). 
 
 
 
1.3.2 TFIID is a large multiprotein complex crucial for eukaryotic 
transcription initiation 
 
The formation of PIC is a prerequisite for eukaryotic transcription initiation, during 
which the RNA pol II is converted from a transcriptionally inert form to a 
transcriptionally active form capable of mediating transcription elongation. During 
PIC assembly, TFIID is the first GTF that recognizes and binds onto the promoters. 
Then, other GTFs and RNA pol II are recruited by the TFIID-promoter scaffold to 
complete the PIC assembly (Fig. 1.16). 
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Figure 1.16: A schematic view of PIC assembly on a TATA-containing 
promoter. The TATA box is represented by a green rectangle. The transcription 
start site is represented by an arrow. (adapted from Holstege et al., 1998; Thomas 
and Chiang, 2006). 
 
TFIID is the largest GTF (human TFIID is of ~1.5 MDa) and a multiprotein 
complex composed of about twenty subunits from 14 different polypeptides – the 
TATA box binding protein (TBP) and TBP associated factors (TAFs) (Dynlacht et al., 
1991; Poon and Weil, 1993), most of which are highly conserved across species (H. 
sapiens, S. cerevisiae, S. pombe, C. elegans, and D. melanogaster) (Dynlacht et al., 
1991; Albright and Tjian, 2000; Tora, 2002).  The relative locations and biological 
functions of TBP and TAFs in TFIID (Fig. 1.17) are closely related to TFIID’s role in 
regulating transcription initiation. 
 
 
Figure 1.17: Subunit assembly and functions of human TFIID (hTFIID). 
hTFIID is composed of TBP and its associated factors (TAFs). The approximate 
subunit composition and locations of hTFIID is shown in a schematic 
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representation (left). Its three lobes are marked as A, B, and C. Key functions of 
the subunits are indicated in the right table. 
 
TFIID regulates transcription initiation in several aspects. First, it is a core-
promoter-binding factor and recognizes both TATA-containing and TATA-less 
promoters via TBP and certain TAFs, which interacts specifically with core promoter 
elements. Second, TFIID acts also as a coactivator, which stimulates PIC assembly by 
bridging enhancer-bound activators and general transcription machinery. Numerous 
activators have been shown to interact with TFIID physically via specific TAFs. Last 
but not least, TFIID possesses multiple enzymatic activities and is involved in 
recognizing and posttranslationally modifying (acetylation, phosphorylation, 
ubiquitination, etc) nucleosomes and GTFs in the context of chromatin during 
transcription initiation (Thomas and Chiang, 2006).  
 
1.3.2.1 TFIID is a core-promoter binding factor with a broad recognition scope  
 
TFIID recognizes a broad spectrum of promoters including TATA-containing and 
TATA-less promoters. Consistently, a genome-wide study in S. cerevisiae showed 
that TFIID is involved in the expression of ~90% Class II genes (Huisinga and Pugh, 
2004). 
The recruitment of TFIID to TATA-containing promoters is mainly mediated by 
TBP, which specifically recognizes and binds TATA box, a consensus A/T-rich 
sequence located ~28 bp upstream of the transcription start site. Besides the TATA 
box, six other highly consensus DNA sequences essential for promoter function have 
also been identified. These DNA sequences are hence named core promoter elements, 
whose interactions with specific TAFs (TAF1, TAF2, TAF4/TAF12, TAF6/TAF9) 
(Fig. 1.18) contribute to the TATA-less promoter recognition of TFIID (Thomas and 
Chiang, 2006; Gazit et al., 2009). Interestingly, although originally perceived as a 
main TATA-containing promoter binding factor, TFIID has been shown to 
predominantly associate with TATA-less promoters by genome-wide chromatin 
immunoprecipitation (ChIP) experiments  in S. cerevisiae (Basehoar et al., 2004). 
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Figure 1.18: Recognition of core promoter elements by TFIID and TFIIB 
(adapted from Thomas and Chiang, 2006). The upper ﬁgure depicts the 
interactions between TAFs and core promoter elements. The lower table lists the 
positions, consensus sequences, and bound proteins for each of these core 
promoter elements. n.a., not available. 
 
 
1.3.2.2 TFIID serves as a coactivator bridging activators and general transcription 
machinery 
 
Besides core promoter elements, TFIID has also been shown to interact with an array 
of activators via specific TAFs. These activator-TFIID interactions stimulate PIC 
Thesis  Chapter 1 
Yan NIE  Introduction 
     36 
assembly on gene-specific promoters and therefore enhance transcription levels of the 
corresponding genes. 
For example, Drosophila TAF4 has been shown to interact with the activation 
domain of Sp1 (Hoey et al., 1993); and human TAF7 was shown to contact the DNA-
binding domain of Sp1 (Chiang and Roeder, 1995), suggesting that Sp1 dependent 
transactivation is mediated by interacting with TFIID via its multiple domains. On the 
other hand, human TAF7 has been shown to interact with a number of activators such 
as Sp1, YY1, USF, CTF, adenovirus E1A, and HIV-1 Tat proteins (Chiang and 
Roeder, 1995), while it remains an integral part within TFIID by contacting TAF1, 
TAF5, TAF11, TAF12, and TAF13 (Lavigne et al., 1996; Gegonne et al., 2001). 
Collectively these findings suggest that transcriptional regulatory signals are 
transmitted from enhancer-bound activators to general transcription machinery via 
activator-TAF and TAF-TAF interaction networks. 
Recent structural analyses on activator-TFIID complexes by single-particle 
electron microscopy (EM) techniques further confirmed the activator-TAF 
interactions and also revealed the binding sites between TFIID and various activators 
(Fig. 1.19), such as  human TFIID complexed with human p53, Sp1, and c-Jun (Liu et 
al., 2009), and also yeast Rap1 bound yeast TFIID (Papai et al., 2010). Interestingly, 
in both studies, no significant structural rearrangement of TFIID upon activator 
binding has been observed. 
 
Figure 1.19: Mapping functional sites on TFIID (Papai et al., 2011). The 
positions of TBP and several TAFs involved in promoter binding are represented 
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in red and the activator binding sites are depicted in blue on the yeast TFIID. The 
positions of the human activator binding sites (p53, Sp1, and c-Jun) were inferred 
from the alignment of the yeast and human TFIID models. A, B, C1, C2, and D 
indicate the five main lobes of yeast TFIID. 
 
 
1.3.2.3 TFIID is involved in recognition and modification of nucleosomes and 
GTFs 
 
Additional to its vital role in promoter recognition and activator binding, TFIID also 
actively interacts with nucleosomes and GTFs, so as to create a chromatin 
environment more accessible for general transcription machinery (Wassarman and 
Sauer, 2001). 
The metazoan TFIID interacts with posttranslationally modified histone tails via 
TAF3 and TAF1. The metazoan TAF3 contains a C-terminal PHD (plant 
homeodomain) finger, which specifically recognizes trimethylated lysine 4 of histone 
H3 (H3K4me3). Since H3K4me3 is found to predominantly associated with 
transcription start sites of active genes, this PHD-H3K4me3 interaction might be 
crucial for recruiting metazoan TFIID onto transcriptionally active promoters (Van 
Ingen et al., 2008). In addition, the metazoan TAF1 has two tandem bromodomains, 
which binds acetylated lysine 5 and lysine 12 of histone H4 (Jacobson et al., 2000). 
The multiple enzymatic domains possessed by TAF1 enable TFIID to 
posttranslationally modify nucleosomes and GTFs, such as phosphorylation, 
acetylation, and ubiquitination (Fig. 1.20).  
Metazoan TAF1 contains two separate kinase domains, one of which locates at 
its N-terminus (N-terminal kinase/NTK) and the other at its C-terminus (C-terminal 
kinase/CTK). Both of them are required to efficiently phosphorylate RAP74, the 
larger subunit of TFIIF (Dikstein et al., 1996), while NTK alone is sufficient to 
phosphorylate the β subunit of TFIIA (Solow et al., 2001).  Consistently, in vitro 
studies showed that dephosphorylated RAP74 has reduced ability of supporting 
transcription elongation comparing to endogenous RAP74, which is 
hyperphosphorylated (Kitajima et al., 1994); while phosphorylation of TFIIA has 
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been shown to stimulate the formation of TFIIA-TBP-TATA-element complex in 
vitro (Solow et al., 2001). 
In human, Drosophila, and yeast, TAF1 is able to acetylate lysines on histones 
H3 and H4 in vitro by its histone acetyltransferase (HAT) domain (Mizzen et al., 
1996). Subsequent studies showed that the β subunit of TFIIE and TFIIF can also be 
acetylated by TAF1 in vitro (Imhof et al., 1997). Since the acetylation level of lysines 
on histone tails is directly correlated to transcription activation (Strahl and Allis, 
2000), which is largely dependent on the compactness of chromatin structures, the 
acetyltransferase activity of TAF1 might contribute to TFIID’s role in modulating 
chromatin structures in order to increase the accessibility of general transcription 
machinery to corresponding promoters. The biological importance of TAF1’s 
acetyltransferase activity has been further confirmed by another study, in which the 
binding of TAF7 to TAF1’s HAT domain suppresses its enzymatic activity and leads 
to transcription inhibition of MHC class I genes (Gegonne et al., 2001). 
The ubiquitin-activating/conjugating activity of TAF1 has first been shown by 
the monoubiquitination of histone H1 by TAF1 in Drosophila (Pham and Sauer, 
2000). The monoubiquitination is mediated by the ubiquitin-activating (E1) domain 
and ubiquitin-conjugating (E2) domain in a sequential manner. Again, it is proposed 
that chromatin environment might be modified to facilitate transcription initiation by 
the monoubiquitination of histone H1, which binds linker DNA between adjunct 
nucleosomes and is important in stabilizing higher-order chromatin structure 
(Wassarman and Sauer, 2001; Luger et al., 2012). 
 
 
Figure 1.20: Enzymatic domains in a metazoan TAF1 protein (Wassarman 
and Sauer, 2001). Locations of enzymatic domains (N-terminal kinase domain 
(NTK), C-terminal kinase domain (CTK), histone acetyltransferase domain 
(HAT), and ubiquitin-activating/conjugating domain (E1/E2)) and bromodomains 
(Bromo) are indicated. Histone and GTF substrates for the enzymatic activities 
are indicated above the corresponding domains. The GTF substrates are 
abbreviated as follows: TFIIA (A), TFIIE (E), and TFIIF (F). 
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1.3.3 Structural elucidation of TFIID complexes shed lights on functional 
delineations 
 
With distinct activator/promoter-binding specificities and enzymatic activities, TBP 
and TAFs function collectively in the context of TFIID to regulate transcription 
initiation. Detailed structural information of its supramolecular assembly is 
indispensible to fully understand how TFIID subunits collaborate to form a stable 
molecular assembly, and target core promoter elements and protein factors 
cooperatively.  
The structures of immunopurified native TFIID (human, yeast, and S. pombe) 
have been reconstructed by single-particle EM analysis, revealing an overall 
horseshoe-like structure, in which a central cavity is formed by several bulky lobes 
connected via thinner linkers (Grob et al., 2006; Elmlund et al., 2009; Liu et al., 2009; 
Papai et al., 2009) (Fig. 1.21). TBP and some promoter-binding TAFs has been 
mapped at or near the central cavity by various immunolabelling experiments (Andel 
et al., 1999; Leurent et al., 2004; Papai et al., 2009) (see Fig. 1.19), indicating that 
TFIID might function like a molecular clamp by recognizing and accommodating 
core promoter elements within its central cavity. Furthermore, several systematic 
structural analyses have shown the flexibility of TFIID architecture, which could be 
important for TFIID’s ability to bind different promoters in which the distances 
between core promoter elements and enhancers vary from one to another (Grob et al., 
2006; Papai et al., 2009, 2011). 
Despite the common structural features conserved between TFIID from various 
species, their variances in size and lobe organization indicate that their subunit 
composition and functional assembly might be species specific, which is consistent 
with the facts that PHD finger in TAF3 and tandem double bromodomains in TAF1 
only exist in metazoans (Wassarman and Sauer, 2001; van Ingen et al., 2008; Papai et 
al., 2011). On the other hand, surprising differences, especially in size, have also been 
observed between two consecutive human TFIID EM models reconstructed by the 
same laboratories (Grob et al., 2006; Liu et al., 2009) (Fig. 1.21c, d), suggesting the 
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necessity for more strict control of sample preparation and maybe also EM data 
processing. 
 
 
Figure 1.21: TFIID EM models from different species. (a) A 23 Å cryo 
negative-stain EM model of native yeast TFIID (Papai et al., 2009). (b) A ~10 Å 
cryo-EM model of native S. pombe TFIID (Elmlund et al., 2009). (c) A ~40 Å 
cryo negative-stain EM model of native human TFIID (Liu et al., 2009). (d) A 32 
Å cryo-EM model of native human TFIID (Grob et al., 2006). The scale bar at 
top right represents 10 nm. 
 
Despite clues of its biological functions from structural studies of its overall 
shape, our current understanding of TFIID architecture and subunit assembly is still 
not comprehensive due to that atomic structures are only available for some TFIID 
subunit domains and the low resolution of EM models reconstructed from native 
TFIID, which exists in very low endogenous amount and is heterogeneous in its 
subunit composition in cells (Müller and Tora, 2004; Müller et al., 2010). Indeed, 
except the S. pombe TFIID EM model, the resolutions (~20-30 Å) of current human 
and yeast TFIID EM models (Grob et al., 2006; Papai et al., 2009) are not 
significantly improved comparing to resolutions (~30-35 Å) of the first human and 
yeast TFIID EM models generated a decade ago (Andel et al., 1999; Brand et al., 
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1999; Leurent et al., 2002). This strongly suggests that the quantity and homogeneity 
of these TFIID samples should be further improved in order to acquire EM models of 
higher resolution.  
To date, atomic models are only available for individual or interacting domains 
of TFIID subunits (Xie et al., 1996; Birck et al., 1998; Kotani et al., 1998; Jacobson et 
al., 2000; Werten et al., 2002; Romier et al., 2007). Although EM models of native 
human and yeast TFIID revealed their overall structural features, they cannot be used 
to fit the existing TBP or TAF atomic models unambiguously due to the low 
resolution (32Å for native human TFIID and 23 Å for native yeast TFIID) (Grob et 
al., 2006; Papai et al., 2009). Nonetheless, the approximate subunit compositions and 
locations in yeast TFIID have been determined by combining immunolabelling and 
EM mapping (Leurent et al., 2002, 2004; Papai et al., 2009). Additionally, the subunit 
stoichiometry of native yeast TFIID has also been roughly determined by analyzing 
the SDS-PAGE resolved TFIID subunits with scanning densitometry, showing that 
TAF4, 5, 6, 9, 10, 12 exist in two copies while the other TAFs are most likely to 
present as single copies (Sanders et al., 2002). 
Besides structural and biochemical experiments, homology alignments have 
also contributed to the identifications of conserved domains in TAFs, whose 
homology models were used for domain localization by structural fitting (Papai et al., 
2009, 2011). For example, histone fold domains (HFDs) have been identified in nine 
TAFs that form a set of defined heterodimers (TAF4-12, TAF6-9, TAF8-10, TAF11-
13, and TAF3-10), indicating their importance in maintaining the structural integrity 
of TFIID (Gangloff et al., 2001). Three conserved regions (the N-terminal LisH 
domain, the NTD2 domain, and six consecutive WD40 repeats at the C-terminus) in 
TAF5 and a TAF2 C-terminal fragment homologous to the leukotriene A4 hydrolase 
have also been identified (Papai et al., 2011). All these structural information have 
been combined to provide a primary overview of TFIID subunit assembly and 
composition in a recent review (Papai et al., 2011). 
Interestingly, besides the holo-TFIID containing TBP and a full set of TAFs, a 
number of stable TFIID core complexes composed of partial sets of TBP and TAFs 
have also been identified and reconstituted (Berger et al., 2004; Wright et al., 2006; 
Demény et al., 2007; Fitzgerald et al., 2007; Berger lab, unpublished data). Recently, 
high resolution cryo-EM structures of three recombinant human TFIID 
subcomoplexes, (3TAF, core-TFIID, and 7TAF; Fig. 1.22) were obtained by the 
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Berger laboratory in collaboration with the Schultz and Tora groups at the IGBMC, 
Strasbourg. The high quality of those structures reveal TFIID architecture in 
unprecedented detail, and allowed for assigning the locations of all conserved 
domains of TAF4, 5, 6, 8, 9, 10 and 12 unambiguously, revealing the two-fold 
symmetry in the TFIID core, consisting of TAF4, 5, 6, 9, 10, 12 which exist in two 
copies in endogenous TFIID. Furthermore, the structures demonstrate and explain 
how the symmetry of core-TFIID is broken upon incorporation of one TAF8/10 
complex, offering invaluable insights of the TFIID assembling pathway. 
 
Figure 1.22: Cryo-EM structures of 3TAF, core-TFIID and 7TAF complexes 
(Bieniossek, Papai, et al., manuscript in press 2012). The fitting of atomic 
coordinates and homology models (ribbons) and of the TAF4 N-terminal domain 
(solid shape) is shown within the density of each structure displayed as a mesh. 
 
Considering that not all the TAFs are required for transcription initiation based 
on TAF depletion or disruption experiments (Moqtaderi et al., 1996; Shen et al., 2003; 
Tatarakis et al., 2008), these TFIID core complexes might present and play a vital role 
for transcription regulation in vivo. 
In summary, previous genetic, biochemical and structural experiments have 
provided valuable insights on the structural and functional assembly of TFIID 
complexes from various species. However the structural elucidation of TFIID 
complexes are currently impeded by samples of insufficient quantity (barely in µg 
range) and the low quality and heterogeneity of the material purified from endogenous 
source. Recombinant overproduction of TFIID core complexes, and also the holo-
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TFIID containing TBP and a complete set of TAFs, is anticipated to greatly improve 
the production level and homogeneity of TFIID samples and facilitate the subsequent 
structural analysis for acquiring 3D models of high resolution, to which atomic 
models of TFIID subunits can be fitted unambiguously. Besides, recombinant 
technology would also enable modifying TFIID subunits (variation, mutation, 
truncation, adding localization tags, etc) individually or combinatorially in order to 
investigate their structural and functional importance in the context of TFIID 
complexes. 
As introduced in previous chapters, the ACEMBL and MultiBac systems, which 
feature in rapid, flexible and automatable assembly of genes encoding subunits of 
multiprotein complexes, are expected to be instrumental for such very challenging but 
also extremely rewarding structural biology projects, to illuminate their biological 
roles. 
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Résumé de la publication 
 
Ces dernières années, notre connaissance de l’organisation de la vie à énormément 
progressée. Des génomes entiers sont maintenant déchiffres à des vitesses et avec des 
précisions jamais égalées jusqu’alors, nous permettant ainsi d’avoir les fondations 
nécessaires à la reconstruction de tous le répertoire cellulaire, pour enfin comprendre 
tous les systèmes biologiques. Les avances techniques en bio-informatique et 
spectrométrie de masse ont révélées de multitude d’interaction au sein du protéome. 
Les complexes multi protéiques émergent comme étant la pierre angulaire de 
l’activité biologique, car beaucoup de protéines fonctionnent, de façon permanente ou 
non, en ensemble de sous-unités multiples. L’analyse de l’architecture de ces 
ensembles et leurs interactions est impérative pour la compréhension de leur fonction 
à l’échelle moléculaire. Les efforts en génomique structurale ont permis le 
développement de nombreuses technologies, dans le but d’atteindre le débit 
nécessaire, pour étudier l’assemblage ainsi que les interactions protéiques a haute 
résolution. Le changement de direction actuel vers les complexes multi protéiques, en 
particulier chez les eucaryotes, appel des à présent à un effort de concert dans le but 
de développer et d’apporter de nouvelles technologies dont le besoin urgent est requis 
pour produire en qualité et en quantité la pléthore d’ensemble multi protéique qui 
forme le complexe, et d’étudier en routine leur structure et leur fonction au niveau 
moléculaire. Les efforts actuels dans le but d’atteindre ces objectifs sont étudies et 
résumes dans cette contribution. 
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Abstract: We are witnessing tremendous advances in our understanding of the organization of life. Complete genomes 
are being deciphered with ever increasing speed and accuracy, thereby setting the stage for addressing the entire gene 
product repertoire of cells, towards understanding whole biological systems. Advances in bioinformatics and mass spec-
trometric techniques have revealed the multitude of interactions present in the proteome. Multiprotein complexes are 
emerging as a paramount cornerstone of biological activity, as many proteins appear to participate, stably or transiently, in 
large multisubunit assemblies. Analysis of the architecture of these assemblies and their manifold interactions is impera-
tive for understanding their function at the molecular level. Structural genomics efforts have fostered the development of 
many technologies towards achieving the throughput required for studying system-wide single proteins and small interac-
tion motifs at high resolution. The present shift in focus towards large multiprotein complexes, in particular in eukaryotes, 
now calls for a likewise concerted effort to develop and provide new technologies that are urgently required to produce in 
quality and quantity the plethora of multiprotein assemblies that form the complexome, and to routinely study their struc-
ture and function at the molecular level. Current efforts towards this objective are summarized and reviewed in this con-
tribution. 
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INTRODUCTION 
 Protein-protein interactions (PPIs) are intrinsic to virtu-
ally every essential process in the cell. Deciphering PPIs is 
imperative for understanding the underlying biological 
mechanisms of living systems. Cellular activities that govern 
health and disease, such as DNA replication, transcription, 
splicing, translation, secretion, cell cycle control, signal 
transduction and intermediary metabolism are controlled by 
PPIs [1-5]. New developments in sequencing technology in 
combination with advances in affinity purification tech-
niques and automation are presenting researchers with the 
opportunity to study the proteome of various organisms at an 
ever increasing pace. Genome-wide protein-protein interac-
tion studies involving affinity chromatography and mass 
spectrometry (MS) analyses of systematically tagged open 
reading frames (ORFs) have been developed and imple-
mented, aided by powerful bioinformatics approaches, to 
address the entirety of PPIs in cells.
 To date, many thousands of PPIs are known, however, 
the precise molecular details are available for only a small 
fraction of these interactions. Structure elucidation can ulti-
mately turn abstract system representations into models that 
more accurately reflect biological reality. The utility of struc-  
*Address correspondence to this author at the European Molecular Biology 
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teractions (UVHCI), UJF-EMBL-CNRS, UMR 5233, 6 rue Jules Horowitz, 
38042 Grenoble CEDEX 9, France; E-mail: iberger@embl.fr 
#These authors contributed equally. 
tural biology is to understand the mechanisms governing 
biological interactions in living systems for designing strate-
gies to modulate, and interfere with these interactions. How-
ever, the large and increasing body of data describing PPIs 
on a genome-wide scale, and the pace at which it is amassed, 
is currently at a pronounced disparity with the rate at which 
the structure and function of representative protein com-
plexes that comprise the identified interactions, are described 
at the molecular level. Despite considerable advances in con-
temporary structure determination techniques and significant 
efforts by structural genomics consortia to streamline the 
process leading to high-resolution structures, many bottle-
necks in the structure determination pipeline remain.  
 Protein complexes are often found in scarce amounts in 
their endogenous host and remain difficult to isolate in the 
quantity and quality required for detailed functional and 
structural analysis. This is often the case already for electron 
microscopy experiments, although the requirements of this 
technique in terms of sample quantity are typically less im-
posing as compared to studies for example by X-ray crystal-
lography or by nuclear magnetic resonance (NMR) spectros-
copy. The latter two are the currently most powerful and 
widely used techniques for providing high-resolution struc-
tural information. Multiplexed overexpression experiments 
by using advanced recombinant production technologies 
could be instrumental not only for overcoming the sample 
production bottleneck, but also for compellingly validating 
proposed interactions in a heterologous setup. Streamlined 
high-throughput technologies for production of multisubunit
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protein complexes, however, have been utterly lacking to 
date. New developments are required to rapidly and repro-
ducibly construct large protein complexes and variations 
thereof at the rate that they are conceptualized from genome-
wide studies.  
DECIPHERING THE INTERACTOME 
 In recent years, new and powerful methods have been 
developed which allow complex cellular protein-protein in-
teraction networks to be mapped (Fig. (1)). Such techniques 
have produced a wealth of data and have given rise to a new 
Fig. (1). Interactomics. Recent technological advances in genome-wide methods enable researchers to address protein-protein interactions 
present in the proteome of organisms in a comprehensive fashion, thus giving rise to the interactome. Native purification of proteins present 
in organelles and entire cells by using tandem affinity purification (TAP) methods, Strep-protein interaction experiment (SPINE) and trans-
genomics involving bacterial artificial chromosomes for generating stable mammalian cell lines, as well as protein-protein screens by yeast 
two-hybrid (Y2H) methods are supported by bioinformatics analyses, and together provide a (growing) picture of the interactome as a com-
plex mixture of multiprotein assemblies. Mass spectrometry (MS) based proteomic methods including matrix-assisted laser desorption ioni-
zation (MALDI) and electro-spray ionization (ESI) techniques coupled to liquid chromatography (LC-MS) and tandem MS-MS measure-
ments add to the catalogue of tools employed to tackle the complexome. The link between ineractome research and structural biology is 
made by native mass spectrometry. Native MS can provide vital information about the structure, topology and architecture of protein 
complexes preserved in the gaseous phase. Ion mobility separation coupled to mass spectrometry (IM-MS) and collision induced dissociation 
(CID) are new approaches holding particular promise for characterizing the properties and composition of even very large protein complexes. 
Recombinant overproduction, functional characterization and eventually 3-D structure determination can help to validate the vast amounts of 
interactome data from recent systems biology efforts. Multiplexed and quantitative MS methods in conjunction with limited proteolysis may 
become critically important to elucidate variants of recombinantly overproduced multiprotein complexes amenable to high-resolution struc-
tural and functional analysis. Combinatorial multigene generation, parallel small-scale expression and biochemical and biophysical analysis 
of multiprotein complexes derived from interactome data constitute likely modules of a conceptual “complexomics“ pipeline in analogy to 
current structural genomics approaches, leading to routine and rapid elucidation of the molecular architecture of many complexes and their 
subunit components by X-ray diffraction analysis, electron microscopy and NMR spectroscopy. 
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sphere of research designated “interactomics”. The term “in-
teractome” is used to describe all known interactions present 
in the cellular gene product repertoire [6].  
Purification from Native Source 
 A celebrated development in high-throughput identifica-
tion of protein complexes is the tandem affinity purification 
(TAP) method [7]. In this approach endogenously tagged 
proteins of interest are produced which are used as bait to 
fish out interacting partners. The original TAP tag comprises 
two affinity tags: the Z-domain of protein A, which binds to 
immunoglobulin G (IgG), and calmodulin-binding peptide 
(CBP), which binds to calmodulin. These two tags are sepa-
rated by the highly specific tobacco etch virus (TEV) prote-
ase site. TAP tagging involves a relatively mild extraction 
procedure in which protein complexes are purified via a two-
step process that yields intact protein complexes composed 
of the tagged bait and any associated partners. This method 
is particularly useful for detecting stable complexes; more 
transient complexes are not observed, as they tend to disso-
ciate during purification. Two major proteome-wide studies 
in S. cerevisiae using the TAP method have revealed many 
previously unknown protein interactions and pathway asso-
ciations [8, 9]. In one study, Gavin et al. TAP-tagged 6406 
ORFs from the S. cerevisiae genome which enabled the puri-
fication of 1993 tagged proteins and the identification of 491 
protein complexes [8]. In an independent study, Krogan et
al. TAP-tagged 4562 ORFs from the yeast proteome. 2357 
of these TAP-tagged proteins were purified revealing 547 
complexes as well as 429 interactions between complexes 
[9]. In both of these extensive studies affinity tags were in-
troduced into the 3’ ends of target ORFs in the yeast chro-
mosome by homologous recombination. Data generated 
from these surveys correlated well with known protein com-
plexes formerly discovered and studied by conventional 
means. More notably, new interaction partners of well-
known complexes were identified, as well as entirely novel 
complexes and associations.  
 Methods to optimize the TAP tagging strategy are under 
way in an effort to obtain larger quantities of tagged protein 
assemblies. One of the challenges of the TAP method is to 
gain insight into the more fleeting interactions present in a 
protein complex. Herzberg et al. have developed a Strep-
protein interaction experiment (SPINE) that deals with the 
inherent false positives otherwise found in TAP tagging ex-
periments [10]. By replacing the TAP tag with a strongly 
interacting variant of Streptavidin called Strep-tactin and 
employing a reversible cross-linking reagent, Herzberg et al.
were able to get an in vivo snap-shot of bait interactors in B.
subtilis in a single affinity purification step.
 In the years since the pioneering initial glimpses into the 
yeast interactome, subsequent affinity purification studies 
have sought to shed light on the interactomes of multicellular 
organism. Multicellular organisms are generally less amena-
ble to TAP-tagging approaches due to the challenge of using 
homologous recombination to insert affinity tags and the 
difficulties in retrieving sufficient quantities of purified ma-
terial. Nevertheless, Cheeseman et al. described a procedure 
using the TAP tagging principle to purify protein complexes 
from C. elegans strains and cultivated HeLa cells [11]. By 
modifying the TAP tag to include green fluorescent protein 
(GFP) followed by the Z-domain of protein G instead of pro-
tein A, and by replacing the CBP-tag with streptavidin pep-
tide, this study revealed intact complexes involved in C. ele-
gans kinetochore formation. 
 Furthermore, Burckstummer et al. overcame the problem 
of low protein yields in TAP tagging experiments in mam-
malian systems by likewise altering the composition of the 
TAP tag [12]. They also replaced the IgG peptides of Protein 
A with those of Protein G and the CBP peptide with strep-
tavidin peptide. Using IKK? with this modified TAP tag as 
bait resulted in a ten-fold increase not only in the amount of 
bait but also of its interacting partner, IKK?. These ad-
vancements in affinity purification techniques promise to 
allow future interactome maps of cultivated human cell lines 
to be determined, as well as maps of other cell types that are 
inherently more difficult to cultivate in large quantities, such 
as neuronal cells and immune cells. By tweaking certain as-
pects of existing purification strategies, such as modifying 
the original TAP tag itself, high-throughput interactome 
maps are moving into the realm of mammalian systems. 
 An interesting approach called BAC TransgeneOmics 
was recently described as a tool for studying protein-protein 
and protein-DNA interactions in addition to protein localiza-
tion [13]. BAC TansgeneOmics describes a method by 
which all known proteins within a proteome of a given orga-
nism are tagged on a genome-wide scale. Using this recom-
binantly tagged genome to create a bacterial artificial chro-
mosome (BAC) library ensures the presence of native regu-
latory regions around the target gene. BACs containing the 
recombinantly tagged genes of interest are then sequentially 
transfected and expressed in mammalian cells. The tags con-
sist of a combination of fluorescent proteins and peptides for 
affinity purification and reporting on factors such as in vivo 
protein localization and endogenous protein interactions. 
Interaction Analysis by Yeast Two-Hybrid Screens 
 Another powerful method for generating interactome 
maps in a high-throughput manner is the yeast two-hybrid 
(Y2H) approach [14]. Interactome-wide binary interaction 
maps resulting from Y2H screens are generally regarded as 
low-coverage studies, noisy and containing a high likelihood 
of false positives. In an attempt to systematically map inte-
ractome networks from Y2H screens, Venkatesan et al. esti-
mate that only 8% of the full human interactome has been 
covered by Y2H screens [15]. However, these surveys conti-
nue to provide a useful concomitant view of the whole inte-
ractome when considered alongside other affinity purificati-
on/MS-based techniques [5]. Y2H screens report on whether 
or not two proteins interact by fusing to a target protein the 
DNA binding domain (DBD) of a transcription factor while 
potential binding partners are fused to an activation domain. 
Any interaction between the two target proteins leads to the 
expression of a reporter gene [16]. There are three common-
ly used high-throughput Y2H screening approaches: (1) the 
yeast mating approach in which haploid DBD strains and 
strains with the activation domains undergo mating and se-
lection for reporter expression; (2) the matrix approach, whe-
re DBD strains can be mated with an array of strains contai-
ning activation domains; and (3) the library approach, which 
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involves the mating of individual DBD strains with a library 
of activation domain strains that represents a cDNA library 
of a given target organism [5]. The latter method is the most 
efficient for high-throughput studies, however, the sampling 
efficiency of individual DBD strains with entire cDNA libra-
ries is greatly reduced.  
 While the Y2H strategy has the capacity to meet the de-
mands of high-throughput interactome mapping, this appro-
ach cannot currently compete with affinity based methods in 
terms of genome coverage. Nonetheless, Y2H surveys have 
realized a rich source of high-quality binary interaction maps 
from a wide range of organisms, including viruses, bacteria 
[17], S. cerevisiae [14, 18, 19], D. melanogaster [2], C. ele-
gans [20-22] and humans [4, 23, 24]. It is also important to 
note that while Y2H screens are critisized for inherent prob-
lems concerning the overexpression of homologous genes, 
the post-translational modification machinery and a bias to-
wards interactions that occur in the nucleus, this approach 
can examine a different subspace of the protein interaction 
world to that sampled by affinity/MS methods. Together, 
both sources of interactome mapping provide a more 
comprehensive outlook of the whole interactome. 
 Two valuable high-throughput Y2H human PPI maps 
were generated by Stelzl et al. [24] and Rual et al. [4]. These 
independent studies both utlized the matrix approach to a-
chieve greatest possible coverage of the human genome and 
between them identified approximately 6000 binary protein 
interactions. In the Stelzl study, where 4456 baits and 5632 
preys were screened, 195 disease related genes were found to 
interact with previously unidentified partners. Furthermore, 
342 uncharacterized proteins were assigned new putative 
roles after being found to interact with a protein of known 
function. In total, new functions were assigned to hundreds 
of different proteins. In a comparable effort, Rual and col-
leagues looked for binary interactions between approximate-
ly 8100 ORF’s and detected approximately 2800 protein 
associations. These interactions were then correlated with 
independant co-affinity purifications which revealed an over-
lap of approximately 78%. Despite the impact these Y2H 
screens have made in the field of interactomics, further deve-
lopments are still required before they reach the coverage 
achieved by affinity methods. The impact of these studies 
will surely propel the current technology in Y2H to new 
heights. 
 In a recent high-quality yeast binary protein interaction 
study, Yu et al. have attempted to deal with a long standing 
criticism that Y2H screens are biased towards interactions 
that occur within the nucleus [25]. To counter this concern, 
Yu et al. performed a Y2H screen in parallel with a yellow 
flourescent protein complementation assay (PCA) in which 
the traditional bait and prey peptides are replaced with non-
flourescing halves of yellow fluorescent protein (YFP). Once 
the interacting partners are in close proximity, the fluores-
cent properties of YFP are reconstituted and thereby create a 
useful marker that is not limited to reporting on interactions 
that occur within the nucleus. Using their dual method, Yu  
et al. were able to validate their own results, which showed a 
greater degree of correlation than that shown between the 
Gavin and Krogan TAP studies. Y2H screens are certainly 
becoming a valuable tool for studying genome-wide protein 
ineractions and will likely continue to make major contribu-
tions to the field of interactomics. 
Computational Approaches  
 Results from high-throughput interactome studies are 
being tabulated with increasing clarity. These efforts are 
resulting in unprecedented amounts of potentially useful data 
for molecular and structural biologists. On the bioinformatics 
side, the major hurdles in analyzing high-throughput interac-
tome data sets include managing databases, creating useful 
clustering algorithms to glean valuable information about 
protein interactions, and using the resulting clustering to 
make predictions about biological systems. Results from 
combined genome-wide interaction studies may contain only 
partially overlapping datasets, false positives (interactions 
that should not normally occur in a cell) and false negatives 
(limited or biased coverage that excludes a true interaction). 
Such issues hamper a comprehensive portrayal of protein 
networking [26]. Today’s bioinformatician faces many chal-
lenges in the emerging field of interactomics. What follows 
is an overview of what challenges are being faced currently 
and those that are on the horizon that will undoubtedly con-
tinue to be a boon for structural biologists in search of com-
plex three dimensional (3-D) structures.  
 Considering that each genome-wide interactome study  
generates characteristic data and that each existing repository  
uses characteristic file formats for storing data, the challenge  
of creating a consolidated resource for a transparent flow of  
data between datasets is startling. The Molecular Interactions  
(MI) group of the Proteomics Standards Initiative (PSI) has  
created an international standard for representing protein  
interaction data by consolidating existing interactome data  
sets from individually curated databases to create the Inter- 
national Molecular Interaction Exchange consortium (IMEx)  
[27]. The consortium, to date, includes the following data- 
bases: DIP (http://dip.doe-mbi.ucla.edu), IntAct (http://www.  
ebi.ac.uk/intact), MINT (http://mint.bio.uniroma2.it/mint),  
MPact (http://mips.gsf.de/genre/proj/mpact), MatrixDB  
(http://www.matrixdb.ibcp.fr), BioGRID (http://www.the- 
biogrid.org), MPIDB (http://www.jcvi.org/mpidb) and BIND  
(http://www.blueprint.org). Alongside IMEx is MIMIx, the  
minimum information required for reporting a molecular  
interaction experiment. MIMIx tackles the lack of commu- 
nity consensus on what information is required to report mo- 
lecular interaction by setting up an international standard to  
facilitate the extraction of useable data from PPI experiments  
by users. Currently, data is exchanged in XML format.  
 A major challenge concerning interactome datasets is 
how to cluster the resulting interactions to accurately report 
on real protein complexes rather than spurious, or false posi-
tive interactions while including more transient members of 
protein complexes rather than only architectural ones. Based 
on the Gavin, Krogan and Ho studies, Hart et al. used an 
unsupervised probabilistic scoring scheme and assigned con-
fidence scores to each interaction. This approach generated a 
matrix-model interpretation of the yeast interactome datasets 
[28]. Unsatisfied with the existing spoke model as a way of 
representing interactome data which only considers bait and 
prey interactions, Hart and colleagues devised a scoring 
method to hone the matrix model which additionally also 
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takes prey/prey interactions into account, thereby including 
the elusive transient members of complexes without decreas-
ing the overall accuracy of reported complexes. In doing so, 
it was shown that the degree of overlap between the reported 
datasets was considerably higher than previously thought, 
and that one of the major problems in previous comparisons 
was the inclusion of ribosomal protein interactions. Based on 
assessments of similarity between the above mentioned 
datasets and with a third yeast interactome dataset [9], Hart 
et al. suggested that these studies are approaching saturation 
of what can be known about the subset of the complexome 
of yeast grown in rich media. Recently, Krogan indicated 
that a rough calculation based on the overlap of the two stud-
ies suggests that approximately 80% of the interactions ca-
pable of detection in yeast by the TAP method have been 
detected [29]. 
 Another consequence of the upsurge in PPI maps and 
genome-wide sequencing efforts is the new wealth of data 
that can be used by the community of scientists who model 
protein interactions and predict protein function from the 
gene sequence. With the ever increasing amounts of data 
about PPIs, it is possible to identify recurring ‘domain signa-
tures’ and to correlate frequent interactions between them, 
the idea being that the interaction may be mediated by the 
signature sequence [30]. Knowledge about where an interac-
tion might occur can also narrow down which portions of a 
protein sequence should be included in designing protein 
complex constructs [31]. 
Mass Spectrometry 
 Mass spectrometry (MS) has emerged as an indispen-
sable tool for studying the interactome [32, 33]. MS is now 
firmly established as one of the main driving forces of prote-
ome studies, and is increasingly the method of choice for 
analyzing complex protein mixtures derived from entire 
cells. Besides protein identification, quantification and profi-
ling, MS has had a significant impact on the analysis of pro-
tein interactions and protein complexes [32]. Combining 
affinity purification with MS allowed a de novo characteriza-
tion of the composition and organization of the cellular ma-
chinery. Data derived from these methods indicated that 
complexes can combine transiently and differentially in a 
modular fashion thus enabling a diversification of the poten-
tial function of individual protein complexes [8]. MS-based 
interactome analysis approaches, using a variety of techni-
ques including matrix-assisted laser desoprtion/ionization 
(MALDI) and liquid-chromatography coupled electro-spray 
ionization (LC-MS), offer several important advantages for 
studying protein complexes as compared to other techniques. 
A protein complex can be isolated directly from its cellular 
environment, fully processed with its full complement of 
modifications and directly studied by MS without the need 
for further manipulations [34]. MS based methods can readi-
ly detect stable interactions which constitute core architectu-
res of protein complexes. Implementation of chemical cross-
linking strategies in MS experiments further offers possibili-
ties to detect and analyze important transient interactions 
[35]. A key issue is the analysis of the vast amount of data 
gathered in MS-based proteome and interactome analysis. 
Progress is being made in developing tools for analyzing 
MS-data based on statistical principles [36, 37]. 
 MS experiments can likewise be used to obtain invento-
ries of biochemically isolated organelles allowing for the 
characterization of sub-interactomes contained within sub-
cellular compartments. High-resolution methods were ap-
plied for accurate protein identification and novel algorithms 
were developed to assign genuine components from co-
purifying proteins in these experiments [38]. This holds par-
ticular promise for accessing the protein repertoire and 
complexome of such cellular subcompartments by high-
resolution structural and functional studies. 
 MS based interactome wide studies are often met with 
skepticism concerning the reproducibility of results [39]. The 
Test Sample working group of the Human Proteome Organi-
zation (HUPO), who have an interest in establishing interna-
tional standards for proteomics studies, attempted to address 
the question of irreproducibility in MS experiments. The 
working group provided a defined test sample containing an 
equimolar mixture of highly purified recombinant proteins to 
27 different laboratories using high-throughput MS methods 
to test their ability to correctly identify the mixture [40]. The 
results were that, initially, only a quarter of the laboratories 
correctly identified the protein mixture. However, upon clo-
ser inspection of each laboratory‘s raw data, it became appa-
rent that the peptides had in fact been identified in every case 
and that the problem arose in environmental contamination 
of the sample, incorrect database matching and poor curation 
of proteins identified. In summary, this study exemplified 
that reproducibility in MS experiments can be achieved by 
carrying out the MS experiments with care and by upgrading 
existing databases for their curation [39, 40]. 
 The link between interactome research and structural 
biology is made by native mass sepctrometry of large protein 
assemblies, an emerging, very promising technology. Native 
mass spectrometry techniques allow sensitive analyses of 
endogenously expressed protein complexes with high speed 
and selectivity [41, 42]. Importantly, native MS can provide 
vital information about the structure, topology and architec-
ture of protein complexes. Protein complexes in native MS 
experiments are prevented from disassociating in the gaseous 
phase during electro-spray ionization (ESI). Additionally, 
nanoflow ES (nano-ES) is employed for improved resolution 
of the sample being studied thereby improving the sensitivity 
of native MS [40]. High-perfomance mass analyzers, such as 
orthogonal ESI-time of flight (TOF) instruments, can be u-
sed to accurately identify ions with a high mass-to-charge 
ratio, a prerequisite for analyzing large protein complexes 
with many subunits by native MS [42]. Tandem MS-MS 
methods, usually used in proteomics experiments to deduce 
the amino acid sequences of small peptides, can be applied 
to native MS to gather information about the subunits pre-
sent in a protein complex [40]. Apparently, peripheral subu-
nits are preferentially eliminated in this setup, thus allowing 
interpretation of the topology of the complexes analyzed.  
 A recent technological advance is ion mobility seperation 
coupled to mass spectrometry (IM-MS), which has been par-
ticulary useful to establish mass spectrometry as a powerful 
tool for structural biology applications [41, 43]. In IM-MS, 
ions are separated on the basis of their mass-to-charge ratio 
and as well on their drift time in a gas-filled ion mobility 
chamber. The drift time depends on the cross-section of the 
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molecule, with larger molecules exhibiting longer drift-
times, thus allowing determination of the average projection 
area of a specimen studied. It is conceivable that this techni-
que will mature into a tool that will be routinely used to 
measure the cross-section of large protein complexes, which 
could be rather useful for providing volume constraints that 
can be utilized in molecular modelling of these assemblies 
[43]. 
 Requiring relatively small amounts of protein sample 
compared to other MS techniques, nanoelectro-spray ioniza-
tion can achieve the maintenance of a solution structure in 
the gas phase. Using collision-induced dissociation (CID), 
even very large protein complexes can be selectively disso-
ciated by collision with neutral gas atoms. Each collision 
event results in the accumulation of internal energy by the 
ion in question. Upon accumulation of sufficient internal 
energy, this ion may undergo dissociation. This approach can 
be used to dissociate protein complexes into subcomplexes 
and subunits which are then analyzed with TOF instruments. 
CID has been used to analyze virus capsids and entire ribo-
somes with a molecular mass of 2.5 MDa [44]. The complete 
subunit architecture of the yeast exosome, the protein ma-
chine which degrades RNA in yeast, could be correctly as-
signed using CID [45]. Furthermore, subcomplexes and pe-
ripheral subunits of human elongation factor elF3 could be 
identified by using this method [46, 47]. 
IMPACT OF STRUCTURAL GENOMICS 
 The description of the 3-D structure of biological mac-
romolecules, at near-atomic resolution, is imperative for un-
derstanding their function at the molecular level. The eluci-
dation of the DNA sequence of the entire genome of many 
organisms, including humans, revealed the gene repertoire 
present in cells. This set the stage to address the proteome, 
which is the comprehensive assemblage of all known gene 
products in an organism. The elucidation of the 3-D structure 
of all encoded proteins, at high resolution, is the goal of 
structural genomics efforts. Structural genomics aims at 
building up a high-resolution library dedicated to catalogu-
ing the protein complement of different organisms via high-
throughput and automated approaches starting from molecu-
lar cloning of the genes to structure elucidation of the en-
coded proteins. Based on structures deposited in the Protein 
Data Bank (PDB), structure determination by single crystal 
X-ray diffraction analysis is currently the predominantly 
used technique, in addition to structure determination in so-
lution by NMR. By means of comparison with structures of 
well-characterized proteins and domains, the biological func-
tion of uncharacterized proteins can often be discovered or 
proposed. Until the beginning of 2008, the combined effort 
from structural genomics consortia worldwide contributed 
about 50% of the newly-deposited structures in the PDB. 
One of the largest structural genomic projects is the Project 
Structure Initiative (PSI) in the United States, which is spon-
sored by the National Institute of Health (NIH). Several 
other large consortia exist in Japan, Canada, and Europe 
[48]. 
 In addition to the very large number of structures to be 
elucidated for describing a proteome, structural genomics 
approaches were confronted with a multitude of challenges. 
Successful structural determination by X-ray crystallography 
typically requires iterative optimization of protein encoding 
sequences for expression and purification of the specimens. 
Several to many expression vectors, host organisms and host 
strains need to be integrated into the experimental work-
flow, in addition to covering a large space of conditions suit-
able for crystallization. All steps involved require consider-
able investment in labor and materials and a very significant 
through-put of experiments. Entire proteomes are addressed 
most often at the single protein or protein domain level. 
Consequently, structural genomics intensively stimulated 
and fostered the implementation of automation and high-
throughput approaches, which now result also in consider-
able benefit for classical, hypothesis driven structural mo-
lecular biology. Many laboratories are now in the process of 
integrating high-throughput approaches at varying levels in 
their research [49].  
 Structural genomics projects generally start from target 
selection, which is based on evaluation of a large amount of 
candidate genes via bioinformatics methods. This is followed 
by cloning, insertion in one or several expression vectors, 
expression and purification, and finally structure determina-
tion. Researchers at centers engaged in structural genomics 
integrated automated cloning strategies based on restric-
tion/ligation [50, 51], ligation-independent cloning [52, 53], 
or recombination [54, 55]. Among them, recombination 
based cloning systems are most widely utilized in high-
throughput experiments. Although the systems used cur-
rently are robust and can be automated, they are often not 
sufficiently flexible when variations of expression elements 
such as purification tags, promoter/terminator combinations, 
protease cleavage sites and others need to be introduced or 
modified [49].  
 Autoinduction procedures were found to be particularly 
useful for automated high-throughput approaches for expres-
sion of the target specimens in E. coli as expression host. 
Autoinduction is based on a defined medium containing 
glycerol, glucose and lactose as inducer, which makes use of 
promoters containing lac operators. Glucose prevents induc-
tion by lactose until it is consumed. Upon glucose depletion 
in the culture, lactose is metabolized and heterologous induc-
tion occurs by means of the lac operator. Autoinduction thus 
simplifies the expression procedure: it alleviates the re-
quirement for monitoring the density of cell cultures, as glu-
cose depletion auto-regulates the time of induction. Further, 
auto-induction does not require the addition of inducer 
chemicals facilitating means for automation [56]. 
 Increasingly, cell-free (CF) protein synthesis methods 
emerge as a viable alternative to in vivo expression in struc-
tural genomics pipelines due to several advantages [57]. Pro-
teins that are toxic to host cells can be expressed by CF ex-
pression, and CF expression, in principle, can be better con-
trolled by using highly purified components [58]. CF expres-
sion is especially useful for structure determination by NMR 
spectroscopy, since it is performed in small volumes and 
therefore requires less isotope label than cellular protein la-
beling [48, 57]. CF methods may be particularly useful for 
efficient screening of detergents required for successful pro-
duction for membrane proteins [59], and may also allow 
rapid, small volume parallel screening of many variants of a 
target protein [60].  
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 Many particularly exciting targets in the proteome will 
require expression in eukaryotic systems. Baculovirus ex-
pression vector systems (BEVS) increasingly become the 
method of choice for many of these targets. While consider-
able effort is being invested into automation and high-
throughput protein expression by using BEVS [61-63], con-
trolled virus generation in sufficient quantity and quality 
remains a challenge with currently available BEVS tech-
nologies [61]. Transient transfection of plasmid DNA into 
the nucleus of insect cells was suggested as a possible, eco-
nomic alternative for analytical screening prior to larger 
scale virus generation [61].  
 Hierarchal multiplex expression and purification strate-
gies utilized by the core Protein Production Platform of the 
Northeast Structural Genomics Consortium (NESG), foster 
an increase in the production of protein samples and also the 
solution of many 3-D protein structures [55]. Initiatives are 
ongoing to set up productive modules for target sampling, 
cloning, sample characterization and crystallization, arranged 
into fully integrated pipelines [64]. Since compact globular 
domains defined by limited proteolysis are good candidates 
for production of diffraction quality crystals, high-
throughput limited proteolysis/mass spectrometry ap-
proaches for protein domain elucidation are being included 
into such pipelines, providing precise definition of domain 
boundaries, with significant impact for success prospects 
[65].  
 Structural genomics has decisively accelerated automa-
tion and the development of robust high-throughput meth-
ods. Nonetheless, critics claim that structural genomics con-
sortia have gone after the “low-hanging fruit”, such as solu-
ble single proteins of prokaryotic origin which are compara-
tively easy to express and purify [66]. Actually, structural 
genomics efforts now are gradually moving to address more 
challenging target proteins of eukaryotic origin. The objec-
tive is to facilitate the structural determination of human 
proteins, integral membrane proteins, and eventually multi-
protein complexes [48]. However, the currently implemented 
approaches for automation and high-throughput methods 
cannot easily accommodate the upgrade required to address, 
in particular, large and complex multicomponent systems. 
The automation currently implemented in cloning routines 
and expression systems are mainly designed for addressing 
single ORFs or small, mostly binary systems [67].  
EUKARYOTIC MULTIPROTEIN EXPRESSION: 
MULTIBAC 
 The interactome can not be rationalized on the basis of 
elucidating single protein structures. It is now increasingly 
clear that the proteins in the cell function as interlocking 
machines containing ten or more interaction partners, that 
associate stably or transiently to realize cellular activities [1]. 
Structural genomics efforts have provided a wealth of detail 
on the level of individual proteins and domains. To address 
the more complex challenge of multicomponent assemblies, 
a number of expression systems have been introduced, that 
are suitable for simultaneous expression of several genes in 
prokaryotic and eukaryotic hosts [68-72]. In spite of consid-
erable improvements of eukaryotic expression systems, E.  
coli still remains to date the expression system of choice in 
most laboratories. Nonetheless, eukaryotic expression is also 
being implemented for production of samples that can not be 
produced in E. coli. In particular the baculovirus/insect cell 
system has been streamlined significantly, and detailed pro-
tocols have become available that considerably simplify 
handling, thus alleviating some of the uncertainties regarding 
this system that impeded its routine application by non-
specialist users [70, 73, 74].  
 Our laboratory has contributed to some of these devel-
opments, with particular focus on the production of mul-
ticomponent protein complexes for structural biology appli-
cations. We are interested in the structural molecular biology 
of eukaryotic complexes. For recombinant overproduction of 
these complexes, a system for multiprotein expression in 
insect cells, called MultiBac, was introduced [70, 73] (Fig. 
(2)). MultiBac uses an engineered deletion baculovirus with 
improved protein production properties including reduced 
proteolysis and a delayed onset of cell fragmentation in the 
late phase of viral infection [73]. This MultiBac baculovirus 
is accessed by two plasmids called transfer vectors at two 
recombination sites present on the virus: a LoxP imperfect 
inverted repeat for site-specific recombination, and a Tn7 
attachment site. The Tn7 attachment site is embedded in a 
LacZ? gene for blue-white selection of recombinant bacu-
loviruses. These transfer vectors harbour the heterologous 
genes of interest. The MultiBac baculovirus exists as a BAC 
in E. coli cells containing also a small plasmid with four 
genes encoding for the Tn7 transposon, similar to the widely 
utilized Bac-to-Bac system from Invitrogen, and essentially 
all other baculovirus systems that rely on Tn7 transposition 
of a transfer vector in vivo in an E. coli host strain.  
 The transfer vectors that we developed for MultiBac con-
tained elements that made it particularly straight forward to 
arrange into multigene expression cassettes several to many 
expression units containing ORFs encoding for example for 
members of a protein complex of choice. One transfer vector 
was designed to provide these multigene cassettes between 
Tn7L and Tn7R DNA sequences for integration into the Tn7 
site of the MultiBac baculovirus. A second transfer vector 
contained a LoxP sequence thus enabling integration of 
multigene cassettes into the LoxP site of the MultiBac virus 
in the presence of Cre recombinase, the enzyme responsible 
for fusing DNA pieces that contain the imperfect inverted 
repeat. Integration into the LoxP and Tn7 site could be car-
ried out simultaneously by co-transfecting the two transfer 
vectors into E. coli cells harboring the MultiBac virus, and 
expressing Tn7 transposon and Cre recombinase, respec-
tively, from helper plasmids [73]. Selection for recombinant 
MultiBac viruses harboring the multigene cargo occurred via 
blue/white selection and antibiotic challenge for the resis-
tance marker contained in the plasmid incorporated into the 
virus by Cre-LoxP fusion (Fig. (2)).  
 The MultiBac system as conceived in 2004 was surpris-
ingly well received in the community, probably indicating 
the present and growing interest in researching eukaryotic 
interactomes and multiprotein complexes. Many laboratories 
requested the MultiBac reagents, many proteins were ex-
pressed, and X-ray crystal structures based on specimens 
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Fig. (2). MultiBac BEVS: Eukaryotic multiprotein expression. ORFs (a-e) encoding for subunits of a protein complex and auxiliary pro-
tein such as modifiers or chaperones, are inserted into a plasmid containing the sequences required for Tn7 transposition (Tn7L, Tn7R), or a 
plasmid containing a LoxP imperfect inverted repeat, respectively. Gene insertion occurs via a multiplication module (small rectangles) de-
signed for facilitating multigene cassette generation. A baculovirus genome containing the Tn7 attachment site (attn7) and a LoxP sequence, 
in addition to deletions beneficial for protein production, is present in bacterial cells in form of a bacterial artificial chromosome (BAC). Inte-
gration of multigene expression cassettes is mediated by the Tn7 transposon and Cre recombinase, respectively, which are expressed from 
helper vectors in the bacteria [73]. Transfection of insect cells with the resulting composite baculovirus results in high-level expression of the 
proteins in cultured insect cells. Adapted from [95].
produced by MultiBac are now being reported [75, 76]. In-
terestingly, our baculovirus expression technologies were not 
only used successfully for protein complex production for 
structural biology as they were designed for, but also for 
rather diverse other applications ranging from production of 
possible vaccine candidates based on papilloma virus like 
particles [77] to preparing recombinant adenoviruses for 
gene therapy treatment of obesity in laboratory rodents [78]. 
 In our view, the genuinely useful contribution in conjunc-
tion with MultiBac, was not only the creation of yet another 
baculovirus and a few transfer vectors. We had realized in 
the process of our experimental work that the parameters of 
virus generation are not really compatible with routine appli-
cation of an expression method in laboratories focusing on 
structural analysis. Baculovirus expression is constrained by 
certain requirements that need to be met to assure that the 
recombinant DNA cargo is properly maintained in the bacu-
loviral genome during virus amplification and eventually 
protein production [79-81]. We found that introducing a 
fluorescent marker gene into the virus backbone, and pre-
cisely monitoring fluorescence intensity as well as the cell 
growth development in a culture, provided a very useful and 
simple regimen to largely alleviate the detrimental loss of 
titer or loss of protein production which are the major im-
pediments encountered when using BEVS. This allowed us 
to establish a robust protocol for virus generation, amplifica-
tion and protein production which then could be applied rou-
tinely and successfully in our laboratory and many others 
including non-specialist users [74]. We feel that BEVS ex-
pression, by using these protocols, can now be performed 
with almost the same ease and effort, as heterologous ex-
pression is commonly carried out in E. coli.
ACEMBLING MULTIPROTEIN COMPLEXES 
 The combination of many genes encoding for subunits of 
a protein complex into vectors used for expression will re-
main a rather laborious task, in particular if it relies on re-
striction digestion and pasting together of DNA fragments by 
ligase in a serial, one-gene-at-a-time mode. This approach is 
essentially refractory to automation. Structural genomics 
consortia have strived to address the problem by implement-
ing recombination methods for gene insertion. These meth-
ods have the advantage that they always use the very same 
reagents and reaction conditions, and therefore can be 
scripted into a robotics routine. The emphasis of most sys-
tems currently was mainly placed on offering a multitude of 
expression options for the one ORF of choice. For instance, 
the Gateway system from Invitrogen, defines an Entry vector 
for the gene of interest, which is inserted by any suitable 
means. This Entry vector is then used to introduce this gene 
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into a wide range of Destination vectors providing a large 
assortment of purification or solubility tags for expression in 
a variety of hosts. The situation presents itself in reverse for 
multiprotein complex expression: here, the challenge is to 
introduce an assortment of genes into probably one expres-
sion system of choice to start with. This needs to be achieved 
in a way that ideally, the genes encoding for the multiprotein 
complex to be studied can not only be assembled fairly eas-
ily, but also options need to be provided to modify the indi-
vidual subunit components rapidly and in a flexible way by 
mutation, truncation or replacing of affinity tags. Already for 
single proteins, altering the wild-type sequence for example 
by removing low complexity regions is often a prerequisite 
for successful high-resolution structural analysis, and intro-
ducing mutations is commonplace for elucidating the func-
tion and activity. This is equally valid for multiprotein com-
plexes, however, the tasks at hand are considerably more 
complicated to achieve as the number of interacting subunits 
increases. 
 These deliberations and underlying experimental necessi-
ties prompted us recently to introduce ACEMBL, an auto-
matable system for multiprotein expression making use of 
multigene recombineering by using a robot [82, 83] (Fig. 
(3)). For matters of simplicity, we first created ACEMBL in 
a version suitable for multiprotein complex production in E.
coli as an expression host, although, the same robotic scripts 
can likewise be applied for generating multigene constructs 
for protein complex expression in eukaryotic hosts. We de-
cided to consequently adapt recombination methods at every 
step of the process of gene insertion and gene combination 
into multigene expression cassettes, and to implement al-
ready existing, robust robotics protocols for small scale ex-
pression and protein extraction by using affinity purification 
[82]. 
 Building on our positive experiences using Cre-LoxP
fusion in MultiBac, we synthesized two families of small 
plasmids with the minimum DNA sequences required. These 
plasmids are called Acceptors and Donors. They are small 
(2-2.5 kb) and each plasmid contains the LoxP inverted im-
perfect repeat. Donors contain a conditional origin of replica-
tion which makes their existence and propagation in regular 
cloning and expression strains dependent on Cre-LoxP me-
diated fusion with Acceptors, which in turn have a regular 
origin of replication derived from the classical ColE1 origin.  
 We settled on sequence and ligation independent cloning 
(SLIC) as the method of choice for inserting genes into Do-
nors and Acceptors, as detailed protocols for this methods 
became available recently [84]. Nonetheless, we needed to 
modify and improve these protocols to achieve robust inte-
gration, in particular when the process was carried out on in 
a robotic setup using a liquid handling workstation [82, 83]. 
This SLIC method, and likewise the BD-InFusion (Clontech 
Takara) or standardized ligation independent cloning (LIC) 
methods (Novagen), are commonly referred to as recombina-
tion methods, although this denotion is slightly misleading 
for these approaches. Rather, these methods have in common 
that they make use of the 3’ exonuclease activity of DNA 
polymerases in the absence of nucleotide triphosphates. 
Thus, long single stranded overhangs are created which can 
serve as sticky ends if complementary single strands become 
available. Nicks are closed and gaps are filled by the E. coli
machinery upon transformation with the annealed DNAs. 
We found that efficient procedures could be established for 
integrating single genes or polycistrons into the ACEMBL 
Donors and Acceptors by SLIC, and scripted into robust rou-
tines, which could be readily carried out by a robot [82]. 
Gene integration into the ACEMBL vectors occurs at inte-
gration sites that make up a so-called multiple integration 
element (MIE), which contains also restriction sites for con-
ventional gene integration as well as homing endonuclease 
sites for facile gene multiplication into multi-expression cas-
settes [82].  
 Donors thus charged with recombinant DNA cargo, each 
containing single genes, polycistrons or multiple expression 
cassettes, are then fused with one Acceptor by using Cre 
recombinase and the LoxP site present on each vector. Ac-
ceptors like Donors can contain one or several genes, poly-
cistrons or a combination thereof. Several Donors can be 
fused with each Acceptor. Selection for multiple resistance, 
each of these characteristic for one Donor or one Acceptor, 
then identifies the Donor-Acceptor fusions in a combinato-
rial fashion. By using this approach, we could easily gener-
ate in a single reaction a series of multigene expression vec-
tors expressing protein complexes as well as all possible 
combinations of genes contained on the individual vectors, 
revealing subcomplexes [82]. Interestingly, our experiments 
showed that multigene expression vectors could not only be 
assembled in this way, but likewise also selectively decon-
structed by using the reverse approach. This is achieved by 
applying Cre recombinase to previously generated Donor-
Acceptor fusions. This is possible due to the equilibrium 
reached between the fusion and excision activities of the Cre 
enzyme. Thus, defined parts of a multigene construct, encod-
ing for subunits of a protein complex, can be excised by our 
procedure, altered for example by truncation, mutation, or 
replacement of the encoding genes, and then reintegrated 
into the multigene expression construct of choice by apply-
ing Cre fusion. This provides useful combinatorial options, 
also for robotics applications [82]. By employing the 
ACEMBL method, we were able to express and purify all 
members of the holotranslocon from E. coli, a large prokary-
otic translocation complex consisting of six transmembrane 
proteins, from a 16 kb multigene plasmid [82]. 
STRUCTURAL COMPLEXOMICS? 
 Genome and proteome-wide studies have clearly re-
vealed the key role of macromolecular complexes in most, if 
not all vital cellular processes. Protein complexes display 
activities that are entirely different from the activities of each 
subunit studied independently, as interaction partners often 
dramatically influence recognition propensities and likewise 
biological activities. In addition, protein complex composi-
tion in particular in higher eukaryotes can depend on tissue 
type and cell state. Importantly, covalent posttranslational 
modifications such as phosphorylation, acetylation, methyla-
tion and many others can have a critical impact on the forma-
tion of protein complexes and their activity. Due to all of the 
variables that need to be controlled when attempting to as-
semble protein complexes recombinantly, it is important to 
have a robust system that allows rapid testing of many dif-
ferent constructs.  
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Fig. (3). ACEMBL System. ACEMBL consists of newly designed, small vectors (A) and automated procedures and routines relying on re-
combineering for gene insertion and vector fusion (B). Multigene expression constructs are generated by insertion of genes into multiple inte-
gration elements (MIE) by recombination, followed by Cre-LoxP fusion of Donors with an Acceptor. Incubation of educt constructs (here 
pDK, pDS, pACE) containing genes of interest (white arrows) results in all possible combinations in a single reaction including Acceptor-
Donor (AD) and Acceptor-Donor-Donor (ADD) fusions as shown here schematically. Creation of even four-plasmid ADDD constructs has
also been completed successfully in our laboratory [82]. All co-existing constructs have characteristic antibiotic marker combinations and 
resistance levels (right). Donor vectors contain a conditional origin of replication derived from R6K?, and thus act as suicide vectors in clon-
ing strains devoid of the pir gene unless fused to an Acceptor with a regular replicon. A second Acceptor, pACE2, is identical to pACE ex-
cept for the encoded marker which confers resistance to tetracycline rather than ampicillin (not shown). Plasmid pACE2 can be used in con-
junction with pACE derivatives for example to co-express auxiliary proteins such as chaperones or modifiers [82]. (C) Recombineering 
workflow by using the ACEMBL system is shown. Genes are integrated in Donors or Acceptors by ligation independent methods such as
SLIC followed by combinatorial multigene vector generation using Cre-LoxP fusion. Expression and purification provide protein complex for 
analysis. Multigene vectors are deconstructed by using Cre excision activity (De-Cre). Encoded genes are modified by PCR and reintegrated 
into the workflow by recombination in an iterative cycle. The entire process is compatible with automation, and was successfully scripted into 
a robotic routine. Adapted in part from [82, 83]. 
 In the current environment, in which valuable informa-
tion about interactomes, complexomes and other genome-
wide studies is pouring in at an ever increasing pace, struc-
tural biology as it is performed to date simply cannot keep 
up with the increasing demand for the validation that only 3-
D structures can provide. Protein structures can offer insights 
into the details of a protein interaction at the molecular or 
near-atomic level, and it is imperative for structural biolo-
gists to move into the arena of protein complex interactions. 
Despite recent colossal efforts in obtaining 3-D structures at 
near atomic resolution by X-ray crystallography, greatly fos-
tered by structural genomics consortia, obtaining diffraction 
quality crystals of protein complexes remains a significant 
challenge and often takes on the order of years achieve. This 
technological state-of-the-art is simply incompatible with the 
speed at which new data is accumulated through high-
throughput research addressing the interactome, and a major 
effort towards the development of new technologies is ur-
gently required to close this gap. 
 3-D structural information can be gained from purified 
material extracted in small amounts from native source by 
electron-microscopic techniques which have significantly 
matured in recent years [85-87]. In particular, cryo-electron 
microscopy in conjunction with single-particle analysis can 
be used to gain information about the quaternary architecture 
of multiprotein assemblies. Although 3-D protein structures 
obtained from cryo-electron microscopy are reaching higher 
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resolutions than ever before, 3-D structures obtained by this 
method provide still limited information when compared to 
the atomic details obtained by X-ray crystallography or 
NMR spectroscopy.  
 Undoubtedly, great benefit could be derived from the 
development of advanced techniques and reproducible pro-
tocols for micropurification of endogenous complexes. Puri-
fication of protein from biological material present in limited 
amounts will certainly be necessary in particular for the iden-
tification of complexes, or variations of complexes, that are 
present in specialized cells or specific tissues, and for a thor-
ough validation of interactome data. This requires highly 
efficient methods to recover the quantities of protein re-
quired for biophysical methods. Due to the considerable in-
crease in sensitivity of mass spectrometers achieved in recent 
years, it is now possible to routinely identify subunits of pro-
tein complexes from pico- to femto-mole quantities of mate-
rial. It is critically important now to develop new strategies 
for the micropurification of protein complexes that will al-
low the simultaneous processing of several samples from 
limited amounts of source material. Such micropurification 
techniques, in conjunction with process automation for en-
dogenous sample preparation will decisively improve current 
research approaches both in terms of throughput and also 
quality of analysis. Size-exclusion chromatography (SEC) is 
often a rate limiting step in the preparation of protein com-
plexes. New purification strategies involving native gels, 
capillary electrophoresis or absorption onto membranes 
could possibly mature into genuine alternatives to SEC, thus 
allowing parallel processing of many samples and increasing 
sample homogeneity.  
 Recombinant expression most certainly had a decisive 
impact on life science research, and is to date the major 
technique for successful production of well-defined macro-
molecular specimens in the quality and quantity required for 
many applications. Apart from notable examples such as 
ribosomes or RNA polymerase [88-91], near-atomic struc-
ture determination of complex multicomponent systems will 
in all likelihood in most cases depend on recombinant over-
production. More recently, several multi-expression systems 
have been introduced for expression of protein complexes in 
a variety of different expression hosts, two of these were 
described in some detail in this contribution. However, most 
systems currently available still require dedicated expertise 
and considerable technical specialisation of the user, which 
is refractory to routine research, in particular for high-
throughput applications. Biological and also pharmaceutical 
research often depend on introducing variations (mutation, 
truncations, fusions with markers, etc) into the specimen 
studied. Multi-expression systems therefore must provide the 
flexibility required for rapid revision of experiments, where 
such alterations can be introduced with ease. The ACEMBL 
system we developed could represent a first step in this di-
rection. Nonetheless, production of many vital protein com-
plexes, especially those requiring a eukaryotic host machin-
ery for sample production, remains a challenge and a major 
bottleneck in the pipeline to high-resolution 3-D structures.  
 A further consideration in protein complex biology are 
those complexes that contain protein subunits as well as 
RNA components which may need to be co-expressed for 
proper complex assembly and folding. Protein-RNA com-
plexes such as telomerase, snRNPs or RNAi containing com-
plexes are a focus of contemporary research efforts aimed at 
elucidating mechanisms of health and disease. The recent 3-
D structure of a human spliceosomal U1 snRNP 
compellingly demonstrates the power of recombinant recon-
stitution of such a complex for structure elucidation [92]. 
Technologies allowing routine multigene expression in pro-
karyotic and eukaryotic hosts will certainly need to incorpo-
rate the means for producing heterologous complexes con-
taining non-protein components such as RNA and other bio-
molecules.  
 Automation is essential for accelerating contemporary 
protein science. Automation depends on standardization and 
simplification of protocols that are robust and reproducible. 
These requirements must be addressed by the development 
of easy-to-use, affordable reagents that are ideally compati-
ble with robotic procedures. Automation has already had a 
considerable impact on cloning, DNA preparation, protein 
purification by affinity tags and assaying protein activities. 
Protocols optimized for automation have at times superseded 
earlier, more laborious procedures even in laboratories not 
applying robots routinely, as manual procedures generally 
also benefit considerably from the standardization and ro-
bustness inherently required for methods that can be used by 
robots. Automation will be particularly important for recon-
stitution of macromolecular complexes by heterologous 
multigene expression as probably a large number of con-
structs will need to be tested for many cases until a satisfac-
tory reconstitution is achieved, yielding specimens suitable 
for detailed studies. The number of possible combinations 
increases dramatically with the number of subunits. This is 
particularly true if the pipeline is geared towards X-ray crys-
tallography. 
 In single crystal structure determination by X-ray diffrac-
tion, a vital prerequisite is the ability of a specimen to ar-
range into a highly ordered crystal lattice that diffracts the 
incident X-ray radiation to near-atomic resolution. Often, 
this challenge can only be met by introducing variation into 
the wild-type sequence until a crystallizable specimen is ob-
tained. Limited proteolysis, in conjunction with mass spec-
trometry, has been particularly useful for defining regions of 
low-complexity that can often interfere with crystallization. 
Such regions are then typically removed by introducing trun-
cations or deletions in encoding DNA sequences, and re-
combinant overexpression of the resulting variant can then 
result in sample more amenable to crystallization. Corre-
sponding procedures are now being introduced in more 
elaborate structural genomics pipelines. Nonetheless, it is 
clear that implementing such limited proteolysis procedures, 
often already laborious for single proteins, will be vastly 
more complicated when several to many ORFs need to be 
diversified concomitantly in a multiprotein complex. Recent 
advances in mass spectrometry, including quantitative, mul-
tiplexed techniques [93, 94] may prove to be invaluable for 
designing tools to analyze limited proteolysis experiments of 
complex multiprotein assemblies in high-throughput for 
structure elucidation.  
 High-resolution structure determination, in particular by 
X-ray crystallography, has developed into an indispensable 
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technology which can be readily applied to elucidate mo-
lecular function in near-atomic detail. While the field of X-
ray crystallography has achieved considerable advancements 
in recent decades, namely in the design of automated crystal-
lization platforms, robotics and greater access to high-
brilliance synchrotron radiation sources, there is still a con-
siderable distance to be covered before X-ray crystallogra-
phy can tackle the number of challenges presented by inter-
actome wide studies and complexomics. Miniaturization and 
standardization are now indispensable components of high-
throughput crystallization platforms. High-throughout meth-
ods will continue to provide many exciting possibilities for 
crystallization experiments aided by the arrival of technolo-
gies requiring unprecedented small amounts of sample for 
screening a very large space of crystallization conditions. 
Structural genomics consortia have played an indispensable 
role by installing automated pipelines for solving 3-D struc-
tures of individual proteins and protein domains. The dis-
covery of a vast plethora of multicomponent assemblies that 
form the interactome, their modifications, overlaps and 
variations poses a challenge for similar efforts that may ap-
pear seemingly unmanageable at the moment. What is now 
required is a concerted effort to advance current technologies 
as well as to develop and implement new methods and pro-
cedures for addressing the complexome of organisms.  
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ABBREVIATIONS 
BAC  = Bacterial artificial chromosome 
BEVS  = Baculovirus expression vector system 
CBP = Calmodulin-binding peptide 
CID = Collision-induced dissociation 
CF = Cell-free 
DBD = DNA binding domain 
EM  = Electron microscopy 
ESI = Electro-spray ionization 
GFP = Green fluorescent protein 
HUPO = Human Proteome Organization 
IM-MS = Ion mobility seperation coupled to mass 
spectrometry 
kb  = Kilobase 
kDa  = Kilodalton 
LC-MS = Liquid-chromatography coupled electro-spray 
ionization 
LIC = Ligation independent cloning 
MALDI = Matrix-assisted laser desorption/ionization  
MIE = Multiple integration element 
MS = Mass spectrometry 
NMR = Nuclear magnetic resonance 
ORF = Open reading frame 
PCR  = Polymerase chain reaction 
PDB = Protein Data Bank 
PPI = Protein-protein interaction 
SEC = Size-exclusion chromatography 
SLIC  = Sequence and ligation independent cloning 
SPINE = Strep-protein interaction experiment 
TAP = Tandem affinity purification 
TOF = Time of flight 
Y2H = Yeast two-hybrid 
YFP  = Yellow fluorescent protein 
REFERENCES 
[1] Alberts, B. The cell as a collection of protein machines: preparing 
the next generation of molecular biologist. Cell, 1998, 92, 291-294. 
[2] Giot, L.; Bader, J.S.; Brouwer, C.; Chaudhuri, A.; Kuang, B.; Li, 
Y.; Hao, Y.L.; Ooi, C.E.; Godwin, B.; Vitols, E.; Vijayadamodar, 
G.; Pochart, P.; Machineni, H.; Welsh, M.; Kong, Y.; Zerhusen, B.; 
Malcolm, R.; Varrone, Z.; Collis, A.; Minto, M.; Burgess, S.; 
McDaniel, L.; Stimpson, E.; Spriggs, F.; Williams, J.; Neurath, K.; 
Ioime, N.; Agee, M.; Voss, E.; Furtak, K.; Renzulli, R.; Aanensen, 
N.; Carrolla, S.; Bickelhaupt, E.; Lazovatsky, Y.; DaSilva, A.; 
Zhong, J.; Stanyon, C.A.; Finley, R.L. Jr.; White, K.P.; Braverman, 
M.; Jarvie, T.; Gold, S.; Leach, M.; Knight, J.; Shimkets, R.A.; 
McKenna, M.P.; Chant, J.; Rothberg, J.M. A protein interaction 
map of Drosophila melanogaster. Science, 2003, 302, 1727-1736. 
[3] Monti, M.; Orrù, S.; Pagnozzi, D.; Pucci, P. Interaction proteomics. 
Biosci. Rep., 2005, 25, 45-56. 
[4] Rual, J.F.; Venkatesan, K.; Hao, T.; Hirozane-Kishikawa, T.; Dri-
cot, A.; Li, N.; Berriz, G.F.; Gibbons, F.D.; Dreze, M.; Ayivi-
Guedehoussou, N.; Klitgord, N.; Simon, C.; Boxem, M.; Milstein, 
S.; Rosenberg, J.; Goldberg, D.S.; Zhang, L.V.; Wong, S.L.; Fran-
klin, G.; Li, S.; Albala, J.S.; Lim, J.; Fraughton, C.; Llamosas, E.; 
Cevik, S.; Bex, C.; Lamesch, P.; Sikorski, R.S.; Vandenhaute, J.; 
Zoghbi, H.Y.; Smolyar, A.; Bosak, S.; Sequerra, R.; Doucette-
Stamm, L.; Cusick, M.E.; Hill, D.E.; Roth, F.P.; Vidal, M. Towards 
a proteome-scale map of the human protein-protein interaction 
network. Nature, 2005, 437, 1173-1178. 
[5] Parrish, J.R.; Gulyas, K.D.; Finley, R.L. Jr. Yeast two-hybrid con-
tributions to interactome mapping. Curr. Opin. Biotechnol., 2006,
17, 387-393. 
[6] Sanchez, C.; Lachaize, C.; Janody, F.; Bellon, B.; Röder, L.; Eu-
zenat, J.; Rechenmann, F.; Jacq, B. Grasping at molecular interac-
tions and genetic networks in Drosophila melanogaster using 
FlyNets, an Internet database. Nucleic Acids Res. , 1999, 27, 89-94. 
[7] Rigaut, G.; Shevchenko, A.; Rutz, B.; Wilm, M.; Mann, M.; 
Séraphin, B. A generic protein purification method for protein 
complex characterization and proteome exploration. Nat. Biotech-
nol., 1999, 17, 1030-1032. 
[8] Gavin, A.C.; Aloy, P.; Grandi, P.; Krause, R.; Boesche, M.; 
Marzioch, M.; Rau, C.; Jensen, L.J.; Bastuck, S.; Dumpelfeld, B.; 
Edelmann, A.; Heurtier, M.A.; Hoffman, V.; Hoefert, C.; Klein, K.; 
Hudak, M.; Michon, A.M.; Schelder, M.; Schirle, M.; Remor, M.; 
Rudi, T.; Hooper, S.; Bauer, A.; Bouwmeester, T.; Casari, G.; 
Drewes, G.; Neubauer, G.; Rick, J.M.; Kuster, B.; Bork, P.; Rus-
sell, R.B.; Superti-Furga, G. Proteome survey reveals modularity of 
the yeast cell machinery. Nature, 2006, 440, 631-636. 
570 Current Genomics, 2009, Vol. 10, No. 8 Nie et al.
[9] Krogan, N.J.; Cagney, G.; Yu, H.; Zhong, G.; Guo, X.; Ig-
natchenko, A.; Li, J.; Pu, S.; Datta, N.; Tikuisis, A.P.; Punna, T.; 
Peregrín-Alvarez, J.M.; Shales, M.; Zhang, X.; Davey, M.; Robin-
son, M.D.; Paccanaro, A.; Bray, J.E.; Sheung, A.; Beattie, B.; 
Richards, D.P.; Canadien, V.; Lalev, A.; Mena, F.; Wong, P.; Sta-
rostine, A.; Canete, M.M.; Vlasblom, J.; Wu, S.; Orsi, C.; Collins, 
S.R.; Chandran, S.; Haw, R.; Rilstone, J.J.; Gandi, K.; Thompson, 
N.J.; Musso, G.; St Onge, P.; Ghanny, S.; Lam, M.H.; Butland, G.; 
Altaf-Ul, A.M.; Kanaya, S.; Shilatifard, A.; O'Shea, E.; Weissman, 
J.S.; Ingles, C.J.; Hughes, T.R.; Parkinson, J.; Gerstein, M.; Wo-
dak, S.J.; Emili, A.; Greenblatt, J.F. Global landscape of protein 
complexes in the yeast Saccharomyces cerevisiae. Nature, 2006,
440, 637-643. 
[10] Herzberg, C.; Weidinger, L.A.; Dörrbecker, B.; Hübner, S.; Stülke, 
J.; Commichau, F.M. SPINE: a method for the rapid detection and 
analysis of protein-protein interactions in vivo. Proteomics, 2007,
7, 4032-4035. 
[11] Cheeseman, I.M.; Desai, A. A combined approach for the localiza-
tion and tandem affinity purification of protein complexes from 
metazoans. Sci. STKE., 2005, 266, pl1. 
[12] Bürckstümmer, T.; Bennett, K.L.; Preradovic, A.; Schütze, G.; 
Hantschel, O.; Superti-Furga, G.; Bauch, A. An efficient tandem 
affinity purification procedure for interaction proteomics in mam-
malian cells. Nat. Methods, 2006, 12, 1013-1019. 
[13] Poser, I.; Sarov, M.; Hutchins, J.R.; Hériché, J.K.; Toyoda, Y.; 
Pozniakovsky, A.; Weigl, D.; Nitzsche, A.; Hegemann, B.; Bird, 
A.W.; Pelletier, L.; Kittler, R.; Hua, S.; Naumann, R.; Augsburg, 
M.; Sykora, M.M.; Hofemeister, H.; Zhang, Y.; Nasmyth, K.; 
White, K.P.; Dietzel, S.; Mechtler, K.; Durbin, R.; Stewart, A.F.; 
Peters, J.M.; Buchholz, F.; Hyman, A.A. BAC TransgeneOmics: a 
high-throughput method for exploration of protein function in 
mammals. Nat. Methods, 2008, 5, 409-415. 
[14] Fromont-Racine, M.; Rain, J.C.; Legrain, P. Towards a functional 
analysis of the yeast genome through exhaustive two-hybrid 
screens. Nat. Genet., 1997, 16, 277-282. 
[15] Venkatesan, K.; Rual, J.F.; Vazquez, A.; Stelzl, U.; Lemmens, I.; 
Hirozane-Kishikawa, T.; Hao, T.; Zenkner, M.; Xin, X.; Goh, K.I.; 
Yildirim, M.A.; Simonis, N.; Heinzmann, K.; Gebreab, F.; Sahalie, 
J.M.; Cevik, S.; Simon, C.; de Smet, A.S.; Dann, E.; Smolyar, A.; 
Vinayagam, A.; Yu, H.; Szeto, D.; Borick, H.; Dricot, A.; Klitgord, 
N.; Murray, R.R.; Lin, C.; Lalowski, M.; Timm, J.; Rau, K.; Boone, 
C.; Braun, P.; Cusick, M.E.; Roth, F.P.; Hill, D.E.; Tavernier, J.; 
Wanker, E.E.; Barabási, A.L.; Vidal, M. An empirical framework 
for binary interactome mapping. Nat. Methods, 2009, 6, 83-90. 
[16] Fields, S.; Song, O. A novel system to detect protein-protein inter-
actions. Nature, 1989, 340, 245-246. 
[17] Rain, J.C.; Selig, L.; De Reuse, H.; Battaglia, V.; Reverdy, C.; 
Simon, S.; Lenzen, G.; Petel, F.; Wojcik, J.; Schächter, V.; Che-
mama, Y.; Labigne, A.; Legrain, P. The protein-protein interaction 
map of Helicobacter pylori. Nature, 2001, 409, 211-215. 
[18] Ito, T.; Chiba, T.; Ozawa, R.; Yoshida, M.; Hattori, M.; Sakaki, Y. 
A comprehensive two-hybrid analysis to explore the yeast protein 
interactome. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 4569-4574. 
[19] Uetz, P.; Giot, L.; Cagney, G.; Mansfield, T.A.; Judson, R.S.; 
Knight, J.R.; Lockshon, D.; Narayan, V.; Srinivasan, M.; Pochart, 
P.; Qureshi-Emili, A.; Li, Y.; Godwin, B.; Conover, D.; 
Kalbfleisch, T.; Vijayadamodar, G.; Yang, M.; Johnston, M.; 
Fields, S.; Rothberg, J.M. A comprehensive analysis of protein-
protein interactions in Saccharomyces cerevisiae. Nature, 2000,
403, 623-627. 
[20] Li, S.; Armstrong, C.M.; Bertin, N.; Ge, H.; Milstein, S.; Boxem, 
M.; Vidalain, P.O.; Han, J.D.; Chesneau, A.; Hao, T.; Goldberg, 
D.S.; Li, N.; Martinez, M.; Rual, J.F.; Lamesch, P.; Xu, L.; Tewari, 
M.; Wong, S.L.; Zhang, L.V.; Berriz, G.F.; Jacotot, L.; Vaglio, P.; 
Reboul, J.; Hirozane-Kishikawa, T.; Li, Q.; Gabel, H.W.; Elewa, 
A.; Baumgartner, B.; Rose, D.J.; Yu, H.; Bosak, S.; Sequerra, R.; 
Fraser, A.; Mango, S.E.; Saxton, W.M.; Strome, S.; Van Den Heu-
vel, S.; Piano, F.; Vandenhaute, J.; Sardet, C.; Gerstein, M.; 
Doucette-Stamm, L.; Gunsalus, K.C.; Harper, J.W.; Cusick, M.E.; 
Roth, F.P.; Hill, D.E.; Vidal, M. A map of the interactome network 
of the metazoan C. elegans. Science, 2004, 303, 540-543. 
[21] Reboul, J.; Vaglio, P.; Rual, J.F.; Lamesch, P.; Martinez, M.; Arm-
strong, C.M.; Li, S.; Jacotot, L.; Bertin, N.; Janky, R.; Moore, T.; 
Hudson, J.R. Jr.; Hartley, J.L.; Brasch, M.A.; Vandenhaute, J.; 
Boulton, S.; Endress, G.A.; Jenna, S.; Chevet, E.; Papasotiropoulos, 
V.; Tolias, P.P.; Ptacek, J.; Snyder, M.; Huang, R.; Chance, M.R.; 
Lee, H.; Doucette-Stamm, L.; Hill, D.E.; Vidal, M. C. elegans OR-
Feome version 1.1: experimental verification of the genome anno-
tation and resource for proteome-scale protein expression. Nat. 
Genet., 2003, 34, 35-41. 
[22] Walhout, A.J.; Boulton, S.J.; Vidal, M. Yeast two-hybrid systems 
and protein interaction mapping projects for yeast and worm. Yeast
2000, 17, 88-94. 
[23] Colland, F.; Jacq, X.; Trouplin, V.; Mougin, C.; Groizeleau, C.; 
Hamburger, A.; Meil, A.; Wojcik, J.; Legrain, P.; Gauthier, J.M. 
Functional proteomics mapping of a human signaling pathway. 
Genome Res., 2004, 14, 1324-1332. 
[24] Stelzl, U.; Worm, U.; Lalowski, M.; Haenig, C.; Brembeck, F.H.; 
Goehler, H.; Stroedicke, M.; Zenkner, M.; Schoenherr, A.; Koep-
pen, S.; Timm, J.; Mintzlaff, S.; Abraham, C.; Bock, N.; Kietz-
mann, S.; Goedde, A.; Toksöz, E.; Droege, A.; Krobitsch, S.; Korn, 
B.; Birchmeier, W.; Lehrach, H.; Wanker, E.E. A human protein-
protein interaction network: a resource for annotating the proteome. 
Cell, 2005, 122, 957-968. 
[25] Yu, H.; Braun, P.; Yildirim, M.A.; Lemmens, I.; Venkatesan, K.; 
Sahalie, J.; Hirozane-Kishikawa, T.; Gebreab, F.; Li, N.; Simonis, 
N.; Hao, T.; Rual, J.F.; Dricot, A.; Vazquez, A.; Murray, R.R.; 
Simon, C.; Tardivo, L.; Tam, S.; Svrzikapa, N.; Fan, C.; de Smet, 
A.S.; Motyl, A.; Hudson, M.E.; Park, J.; Xin, X.; Cusick, M.E.; 
Moore, T.; Boone, C.; Snyder, M.; Roth, F.P.; Barabási, A.L.; Tav-
ernier, J.; Hill, D.E.; Vidal, M. High-quality binary protein interac-
tion map of the yeast interactome network. Science 2008, 322, 104-
110. 
[26] Devos, D.; Russel, R.B. A more complete, complexed and struc-
tured interactome. Curr. Opin. Struct. Biol., 2007, 17, 370-377. 
[27] Orchard, S.; Salwinski, L.; Kerrien, S.; Montecchi-Palazzi, L.; 
Oesterheld, M.; Stümpflen, V.; Ceol, A.; Chatr-aryamontri, A.; 
Armstrong, J.; Woollard, P.; Salama, J.J.; Moore, S.; Wojcik, J.; 
Bader, G.D.; Vidal, M.; Cusick, M.E.; Gerstein, M.; Gavin, A.C.; 
Superti-Furga, G.; Greenblatt, J.; Bader, J.; Uetz, P.; Tyers, M.; 
Legrain, P.; Fields, S.; Mulder, N.; Gilson, M.; Niepmann, M.; 
Burgoon, L.; De Las Rivas, J.; Prieto, C.; Perreau, V.M.; Hogue, 
C.; Mewes, H.W.; Apweiler, R.; Xenarios, I.; Eisenberg, D.; Ce-
sareni, G.; Hermjakob, H. The minimum information required for 
reporting a molecular interaction experiment (MIMIx). Nat. Bio-
technol., 2007, 25, 894-898. 
[28] Hart, G.T.; Lee, I.; Marcotte, E.R. A high-accuracy consensus map 
of yeast protein complexes reveals modular nature of gene essen-
tiality. BMC Bioinformatics, 2007, 8, 236. 
[29] Collins, S.R.; Miller, K.M.; Maas, N.L.; Roguev, A.; Fillingham, 
J.; Chu, C.S.; Schuldiner, M.; Gebbia, M.; Recht, J.; Shales, M.; 
Ding, H.; Xu, H.; Han, J.; Ingvarsdottir, K.; Cheng, B.; Andrews, 
B.; Boone, C.; Berger, S.L.; Hieter, P.; Zhang, Z.; Brown, G.W.; 
Ingles, C.J.; Emili, A.; Allis, C.D.; Toczyski, D.P.; Weissman, J.S.; 
Greenblatt, J.F.; Krogan, N.J. Functional dissection of protein 
complexes involved in yeast chromosome biology using a genetic 
interaction map. Nature, 2007, 446, 806-810. 
[30] Aloy, P.; Russell, R.B. Structural systems biology: modelling pro-
tein interactions. Nat. Rev. Mol. Cell Biol., 2006, 7, 188-197. 
[31] Sprinzak, E.; Altuvia, Y.; Margalit, H. Characterization and predic-
tion of protein-protein interactions within and between complexes.
Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 14718-14723. 
[32] Aebersold, R.; Mann, M. Mass spectrometry-based proteomics. 
Nature, 2003, 422, 198-207. 
[33] Han, X.; Aslanian, A.; Yates, J.R. III. Mass spectrometry for pro-
teomics. Curr. Opinion Chem. Biol., 2008, 12, 483-490. 
[34] Domon, B. Aebersold, R. Mass Spectrometry and Protein Analysis. 
Science, 2006, 312, 212-217. 
[35] Ashman, K.; Moran, M.F.; Sicheri, F.; Pawson, T.; Tyers, M. Cell 
signaling - the proteomics of it all. Sci. STKE, 2001, 103, pe33. 
[36] Rappsilber, J.; Siniossoglou, S.; Hurt, E.C.; Mann, M. A generic 
strategy to analyze the spatial organization of multi-protein com-
plexes by cross-linking and mass-spectrometry. Anal. Chem., 2000,
72, 267-275. 
[37] Keller, A.; Nesvizhskii, A. I.; Kolker, E.; Aebersold, R. Empirical 
statistical model to estimate the accuracy of peptide identifications 
made by MS/MS and database search. Anal. Chem., 2000, 74,
5383-5392. 
[38] Andersen, J.S.; Mann, M. Organellar proteomics: turning invento-
ries into insights. EMBO Rep., 2006, 7, 874-879. 
[39] Aebersold, R. A stress test for mass spectrometry-based pro-
teomics. Nat. Methods, 2009, 6, 411-412. 
Getting a Grip on Complexes Current Genomics, 2009, Vol. 10, No. 8    571
[40] Bell, A.W.; Deutsch, E.W.; Au, C.E.; Kearney, R.E.; Beavis, R.; 
Sechi, S.; Nilsson, T.; Bergeron, J.J. HUPO Test Sample Working 
Group. Nat. Methods, 2009, 6, 423-430. 
[41] Benesch, J.L.; Robinson, C.V. Mass spectrometry of macromolecu-
lar assemblies: preservation and dissociation. Curr. Opin. Struct. 
Biol., 2006, 16, 245-251. 
[42] Heck, A.J. Native mass spectrometry: a bridge between interactom-
ics and structural biology. Nat. Methods, 2008, 5, 927-933. 
[43] Ruotolo, B.T.; Giles, K.; Campuzano, I.; Sandercock, A.M.; Bate-
man, R.H.; Robinson, C.V. Evidence for macromolecular protein 
rings in the absence of bulk water. Science, 2005, 310, 1658-1661. 
[44] Benesch, J.L.; Ruotolo, B.T.; Simmons, D.A.; Robinson, C.V. 
Protein complexes in the gas phase: technology for structural ge-
nomics and proteomics. Chem. Rev., 2007, 107, 3544-3567. 
[45] Hernandez, H.; Dziembowski, A.; Traverner, T.; Seraphin, B.; 
Robinson, C.V. Subunit architecture of multimeric complexes iso-
lated directly from cells. EMBO Rep., 2006, 7, 605-610. 
[46] Damoc, E.; Fraser, C.S.; Zhou, M.; Videler, H.; Mayeur, G.L.; 
Hershey, J.W.; Doudna, J.A.; Robinson, C.V.; Leary, J.A. Struc-
tural characterization of the human eukaryotic initiation factor 3 
protein complex by mass spectrometry. Mol. Cell. Proteomics,
2007, 6, 1135-1146. 
[47] Zhou, M.; Sandercock, A.M.; Fraser, C.S.; Ridlova, G.; Stephens, 
E.; Schenauer, M.R.; Yokoi-Fong, T.; Barsky, D.; Leary, J.A.; Her-
shey, J.W.; Doudna, J.A.; Robinson, C.V. Mass spectrometry re-
veals modularity and a complete subunit interaction map of the eu-
karyotic translation factor eIF3. Proc. Natl. Acad. Sci. U.S.A.,
2008, 105, 18139-18144. 
[48] Fox, B.G.; Goulding, C.; Malkowski, M.G.; Stewart, L.; Deacon, 
A. Structural genomics: from genes to structures with valuable ma-
terials and many questions in between. Nat. Methods, 2008, 5, 129-
132. 
[49] Kambach, C. Pipelines, robots, crystals and biology: what use high 
throughput solving structures of challenging targets? Curr. Protein 
Pept. Sci., 2007, 8, 205-217. 
[50] Klock, H.E.; White, A.; Koesema, E.; Lesley, S.A. Methods and 
results for semi-automated cloning using integrated robotics. J. 
Struct. Funct. Genomics, 2005, 6, 89-94. 
[51] Blommel, P.G.; Martin, P.A.; Wrobel, R.L.; Steffen, E.; Fox, B.G. 
High efficiency single step production of expression plasmids from 
cDNA clones using the Flexi Vector cloning system. Protein Expr. 
Purif., 2006, 47, 562-570. 
[52] Stols, L.; Gu, M.; Dieckman, L.; Raffen, R.; Collart, F.R.; Don-
nelly, M.I. A new vector for high-throughput, ligation-independent 
cloning encoding a tobacco etch virus protease cleavage site. Pro-
tein Expr. Purif. 2002, 25, 8-15. 
[53] Klock, H.E.; Koesema, E.J.; Knuth, M.W.; Lesley, S.A. Combining 
the polymerase incomplete primer extension method for cloning 
and mutagenesis with microscreening to accelerate structural ge-
nomics efforts. Proteins, 2008, 71, 982-994. 
[54] Thao, S.; Zhao, Q.; Kimball, T.; Steffen, E.; Blommel, P.G.; Riters, 
M.; Newman, C.S.; Fox, B.G.; Wrobel, R.L. Results from high-
throughput DNA cloning of Arabidopsis thaliana target genes using 
site-specific recombination. J. Struct. Funct. Genomics, 2004, 5,
267-276. 
[55] Acton, T.B.; Gunsalus, K.C.; Xiao, R.; Ma, L.C.; Aramini, J.; Ba-
ran, M.C.; Chiang, Y.W.; Climent, T.; Cooper, B.; Denissova, 
N.G.; Douglas, S.M.; Everett, J.K.; Ho, C.K.; Macapagal, D.; Ra-
jan, P.K.; Shastry, R.; Shih, L.Y.; Swapna, G.V.; Wilson, M.; Wu, 
M.; Gerstein, M.; Inouye, M.; Hunt, J.F.; Montelione, G.T. Robotic 
cloning and Protein Production Platform of the Northeast Structural 
Genomics Consortium. Methods Enzymol., 2005, 394, 210-243. 
[56] Studier, F.W. Protein production by auto-induction in high density 
shaking cultures. Protein Expr. Purif., 2005, 41, 207-234. 
[57] Manjasetty, B.A.; Turnbull, A.P.; Panjikar, S.; Büssow, K.; 
Chance, M.R. Automated technologies and novel techniques to ac-
celerate protein crystallography for structural genomics. Pro-
teomics, 2008, 8, 612-625. 
[58] Shimizu, Y.; Inoue, A.; Tomari, Y.; Suzuki, T.; Yokogawa, T.; 
Nishikawa, K.; Ueda, T. Cell-free translation reconstituted with pu-
rified components. Nat. Biotechnol., 2001, 19, 751-755. 
[59] Liguori, L.; Marques, B.; Villegas-Méndez, A.; Rothe, R.; Lenor-
mand, J.L. Production of membrane proteins using cell-free expres-
sion systems. Expert Rev. Proteomics, 2007, 4, 79-90. 
[60] Kukimoto-Niino, M.; Takagi, T.; Akasaka, R.; Murayama, K.; 
Uchikubo-Kamo, T.; Terada, T.; Inoue, M.; Watanabe, S.; Tanaka, 
A.; Hayashizaki, Y.; Kigawa, T.; Shirouzu, M.; Yokoyama, S. 
Crystal structure of the RUN domain of the RAP2-interacting pro-
tein x. J. Biol. Chem., 2006, 281, 31843-31853. 
[61] Buchs, M.; Kim, E.; Pouliquen, Y.; Sachs, M.; Geisse, S.; Mahnke, 
M.; Hunt, I. High-throughput insect cell protein expression applica-
tions. Methods Mol. Biol., 2009, 498, 199-227. 
[62] Schlaeppi, J.M.; Henke, M.; Mahnke, M.; Hartmann, S.; Schmitz, 
R.; Pouliquen, Y.; Kerins, B.; Weber, E.; Kolbinger, F.; Kocher, 
H.P. A semi-automated large-scale process for the production of 
recombinant tagged proteins in the Baculovirus expression system. 
Protein Expr. Purif., 2006, 50, 185-195. 
[63] Kärkkäinen, H.R.; Lesch, H.P.; Määttä, A.I.; Toivanen, P.I.; 
Mähönen, A.J.; Roschier, M.M.; Airenne, K.J.; Laitinen, O.H.; 
Ylä-Herttuala, S. A 96-well format for a high-throughput baculovi-
rus generation, fast titering and recombinant protein production in 
insect and mammalian cells. BMC Res. Notes, 2009, 2, 63. 
[64] Bonanno, J.B.; Almo, S.C.; Bresnick, A.; Chance, M.R.; Fiser, A.; 
Swaminathan, S.; Jiang, J.; Studier, F.W.; Shapiro, L.; Lima, C.D.; 
Gaasterland, T.M.; Sali, A.; Bain, K.; Feil, I.; Gao, X.; Lorimer, D.; 
Ramos, A.; Sauder, J.M.; Wasserman, S.R.; Emtage, S.; D'Amico, 
K.L.; Burley, S.K. New York-Structural GenomiX Research Con-
sortium (NYSGXRC): a large scale center for the protein structure 
initiative. J. Struct. Funct. Genomics, 2005, 6, 225-232. 
[65] Gao, X.; Bain, K.; Bonanno, J.B.; Buchanan, M.; Henderson, D.; 
Lorimer, D.; Marsh, C.; Reynes, J.A.; Sauder, J.M.; Schwinn, K.; 
Thai, C.; Burley, S.K. High-throughput limited proteolysis/mass 
spectrometry for protein domain elucidation. J. Struct. Funct.  
Genomics, 2005, 6, 129-134. 
[66] Editorial. Structural genomics in the spotlight. Nat. Methods, 2008,
5, 115. 
[67] Romier, C.; Ben Jelloul, M.; Albeck, S.; Buchwald, G.; Busso, D.; 
Celie, P.H.; Christodoulou, E.; De Marco, V.; van Gerwen, S.; 
Knipscheer, P.; Lebbink, J.H.; Notenboom, V.; Poterszman, A.; 
Rochel, N.; Cohen, S.X.; Unger, T.; Sussman, J.L.; Moras, D.; 
Sixma, T.K.; Perrakis, A. Co-expression of protein complexes in 
prokaryotic and eukaryotic hosts: experimental procedures, data-
base tracking and case studies. Acta Crystallogr. D Biol. Crystal-
logr., 2006, 62, 1232-1242. 
[68] Tan, S.; Kern, R.C.; Selleck, W. The pST44 polycistronic expres-
sion system for producing protein complexes in Escherichia coli.
Protein Expr. Purif., 2005, 40, 385-395. 
[69] Tolia, N.H.; Joshua-Tor, L. Strategies for protein coexpression in 
Escherichia coli. Nat. Methods, 2006, 3, 55-64. 
[70] Fitzgerald, D.J.; Berger, P.; Schaffitzel, C.; Yamada, K.; Rich-
mond, T.J.; Berger, I. Protein complex expression by using 
multigene baculoviral vectors. Nat. Methods, 2006, 3, 1021-1032. 
[71] Chanda, P.K.; Edris, W.A.; Kennedy, J.D. A set of ligation-
independent expression vectors for co-expression of proteins in Es-
cherichia coli. Protein Expr. Purif., 2006, 47, 217-224. 
[72] Scheich, C.; Kümmel, D.; Soumailakakis, D.; Heinemann, U.; 
Büssow, K. Vectors for co-expression of an unrestricted number of 
proteins. Nucleic Acids Res., 2007, 35, e43. 
[73] Berger, I.; Fitzgerald, D.J.; Richmond, T.J. Baculovirus expression 
system for heterologous multiprotein complexes. Nat. Biotechnol., 
2004, 22, 1583-1587. 
[74] Bieniossek, C.; Richmond, T.J.; Berger, I. MultiBac: multigene 
baculovirus-based eukaryotic protein complex production. Curr. 
Prot. Protein Sci., 2008, ch. 5, Unit 5.20. pp. 2001-2025, Wiley, 
New York. 
[75] Cui, S.; Eisenächer, K.; Kirchhofer, A.; Brzózka, K.; Lammens, A.; 
Lammens, K.; Fujita, T.; Conzelmann, K.K.; Krug, A.; Hopfner, 
K.P. The C-terminal regulatory domain is the RNA 5'-triphosphate 
sensor of RIG-I. Mol. Cell, 2008, 29, 169-179. 
[76] Murzina, N.V.; Pei, X.Y.; Zhang, W.; Sparkes, M.; Vicente-Garcia, 
J.; Pratap, J.V.; McLaughlin, S.H.; Ben-Shahar, T.R.; Verreault, A.; 
Luisi, B.F. and Laue, E.D. Structural basis for the recognition of 
histone H4 by the histone-chaperone RbAp46. Structure, 2008, 16,
1077-1085. 
[77] Senger, T.; Schädlich, L.; Gissmann, L.; Müller, M. Enhanced 
papillomavirus-like particle production in insect cells. Virology,
2009, 388, 344-353. 
[78] Shapiro, A.; Matheny, M.; Zhang, Y.; Tümer, N.; Cheng, K.Y.; 
Rogrigues, E.; Zolotukhin, S.; Scarpace, P.J. Synergy between 
leptin therapy and a seemingly negligible amount of voluntary 
wheel running prevents progression of dietary obesity in leptin-
resistant rats. Diabetes, 2008, 57, 614-622. 
572 Current Genomics, 2009, Vol. 10, No. 8 Nie et al.
[79] Kool, M.; Voncken, J.W.; van Lier, F.L.; Tramper, J.; Vlak, J.M. 
Detection and analysis of Autographa californica nuclear polyhe-
drosis virus mutants with defective interfering properties. Virology,
1991, 183, 739-746. 
[80] De Gooijer, C.D.; Koken, R.H.; Van Lier, F.L.; Kool, M.; Vlak, 
J.M.; Tramper, J. A structured dynamic model for the baculovirus 
infection process in insect-cell reactor configurations. Biotechnol. 
Bioeng., 1992, 40, 537-548. 
[81] Simón, O.; Williams, T.; Caballero, P.; López-Ferber, M. Dynam-
ics of deletion genotypes in an experimental insect virus popula-
tion. Proc. Biol. Sci., 2006, 273, 783-790. 
[82] Bieniossek, C.; Nie, Y.; Frey, D.; Olieric, N.; Schaffitzel, C.; 
Collinson, I.; Romier, C.; Berger, P.; Richmond, T.J.; Steinmetz, 
M.O.; Berger, I. Automated unrestricted multigene recombineering 
for multiprotein complex production. Nat. Methods, 2009, 6, 447-
450. 
[83] Nie, Y.; Bieniossek, C.; Frey, D.; Olieric, N.; Schaffitzel, C.; Ste-
inmetz, M.O.; Berger, I. ACEMBLing multigene expression vec-
tors by recombineering. Nat. Protocols, 2009, DOI: 10.1038/ 
nprot.2009.104. 
[84] Li, M.Z.; Elledge, S.J. Harnessing homologous recombination in 
vitro to generate recombinant DNA via SLIC. Nat. Methods, 2007,
4, 251-256. 
[85] Chiu, W.; Baker, M.L.; Almo, S.C. Structural biology of cellular 
machines. Trends Cell Biol., 2006, 16, 144-150. 
[86] Zhou, Z.H. Towards atomic resolution structural determination by 
single-particle cryo-electron microscopy. Curr. Opin. Struct. Biol.
2008, 18, 218-228. 
[87] Cheng, Y.; Walz, T. The Advent of Near-Atomic Resolution in 
Single-Particle Electron Microscopy. Annu. Rev. Biochem., 2009,
78, 723-742. 
[88] Korostelev, A.; Noller, H.F. The ribosome in focus: new structures 
bring new insights. Trends Biochem. Sci., 2007, 32, 434-441. 
[89] Kornberg, R.D. The molecular basis of eukaryotic transcription. 
Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 12955-12961. 
[90] Ramakrishnan, V. What we have learned from ribosome structures. 
Biochem. Soc. Trans., 2008, 36, 567-574. 
[91] Cramer, P.; Armache, K.J.; Baumli, S.; Benkert, S.; Brueckner, F.; 
Buchen, C.; Damsma, G.E.; Dengl, S.; Geiger, S.R.; Jasiak, A.J.; 
Jawhari, A.; Jennebach, S.; Kamenski, T.; Kettenberger, H.; Kuhn, 
C.D.; Lehmann, E.; Leike, K.; Sydow, J.F.; Vannini, A. Structure 
of eukaryotic RNA polymerases. Annu. Rev. Biophys., 2008, 37,
337-352. 
[92] Pomeranz Krummel, D.A.; Oubridge, C.; Leung, A.K.; Li, J.; Na-
gai, K. Crystal structure of human spliceosomal U1 snRNP at 5.5 A 
resolution. Nature, 2009, 458, 475-480. 
[93] Yan, W.; Hwang, D.; Aebersold, R. Quantitative proteomic analy-
sis to profile dynamic changes in the spatial distribution of cellular 
proteins. Methods Mol. Biol., 2008, 432, 389-401. 
[94] Pflieger, D.; Jünger, M.A.; Müller, M.; Rinner, O.; Lee, H.; Gehrig, 
P.M.; Gstaiger, M.; Aebersold, R. Quantitative proteomic analysis 
of protein complexes: concurrent identification of interactors and 
their state of phosphorylation. Mol. Cell. Proteomics, 2008, 7, 326-
346. 
[95] Roy, P. Baculovirus solves a complex problem. Nat. Biotechnol.,
2004, 22, 1527-1528. 
Thesis  Chapter 1 
Yan NIE  Introduction 
     46 
 
 
 
 
 
Publication 2 
 
 
 
 
 
New baculovirus expression tools for recombinant protein complex production. 
 
Simon Trowitzsch, Christoph Bieniossek, Yan Nie, Frederic Garzoni, and Imre 
Berger. 
 
Journal of Structural Biology. 2010; 172(1):45-54. 
Thesis  Chapter 1 
Yan NIE  Introduction 
     47 
Résumé de la publication 
 
La plupart des protéines eucaryotes existent sous forme d’assemblage multi protéique 
avec plusieurs sous-unités, qui, ensemble, catalysent des activités cellulaires 
spécifiques. Plusieurs de ces machines moléculaires, sont uniquement présentent en 
petites quantités dans leur hôte naturel, ce qui empêche la purification directement à 
partir de leur environnement. Résoudre leur structure ainsi que leur fonction a haute 
résolution dépendra souvent de leur surproduction de façon hétérologue. L’expression 
recombinante de complexes multi protéiques à des fins d’études structurales peut 
impliquer de façon considérable, parfois rédhibitoire, un investissement de dur labeur 
et de matériel, en particulier si chaque sous-unités doivent être altères ou diversifies 
pour déterminer la structure avec succès. Notre laboratoire a relevé ce chalenge en 
développant des technologies qui ont rationalise le processus complexe de production 
et de diversification. Nous passons en revue, ici, plusieurs de ces développements 
pour la production recombinante de complexe multi protéiques en cellules d’insecte 
via baculovirus en utilisant le système MultiBac que nous avons créé. En parallèle, 
nous avons également développe l’assemblage de gêne automatise pour la production 
de complexe multi protéique grâce à la robotique. Nous nous sommes également 
concentre sur plusieurs améliorations du système d’expression en baculovirus que 
nous avons implémentes: modifications des plasmides de transfert, les méthodes de 
générations d’ADN contenant plusieurs gènes, et enfin, la simplification et la 
standardisation des procédures d’expression que nous avons en décrit utilisant notre 
système MultiBac. 
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a b s t r a c t
Most eukaryotic proteins exist as large multicomponent assemblies with many subunits, which act in
concert to catalyze specific cellular activities. Many of these molecular machines are only present in
low amounts in their native hosts, which impede purification from source material. Unraveling their
structure and function at high resolution will often depend on heterologous overproduction. Recombi-
nant expression of multiprotein complexes for structural studies can entail considerable, sometimes
inhibitory, investment in both labor and materials, in particular if altering and diversifying of the individ-
ual subunits are necessary for successful structure determination. Our laboratory has addressed this chal-
lenge by developing technologies that streamline the complex production and diversification process.
Here, we review several of these developments for recombinant multiprotein complex production using
the MultiBac baculovirus/insect cell expression system which we created. We also addressed paralleliza-
tion and automation of gene assembly for multiprotein complex expression by developing robotic rou-
tines for multigene vector generation. In this contribution, we focus on several improvements of
baculovirus expression system performance which we introduced: the modifications of the transfer plas-
mids, the methods for generation of composite multigene baculoviral DNA, and the simplified and stan-
dardized expression procedures which we delineated using our MultiBac system.
Ó 2010 Elsevier Inc. All rights reserved.
1. Introduction
There is growing evidence to support the concept of the eukary-
otic cell as a collection of multisubunit protein machines. These
assemblies participate in most cellular activities such as replica-
tion, transcription, gene regulation, RNA metabolism, translation
and many other processes (Alberts, 1998; Nie et al., 2009; Parrish
et al., 2006; Rual et al., 2005; Wahl et al., 2009). Although some
complexes can be isolated from cells, many other biologically
important assemblies are present in very low amounts and, if at
all, can only be purified with enormous investments from native
source material. Therefore, recombinant protein production tech-
niques have become increasingly indispensable for studying these
complexes at the molecular level (Bieniossek and Berger, 2009; Nie
et al., 2009; Palomares et al., 2004).
Eukaryotic protein complexes often contain many subunits
which depend on each other for proper folding and solubility. If
produced separately, their activity may be compromised due to
the absence of key interaction partners. Overexpression in Esche-
richia coli is the method most commonly used to produce recombi-
nant proteins for structural studies, and significant advances have
been made in the field of recombinant protein complex production
in this cheap and versatile host (Bieniossek et al., 2009; Perrakis
and Romier, 2008; Romier et al., 2006; Tan et al., 2005; Tolia and
Joshua-Tor, 2006). However, many eukaryotic proteins and their
complexes may fail to produce properly in E. coli, due to particular
requirements for chaperone systems or post-translational modifi-
cations that E. coli cannot support. Overproduction of such speci-
mens then necessitates a eukaryotic expression system.
The baculovirus/insect cell system (also called baculovirus
expression vector system, BEVS) more recently has gained particu-
lar prominence for producing such eukaryotic targets. Methods
and vectors for generating recombinant baculoviruses for infecting
insect cell cultures have emerged more than 20 years ago when the
first foreign gene expression with a baculovirus was demonstrated
(Smith et al., 1983). BEVS is robust and well suited for producing
eukaryotic proteins for many applications including the production
of pharmaceuticals, pesticides, vaccines and more recently of gene
therapy vectors (Kost et al., 2005). A number of features of BEVS
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add to the advantages of this method. Importantly, baculoviruses
do not replicate in eukaryotic cells besides their insect cell hosts,
therefore, insect cell expression in the laboratory does not require
particular safety measures (Murphy and Piwnica-Worms, 1994a,b;
Murphy et al., 2004). Large proteins with several hundred kilodal-
ton molecular weight can be produced by BEVS, and the proteins
are often authentically processed. If required, insect cell cultures
are easily grown in bioreactors (Weber et al., 2002). However, cul-
tures grown in regular Erlenmeyer shaker flasks often yield 1–
100 mg per 1 liter insect cell culture, which is sufficient for high-
resolution structural biology projects including X-ray crystallogra-
phy (Fitzgerald et al., 2006, 2007; Bieniossek et al., 2008). To date,
hundreds of eukaryotic proteins, mainly single proteins or do-
mains, have been successfully produced using baculoviral expres-
sion vector systems (Kost and Condreay, 1999; Kost et al., 2005;
Possee, 1997).
Recent genome- and proteome-wide studies have led to biolog-
ical research efforts increasingly focusing on large multiprotein
complexes. As a consequence, baculovirus expression systems for
producing eukaryotic multiprotein assemblies have become a
method of choice in many laboratories. However, a technical draw-
back of the baculovirus/insect cell system was the lack of straight-
forward and easy-to-implement procedures to generate recombi-
nant baculoviruses containing many foreign genes. Furthermore,
once a composite baculovirus was constructed, it could not be
modified easily, partly due to its large size (>130 kb). Exchange
of genes and/or diversifying them by truncation or mutagenesis,
however, is often a prerequisite for successful structural studies
especially by X-ray crystallography. Proteins often need to be
extensively truncated or mutated before they can be coaxed into
forming highly ordered single crystals. We have developed strate-
gies that address these shortcomings of BEVS. We implemented
methods that improve protein production and facilitate protein
diversification. Here, we review strategies that allow rapid and
flexible multiprotein production, and furthermore are adaptable
for high throughput approaches in a robotic setup.
2. Background
Baculoviruses, such as the Autographa californica nuclear poly-
hedrosis virus (AcNPV) of the Baculoviridae family, have three dis-
tinct classes of genes, which are expressed in a chronologically
regulated, sequential manner (Smith et al., 1983; Pennock et al.,
1984). The first class of genes comprises the early genes, which
have host-like promoters and can be transcribed by the host tran-
scriptional machinery (Friesen, 1997). After the onset of viral DNA
replication the late genes are expressed, such as the p10-coding
gene, which require the virus-encoded transcriptional machinery
(Lu and Miller, 1997; Passarelli and Guarino, 2007). Closer to the
end of the infectious cycle the very late genes are expressed which
code for several proteins including polyhedrin. Polyhedrin is the
most abundantly produced protein and forms the characteristic
polyhedra or occlusion bodies in the nuclei of insect cells infected
with wild-type virus. Although late and very late promoter ele-
ments share many similarities, an additional downstream se-
quence, which leads to extremely high levels of transcription, is
present in very late promoters (Ooi et al., 1989).
Heterologous genes driven by AcNPV late and very late promot-
ers are typically abundantly expressed (Roy et al., 1997). This cir-
cumstance was originally exploited for producing the first
recombinant baculoviruses by standard homologous recombina-
tion procedures using transfer plasmids carrying the foreign genes.
These baculoviruses were designed to express chimeric genes con-
sisting of the polyhedrin promoter and the foreign coding sequence.
Expression cassettes comprising the gene of choice flanked by
baculoviral sequences of the polyhedrin region were provided on
the transfer plasmids and integrated into the circular baculovirus
genome by homologous recombination in Spodoptera frugiperda in-
sect cells (usually Sf9 or Sf21 cell lines). Integration occurred into
the polyhedrin locus, thereby eliminating the native polyhedrin
gene, and thus giving rise to occlusion-incompetent recombinants.
A recombination frequency of 0.1% and a tedious isolation proce-
dure of recombinant clones by their distinctive occlusion-negative
plaque phenotype (visualized in plaque assay), however, made
the integration process of foreign genes laborious and difficult.
Integration of DNA fragments into the baculoviral genome was
significantly improved by using linearized rather than circular
baculoviral DNA in the co-transfection experimentwith the transfer
plasmid harboring the gene(s) of choice (Kitts et al., 1990). Homol-
ogy regions present on the baculoviral DNA and the transfer plas-
mid allowed integration of the expression cassettes via
recombination within the insect cell. Heterologous gene products
were only produced from re-circularized, replication competent
viral DNA. This strategy increased the efficiency of recombinant
baculovirus production from 0.1% to 20%. Later, this approach
was further improved by using not only one but several restriction
sites for linearization, thereby reducing background. One restriction
site was placed within an essential viral gene, which was thus trun-
cated. Themissing piece (i.e. a complete gene)was then replenished
from the transfer plasmid upon productive homologous recombina-
tion. Multiple-site linearization of parental virus DNA and concom-
itant functional inactivation of this essential viral gene lead to an
increase in efficiency of recombinant virus production to over 90%
(Kitts and Possee, 1993). A number of companies undertook to com-
mercialize linearized baculoviruses and the corresponding transfer
plasmids (Pharmingen Baculogold, Novagen BacVector series, OET
FlashBac systems and others). Still, the baculovirus plaque assay
to identify positive recombinants remained an essential part of
the method, somewhat complicating its handling.
An elegant way to eliminate the tedious plaque assay for clonal
separation and purification of recombinant viruses relies on in vivo
bacterial transposition (Luckow et al., 1993). Here, baculoviral
genomic DNA isolated from native virus was engineered into an
artificial bacterial chromosome (BAC) containing a resistance mar-
ker and a single-copy bacterial origin of replication. Integration of
DNA fragments into this BAC was accomplished in vivo via a Tn7
attachment site embedded in a lacZa gene on the BAC (Invitrogen,
Bac-to-Bac). Recombinant BACs could be identified in their E. coli
hosts by fast and convenient blue/white screening of bacterial
clones harboring the BAC. Foreign genes flanked by the Tn7L and
Tn7R sequence elements of the Tn7 transposon system, were pro-
vided on the transfer plasmid. Development of a bicistronic trans-
fer vector, pFastBacDUAL, facilitated sequential sub-cloning of two
foreign genes into two separate cassettes for co-expression. A help-
er plasmid provided the Tn7 transposon enzyme complex for cata-
lyzing the transposition event. This Tn7 transposition-based gene
integration principle and its more recent improvements probably
remain most widely used in the community to date (Airenne
et al., 2003; Berger et al., 2004; Laitinen et al., 2005).
Two further approaches to generate recombinant baculoviruses
by transposition were described. In an in vitro transposition system
(BaculoDirect), a gene of choice is transferred from a plasmid into
viral DNA utilizing purified transposase. Upon transposition, a neg-
ative selection marker gene is eliminated from the parental viral
DNA, thus allowing only insect cells transfected with recombined
viral DNA to survive. In an alternative approach, viral DNA carrying
a lethal mutation in a gene product (ORF1629) essential for virus
replication is propagated in E. coli as a BAC and purified. A recom-
bination event in insect cells co-transfected with the mutated bac-
ulovirus genome and a transfer plasmid carrying the gene of
interest and the wild-type viral ORF, reconstitutes the essential
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gene activity upon integration into the viral DNA (Zhao et al.,
2003). In both cases tedious plaque assays are in theory no longer
necessary. Apart from purifying clonal viral populations, the pla-
que assay is also commonly used to determine viral titers, i.e. the
number of infectious viral particles (plaque forming units, pfu)
present in a defined volume of viral supernatant. Also for this pur-
pose, useful alternatives to the time intensive (5–7 days) plaque
assay were developed based on an immunological assay or a PCR
reaction, which can also be used on automated platforms (Bahia
et al., 2005; Chambers et al., 2004; Kitts and Green, 1999; Kwon
et al., 2002; Lo and Chao, 2004; Shen et al., 2002).
Initially, BEVS was used mainly to produce single proteins or
protein domains. Useful concepts for simultaneously integrating
many genes into a single baculovirus were largely lacking. A few
rather make-shift transfer plasmids were commercially available
(Pharmingen, Novagen), that offered single restriction sites in
three, or four, expression cassettes to serially subclone genes of
choice. These plasmids, themselves already around 10 kb in size,
were inconvenient to use in particular if large genes needed to
be integrated. In addition, they did not offer simple means to ex-
change or alter individual genes easily once the vector was assem-
bled, thus severely constraining their utility. An alternative way to
produce complexes is by co-infecting insect cells with several re-
combinant baculoviruses at the same time, with each virus provid-
ing one or two heterologous genes encoding for subunits of the
complex of choice. This strategy certainly has its merit for complex
production in small-scale, which may be sufficient for many bio-
chemical analyses. Reproducible large-scale production, in con-
trast, is a serious challenge with this method, in particular if the
complex contains many subunits and therefore requires many
viruses for simultaneous co-infection. All viruses need to be pro-
duced and maintained at high titer simultaneously. Even then, it
is difficult to ascertain in the experiment if all cells are infected
with all viruses at the same ratio in the culture. In short, co-infec-
tion is not practical for reproducible complex productions on the
scale required for more ambitious structural biology projects
aimed at complex structure elucidation.
Complex production from a single baculovirus, which provides
all genes required, is a viable alternative to co-infection experi-
ments using many different viruses. Evidence suggested that
multigene expression from a single baculovirus indeed is the supe-
rior method for complex production (Bertolotti-Ciarlet et al., 2003;
Miller, 1988; Roy et al., 1997). Virus-like particles, for instance,
were produced successfully in this way (Belyaev and Roy, 1993;
Emery and Bishop, 1987; Noad and Roy, 2003). A prerequisite for
the multigene baculovirus strategy for structural biology of com-
plex eukaryotic systems is that the assembly of the multigene bac-
ulovirus be quick and efficient. Likewise, simple means needed to
be put in place to allow for rapid exchange and alteration of genes
encoding for individual subunits. Ideally, these changes imple-
mented should be compatible with automated procedures, which
are becoming increasingly indispensable in structural biology to
handle the throughput required.
We addressed several of these issues by creating the MultiBac
system for expression of eukaryotic multiprotein complexes in in-
sect cells (Berger et al., 2004). We have since improved the system
and protocols used with a particular view to structural biology
(Fitzgerald et al., 2006, 2007; Bieniossek et al., 2008; Bieniossek
and Berger 2009).
3. The MultiBac system
The MultiBac system utilizes an engineered AcNPV baculovirus
genome derived from the Tn7-based BAC variant described above
(Luckow and Summers, 1988). The MultiBac baculoviral genome,
like its progenitor, is also propagated as a bacterial artificial chro-
mosome in E. coli cells, and contains the F factor as a (mostly) sin-
gle copy origin of replication (occasionally, two copies of the same
DNA with an F origin may exist in the same cell). MultiBac utilizes
a Tn7 attachment site embedded in a lacZa gene for integrating for-
eign genes, via specially designed multigene transfer plasmids into
the baculoviral genome (Fig. 1A). Successful integration of expres-
sion cassettes leads to disruption of the lacZa gene and positive
clones are selected by blue/white screening. We further engineered
a second entry site into the BAC for utilizing the Cre–LoxP recom-
bination system. The system is based on LoxP imperfect inverted
repeats which can be present on different DNA molecules (Ghosh
and Van Duyne, 2002). These LoxP repeats are then recognized
and combined in a site-specific recombination reaction by Cre
recombinase, leading to fusion of the DNAmolecules. To access this
site in the MultiBac BAC, we created a second transfer plasmid
(pUCDM) with a conditional origin of replication (derived from
R6 Kc phage). We carried out recombination of the MultiBac BAC
and this transfer plasmid in vivo in a cell line we created
(DH10MultiBacCre). These cells provide the MultiBac BAC, a plas-
mid for expressing Cre-recombinase, and, a second helper plasmid.
This helper plasmid provides the Tn7 transposon complex for
accessing the Tn7 site on the same MultiBac BAC (Berger et al.,
2004).
The MultiBac baculovirus contains modifications to improve
protein production. We eliminated the baculoviral genes v-cath
and chiA by ET recombination (Berger et al., 2004; Muyrers et al.,
2004) and in the process also integrated the said LoxP imperfect re-
peat sequence (Fig. 1B). V-cath codes for a viral protease which is
activated upon cell death by a process depending on the juxta-
posed gene, chiA (Hom and Volkman, 2000). Deletion of the prote-
ase from a Bombyx mori polyhedrosis virus was shown to improve
protein production (Suzuki et al., 1997). Expression trials with our
modified MultiBac virus showed a remarkable reduction of prote-
olytic breakdown of overproduced proteins (Berger et al., 2004).
Interestingly, it also appeared as if the onset of cell lysis caused
by the viral infection would be considerably delayed as compared
to other baculoviruses available at the time, resulting in benefits to
the heterologous product (Berger et al., 2004; Bieniossek and Ber-
ger, 2009). In fact, several commercial suppliers integrated these
beneficial deletions (and others) into their BEVS (Novagen, OET)
more recently.
3.1. MultiBac 2004: 1st generation transfer plasmids
For multiprotein expression, we engineered modular transfer
plasmids specifically suited for multigene integration. The first
generation of the MultiBac system consisted of two such modular
transfer plasmids, pFBDM and pUCDM (Fig. 1B). pFBDM was de-
rived from pFastBacDUAL (Invitrogen) and has Tn7 transposition
sequences (Tn7R, Tn7L) and an origin of replication (ColE1) that al-
lows propagation in standard E. coli cloning strains (such as TOP10,
DH5a and HB101). pUCDM, on the other hand, has a LoxP recom-
bination site and a conditional origin of replication derived from
the phage R6 Kc. Due to the conditional origin of replication, pUC-
DM requires for its propagation the presence of the pir gene prod-
uct in special E. coli strains, such as BW23473 or BW23474 (Metcalf
et al., 1994). Both pFBDM and pUCDM contained identical dual
expression cassettes driven by polh and p10 viral promoters, as
well as a so-called multiplication module. This multiplicationmod-
ule consists of a set of unique restriction enzyme sites in between
and flanking the expression cassettes. These restriction sites were
designed to facilitate iterative expansion of the expression cas-
settes to accommodate a theoretically unlimited number of genes
in pFBDM and pUCDM (Berger et al., 2004).
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The concept of modular assembly was likewise extended to the
integration of expression cassettes from pFBDM derivatives and/or
pUCDM derivatives into the recipient MultiBac baculoviral gen-
ome. Integration could be carried out in vivo via Cre recombination
and/or Tn7 transposition either simultaneously or sequentially in
DH10MultiBacCre cells, with the Tn7 transposon complex and Cre
recombinase provided on two helper plasmids in trans (Berger
et al., 2004). This explains also the need for the conditional origin
present on pUCDM. During Tn7 transposition, only the DNA in be-
tween the Tn7L and Tn7R sites is integrated into the MultiBac BAC,
and the ColE1 origin of replication, which is located elsewhere on
pFBDM, is not. The Cre reaction, in contrast, results in plasmid fu-
sion, which leads to the integration of the entire pUCDM deriva-
tive, including the replication origin, into the LoxP site on the
MultiBac BAC. The R6 Kc origin is not recognized as a replicon in
DH10MultiBacCre cells, therefore, the copy number of the compos-
ite MultiBac BAC remains under control of the F factor.
The Tn7 transposition site is embedded in a lacZa gene allowing
the selection of positive MultiBac recombinants by blue/white
screening. Since pUCDM carries a chloramphenicol resistance mar-
ker gene, productive MultiBac recombinants can be selected by
challenging with this antibiotic on the selection plate (Berger
et al., 2004). For virus production, we then used the isolated com-
posite MultiBac multigene baculoviral DNA for transfecting Sf21
cells (Sf9 cells or others can likewise be utilized).
Due to its modular nature, the MultiBac system already in its
original conception was adaptable to combinatorial applications
for protein complex production (Berger et al., 2004). Further, low
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Fig. 1. The MultiBac System. (A) The principle of protein production by BEVS relying on Tn7 transposition is shown. The gene of interest, present on a transfer vector, is
integrated via Tn7 transposition into a baculovirus genome maintained as a BAC in special E. coli cells. Composite BAC with the integrated gene of interest is isolated from the
bacterial host and used to transfect insect cell cultures, often resulting in high-level heterologous protein production. (B) Central to protein expression by the MultiBac system
is a BAC carrying a minimal Tn7 attachment site embedded in a lacZa gene and the LoxP imperfect inverted repeat sequence (gray sphere). Both sites are used for gene
integration via transfer plasmid constructs (here pFBDM and pUCDM). Baculoviral genes v-cath and chiA, coding for a cathepsin protease and a chitinase, were eliminated, and
the LoxP imperfect inverted repeat introduced together with an ampicillin resistance marker instead of v-cath. Derivatives of pUCDM are integrated in vivo via Cre
recombination (marked by cross). Derivatives of pFBDM are integrated via Tn7L and Tn7R transposition sequences (black triangles) into the Tn7 attachment site (gray arrow).
Expression cassettes can be generated using multiple-cloning sites (MCS1 and MCS2) and a so-called multiplication module (M) for expression cassette multiplication.
Origins of replication (ColE1, R6 Kc and F-replicon) are indicated. Genes mediating resistance to kanamycin (KanR), chloramphenicol (ChlR), gentamycin (GentR),
spectinomycin (SpecR) and ampicillin (AmpR) are shown as boxes. Gentamycin is used for selecting composite BACs upon productive Tn7 recombination. (C) EMBacY is a more
recent BAC constructed by integration of an expression cassette for enhanced YFP production via Cre recombination. Expression of the YFP-coding gene (arrowmarked YFP) is
under control of the polh promoter and allows for efficient monitoring of virus performance and expression of other heterologous proteins driven by polh from the same BAC.
All transfer plasmids utilized in conjunction with EMBacY contain a LoxP sequence. Assembly of multigene transfer plasmids is performed by using the MCS and the
multiplication module to integrate genes, and subsequent Cre-mediated fusion of Acceptors (derivatives of pFL or pKL) and Donors (derivatives of pUCDM and/or pSPL)
in vitro prior to Tn7 transposition into EMBacY. Acceptors pFL and pKL differ in the origin of replication (ColE1 or BR322, respectively) and the resistance marker (ampicillin or
kanamycin, respectively). pSPL and pUCDM are identical except for the resistance marker (spectinomycin or chloramphenicol, respectively). Derivatives of pUCDM and pSPL
can be used separately or simultaneously for Cre–LoxP fusion with derivatives of either pFL or pKL.
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expression levels of a particular protein subunit could be compen-
sated for by introducing multiple copies of the same gene by using
the multiplication module. The MultiBac system also allows for the
combinatorial co-synthesis of modifying enzymes, such as kinases
or phosphatases and their substrates, in order to enable post-trans-
lational modifications of expressed gene products (Fitzgerald et al.,
2007).
3.2. MultiBac 2006: 2nd generation transfer plasmids
While useful beyond the state-of-the-art for multiprotein com-
plex expression at that time, certain shortcomings of our system
nevertheless soon became evident, particularly when we became
interested in possibly automating multigene assembly. We found
that the concept of the multiplication module still lacked sufficient
flexibility as it relied on cumbersome restriction enzyme reactions
and ligations. Also, the assembly of the multigene baculoviral gen-
ome was dependent on two in vivo events in the DH10MultiBacCre
cells, namely the Cre–LoxP fusion and the Tn7 transposition. Fur-
thermore, due to the size of the BAC being too large for sequencing
or standard restriction mapping (>130 kb), it was not trivial to ver-
ify productive integration events into the LoxP site. However, we
realized that we could instead actually use the Cre–LoxP reaction
before the Tn7 integration step into the baculoviral genome, sim-
ply by providing a LoxP site somewhere in between the Tn7L and
Tn7R sites on the pFBDM transfer vector. By integrating pUCDM
derivatives into such a modified pFBDM variant rather than di-
rectly into the virus, the resulting fusion plasmid could be verified
easily by standard procedures (PCR, sequencing, restriction map-
ping). The entire region between the Tn7L and Tn7R sites contain-
ing the complete pUCDM construct and the genes present on
pFBDM, would then be integrated into the MultiBac BAC by a single
in vivo Tn7 reaction (Fig. 1C). When we used this new approach, we
also noticed that we sometimes integrated two rather than one
copy of the pUCDM derivative into the pFBDM plasmid fitted with
the LoxP site. This multiple insertion would usually occur when we
used a comparatively large excess of pUCDM derivative in the fu-
sion reaction.
These concepts and observations lead us to the creation of the
2nd generation MultiBac system (Fitzgerald et al., 2006, 2007). It
had now two families of modular transfer plasmids, which we
denominated Acceptors (pFL and pKL) and Donors (pUCDM and
pSPL). Acceptors are based on pFBDM and comprise the Tn7 trans-
position elements and regular origins of replication, whereas Do-
nors contain a conditional origin of replication derived from the
phage R6 Kc and a LoxP site (Fig. 1C) Since we had seen that more
than one Donor could be integrated in a single Cre reaction, we
decided to use this to our advantage by creating two Donors which
were identical except for the resistance marker (pUCDM: chloram-
phenicol, pSPL: spectinomycin). The system also provides two
Acceptors, with either a high copy-number (ColE1, pFL) or a low
copy-number (BR322, pKL) origin of replication. We made pKL be-
cause, occasionally, we observed plasmid instability with the high
copy-number origin when sensitive genes were integrated. Fusion
products made by using one Acceptor and one or optionally two
Donors simultaneously are selected via the appropriate antibiotic
resistance marker combinations in pir-negative bacterial strains
(Bieniossek et al., 2008). Multigene cassette containing fusions
can thus be assembled, analyzed and modified in vitro prior to inte-
gration into the baculoviral genome by Tn7 transposition. Both
types of plasmids have independent expression cassettes into
which further expression cassettes can be inserted via the multipli-
cation module, or, alternatively, by seamless cloning procedures
(Berger et al., 2004; Bieniossek et al., 2008). In vitro fusion reactions
of one Acceptor and several Donors can be carried out sequentially
or simultaneously, only requiring a combination of purified Cre en-
zyme, buffer and DNA (Bieniossek et al., 2008; Fitzgerald et al.,
2006).
Notwithstanding the relative ease of combining several to many
genes by taking advantage of multiplication modules, seamless
cloning, Cre fusions and Tn7 transposition in combination, we still
advise to test expression from individual transfer constructs also
before generating the ultimate fusion constructs and moving pre-
maturely to large-scale protein complex production (Fig. 2). Such
a stepwise validation provides a convenient means to identify
‘‘problematic” (in terms of expression) subunits early on, and al-
lows for designing counterstrategies (such as provision of several
copies of that gene). Acceptor derivatives can be directly used for
expression tests by Tn7 transposition into the MultiBac BAC. Donor
derivatives can and should be likewise tested. We recommend
testing the expression of genes in Donor derivatives by fusing with
an ‘‘empty” Acceptor (by Cre–LoxP reaction) and then integrating
the fusion by Tn7 transposition into the MultiBac BAC (Fig. 2).
Composite MultiBac BACs, each carrying expression cassettes
encoding for parts of the multiprotein complex of choice, can be
tested in turn as described. This strategy provides a convenient op-
tion to identify and produce sub-assemblies of a multiprotein com-
plex of choice, which may be of interest for structural analysis.
Virus performance and protein production should be monitored
for all constructs (Fig. 2). Additionally, we typically prepare glyc-
erol stocks of all positive bacterial clones carrying composite Mul-
tiBac BAC.
More recently, we observed that Acceptor–Donor fusions could
be easily deconstructed by making use of the excision activity of
Cre recombinase (Bieniossek et al., 2009). Selective deconstruction
of fusion plasmids enables specific modification of DNA fragments
coding for single subunits of a complex. Vectors carrying the mod-
ified DNA can be readily reintegrated by Cre–LoxP fusion into the
multigene transfer construct and used for expression experiments.
This possibility is especially attractive when multiple versions of a
complex should be tested, for example when limited proteolysis
experiments indicate that certain regions of the subunits should
be altered or eliminated to enhance crystallization prospects. The
simplicity of the combination of various Donors with an Acceptor
by Cre fusion allowed us to script the procedure into a simple rou-
tine which can be easily implemented on a robot, which is useful
for example if many Cre-mediated Acceptor–Donor assembly (or
deconstruction) reactions need to be carried out in parallel (Bieni-
ossek et al., 2009).
3.3. MultiBac 2008: EMBacY virus and standard expression procedures
One of the reasons why E. coli expression is so successful is the
availability of simple standard protocols to carry out expression
experiments even by non-specialist users. We endeavored to de-
sign similar accessible, standardized protocols for protein complex
production using the MultiBac system. We felt that the ‘‘classical”
protocols for baculovirus expression could be significantly stream-
lined to make them more suitable for structural biology applica-
tions at the throughput required. Towards this goal, we
integrated an enhanced yellow fluorescence protein-coding gene
(YFP) under the control of the polyhedrin promoter into the LoxP
site present on the MultiBac BAC (Fig. 1C). The availability of the
new Acceptors with LoxP sequences for in vitro Donor/Acceptor fu-
sions essentially had made the LoxP site on the MultiBac BAC
superfluous. The resulting BAC is called EMBacY. The presence of
YFP serves the purpose of directly observing virus performance
by a very sensitive means, namely by using a fluorescence spectro-
photometer (Bieniossek et al., 2008). YFP is under control of a very
late promoter (polh) as, typically, the heterologous genes of choice.
We observed that when YFP expression reaches a plateau, expres-
sion of other heterologous proteins under the same promoter (and
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by analogy also of p10, another frequently used promoter) also
reach their peak production. Thus, we can follow heterologous pro-
tein production levels by following YFP expression. We had origi-
nally introduced YFP because we wanted to find out whether co-
expression of many foreign genes would saturate our MultiBac
expression experiments and thereby limit recombinant protein
yields. Interestingly, YFP expression remained fairly constant irre-
spective of other heterologous protein products expressed from the
same baculovirus (Berger et al., 2004). With the EMBacY virus we
now were in a position to work out highly standardized protocols
both for virus production and also for heterologous protein expres-
sion by taking advantage of YFP fluorescence (Bieniossek et al.,
2008). In this new setup, we aimed to eliminate all steps we
deemed unnecessary, including for example all virus titer mea-
surements. In summary, we established simple standard protocols
for routine use also by non-specialist users which lead to large-
scale protein production in a reasonable short time frame of not
more than 2 weeks (Fig. 3).
Briefly, selection and isolation of composite BACs requires
roughly 4 days. To obtain initial virus (V0), adhesive Sf21 cells are
transfected with composite EMBacY BACs in a 6-well plate format.
V0 is harvested no later than 48–60 h post-transfection and imme-
diately used to start virus amplification in an Erlenmeyer shaker
flask. After V0 is removed, the monolayers in the 6-well plate are
overlaid with fresh medium and incubated for another 48 h. Then,
these cells are harvested, the YFP signal is measured, and protein
production is analyzed by SDS–PAGE analysis and/or Western blot.
Concomitantly, V1 is amplified in suspension culture in a shaker
flask. In our protocol, it is absolutely mandatory to maintain a low
multiplicity of infection (MOI) during virus production and ampli-
fication. MOI is the number of infectious virus particles (plaque
forming units, pfu) per cell in a cell culture. We experienced that
a low MOI regimen is, in our hands at least, the best way to avoid
detrimental gene deletions which can occur during baculovirus
amplification, adversely affecting protein yields (Braunagel et al.,
1998). Since we choose not to determine virus titers, we ascertain
a low MOI by allowing at least one doubling of the cells in shaker
flask after addition of V0 (Bieniossek et al., 2008). Infected cell cul-
tures in the shaker flasks are split every 24 h to a cell count of be-
low 106 cells/ml until cell proliferation arrest (pa) occurs. After cell
proliferation arrest, 106 cells are sampled from the culture every
12 h and the YFP fluorescence signal is recorded. Amplified virus
(V1) is harvested 48–60 h after cell proliferation arrest and fresh
medium is supplemented to the culture. Again, 106 cells are sam-
pled from the culture every 12 h and the fluorescence signal of
YFP is followed. Finally, cells are harvested when YFP signal has
reached a plateau (typically after 3–4 days), and protein production
is analyzed. Approximately 400 ml of V2 virus are next produced in
2 L Erlenmeyer shaker flasks, strictly repeating the procedures out-
lined for generation of V1. Rather than storing at 4 °C, we freeze V2
by using the space-economic method of storing baculovirus-in-
fected insect cell (BIIC) stocks in liquid nitrogen (Wasilko et al.,
2009). Typically, 1–100 mg of pure protein/protein complex are ob-
tained from 1 L culture by using the MultiBac system and our pro-
tocols. We experimentally determined that occurrence of
defective virus, in which heterologous genes are preferentially
eliminated, is significantly reduced when strictly adhering to our
protocols (Bieniossek et al., 2008; Fitzgerald et al., 2006).
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4. MultiBac exploits
In the years since its introduction, the MultiBac system has
been put to good use in many laboratories (close to 300 by now)
both in academia and industry, in addition to our own. The re-
search interest of our laboratory is eukaryotic gene expression,
and we have produced with MultiBac numerous multisubunit
complexes that are involved in human transcription and its regula-
tion, including chromatin remodeling enzymes and (sub)assem-
blies of human TFIID, a megadalton general transcription factor
(Berger et al., 2004; Fitzgerald et al., 2006, 2007). Others have uti-
lized MultiBac successfully to express a broad range of proteins
and complexes with diverse functions, for biochemical and struc-
tural analyses, with a particularly prominent recent example being
the crystal structure elucidation of the LKB1–STRAD–MO25 com-
plex that revealed an allosteric mechanism of kinase activation
(Zeqiraj et al., 2009) (Fig. 4). We had developed MultiBac for struc-
tural biology applications, and the system initially caught the
interest mainly of other scientists in the structural biology commu-
nity. Interestingly, however, the MultiBac system has in the mean-
time also been put to use by others whose main interest is not
primarily structure. Thus, MultiBac has been used for efficiently
producing virus-like particles (VLPs) from human papilloma virus
serotypes. Here, it turned out to be crucial to integrate more than
one copy of the encoding gene into the baculovirus used in the
expression experiment to achieve efficient VLP formation (Senger
et al. 2009). Among the most intriguing examples for MultiBac ex-
ploits beyond structural biology is its use for generating recombi-
nant adenoviruses for gene therapy-based treatment of obesity in
animals (Shapiro et al., 2008).
5. Outlook: towards automating MultiBac
Baculovirus expression vector systems have proven their worth
over the years for many applications ranging from use as pesticides
to gene therapy vectors (Boyce and Bucher, 1996; Cox and Hollis-
ter, 2009; Garcea and Gissmann, 2004; Hofmann et al., 1995; Jar-
vis, 2009; Kost and Condreay, 1999; Kost et al., 2005; Noad and
Roy, 2003; Petry et al., 2003). BEVS is becoming increasingly uti-
lized in many laboratories, particularly for producing eukaryotic
proteins and their complexes. Illustrative examples for the power
of the method include production of a wide range of virus-like par-
ticles which have been made by using BEVS, for structural and
functional studies and also as promising vaccine candidates (Mar-
anga et al., 2002; Noad and Roy, 2009; Roy and Noad, 2008; Roy
et al., 2009).
Multiprotein complexes with many subunits are increasingly in
the focus of biological research efforts and in order to study them
recombinant overexpression is often required. The production of
multiprotein complexes poses significant challenges in particular
for structural biology applications, where a specimen of interest of-
ten needs to be appropriately tailored and diversified to reach the
quality and homogeneity required for high-resolution analysis.
This necessity is particularly the case in X-ray crystallography.
Here, regions of low complexity may need to be eliminated to al-
low a sample to crystallize. Post-translational modifications may
need to be removed or mimicked, or surface residues may need
to be altered by mutagenesis. Such interventions have often been
indispensable already for single proteins or small binary or ternary
systems. It can be expected that they will be likewise crucial for
analyzing large multisubunit complexes. Certainly, the workload
is bound to increase exponentially when several to many subunits
need to be diversified simultaneously in a multigene expression
setup.
We have recently addressed this imposing bottleneck by
designing experimental procedures for multigene assembly that
were simple and robust enough to be carried out in a parallel fash-
ion for example by using a liquid-handling workstation (Bieniossek
et al., 2009). We have translated corresponding routines into
robotics scripts and validated them by expressing many assemblies
including membrane protein complexes in E. coli (Bieniossek et al.,
2009). We chose E. coli expression as a model system for testing
our automation development, since in this host the multigene con-
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struction could be immediately used for expression trials bypass-
ing the more intricate procedures for composite baculovirus gener-
ation and amplification. The routines we developed included gene
insertion into Donors and Acceptors (fitted with bacterial promot-
ers and terminators) by using sequence and ligation independent
cloning procedures (SLIC, Li and Elledge, 2007), combinatorial Do-
nor–Acceptor fusions using the Cre–LoxP reaction, small-scale
expression of multigene constructs in E. coli and small-scale purifi-
cation in multi-well plate format (Bieniossek et al., 2009).
Originally, our robotic approach was limited to E. coli as an
expression host. Nonetheless, the same procedures with appropri-
ate vectors containing baculoviral promoters and terminators can,
by the same token, be applied to the generation of multigene trans-
fer plasmids by using SLIC and Cre–LoxP reactions for MultiBac
expression experiments. The resulting multigene transfer plasmids
then simply will have to be integrated into the MultiBac or EMBacY
baculoviral genomes by a robust transposition event that can be
automated (Fig. 5). Several studies have emerged recently that
investigated automation of baculovirus generation and small-scale
expression for library screening (Airenne et al., 2003; Laitinen
et al., 2005). We are currently evaluating these and other ap-
proaches for fully automating multigene assembly and small-scale
expression by using our MultiBac system, including means for pro-
ducing biological subunits other than proteins that are parts of
complexes. We anticipate that the successful assembly of such a
eukaryotic complex expression pipeline will prove to be invaluable
for structurally addressing the complex proteome of eukaryotic
organisms.
Fig. 4. Selected MultiBac structure exploits. MultiBac expression was successfully used to produce samples for X-ray structure elucidation of a number of complexes,
including the RbAp46/H4 complex (left, Murzina et al., 2008; PDB code 3CFS); the yeast polymerase a/B subunit complex (center, Klinge et al., 2008; PDB code 3FLO) and
human LKB1–STRAD–MO25 complex (right, Zeqiraj et al., 2009; PDB code 2WTK) and others. Subunits are shown in colors.
Structure Determination 
Analysis of Complex
Small-Scale Complex Purification
Small-Scale Test Expression
Multigene Construct Generation
Gene Integration (e.g. SLIC)
Vector Deconstruction &
Gene Modification
Diversification
Amp
R
Chl
R
Spec
R
X
X X
X X
X X
Experimental Concept
High Throughput Cloning,
Expression & Purification
a
b
c
Automated Eukaryotic 
“Complexomics” Pipeline
Composite Baculovirus
Fig. 5. Towards automating MultiBac. A future automated workflow from target selection to structural characterization of a protein complex, which is adaptable to
automation, is shown schematically (left). After carefully choosing the co-expression strategy to be employed, genes are integrated into Donors and Acceptors by sequence
and ligation independent cloning (SLIC). Multigene Acceptor–Donor fusions are generated by Cre–LoxP reaction and integrated into EMBacY via Tn7 transposition. Insect cell
cultures are infected in small-scale (24-well plate format) for virus and protein production, and proteins are purified (48- or 96-well plate format). Complexes are analyzed
biochemically and biophysically for integrity and functionality. Diversification of complex subunits may be required by mutating or truncating encoding genes to enhance
success prospects for example for obtaining crystals for X-ray diffraction experiments. These can be easily integrated into the workflow in an iterative fashion (right). Fusions
can be deconstructed by using the reverse Cre reaction (excision), and genes of individual expression cassettes are replaced with modified DNA fragments. All constructs are
pre-purified via immobilized metal affinity chromatography in a 96-well plate format and complexes visualized by SDS–PAGE. Ideally, the steps involve only routines that can
be translated into robotics scripts to create an automated ‘‘complexomics” pipeline on a liquid-handling workstation.
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Chapter 2: The ACEMBL system 
 
Abstract 
 
In this chapter I introduce the design, concepts, and applications of our novel 
ACEMBL system, the first truly automatable system in overproducing multiprotein 
complexes in E. coli, by presenting Publication 3 and 4. 
In Publication 3, the design of ACEMBL vectors and the overall workflow of 
the ACEMBL pipeline are presented, together with 22 complex expressions, which 
compellingly validated the production capacity of our ACEMBL system. Detailed 
methods describing subcloning and automation process can be found in the 
Supplementary Material. 
In Publication 4, a protocol detailing gene insertion, assembling single vectors 
and disassembling multifusion plasmids via Cre-LoxP recombination is presented, as 
well as instructions for troubleshooting critical steps. 
 
Résumé 
 
Dans ce chapitre sont introduits au travers des publications 3 et 4: le design, les 
concepts et les applications de notre nouveau system ACEMBL, le premier système 
vraiment automatisable pour la production de complexes multiprotéiques dans E. coli. 
Dans la publication 3 sont présentés la conception des vecteurs du système 
ACEMBL et le déroulement global des opérations lors de l’utilisation de ce système 
automatisé, ainsi que les expressions de 22 complexes, ce qui valide de manière 
convaincante la capacité productive de notre système. Les méthodes détaillées 
décrivant le clonage et l’automatisation du procédé sont décrites dans la partie 
Supplementary Material. 
Dans la publication 4, un protocole détaillant l’insertion de gènes, la fusion de 
vecteurs simples et le désassemblage de plasmides fusionnés par recombinaison Cre-
LoxP est présenté, ainsi que des instructions concernant la résolution des problèmes 
pouvant survenir lors des étapes critiques. 
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Publication 3 
 
 
 
 
 
Automated unrestricted multigene recombineering for multiprotein complex 
production. 
 
Christoph Bieniossek*, Yan Nie*, Daniel Frey, Natacha Olieric, Christiane 
Schaffitzel, Ian Collinson, Christophe Romier, Philipp Berger, Timothy J Richmond, 
Michel O Steinmetz and Imre Berger. 
*contributed equally 
 
Nature Methods 6, 447 - 450 (2009). 
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Résumé de la publication 
 
L’étude fonctionnelle et structurale de plusieurs complexes multi protéiques 
dépendent de la surexpression recombinante de protéine. Les diverses rapides 
expériences ainsi que la diversification de complexes sont souvent cruciales pour le 
succès de ces projets; c’est pourquoi, l’automatisation est de plus en plus 
indispensable. Nous implémentons ici Acembl, un système automatise facile 
d’utilisation pour l’expression de complexe protéiques chez Escherichia coli qui 
utilise le recombinassions pour faciliter l’assemblage de plusieurs gènes ainsi que la 
diversification. Nous avons démontres l’expression de protéines ou de complexes en 
utilisant Acembl, et également la production complète de l’holotranslocon procaryote. 
 
Automated unrestricted
multigene recombineering
for multiprotein complex
production
Christoph Bieniossek1–3,8, Yan Nie1,2,4,8, Daniel Frey5,
Natacha Olieric5, Christiane Schaffitzel1,2,
Ian Collinson6, Christophe Romier7, Philipp Berger5,
Timothy J Richmond3, Michel O Steinmetz5 &
Imre Berger1,2
Structural and functional studies of many multiprotein complexes
depend on recombinant-protein overexpression. Rapid revision of
expression experiments and diversification of the complexes are
often crucial for success of these projects; therefore, automation
is increasingly indispensable. We introduce Acembl, a versatile
and automatable system for protein-complex expression in
Escherichia coli that uses recombineering to facilitate multigene
assembly and diversification. We demonstrated protein-complex
expression using Acembl, including production of the complete
prokaryotic holotranslocon.
Many essential processes in cells are controlled by proteins associat-
ing into interlocking molecular machines, often containing ten or
more subunits1,2. Functional and structural studies that aim to
decipher the physiologically relevant molecular mechanisms of
these complexes are becoming increasingly important in biology.
The low abundance and frequently heterogeneous nature of many
multisubunit complexes, however, often precludes their extraction
from a native source.
Recombinant production methods, with E. coli as the most
common expression host, are thus used for overexpressing proteins
for a variety of applications. Successful functional analysis of
proteins and elucidation of their molecular architecture often
crucially depends on introducing alterations, such as truncations,
mutations and extensions with purification tags, or with particular
promoter and terminator elements. The ensuing requirements in
terms of experimental throughput are already considerable for
diversifying single open reading frames. To streamline the process,
researchers involved in structural genomics efforts have developed
standardized subcloning routines and implemented automated
procedures. The exponential increase in workload when many
open reading frames have to be rapidly diversified and assembled
in the context of a multisubunit complex is daunting and remains
an unresolved challenge.
Several systems have been introduced in recent years for expres-
sion of multiple genes in both eukaryotic and prokaryotic hosts3–7.
Despite considerable improvements of eukaryotic expressionmeth-
ods, in particular baculovirus-based systems3, E. coli still remains
the dominant workhorse in most laboratories, for many good
reasons such as low cost and the availability of many specialized
expression strains. Current co-expression systems for E. coli rely
essentially on serial, mostly conventional (that is, restriction and
ligation) subcloning of protein-coding genes either as single
expression cassettes5,6 or as polycistrons comprising several genes
under the control of the same promoter4. This approach
considerably limits the applicability of these co-expression
techniques for the production of protein complexes with many
subunits, in particular at the throughput typically required for
structural characterization.
A major impediment of such largely serial (one gene at a time)
constructions is the inherent inability to rapidly revise an expres-
sion experiment once the multiprotein complex has been pro-
duced, purified and characterized. However, the ability to make
such changes, including variations of the protein subunits, is
essential for functional and structural analysis. To address this,
we designed a modular multiprotein complex expression system in
E. coli, called Acembl. Multilevel automation is a priority in protein
science, especially in structural genomics efforts8. To our knowl-
edge, Acembl is the first fully automatable system for simple and
rapid assembly and disassembly of multigene constructs for multi-
protein complex expression (Fig. 1).
We had previously introduced the concept of acceptor and donor
vectors for multigene construction via Cre-loxP fusion3. Acembl
uses small (2–3 kb) de novo designed donor and acceptor vectors
that are devoid of surplus DNA (Fig. 1a). Donor vectors have a
conditional origin of replication depending on the expression of a
protein encoded by the phage R6Kg pir gene in trans9. Therefore,
donor vectors can not be propagated in cell strains that do not
express the pir gene, unless they are fused with an acceptor
containing a regular E. coli origin of replication.
Acceptor and donor vectors (Fig. 1a) contain an identical
multiple integration element (MIE) derived from a polylinker4.
One gene (single expression cassette) or several genes (polycistron)
can be inserted into the MIE. We inserted genes by recombination
RECEIVED 6 FEBRUARY; ACCEPTED 16 MARCH; PUBLISHED ONLINE 3 MAY 2009; DOI:10.1038/NMETH.1326
1European Molecular Biology Laboratory, Grenoble Outstation, B.P. 181, Grenoble, France. 2Unit of Virus Host-Cell Interactions, Unite´s Mixtes de Recherche 5233,
Grenoble, France. 3Eidgeno¨ssische Technische Hochschule Zu¨rich, Institut fu¨r Molekularbiologie und Biophysik, Ho¨nggerberg, Zu¨rich, Switzerland. 4Department of
Applied Physics, Royal Institute of Technology, Albanova University Center, Stockholm, Sweden. 5Biomolecular Research, Structural Biology, Paul Scherrer Institut,
Villigen, Switzerland. 6Department of Biochemistry, School of Medical Sciences, Bristol, UK. 7Department of Biology and Structural Genomics, Institute Ge´ne´tique
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using sequence- and ligation-independent cloning (SLIC) proce-
dures10 making use of T4 DNA ligase exonuclease activity to
generate long single-stranded overhangs that can anneal to each
other efficiently (Fig. 1b). Tried-and-tested primer sequences are
present in the MIE, which can be used as adaptors in PCRs to
generate these regions of homology for single or multifragment
SLIC (Supplementary Protocol online). In the experiments shown
here, MIEs are flanked by a T7 (pACE, pACE2 and pDC) or lac
(pDK and pDS) promoter and terminator sequences. These are the
most powerful and widely used promoter systems for E. coli
expression. Note that all donor and acceptor vectors can be fitted
easily with exclusively T7 (or lac) promoters if desired, by exchan-
ging the corresponding DNA fragments (Supplementary Proto-
col). In principle, any other promoter and terminator system can
be inserted in this way.
Each vector contains a homing endonuclease recognition site
(acceptor vectors: I-CeuI; donor vectors: PI-SceI) and a comple-
mentary BstXI site (Fig. 1a). Homing endonucleases are rare cutters
with long (B20–30 bp) recognition sequences that are unique even
in very large DNAs. Digestion by homing endonuclease gives rise to
a specific overhang that matches a corresponding BstXI site. This
can be used to generate multiple expression cassettes iteratively by
insertion of expression cassettes liberated by homing endonuclease
and BstXI digestion into constructs linearized at the homing
endonuclease site (Supplementary Protocol).
We fused donor and acceptor vectors carrying genes of choice via
Cre-loxP plasmid fusion. Cre recombinase–catalyzed plasmid
fusion is an equilibrium reaction that favors the excision reaction11.
When a mixture of donor vectors and an acceptor vector is
incubated with Cre recombinase, single plasmids and all possible
plasmid fusion combinations co-existed in the reaction (Fig. 1c).
These could be conveniently recovered by transforming themixture
into pirÿ strains. By challenging aliquots of the transformed cells
with the appropriate antibiotic combinations and then counter-
selecting in a 96-well microtiter plate, all possible donor-acceptor
fusions could be recovered for expression of the encoded genes in a
combinatorial fashion (Fig. 2).
Notably, the reverse applies as well in the disassembly of
acceptor-donor multigene fusion constructs (Fig. 1c,d). We incu-
bated the tetrameric fusion vector consisting of the acceptor and all
three donors (ADDD) shown in Figure 2 with Cre recombinase
and transformed the reaction into a pir+ strain. Microtiter plate
analysis of the resulting transformants efficiently recovered all
starting plasmids (Z50% efficacy) from the deconstruction
reaction (Supplementary Protocol). We identified partially de-
constructed double and triple fusions in this experiment, implying
that donor or acceptor constructs can be selectively liberated
from the tetramer. This can be exploited, for example, to modify
the gene(s) present in the liberated entity, by mutation, trunca-
tion, replacement with isoforms or homologs of the encoded
protein(s) and so forth, without having to restart the multigene
combination procedure.
We validated Acembl by performing 22 complex expressions,
each with 2–6 different subunits (protein and RNA) and with
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Figure 1 | Multiprotein complex expression with
Acembl. (a) Donor and acceptor vectors contain
loxP sequences and identical MIEs. Origins of
replication (BR322 and R6Kg ori) are indicated.
Promoters (T7, lac), terminators (black squares)
and homing endonuclease sites (dark blue, I-CeuI
and PI-SceI sites) and matching BstXI sites (small
light blue squares) are shown. Antibiotic resistance
genes indicate resistance to the following
antibiotics: Ap, ampicillin; Cm, chloramphenicol;
Kn, kanamycin; and Sp, spectinomycin. (b) Genes
of interest (A, B and C) were amplified by PCR and
inserted into acceptor or donor vectors by single-
gene or multigene SLIC. Ribosome binding sites
(RBS) on forward primers are boxed in black.
Complementary sequences are colored identically.
T4 DNA polymerase-exonuclease–treated DNA
fragments (insert and vector) were mixed and
transformed into appropriate cells (pir+ for donor
vectors). (c) Incubation of acceptor and donor
constructs (genes shown as white arrows) with
Cre recombinase resulted in all combinations of
fusions, including acceptor-donor (AD) and
acceptor-donor-donor (ADD). Fusion constructs
were readily deconstructed in the reverse
approach. (d) In Acembl, genes are integrated by
ligation-independent methods (SLIC) followed by
combinatorial multigene vector generation using
Cre-loxP fusion, protein expression and analysis
of purified complex. Deconstruction by Cre
recombinase–mediated excision liberates starting
vectors for gene modification that are reintegrated
into the workflow in an iterative cycle. The
reactions were scripted into robotic routines
(Supplementary Protocol).
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different protein classes (Fig. 3 and Supplementary Results online)
both manually and also with a robotics setup using a Tecan
Freedom EvoII 200 liquid-handling workstation (Supplementary
Protocol). We expressed fusion constructs and isolated the com-
plexes from E. coli lysates by Ni2+ affinity capture, except in
the case of the holotranslocon transmembrane complex, for
which we prepared and solubilized membrane vesicles manually.
We achieved multigene expression from single gene cassettes,
polycistrons or a combination thereof, involving double,
triple and quadruple acceptor-donor combinations (Fig. 3 and
Supplementary Results).
The efficient soluble expression of full-length human general
transcription factor II F (TFIIF) (Fig. 3a) is noteworthy, as
individual expression of the subunits leads to insoluble material.
Crystal structure analysis of human TFIIF dimerization domain
had necessitated many iterative cycles of limited proteolysis,
recloning, insoluble expression of the designed fragments and co-
refolding12. Such laborious situations are commonplace when
analyzing protein complexes. It is conceivable that the large
investment of labor involved can be substantially reduced applying
the Acembl approach.
In 24-well deep-well plates, we performed multiprotein expres-
sion experiments from all acceptor-donor combination constructs
shown in Figure 2. Analysis of the lysates by Ni2+ affinity capture,
denaturing and western blot revealed expression of all recombinant
proteins and proper complex assembly (Fig. 3b and Supple-
mentary Fig. 1 online), thus illustrating how, with our approach,
multiple genes can be co-expressed in parallel in a combina-
torial fashion.
Using Acembl, we also produced a large multiprotein complex,
the YidC-SecYEGDF holotranslocon, which contains 33 transmem-
brane helices. This machinery is used to transport unfolded
polypeptides into the cell membrane or for translocation into
the periplasm of bacteria13. We isolated the complex from
Figure 3 | Expression of complexes. (a) Denaturing
polyacrylamide gel analysis of uninduced and
induced whole-cell extracts of cells transformed
with pACEMBL-TFIIF, and of hTFIIF purified from
these cells with subunits marked. RAP74 contained
a C-terminal oligohistidine tag. pACEMBL_TFIIF
plasmid diagram is shown below the gel;
30 and 74 mark genes encoding RAP30 and
RAP74-His, respectively. T7, T7 promoter; CmR,
chloramphenicol resistance marker; ApR, ampicillin
resistance marker. (b) All multigene constructs
shown in Figure 2 were assembled and expressed,
and cell lysates were analyzed. The VCB complex
was captured by an oligohistidine-thioredoxin
fusion tag on the Van Hippel–Lindau subunit4
(His-TRX-VHL). FtsH contains an oligohistidine tag at its C terminus14. Fluorescent proteins were identified in lysates by western blot with a mouse
antibody to GFP and a secondary goat antibody to the mouse antibody coupled to alkaline phosphatase. Full-length western blots are presented in
Supplementary Figure 1. (c) Production of the entire prokaryotic transmembrane holotranslocon YidC-SecYEGDF. A breakdown product of SecY is marked with
an asterisk. Marker, Biorad Precision Plus broad range marker. pACEMBL-HTL plasmid diagram is shown below the gel. Y, E, G, D and E mark genes encoding
SecYEGDF. Ara, arabinose promoter; and trc, trp-lac promoter.
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Figure 2 | Acceptor-donor recombineering. Genes encoding for Van Hippel–
Lindau ElonginC-ElonginB (VCB) complex4, FtsH soluble domain14, BFP and
monomeric GFP (mGFP) with a coiled-coil domain15 were inserted into pACE,
pDC, pDK and pDS, respectively. Cre recombinase–mediated fusion was
followed by transformation into pirÿ cells (TOP10). Aliquots were plated on
agar with two, three or four antibiotics as indicated by boxes outlining
regions of the 96-well plate. Four colonies from each plate were grown in a
96-well microtiter plate. Labels left of the plate image denote antibiotics
contained in media aliquots in horizontal rows. Wells in the bottom two rows
were charged differently (labels below the plate image). Those inoculated
with four colonies each from one agar plate are boxed in black and labeled
with antibiotics contained in the agar plate. Four vertical rows in each such
16-well box were inoculated with the same colony. In the bottom two rows,
four wells in a row were inoculated with the same colony. Expected vector
architecture of the double (AD), triple (ADD) and quadruple (ADDD) fusions is
shown left or right (16-well boxes), respectively, or below (bottom two rows)
the plate image. Red dye was used as positional marker.
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detergent-solubilized membrane vesicles (Fig. 3c). We anticipate
that factorial approaches for detergent solubilization will mature
into formats that eventually can be incorporated into our robotic
process to allow expression and detergent-mediated solubilization
of many other membrane protein complexes. Moreover, proteins
such as YajC and SecA associate with the translocon13. Using pDK
and pDS for Cre recombinase–mediated integration of genes
encoding SecA and YajC, our modular setup should allow us to
assemble an even larger functional translocon complex.
Arrays of genes, encoding subunits of a particular multiprotein
complex, and potentially also accessory proteins such as chaper-
ones, specific kinases or phosphatases, can be assembled, dis-
assembled and exchanged using the Acembl system. This offers
intriguing avenues for combinatorial analyses of protein-protein
interactions or of interactions between protein complexes and
modifiers. Interactions between several multiprotein complexes
may also be studied in this way. We showed that the steps involved
in multigene assembly, construct analysis, small scale expression
and complex purification can be scripted into a robotics routine.
We anticipate that automated recombineering will be extended to
investigating reciprocal functional relationships between entire
arrays of protein complexes and their variants, in a rapid and
flexible systems approach, by using E. coli as a convenient and
robust expression host.
METHODS
Methods and any associated references are available in the online
version of the paper at http://www.nature.com/naturemethods/.
Note: Supplementary information is available on the Nature Methods website.
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ONLINE METHODS
System design and vector preparation. Acembl vectors were
created from the respective fragments (origin of replication,
resistance marker gene, loxP) by standard methods including SLIC
methods10 as well as restriction and ligation. An AlwNI site
(asymmetric recognition sequence) was incorporated in every
vector backbone between the antibiotic resistance marker and
the origin of replication, to render these elements easily exchange-
able. The MIE including homing endonuclease sites and comple-
mentary BstXI sites were synthesized by a commercial supplier
(GenScript Corporation). All vectors were verified by DNA
sequencing (Macrogen Inc.). Vector sequences were compiled by
using the program VectorNTI (Invitrogen) and plasmid maps were
generated by using the program DNAMAN version 4.0 (Lynnon
Corporation). Sequences and maps are provided in the Supple-
mentary Protocol. Requests for Acembl reagents should be
addressed to I.B. (iberger@embl.fr).
DNA manipulation. Genes of interest were inserted into the MIE
of the Acembl system by using SLIC and, in select cases, also
restriction and ligation (Supplementary Results). Primers contain
the sequences necessary for insertion (SLIC homology region or
restriction sites) and optionally the sequences encoding ribosome
binding sites, tags or stop codons. DNA sequences used to design
the primers are listed in the Supplementary Protocol. Step-by-
step instructions to insert genes, both by SLIC (manually and with
a robot) as well as by restriction and ligation (manually) are
provided in the Supplementary Protocol. If only domains rather
than full-length proteins were used in the complex expression
experiments, the exact amino acid residue boundaries are listed in
Supplementary Results.
Reactions using Cre recombinase enzyme (fusion and decon-
struction) were carried out according to the recommendations of
commercial suppliers of the Cre enzyme. In the experiments,
commercial Cre recombinase (New England Biolabs) was used,
as well as Cre recombinase supplied by the European Molecular
Biology Laboratory (EMBL) core facility (EMBL Heidelberg).
All DNA manipulation, including expression cassette multi-
plication by using homing endonucleases, is detailed, both for
manual and robotic applications, in the Supplementary Protocol.
Multiprotein expression and purification. hTFIIF and VCB-BFP-
mGFP-FtsH series: fusion plasmids encoding for hTFIIF, or the
VCB-BFP-mGFP-FtsH series, respectively, were expressed over-
night in BL21(DE3) cells in 24 well deep-well plates in small scale
using Studier autoinduction media. Ampicillin was added to the
growth media (to 100 mg mlÿ1). Proteins were purified by Ni2+
capture as described in the Supplementary Protocol.
Holotranslocon YidC-SecYEGDF: subunits SecY, SecE and SecG
were present as a polycistron in pDCtrc, a derivative of pDC
containing a trc promoter instead of T7. Subunits YidC, SecD and
SecF are present as a polycistron in pACEara, a derivative of pACE
with an arabinose promoter instead of T7 (Supplementary
Results). Owing to the presence of two separately inducible
promoters, expression of the respective polycistrons is regulated
separately by addition of isopropyl b-D-1-thiogalactopyranoside
(IPTG) and L-arabinose, respectively. Holotranslocon was
expressed in BL21 cells in Terrific Broth (TB) media in the
presence of ampicillin (100 mg mlÿ1) and chloramphenicol
(25 mg mlÿ1). Overexpressed holotranslocon components were
identified by specific immunological staining of the subunits in a
western blot (data not shown). Membrane vesicles were prepared
manually using standard buffers and procedures13. Detergent
solubilised holotranslocon was purified by our standard Ni2+
capture as described in the Supplementary Protocol. For purifica-
tion by size exclusion chromatography using a S300 gel filtration
column (GE Healthcare), expression was scaled up to 1-l volume,
and Ni2+ capture was carried out by using nickel-NTA agarose
(Qiagen GmbH) packed in a 5 ml column (GE Healthcare).
Complexes S1–S12: complexes S1–S12 (Supplementary
Results) were expressed using the standard protocols provided
in the Supplementary Protocol. Exceptions with respect to
expression strains used, as well as special buffer conditions,
necessary owing to the particular nature of the complexes, are
listed in the Supplementary Results. All expressions were scaled
up to 1 l of culture volume for purifying the protein complexes by
size exclusion chromatography (SEC). All preparations were
carried out by applying the following standard protocol.
Cell pellets from 1 l cultures were obtained by centrifugation at
6,891g (6,000 r.p.m. using a Beckman Coulter Avanti J20 centri-
fuge with a Beckman JLA rotor) at 4 1C. Pellets were resuspended
in Buffer A (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
DTT). Cells were lysed by sonication on ice, with a Bioblock
Scientific Ultrasonic Processor Vibracell 75115. A broad tip was
used, with a total sonication time of 7 min, 10-s pulse at 15-s
intervals, at an amplitude of 80%. Lysates were cleared by
centrifugation at 15,366g (14,000 r.p.m. in a Beckman Coulter
Avanti J-20 XP centrifuge with a Beckman JA20 rotor) for 30 min
at 4 1C. Lysates then were passed to fresh tubes and centrifugation
repeated with identical equipment settings.
Cleared lysates were passed over a nickel-NTA HighTrap col-
umn with 1-ml volume (Qiagen) by using an Aekta Prime FPLC
(GE Healthcare). Complexes were washed with 10 column
volumes Buffer A and eluted by applying a linear gradient to
100% Buffer B (50 mM TrisHCl pH 7.5, 150 mM NaCl, 1 mM
DTT, 500 mM imidazole). In certain cases, Buffers A and B
contained additives that were required for complex formation
(Supplementary Results).
Eluates from Ni-NTA affinity capture were pooled and con-
centrated by using Millipore concentrators with 3 kDa molecular
weight cutoff. Concentrates were then purified by using an Aekta
Explorer FPLC or Aekta Purifier FPLC (GE Healthcare) by SEC
using the columns listed in Supplementary Results. The columns
used for SEC were pre-equilibrated by passing at least ten column
volumes of Buffer A over the columns, optionally supplemented
by specific reagents as listed in the Supplementary Results.
Gel electrophoresis. Samples (10–12 ml) from peak fractions of
SEC or from Ni-NTA plate elutions, respectively, were loaded
manually on 12% or 15% denaturing gels using a Biorad Minigel
system, pre-run at 135 V for 25 min, and then run for 65–70 min
at 185 V. Gels were stained with Coomassie Brilliant Blue accord-
ing to standard procedures. Gel images were prepared by scanning
with a HP Scanjet 7650 photo scanner using software HPScanning
version 4.5 with default settings (highlights, 15; shadows, ÿ69; and
midtones, 0) at 300 d.p.i., or, alternatively by photography using a
Vilber-Lourmat Bioprint 6.21 photo documentation system with
softwareBioCapt version 11.02 (Vilber-Lourmat). The obtained
doi:10.1038/nmeth.1326 NATURE METHODS
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TIF files were integrated into images of the SEC traces by using
Adobe Illustrator CS3 version 13.0.0.
Agarose gels were stained with ethidium bromide and gel
images recorded by using the Vilber-Lourmat documentation
system in conjunction with a LKB 2011 MacroVue transillumina-
tor (LKB-Produkter AB).
Western blot. Fluorescent proteins mGFP and BFP in the VCB-
mGFP-mBFP-FtsH expression series were detected by western
blotting. The pellet of a 1.5 ml bacterial culture was resuspended
in 500 ml of 1 La¨mmli buffer and the cells were lysed with 5
pulses of a Branson sonifier (Cell Disruptor B15, output control
on level 4, 40% duty cycle). The disrupted cells were centrifuged
for 5 min at 10,000g, and the supernatant transferred to a new
tube. The supernatants separated by 12% SDS–polyacrylamide gel
electrophoresis (BioRad Mini Protean II, 1 mm thick, 10 slots per
gel). Three gels with different amounts of lysate were run in
parallel (Supplementary Fig. 1) for 1 h at 25 mA with All Blue
Precision Plus Protein standards (BioRad) as marker.
Proteins were transferred on PVDF membrane (Immobilon-P,
Millipore IPV00010) with a Biometra semidry blotter according to
manufacturer’s recommendations. Fluorescent proteins were iden-
tified by western blotting with a mouse antibody to GFP (Roche;
1814460, 1:1000 in Tris-buffered (pH. 7.5) saline Tween-20 (TBST)
with 3% BSA. A goat antibody to mouse antibody coupled to
alkaline phosphatase (Sigma), diluted 1:10,000 in TBST with 3%
milk powder was used as the secondary antibody. Blots were deve-
loped with the ECL Plus Western Blotting System (GE Healthcare),
exposed for 5 s on Hyperfilm ECL X-ray film (GE Healthcare) and
the X-ray film was then developed with an Agfa Curix 60 machine.
The positions of the visible marker lanes were assigned with a pen.
The film was scanned in the grayscale mode with 8 bit depth on an
Epson Perfection 4870 Photo scanner and then saved as a TIF file.
The three full length blots are shown in Supplementary Figure 1.
NATURE METHODS doi:10.1038/nmeth.1326
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Supplementary Figure 1  
Full-length Western blots of fluorescent proteins 
In each image, lane 1 corresponds to the lysate of the VCB expression, lane 2 to VCB-BFP, 
lane 3 to VCB-mGFP, lane 4 to VCB-BFP-mGFP, and lane 5 to VCB-BFP-mGFP-FtsH (c.f. 
Fig. 3b). Three gels with different amounts of lysate (40 ?l on upper left gel, 20 ?l on upper 
right gel, and 10 ?l on lower left gel) were run in parallel for 1 hour at 25 mA with All Blue 
Precision Plus Protein Standards as marker (BioRad, 161-0373). Proteins were transferred 
onto PVDF membrane (Immobilon-P, Millipore IPV00010) with a Biometra semidry blotter 
according to manufacturer’s recommendation. Fluorescent proteins were identified by 
Western blotting with a mouse anti GFP antibody (Roche 1814460, 1:1000 in 3% 
BSA/TBST).  A goat anti mouse antibody coupled to alkaline phosphatase (Sigma, 1:10'000 
in 3% milk powder/TBST) was used as the secondary antibody. The blots were developed 
with the ECL Plus Western Blotting System (Amersham), exposed for 5 seconds on 
Hyperfilm ECL X-ray film (Amersham) and the X-ray film was then developed with an Agfa 
Curix 60 machine. The positions of the visible marker lanes were assigned with a pen. The 
film was scanned in the grayscale mode with 8 bit depth on a Epson Perfection 4870 Photo 
scanner and then saved as a TIF file. Segments shown in Fig. 3b were generated from the 
lower left image by using the crop tool in Adobe Photoshop CS3 Extended Version 10.0. 
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1Supplementary Results
Subunit    MW Affinity Tag1 Vector Remarks2,3
I.  Protein-RNA Complexes 
Signal recognition particle SRP (E. coli)
Ffs 4.5 S - pACE Complex S1
Ffh 45 kDa His5 (C) pDK 
SRP/SRP Receptor (E. coli)
FtsY 56 kDa - pDS Complex S2
Ffs 4.5 S - pACE 
Ffh 45 kDa His5 (C) pDK 
II. Transmembrane Complexes 
SecA/SecYEG/AMPPNP (E. coli)
SecA 96 kDa His6 (N) pACE Complex S3
50 ?M AMPPNP in buffers SecY 49 kDa - pDCtrc
(tricistron)SecE 15 kDa His6 (N)
SecG 12 kDa - 
Holotranslocon HTL (E. coli)
YidC 63 kDa His6 (C) pACEara
(tricistron)
Main text, Fig. 3c 
ara and trc promoters 
S300 SEC 
SecD 68 kDa -  
SecF 36 kDa - 
SecY 49 kDa - pDCtrc
(tricistron)SecE 15 kDa His6 (N)
SecG 12 kDa - 
III. Pathogen Complex 
Urease AB (H. pylori)
UreA 27 kDa His6 (N) pACE Complex S4
2 mM Ni2+ in SEC bufferUreB 62 kDa - pDK 
IV. Viral Targeting Complex 
Influenza PB2c/human Importin 5 
PB2c  11 kDa - pDK Complex S5
PB2c: PB2 AA 693-736 Importin 5  53 kDa His6 (N) pACE 
V. RNA Quality Control Complex4
UPF1/UPF2/UPF3 (human)
UPF1 90 kDa His6 (N) pDC Complex S6
UPF1: AA 115-914 
UPF2: AA 761-1237 
UPF3: AA 45-217 
UPF2 50 kDa - pACE 
UPF3 21 kDa - pDK 
VI. Transcription Factor Complexes 
TFIIF 
RAP30 28 kDa - pACE Main text,  Fig. 3a 
RAP74 60 kDa His5 (C) pDC 
   NFYB/NFYC (A, 2 plasmids, co-transformed)
NFYB 11.3 kDa - pACE Complex S7a
Restriction/Ligation,
S75HR SEC 
NFYB: AA 49-141 
NFYC: AA 27-120 
NFYC 10.8 kDa His6 (N) pACE2 
Nature Methods: doi: 10.1038/nmeth.1326
2   NFYB/NFYC (B, 2 cassettes, single plasmid)
NFYB 11.3 kDa - pACE2 Complex S7b
Restriction/Ligation,
S75HR SEC 
NFYB: AA 49-141 
NFYC: AA 27-120 
NFYC 10.8 kDa His6 (N)
TFIIA complex  
TFIIA?  7 kDa  - pDS Complex S8
TFIIA?: AA 2-59  
          ???AA 325-376?
TFIIA??? AA 2-103?
     TFIIA?  9 kDa His (N) pACE 
TFIIA? 12 kDa - pDC
VII. Nuclear Repressor Complex 
HDAC5 Rprc/CaM/Ca
2+
CaM 17 kDa - pACE Complex S9
Rprc: HDAC5 AA 40-308 
2 mM Ca2+ in all buffers
Rprc  21 kDa His6 (C) pDC 
IIX. Tumor Supressor Complex 
Van Hippel-Lindau/ElonginB/ElonginC5
VHL 33 kDa HisTRX (N) pACE 
(tricistron)
Main text, Fig. 3b 
FtsH: AA 147-610 
VHL: AA 54-213 
ElonginC: AA 17-112
ElonginB 13 kDa - 
ElonginC 11 kDa - 
FtsH 53 kDa His6 (C) pDC 
mGFP 32 kDa - pDS 
BFP 28 kDa - pDK 
IX. Endosomal trafficking complex 
AMSH/CHMP
AMSH 38 kDa HisTRX (N) pACE Complex S10
AMSH: AA 1-206 
CHMP: AA 8-222 
CHMP 25 kDa - pDK 
X. mRNA maturation complex (yeast)
Snu17p/PmI1p  complex  
Snu17p  19 kDa His6 (N) pACE Complex S11
Restriction/LigationPmI1p 24 kDa - pDC 
RES complex (A, two plasmid fusion)
Snu17p  19 kDa His6 (N) pACE Complex S12a
Restriction/Ligation,
HE/BstXI multiplication 
Bud13p 31 kDa - pDC 
(2 cassette) PmI1p 24 kDa - 
RES complex (B, three plasmid fusion)
Snu17p  19 kDa His6 (N) pACE Complex S12b
Restriction/LigationBud13p 31 kDa - pDK 
PmI1p 24 kDa - pDC 
1 C and N denote carboxy- and amino-terminal tag placement, respectively. 
2 Protein classes are denoted with roman numerals. Proteins are full-length unless indicated. 
3  All complexes were expressed in BL21 or BL21(DE3) E.coli cells, and  purified by Ni2+ capture 
and S200 SEC (or S75HR for NFYB/NFYC) in 50mM Tris pH 7.5, 150 mM NaCl, 1mM DTT. 
4 Protein complexes in classes V to IX are all from human. 
5 Co-expressions of VCB complex with fluorescent marker proteins and FtsH. 
Nature Methods: doi: 10.1038/nmeth.1326
3Complexes S1-S12b were purified by IMAC followed by size exclusion chromatography 
(SEC) as indicated. SEC chromatograms are shown below. An S200HR (Pharmacia) column 
was used unless indicated otherwise. Arrows denote elution position of smaller assemblies or 
individual subunits. 
SDS-PAGE sections of fractions through the SEC peaks were stained with Coomassie Brilliant 
Blue. For complexes S1 and S2, agarose gels (2%) of same fractions were analyzed by 
ethidium bromide staining of the RNA component. Molecular weights (kDa) or sizes (bp) are 
indicated.
Methods: doi: 10.1038/nmeth.1326
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A. Synopsis 
ACEMBL is a 3
rd
 generation multigene expression system for complex production in 
E. coli, created at the European Molecular Biology Laboratory EMBL, at Grenoble.
ACEMBL can be applied both manually and also in an automated setup by using a 
liquid handling workstation. ACEMBL applies tandem recombination steps for 
rapidly assembling many genes into multigene expression cassettes. These can be 
single or polycistronic expression modules, or a combination of these elements. 
ACEMBL also offers the option to employ conventional approaches involving 
restriction enzymes and ligases if desired, which may be the methods of choice in 
laboratories not familiar with recombination approaches. 
The following strategies for multigene assembly and expression are provided 
for in the ACEMBL system and detailed in Sections B and C:  
(1) Single gene insertions into vectors (recombination or restriction/ligation) 
(2) Multigene assembly into a polycistron (recombination or restriction/ligation) 
(3) Multigene assembly using homing endonucleases 
(4) Multigene plasmid fusion by Cre-LoxP reaction 
(5) Multigene expression by cotransformation 
These strategies can be used individually or in conjunction, depending on the project 
and user. 
In Section C, step-by-step protocols are provided for each of the methods for 
multigene cassette assembly that can be applied in the ACEMBL system. Each 
procedure is illustrated by corresponding complex expression experiments in Section 
D of this Supplement.  
In Section F, detailed workflows are provided for implementing ACEMBL in 
a robotic environment, here by using a Tecan EvoII 200 liquid handling workstation. 
DNA sequences of ACEMBL vectors are provided in the Appendix and can 
be copied from there for further use. 
A  Manual further detailing ACEMBL procedures can be downloaded from 
http://www.embl.fr/research/services/berger/ACEMBL.pdf. Updates to this Manual 
will be made available there. 
Requests for ACEMBL system kit components can be addressed to Imre 
Berger (iberger@embl.fr). 
Nature Methods: doi: 10.1038/nmeth.1326
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B. ACEMBL System    
B.1. ACEMBL vectors 
At the core of the technology are five small de novo designed vectors which are 
called “Acceptor” and “Donor” vectors (Illustration 1). Acceptor vectors (pACE, 
pACE2) contain origins of replication derived from ColE1 and resistance markers 
(ampicillin or tetracycline). Donor vectors contain conditional origins of replication 
(derived from R6K?), which make their propagation dependent on hosts expressing 
the pir gene. Donor vectors contain resistance markers kanamycin, chloramphenicol, 
spectinomycin. Up to three Donor vectors can be used in conjunction with one 
Acceptor vector 
Illustration 1: ACEMBL system for multiprotein complex production. 
 
All Donor and Acceptor vectors contain a loxP imperfect inverted repeat and 
in addition, a multiple integration element (MIE). This MIE consists of an expression 
cassette with a promoter of choice (prokaryotic, mammalian, insect cell specific or a 
combination thereof) and a terminator (prokaryotic, mammalian, insect cell specific 
Nature Methods: doi: 10.1038/nmeth.1326
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or a combination thereof). In between is a DNA segment which contains a number of 
restriction sites that can be used for conventional cloning approaches or also for 
generating double-strand breaks for the integration of expression elements of choice 
(further promoters, ribosomal binding sites, terminators and genes). The MIE is 
completed by a homing endonuclease site and a specifically designed restriction 
enzyme site (BstXI) flanking the promoter and the terminator (see B.2.) Vector DNA 
sequences are provided in the Appendix. Maps of all vectors are shown at the end of 
this manual. 
B.2. The multiple integration element (MIE) 
Illustration 2: The multiple integration element, schematic view. 
 
The MIE was derived from a polylinker
1
 and allows for several approaches for 
multigene assembly (Section C). Multiple genes can be inserted into the MIE of any 
one of the vectors by a variety of methods, for example BD-In-Fusion recombination
2
 
or SLIC (sequence and ligation independent cloning
3
. For this, the vector needs to be 
linearized, which can also be carried out efficiently by PCR reaction with appropriate 
primers, since the vectors are all small (2-3.0 kb). Use of ultrahigh-fidelity 
polymerases such as Phusion
4
 is recommended. Alternatively, if more conventional 
approaches are preferred i.e. in a regular wet lab setting without robotics, the vectors 
can also be linearized by restriction digestion, and a gene of interest can be integrated 
by restriction / ligation (Section C). The DNA sequence of the MIE is shown in the 
Appendix. 
1
 Tan, S. et al. Protein Expr. Purif. 40, 385 (2005) 
2
 ClonTech TaKaRa Bio Europe, www.clontech.com  
3
 Li, M. and Elledge, S., Nat. Methods 4, 251 (2007) 
4
 Finnzymes/New England BioLabs, www.neb.com 
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B.3. Tags, promoters, terminators 
 
Current vectors of the ACEMBL system contain per default promoters T7 and Lac, as 
well as the T7 terminator element (Illustr.1, 10). The T7 system is most commonly 
used currently; it requires bacterial strains which contain a T7 polymerase gene in the       
E. coli genome. The Lac promoter is a strong endogenous promoter which can be 
utilized in most strains. All ACEMBL vectors contain the lac operator element for 
repression of heterologous expression.  
  
Evidently, all promoters and terminators present in ACEMBL Donor and 
Acceptor vectors, and in fact the entire multiple integration element (MIE) can be 
exchanged with a favored expression cassette of choice by using restriction/ligation 
cloning with appropriate enzymes (for example ClaI/PmeI, Illustration 2) or insertion 
into linearized ACEMBL vectors where the MIE was removed by sequence and 
ligation independent approaches such as SLIC. We have substituted the T7 promoter 
in pDC with a trc promoter (pDC
trc
), and the T7 promoter in pACE with an arabinose 
promoter (pACE
ara
) and used the resulting vectors successfully in coexpression 
experiments by inducing with arabinose and IPTG.  
 
Currently, the ACEMBL system vectors do not contain DNA sequences 
encoding for affinity tags to facilitate purification or solubilization of the protein(s) of 
interest. We typically use C- or N-terminal oligohistidine tags, with or without 
protease sites for tag removal. We introduce these by means of the respective PCR 
primers used for amplification of the genes of interest prior to SLIC mediated 
insertion. We recommend to outfit Donors or Acceptors of choice by the array of 
custom tags that are favored in individual user laboratories prior to inserting 
recombinant genes of interest. This is best done by a design which will, after tag 
insertion, still be compatible with the recombination based principles of ACEMBL 
system usage. 
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B.4. Complex Expression 
For expression in E.coli, the ACEMBL multigene expression vector fusions with 
appropriate promoters or terminators are transformed into the appropriate expression 
host of choice. In the current version (T7 and lac promoter elements), most of the 
wide array of currently available expression strains can be utilized. If particular 
expression strains already contain helper plasmids with DNA encoding for 
chaperones, lysozyme or else, the design of the multigene fusion should ideally be 
such that the ACEMBL vector containing the resistance marker that is also present on 
the helper plasmid is not included in multigene vector construction (although this is 
probably not essential). 
Alternatively, the issue can be resolved by creating new versions of the 
ACEMBL vectors containing resistance markers that circumvent the conflict. This 
can be easily performed by PCR amplifying the vectors minus the resistance marker, 
and combine the resulting fragments with a PCR amplified resistance marker by 
recombination (SLIC) or blunt-end ligation (using 5’phosphorylated primers). Note 
that resistance markers can also be exchanged in between ACEMBL vectors by 
restriction digestion with AlwNI and ClaI (for Donors) and AlwNI and PmeI (for 
Acceptors). 
Donor vectors depend on the pir gene product expressed by the host, due to 
the R6K? conditional origin of replication. In regular expression strains, they rely on 
fusion with an Acceptor for productive replication. Donors or Donor-Donor fusions 
can nonetheless be used even for expression when not fused with an Acceptor, by 
using expression strains carrying a genomic insertion of the pir gene. Such strains 
have more recently become available (Novagen Inc., Madison WI, USA). 
Cotransformation of two plasmids can also lead to successful protein complex 
expression. The ACEMBL system contains two Acceptor vectors, pACE and pACE2, 
which are identical except for the resistance marker (Illustration 1). Therefore, genes 
present on pACE or pACE2, respectively, can be expressed by cotransformation of 
the two plasmids and subsequent exposure to both tetracyclin and ampicillin 
simultaneously. In fact, entire Acceptor-Donor fusions containing several genes, 
based on pACE or pACE2 as Acceptors, can in principle be cotransformed for mutli-
expression, if needed. 
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C. Procedures 
 
C.1. Cloning into ACEMBL vectors   
All Donors and Acceptors contain an identical MIE with exception of the homing 
endonuclease site / BstXI tandem encompassing the MIE (Illustrations 1 and 12). The 
MIE is tailored for sequence and ligation independent gene insertion methods. In 
addition, the MIE also contains a series of unique restriction sites, and therefore can 
be used as a classical polylinker for conventional gene insertion by 
restriction/ligation. We suggest to choose the methods a user lab is most proficient 
with. For automated applications, restriction/ligation is essentially ruled out. In this 
case, recombination approaches can be used efficiently for gene insertion (SLIC). 
C1.1. Single gene insertion into the MIE by SLIC 
Several procedures for restriction/ligation independent insertion of genes into vectors 
have been published or commercialized (Novagen LIC, Becton-Dickinson BD In-
Fusion and others), each with its own merit. These systems share in common that 
they rely on the exonuclease activity of DNA polymerases. In the absence of dNTPs, 
5’ extensions are created from blunt ends or overhangs by digestion from the 3’ end. 
If two DNA fragments contain the same ~20 bp sequence at their termini at opposite 
ends, this results in overhangs that share complementary sequences capable of 
annealing. This can be exploited for ligation independent combination of two or 
several DNA fragments containing homologous sequences.  
If T4 DNA polymerase is used, this can be carried out in a manner that is 
independent of the sequences of the homology regions (Sequence and Ligation 
Independent Cloning, SLIC) and detailed protocols became available. In the context 
of multiprotein expression, this is particularly useful, as the presence of unique 
restriction sites, or their creation by mutagenesis, in the ensemble of encoding DNAs 
ceases to be an issue.  
We adapted SLIC for inserting encoding DNAs amplified by Phusion 
polymerase into the ACEMBL Acceptor and Donor vectors according to the 
published protocols. In this way, not only seamless integration of genes into the 
expression cassettes, but also concatamerization of expression cassettes to multigene 
constructs can be achieved by applying the same, simple routine that can be readily 
automated.  
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Illustration 3:  Single gene insertion by SLIC. A gene of interest (GOI 1) is PCR 
amplified with specific primers and integrated into a vector (Acceptor, Donor) 
linearized by PCR with complementary primers (complementary regions are 
shaded in light gray or dark grey, respectively).  Resulting PCR fragments contain 
homology regions at the ends. T4 DNA polymerase acts as an exonuclease in the 
absence of dNTP and produces long sticky overhangs. Mixing (optionally 
annealing) of T4DNA polymerase exonuclease treated insert and vector is 
followed by transformation, yielding a single gene expression cassette. 
 
We use an improved protocol for SLIC which was modified from the original 
publication
5
. This protocol as applied manually is detailed below (Protocol 1). If 
other systems are used (BD-InFusion etc.), follow manufacturers’ recommendations. 
For robotics applications, modifications of the protocol may be necessary and are 
detailed elsewhere in Section F. 
Protocol 1: Single gene insertion by SLIC.  
Reagents required: 
Phusion Polymerase 
5x HF Buffer for Phusion Polymerase 
dNTP mix (10 mM) 
T4 DNA polymerase (and10x Buffer) 
DpnI enzyme 
E. coli competent cells  
100mM DTT, 2M Urea, 500 mM EDTA 
 Antibiotics 
                                                
5
 Li, M. and Elledge, S., Nat. Methods 4, 251 (2007) 
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Step 1: Primer design 
Primers for the SLIC procedure are designed to provide the regions of homology  
which result in the long sticky ends upon treatment with T4 DNA polymerase in 
the absence of dNTP: 
Primers for the insert contain a DNA sequence corresponding to this region of 
homology (“Adaptor sequence” in Illustration 3, inset), followed by sequence 
which specifically anneals to the insert to be amplified Illustration 3, inset). 
Useful adaptor sequences for SLIC are listed below (Table I). 
If the gene of interest (GOI) is amplified from a vector already containing 
expression elements (e.g. the pET vector series), this “insert specific sequence” 
can be located upstream of a ribosome binding site (rbs). Otherwise, the forward 
primer needs to be designed such that a ribosome binding site is also provided in 
the final construct (Illustration 3, inset). 
Primers for PCR linearization of the vector backbone are simply complementary 
to the two adaptor sequences present in the primer pair chosen for insert 
amplification (Illustration 3). 
Step 2: PCR amplification of insert and vector 
Identical reactions are prepared in 100-?l volume for DNA insert to be cloned 
and vector to be linearized by PCR: 
 
ddH2O    75 ?l 
5? Phusion HF Reaction buffer    20 ?l 
dNTPs (10 mM stock)      2 ?l 
Template DNA (100 ng/?l)      1 ?l 
5??SLIC?primer (100 ?M stock)      1 ?l 
3??SLIC?primer (100 ?M stock)      1 ?l 
Phusion polymerase (2 U/?l)   0.5 ?l 
PCR reactions are then carried out with a standard PCR program (unless very 
long DNAs are amplified, then double extension time): 
1 x 98? C for 2 min 
30 x [98? C for 20 sec. -> 50?C for 30 sec. -> 72?C for 3 min] 
Hold at 10?C 
Analysis of the PCR reactions by agarose gel electrophoresis and ethidium 
bromide staining is recommended. 
Methods: doi: 10.1038/nmeth.1326
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Step 3: DpnI treatment of PCR products (optional) 
PCR reactions are then supplied with 1 ?l DpnI enzyme which cleaves parental 
plasmids (that are methylated). For insert PCR reactions, DpnI treatment is not 
required if the resistance marker of the template plasmid differs from the 
destination vector. 
Reactions are then carried out as follows: 
Incubation:  37?C for 1-4h 
Inactivation:  80?C for 20 min 
Step 4: Purification of PCR products 
! PCR products must be cleaned of residual dNTPs !
Otherwise, the T4 DNA polymerase reaction (Step 5) is compromised. 
Product purification is best performed by using commercial PCR Purification Kits 
or NulceoSpin Kits (Qiagen, MacheryNagel or others). It is recommended to 
perform elution in the minimal possible volume indicated by the manufacturer. 
Step 5: T4 DNA polymerase exonuclease treatment  
Identical reactions are prepared in 20-?l volume for insert and for vector (eluted 
in Step 4): 
10x T4 DNA polymerase buffer     2 ?l 
100mM DTT     1 ?l 
2M Urea     2 ?l 
DNA eluate from Step 3 (vector or insert)    14 ?l 
T4 DNA polymerase       1 ?l 
Reactions are then carried out as follows: 
Incubation:  23?C for 20 min 
Arrest:      Addition of 1 ?l 500 mM EDTA 
Inactivation:  75?C for 20 min 
Step 6: Mixing and Annealing 
T4 DNA polymerase exonuclease treated insert and vector are then mixed, 
followed by an (optional) annealing step which was found to enhance efficiency
6
: 
T4 DNA pol treated insert:     10 ?l 
T4 DNA pol treated vector:     10 ?l 
Annealing:  65?C for 10 min 
Cooling:  Slowly (in heat block) to RT 
Step 7: Transformation 
Mixtures are next transformed into competent cells following standard 
transformation procedures.  
Reactions for pACE and pACE2 derivatives are  transformed into standard E. coli 
cells for cloning (such as TOP10, DH5?, HB101) and after recovery (24h) plated 
                                                
6 Dr. Rolf Jaussi, PSI Villigen, personal communication 
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on agar containing ampicillin (100 ?g/ml) or tetracycline (25 µg/ml), 
respectively. 
Reactions for Donor derivatives are transformed into E. coli cells expressing the 
pir gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated 
on agar containing chloramphenicol (25 ?g/ml, pDC), kanamycin (50 µg/ml, 
pDK), and spectinomycin (50 µg/ml, pDS).  
Step 8: Plasmid analysis 
Plasmids are cultured in small-scale in media containing the corresponding 
antibiotic, and analyzed by sequencing and (optionally) restriction mapping with 
an appropriate restriction enzyme. 
 
C1.2. Polycistron assembly in MIE by SLIC 
The multiple integration element can also be used to integrate genes of interest by 
using multi-fragment SLIC recombination as shown in Illustration 4. Genes preceded 
by ribosome binding sites (rbs) can be assembled in this way into polycistrons. 
Illustration 4: Generating a polycistron by SLIC. Genes of interest (GOI 
1,2,3) are PCR amplified with specific primers and integrated into a vector 
(Acceptor, Donor) linearized by PCR with primers complementary to the ends of 
the forward primer of the first (GOI 1) and the reverse primer of the last (GOI 3) 
gene to be assembled in the polycistron (complementary regions are shaded in 
light gray or dark grey, respectively).  Resulting PCR fragments contain 
homology regions at the ends. T4 DNA polymerase acts as an exonuclease in the 
absence of dNTP and produces long sticky overhangs. Mixing (optionally 
annealing) of T4DNA polymerase exonuclease treated insert and vector is 
followed by transformation, yielding a polycistronic expression cassette. 
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Protocol 2. Polycistron assembly by SLIC. 
Reagents required: 
Phusion Polymerase 
5x HF Buffer for Phusion Polymerase 
dNTP mix (10 mM) 
T4 DNA polymerase (and 10x Buffer) 
DpnI enzyme 
E. coli competent cells  
100mM DTT, 2M Urea, 500 mM EDTA 
 Antibiotics 
Step 1: Primer design 
The MIE element is composed of tried-and-tested primer sequences. These 
constitute the “Adaptor” sequences that can be used for inserting single genes or 
multigene constructs. Recommended adaptor sequences are listed in Table I.  
Adaptor sequences form the 5’ segments of the primers used to amplify DNA 
fragments to be inserted into the MIE. Insert specific sequences are added at 3’, 
DNA encoding for a ribosome binding sites can be inserted optionally if not 
already present on the PCR template 
Step 2: PCR amplification of insert and primer 
Identical reactions are prepared in 100-?l volume for all DNA insert (GOI 1,2,3) 
to be cloned and the vector to be linearized by PCR: 
 
ddH2O    75 ?l 
5? Phusion HF Reaction buffer    20 ?l 
dNTPs (10 mM stock)      2 ?l 
Template DNA (100 ng/?l)      1 ?l 
5??SLIC?primer (100 ?M stock)      1 ?l 
3??SLIC?primer (100 ?M stock)      1 ?l 
Phusion polymerase (2 U/?l)   0.5 ?l 
PCR reactions are then carried out with a standard PCR program (unless very 
long DNAs are amplified, then double extension time): 
1 x 98? C for 2 min 
30 x [98? C for 20 sec. -> 50?C for 30 sec. -> 72?C for 3 min] 
Hold at 10?C 
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Analysis of the PCR reactions by agarose gel electrophoresis and ethidium 
bromide staining is recommended. 
Step 3: DpnI treatment of PCR products (optional) 
PCR reactions are then supplied with 1 ?l DpnI enzyme which cleaves parental 
plasmids (that are methylated). For insert PCR reactions, DpnI treatment is not 
required if the resistance marker of the template plasmids differs from the 
destination vector. 
Reactions are then carried out as follows: 
Incubation:  37?C for 1-4h 
Inactivation:  80?C for 20 min 
Step 4: Purification of PCR products 
! PCR products must be cleaned of residual dNTPs !
Otherwise, the T4 DNA polymerase reaction (Step 5) is compromised. 
 
Product purification is best performed by using commercial PCR Purification Kits 
or NulceoSpin Kits (Qiagen, MacheryNagel or others). It is recommended to 
perform elution in the minimal possible volume indicated by the manufacturer. 
Step 5: T4 DNA polymerase exonuclease treatment 
Identical reactions are prepared in 20-?l volume for each insert (GOI 1,2,3) and 
for the vector (eluted in Step 4): 
 
10x T4 DNA polymerase buffer     2 ?l 
100mM DTT     1 ?l 
2M Urea     2 ?l 
DNA eluate from Step 3 (vector or insert)    14 ?l 
T4 DNA polymerase      1 ?l 
Reactions are then carried out as follows: 
Incubation:  23?C for 20 min 
Arrest:      Addition of 1 ?l 500 mM EDTA 
Inactivation:  75?C for 20 min 
Step 6: Mixing and Annealing 
T4 DNA polymerase exonuclease treated insert and vector are then mixed, 
followed by an (optional) annealing step which was found to enhance efficiency
7
: 
 
T4 DNA pol treated insert 1 (GOI 1):       5 ?l 
T4 DNA pol treated insert 2 (GOI 2):       5 ?l 
T4 DNA pol treated insert 3 (GOI 3):       5 ?l 
T4 DNA pol treated vector:       5 ?l 
Annealing:  65?C for 10 min 
Cooling:  Slowly (in heat block) to RT 
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Step 7: Transformation 
Mixtures are next transformed into competent cells following standard 
transformation procedures.  
Reactions for pACE and pACE2 derivatives are  transformed into standard E. coli 
cells for cloning (such as TOP10, DH5?, HB101) and after recovery plated on 
agar containing ampicillin (100 ?g/ml) or tetracycline (25 µg/ml), respectively. 
Reactions for Donor derivatives are transformed into E. coli cells expressing the 
pir gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated 
on agar containing chloramphenicol (25 ?g/ml, pDC), kanamycin (50 µg/ml, 
pDK), and spectinomycin (50 µg/ml, pDS).  
Step 8: Plasmid analysis 
Plasmids are cultured and correct clones are selected based on specific restriction 
digestion and DNA sequencing of the inserts. 
 
 
Table I. Adaptor DNA sequences. 
For single gene or multigene insertions into ACEMBL vectors by SLIC. 
Adaptor1 Sequence Description
T7InsFor TCCCGCGAAATTAATACGAC
TCACTATAGGG
Forward primer for insert amplification, if gene of 
interest (GOI) is present in a T7 system vector (i.e. 
pET series).  
No further extension (rbs, insert specific overlap) 
required. 
T7InsRev CCTCAAGACCCGTTTAGAGG
CCCCAAGGGGTTATGCTAG
Reverse primer for insert amplification, if GOI is 
present in a T7 system vector (i.e. pET series).  
No further extension (stop codon, insert specific 
overlap) required. 
T7VecFor CTAGCATAACCCCTTGGGGC
CTCTAAACGGGTCTTGAGG
Forward primer for vector amplification, reverse 
complement of T7InsRev. 
No further extension required. 
T7VecRev CCCTATAGTGAGTCGTATTA
ATTTCGCGGGA
Reverse primer for vector amplification, reverse 
complement of T7InsFor. 
No further extension required. 
NdeInsFor GTTTAACTTTAAGAAGGAGA
TATACATATG
Forward primer for insert amplification for 
insertion into MIE site I1 (Illustration 2). 
Further extension at 3’ (insert specific overlap) 
required. 
Can be used with adaptor  XhoInsRev in case of 
single fragment SLIC (Illustr. 3). 
XhoInsRev GGGTTTAAACGGAACTAGTC
TCGAG
Reverse primer for insert amplification for 
insertion into MIE site I4 (Illustr. 2). 
Further extension at 3’ (stop codon, insert specific 
overlap) required. 
Can be used with adaptor NdeInsFor in case of 
single fragment SLIC (Illustr. 3). 
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XhoVecFor CTCGAGACTAGTTCCGTTTA
AACCC
Forward primer for vector amplification, reverse 
complement of .XhoInsRev 
No further extension required. 
NdeVecRev CATATGTATATCTCCTTCTT
AAAGTTAAAC
Reverse primer for vector amplification, reverse 
complement of NdeInsFor. 
No further extension required. 
SmaBam GAATTCACTGGCCGTCGTTT
TACAGGATCC
Reverse primer for insert amplification (GOI1) for 
insertion into MIE site I1 (Illustr. 2). 
Further extension at 3’ (stop codon, insert specific 
overlap) required. 
Use with adaptor .NdeInsFor. 
BamSma GGATCCTGTAAAACGACGGC
CAGTGAATTC
Forward primer for insert amplification (GOI2) for 
insertion into site I2 (Illustr. 2,4). 
Further extension at 3’ (rbs, insert specific 
overlap) required. 
Use with adaptor .SacHind.(multifragment SLIC, 
Illustr. 4) 
SacHind GCTCGACTGGGAAAACCC
TGGCGAAGCTT
Reverse primer for insert amplification (GOI2) 
insertion into MIE site I2 (Illustr. 2, 4). 
Further extension at 3’ (stop codon, insert specific 
overlap) required. 
Use with adaptor .BamSma.(multifragment SLIC, 
Illustr. 4) 
HindSac AAGCTTCGCCAGGGTTTT
CCCAGTCGAGC
Forward primer for insert amplification (GOI3) for 
insertion into site I3 (Illustr. 2,4). 
Further extension at 3’ (rbs, insert specific 
overlap) required. 
Use with adaptor .BspEco.(multifragment SLIC, 
Illustr. 4) 
BspEco5 GATCCGGATGTGAAATTG
TTATCCGCTGGTACC
Reverse primer for insert amplification (GOI3) 
insertion into MIE site I3 (Illustr. 2, 4). 
Further extension at 3’ (stop codon, insert specific 
overlap) required. 
Use with adaptor .HindSac.(multifragment SLIC, 
Illustr. 4) 
Eco5Bsp GGTACCAGCGGATAACAA
TTTCACATCCGGATC
Forward primer for insert amplification (GOI3) for 
insertion into site I4 (Illustr. 2,4). 
Further extension at 3’ (rbs, insert specific 
overlap) required. 
Use with adaptor .XhoInsRev .(multifragment 
SLIC, Illustr. 4) 
1
All Adaptor primers (without extension) can be used as sequencing primers for 
genes of interest that were inserted into the MIE. 
___________________________________________________________________________
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C.1.3. Gene insertion by restriction/ligation 
The MIE can also be interpreted as a simple multiple cloning site with a series of 
unique restriction sites. The MIE is preceded by a promoter and a ribosome binding 
site, and followed by a terminator, therefore, cloning into the MIE by classical 
restriction/ligation also yields functional expression cassettes.  
Genes of interest can be subcloned by using standard cloning procedures into 
the multiple integration element (MIE) (see Appendix) of ACEMBL vectors (the 
MIE is identical in all vectors).  
Protocol 3. Restriction/ligation cloning into the MIE. 
Reagents required: 
Phusion Polymerase 
5x HF Buffer for Phusion Polymerase 
dNTP mix (10 mM) 
10 mM BSA 
Restriction endonucleases (and 10x Buffer) 
T4 DNA ligase (and 10x Buffer) 
Calf or Shrimp intestinal alkaline phosphatase 
E. coli competent cells  
 Antibiotics 
Step 1: Primer design 
 
For conventional cloning, PCR primers are designed containing chosen restriction 
sites, preceded by appropriate overhangs for efficient cutting (c.f. New England 
Biolabs catalogue), and followed by ?20 nucleotides overlapping with the gene of 
interest that is to be inserted. 
All MIEs are identical in the ACEMBL vectors. They contain a ribosome binding 
preceding the NdeI site. For single gene insertions, therefore, a rbs need not be 
included in the primer.  
If multigene insertions are planned (for example in insertion sites I1-I4 of the 
MIE), primers need to be designed such that a rbs preceding the gene and a stop 
codon at its end are provided.    
In particular for polycistron cloning by restriction/ligation, is recommended to 
construct templates by custom gene synthesis. In the process, the restriction sites 
present in the MIE can be eliminated from the encoding DNAs.  
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Step 2: Insert preparation 
PCR of insert(s): 
Identical PCR reactions are prepared in 100 ?l volume for genes of interest to be 
inserted into the MIE: 
 
ddH2O    75 ?l 
5? Phusion HF Reaction buffer    20 ?l 
dNTPs (10 mM stock)      2 ?l 
Template DNA (100 ng/?l)      1 ?l 
5??primer (100 ?M stock)      1 ?l 
3??primer (100 ?M stock)      1 ?l 
Phusion polymerase (2 U/?l)   0.5 ?l 
PCR reactions are then carried out with a standard PCR program (unless very 
long DNAs are amplified, then double extension time): 
1 x 98? C for 2 min 
30 x [98? C for 20 sec. -> 50?C for 30 sec. -> 72?C for 3 min] 
Hold at 10?C 
Analysis of the PCR reactions by agarose gel electrophoresis and ethidium 
bromide staining is recommended. 
 
Product purification is best performed by using commercial PCR Purification 
Kits or NulceoSpin Kits (Qiagen, MacheryNagel or others). It is recommended to 
perform elution in the minimal possible volume indicated by the manufacturer. 
Restriction digestion of insert(s): 
Restriction reactions are carried out in 40 ?l reaction volumes, using specific 
restriction enzymes as specified by manufacturer’s recommendations (c.f. New 
England Biolabs catalogue and others). 
  
PCR Kit eluate (?1 ?g)   30 ?l 
10x Restriction enzyme buffer     4 ?l 
10 mM BSA     2 ?l 
Restriction enzyme for 5’      2 ?l 
Restriction enzyme for 3’  2 ?l  (in case of double 
digestion, otherwise 
ddH2O) 
Restriction digestions are performed in a single reaction with both enzymes 
(double digestion) or sequentially (two single digestions) if the buffer conditions 
required are incompatible. 
Gel extraction of insert(s): 
Processed insert is then purified by agarose gel extraction using commercial kits 
(Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in 
the minimal volume defined by the manufacturer. 
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Step 3: Vector preparation 
Restriction digestion of ACEMBL plasmid(s): 
Restriction reactions are carried out in 40 ?l reaction volumes, using specific 
restriction enzymes as specified by manufacturer’s recommendations (c.f. New 
England Biolabs catalogue and others). 
  
ACEMBL plasmid (?0.5 ?g) in ddH2O   30 ?l 
10x Restriction enzyme buffer     4 ?l 
10 mM BSA     2 ?l 
Restriction enzyme for 5’      2 ?l 
Restriction enzyme for 3’   2 ?l  (in case of double 
digestion, otherwise 
ddH2O) 
Restriction digestions are performed in a single reaction with both enzymes 
(double digestion) or sequentially (two single digestions) if the buffer conditions 
required are incompatible. 
Gel extraction of vector(s): 
Processed vector is then purified by agarose gel extraction using commercial kits 
(Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in 
the minimal volume defined by the manufacturer. 
Step 4: Ligation 
Ligation reactions are carried out in 20 ?l reaction volumes according to the 
recommendations of the supplier of T4 DNA ligase: 
 
ACEMBL plasmid (gel extracted)     8 ?l 
Insert (gel extracted)   10 ?l 
10x T4 DNA Ligase buffer     2 ?l 
T4 DNA Ligase     0.5 ?l 
Ligation reactions are performed at 25ºC (sticky end) for 1h or at 16ºC (blunt 
end) overnight.  
Step 5: Transformation 
Mixtures are next transformed into competent cells following standard 
transformation procedures.  
Reactions for pACE and pACE2 derivatives are  transformed into standard E. coli 
cells for cloning (such as TOP10, DH5?, HB101) and after recovery plated on 
agar containing ampicillin (100 ?g/ml) or tetracycline (25 µg/ml), respectively. 
Reactions for Donor derivatives are transformed into E. coli cells expressing the 
pir gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated 
on agar containing chloramphenicol (25 ?g/ml, pDC), kanamycin (50 µg/ml, 
pDK), and spectinomycin (50 µg/ml, pDS).  
Step 6: Plasmid analysis 
Plasmids are cultured and correct clones are selected based on specific restriction 
digestion and DNA sequencing of the inserts. 
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C.1.4. Multiplication by using the HE and BstXI sites 
All ACEMBL system vectors contain a homing endonuclease (HE) site and a 
designed BstXI site that envelop the multiple integration element (MIE). The homing 
endonuclease site can be used to insert entire expression cassettes, containing single 
genes or polycistrons, into a vector already containing one gene or several genes of 
interest. Homing endonucleases have long recognition sites (20-30 base pairs or 
more). Although not all equally stringent, homing endonuclease sites are most 
probably unique in the context of even large plasmids, or, in fact, entire genomes.  
In the ACEMBL system, Donor vectors contain a recognition site for homing 
endonuclease PI-SceI (Illustr. 2). This HE site yields upon cleavage a 3’ overhang 
with the sequence -GTGC. Acceptor vectors contain the homing endonuclease site I-
CeuI, which upon cleavage will result in a 3’ overhang of -CTAA. On Acceptors and 
Donors, the respective HE site is preceding the MIE. The 3’ end of the MIE contains 
a specifically designed BstXI site, which upon cleavage will generate a matching 
overhang. The basis of this is the specificity of cleavage by BstXI. The recognition 
sequence of BstXI is defined as CCANNNNN’NTGG (apostrophe marks position of 
phosphodiester link cleavage). The residues denoted as N can be chosen freely. 
Donor vectors thus contain a BstXI recognition site of the sequence 
CCATGTGC’CTGG, and Acceptor vectors contain CCATCTAA’TTGG. The 
overhangs generated by BstXI cleavage in each case will match the overhangs 
generated by HE cleavage. Note that Acceptors and Donors have different HE sites. 
 The recognition sites are not symmetric. Therefore, ligation of a HE/BstXI 
digested fragment into a HE site of an ACEMBL vector will be (1) directional and (2) 
result in a hybrid DNA sequence where a HE halfsite is combined with a BstXI 
halfsite. This site will be cut by neither HE nor BstXI. Therefore, in a construct that 
had been digested with a HE, insertion by ligation of HE/BstXI digested DNA 
fragment containing an expression cassette with one or several genes will result in a 
construct which contains all heterologous genes of interest, enveloped by an intact 
HE site in front, and a BstXI site at the end. Therefore, the process of integrating 
entire expression cassettes by means of HE/BstXI digestion and ligation into a HE 
site can be repeated iteratively. 
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Protocol 4. Multiplication by using homing endonuclease/BstXI. 
Reagents required: 
Homing endonucleases PI-SceI, I-CeuI 
10x Buffers for homing endonucleases 
Restriction enzyme BstXI (and 10x Buffer) 
T4 DNA ligase (and 10x Buffer) 
E. coli competent cells  
 Antibiotics 
Step 1: Insert preparation 
Restriction reactions are carried out in 40 ?l reaction volumes, using homing 
endonucleases PI-SceI (Donors) or I-CeuI (Acceptors) as recommended by the 
supplier (c.f. New England Biolabs catalogue and others). 
  
ACEMBL plasmid ( ? 0.5 ?g) in ddH2O    32 ?l 
10x Restriction enzyme buffer     4 ?l 
10 mM BSA     2 ?l 
PI-SceI (Donors) or I-CeuI (acceptors)      2 ?l 
  
Reactions are then purified by PCR extraction kit or acidic ethanol precipitation, 
and next digested by BstXI according to the recommendations of the supplier. 
 
HE digested DNA in ddH2O   32 ?l 
10x Restriction enzyme buffer     4 ?l 
10 mM BSA     2 ?l 
BstXI     2 ?l 
Gel extraction of insert(s): 
Processed insert is then purified by agarose gel extraction using commercial kits 
(Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in 
the minimal volume defined by the manufacturer. 
Step 2: Vector preparation 
Restriction reactions are carried out in 40 ?l reaction volumes, using homing 
endonucleases PI-SceI (Donors) or I-CeuI (Acceptors) as recommended by the 
supplier (c.f. New England Biolabs catalogue and others). 
  
ACEMBL plasmid ( ? 0.5 ?g) in ddH2O    33 ?l 
10x Restriction enzyme buffer     4 ?l 
10 mM BSA     2 ?l 
PI-SceI (Donors) or I-CeuI (acceptors)      1 ?l 
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Reactions are then purified by PCR extraction kit or acidic ethanol precipitation, 
and next treated with intestinal alkaline phosphatase according to the 
recommendations of the supplier. 
 
HE digested DNA in ddH2O   17 ?l 
10x Alkaline phosphatase buffer     2 ?l 
Alkaline phosphatase     1 ?l 
 
Gel extraction of vector: 
Processed vector is then purified by agarose gel extraction using commercial kits 
(Qiagen, MachereyNagel etc). It is recommended to elute the extracted DNA in 
the minimal volume defined by the manufacturer.  
Step 3: Ligation 
Ligation reactions are carried out in 20 ?l reaction volumes: 
HE/Phosphatase treated vector (gel extracted)     4 ?l 
HE/BstXI treated insert (gel extracted)   14 ?l 
10x T4 DNA Ligase buffer     2 ?l 
T4 DNA Ligase  0.5 ?l 
Ligation reactions are performed at 25ºC for 1h or at 16ºC overnight.  
Step 4: Transformation 
Mixtures are next transformed into competent cells following standard 
transformation procedures.  
Reactions for pACE and pACE2 derivatives are  transformed into standard E. coli 
cells for cloning (such as TOP10, DH5?, HB101) and after recovery plated on 
agar containing ampicillin (100 ?g/ml) or tetracycline (25 µg/ml), respectively. 
Reactions for Donor derivatives are transformed into E. coli cells expressing the 
pir gene (such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plated 
on agar containing chloramphenicol (25 ?g/ml, pDC), kanamycin (50 µg/ml, 
pDK), and spectinomycin (50 µg/ml, pDS).  
Step 5: Plasmid analysis 
Plasmids are cultured and correct clones selected based on specific restriction 
digestion and DNA sequencing of the inserts. 
 
Note: Integration can likewise be performed by sequence and ligation independent 
cloning. It is recommended to carry out linearization of the vector by digestion with 
HE, if heterologous genes are already present, to avoid PCR amplifications over 
encoding regions. The fragment to be inserted is generated by PCR amplification 
resulting in a PCR fragment containing a 20-25 base pair stretch at its 5’ end that is 
identical to the corresponding DNA sequence present at the HE site counted from the 
site of cleavage towards 5’ (site of cleavage is position -4). At the 3’ end of the PCR 
fragment, the homology region is 20-25 base pairs counted from the site of cleavage 
towards 3’. 
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C.2. Cre-LoxP reaction of Acceptors and Donors 
 
Cre recombinase is a member of the integrase family (Type I topoisomerase from 
bacteriophage P1). It recombines a 34 bp loxP site in the absence of accessory protein 
or auxiliary DNA sequence. The loxP site is comprised of two 13 bp recombinase-
binding elements arranged as inverted repeats which flank an 8 bp central region 
where cleavage and ligation reaction occur. 
The site-specific recombination mediated by Cre recombinase involves the 
formation of a Holliday junction (HJ). The recombination events catalyzed by Cre 
recombinase are dependent on the location and relative orientation of the loxP sites. 
Two DNA molecules, for example an Acceptor and a Donor plasmid, containing 
single loxP sites will be fused. Furthermore, the Cre recombination is an equilibrium 
reaction with 20-30% efficiency in recombination. This provides useful options for 
multigene combinations for multiprotein complex expression. 
Illustration 5: LoxP imperfect inverted repeat 
 
             13bp                      8bp                       13bp 
 
5’…ATAACTTCGTATA GCATACAT TATACGAAGTTAT…3’ 
3’…TATTGAAGCATAT CGTATGTA ATATGCTTCAATA…5’ 
                          inverted repeat     spacer     inverted repeat 
 
In a reaction where several DNA molecules such as Donors and Acceptors are 
incubated with Cre recombinase, the fusion/excision activity of the enzyme will result 
in an equilibrium state where single vectors (educt vectors) and all possible fusions 
coexist. Donor vectors can be used with Acceptors and/or Donors, likewise for 
Acceptor vectors. Higher order fusions are also generated where more than two 
vectors are fused. This is shown schematically in Illustration 6. 
The fact that Donors contain a conditional origin of replication that depends 
on a pir
+
 (pir positive) background now allows for selecting out from this reaction 
mix all desired Acceptor-Donor(s) combinations. For this, the reaction mix is used to 
transform to pir negative strains (TOP10, DH5?, HB101 or other common laboratory 
cloning strains). Then, Donor vectors will act as suicide vectors when plated out on 
agar containing the antibiotic corresponding to the Donor encoded resistance marker, 
unless fused with an Acceptor. By using agar with the appropriate combinations of 
antibiotics, all desired Acceptor-Donor fusions can be selected for. 
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We have generated fusion vectors of 25 kb and larger. In stability tests (serial 
passaging for more than 60 generations), even such large plasmids proved to be stable 
as checked by restriction mapping, even if only one of the antibiotics corresponding 
to the encoded resistance markers was provided in the growth medium. 
Illustration 6: Cre and De-Cre reaction pyramid 
 
Cre-mediated assembly and disassembly of pACE, pDK, and pDS vectors are 
shown in a schematic representation (left). LoxP sites are shown as red 
circles, resistance markers and origins are labelled. White arrows stand for the 
entire expression cassette (including promoter, terminator and multiple 
integration elements) in the ACEMBL vectors. Not all possible fusion 
products are shown for clarity. Levels of multiresistance are indicated (right).
C.2.1. Cre-LoxP fusion of Acceptors and Donors 
This protocol is designed for generating multigene fusions from Donors and 
Acceptors by Cre-LoxP reaction. 
Reagents: 
Cre recombinase (from NEB or self made) 
Standard E. coli competent cells (pir
-
 strain) 
Antibiotics  
96well microtiter plates 
12 well tissue-culture plates (or petri dishes) w. agar/antibiotics 
LB media 
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1. For a 20µl Cre reaction, mix 1~2 µg of each educt in approximately equal 
amounts. Add ddH2O to adjust the total volume to 16~17 µl, then add 2 µl 
10x Cre buffer and 1~2µl Cre recombinase. 
 
2. Incubate Cre reaction at 37°C (or 30°C) for 1 hour. 
3. Optional: load 2-5 µl of Cre reaction on an analytical agarose gel for 
examination.  
Heat inactivation at 70°C for 10 minutes before the gel loading is strongly 
recommended. 
4. For chemical transformation, mix 10-15µl Cre reaction with 200 µl chemical 
competent cells. Incubate the mixture on ice for 15-30 minutes. Then perform 
heat shock at 42°C for 45-60 s. 
Up to 20 µl Cre reaction (0.1 volumes of the chemical competent cell suspension) 
can be directly transformed into 200 µl chemical competent cells.
 
For electrotransformation, up to 2 µl Cre reaction could be directly mixed 
with 100 µl electrocompetent cells, and transformed by using an 
electroporator (e.g. BIORAD E. coli Pulser) at 1.8-2.0 kV. 
Larger volume of Cre reaction must be desalted by ethanol precipitation or PCR 
purification column before electrotransformation. The desalted Cre reaction mix 
should not exceed 0.1 volumes of the electrocompetent cell suspension.  
The cell/DNA mixture could be immediately used for electrotransformation without 
prolonged incubation on ice. 
5. Add up to 400 µl of LB media (or SOC media) per 100 µl of cell/DNA 
suspension immediately after the transformation (heat shock or 
electroporation).  
6. Incubate the suspension in a 37°C shaking incubator overnight or for at least 4 
hours (recovery period). 
For recovering multifusion plasmid containing more than 2 resistance markers, it is 
strongly recommended to incubate the suspension at 37°C overnight.
 
7. Plate out the recovered cell suspension on agar containing the desired 
combination of antibiotics. Incubate at 37°C overnight. 
 
8. Clones from colonies present after overnight incubation can be verified by 
restriction digestion at this stage (refer to steps 12-16). 
Especially in the case that only one multifusion plasmid is desired.
For further selection by single antibiotic challenges on a 96 well microtiter 
plate, continue to step 9. 
Several to many different multifusion plasmid combinations can be processed and 
selected on one 96 well microtiter plate in parallel. 
9. For 96 well antibiotic tests, inoculate four colonies from each agar plate with 
different antibiotic combination into ~500 µl LB media without antibiotics. 
Incubate the cell cultures in a 37°C shaking incubator for 1-2 hours. 
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10. During the incubation of colonies, fill a 96 well microtiter plate with 150 µl 
antibiotic-containing LB media (following Illustration 7). It is recommended 
to add coloured dye (positional marker) in the wells indicated.  
A typical arrangement of the solutions, which is used for parallel selections of 
multifusion plasmids, is shown in Illustration 7. The concept behind the 96 well plate 
experiment is that every cell suspension from single colonies needs to be challenged 
by all four single antibiotics for unambiguous interpretation. 
Illustration 7: 96 well analysis of Cre assembly 
 
 
 
11. Add 1 µl aliquots of pre-incubated cell culture (Step 9) to the corresponding 
wells. Then incubate the inoculated 96 well microtiter plate in a 37°C shaking 
incubator overnight at 180-200 rpm.  
Recommended: use parafilm to wrap the plate to avoid drying out.  
The remainder of the pre-incubated cell cultures could be kept at 4°C for further 
inoculations if necessary. 
12. Select transformants containing desired multifusion plasmids based on 
antibiotic resistance, according to the combination of dense (positive) and 
clear (no growth) cell microcultures from each colony. Inoculate 10-20 µl cell 
culture into 10 ml LB media with corresponding antibiotics. Incubate in a 
37°C shaking incubator overnight. 
 
13. Centrifuge the overnight cell cultures at 4000g for 5-10 minutes. Purify 
plasmid from the resulting cell pellets with common plasmid miniprep kits, 
according to manufacturers’ recommendation.  
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14. Determine the concentrations of purified plasmid solutions by using UV 
absorption  spectroscopy (e.g. by using a NanoDrop
TM
 1000 machine).  
 
15. Digest 0.5~1 µg of the purified plasmid solution in a 20 µl restriction 
digestion with appropriate endonuclease(s). Incubate under recommended 
reaction condition for ~2 hours.  
 
16. Use 5-10 µl of the digestion for analytical agarose (0.8-1.2%) gel 
electrophoresis. Verify plasmid integrity by comparing the experimental 
restriction pattern to a restriction pattern predicted in silico (e.g. by using 
program VectorNTI from Invitrogen or similar programs). 
C.2.2. Deconstruction of fusion vectors by Cre  
The following protocol can be used for example also for the recovery of all four 
single ACEMBL vectors by deconstructing tetra-fused pACKS plasmid (pACE-pDC-
pDK-pDS); which is part of the ACEMBL System kit (Section D). Likewise, the 
protocol is suitable for releasing any single educt from multifusion constructs 
(deconstruction). This is achieved by Cre-LoxP reaction, transformation and plating 
on agar with appropriately reduced antibiotic resistance level (c.f. Illustration 6). In 
the liberated educt entity, encoding genes can be modified and diversified. Then, the 
diversified construct is resupplied by Cre-LoxP reaction (C.2.1.). 
Reagents: 
Cre recombinase (and 10x Buffer) 
E. coli competent cells  
(pir
+
 strains, pir
-
 strains could be used only when partially deconstructed 
Acceptor-Donor fusions are desired). 
Antibiotics 
1. Incubate ~1 µg multifusion plasmid with 2 µl 10x Cre buffer, 1~2 µl Cre 
recombinase, add ddH2O to adjust the total reaction volume to 20 µl. 
2. Incubate this Cre deconstruction reaction mixture at 30°C for 1 hour (partial 
deconstruction) or up to 4 hours (complete deconstruction of the multifusion 
plasmid). 
3. Optional: load 2-5 µl of the reaction on an analytical agarose gel for 
examination.  
Heat inactivation at 70°C for 10 minutes before the gel loading is strongly 
recommended. 
4. For chemical transformation, mix 10-15µl De-Cre reaction with 200 µl 
chemical competent cells. Incubate the mixture on ice for 15-30 minutes. 
Then perform heat shock at 42°C for 45-60 s. 
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Up to 20 µl De-Cre reaction (0.1 volumes of the chemical competent cell suspension) 
can be directly transformed into 200 µl chemical competent cells.
For electrotransformation, up to 2 µl De-Cre reaction could be directly mixed 
with 100 µl electrocompetent cells, and transformed by using an 
electroporator (e.g. BIORAD E. coli Pulser) at 1.8-2.0 kV. 
Larger volume of De-Cre reaction must be desalted by ethanol precipitation or PCR 
purification column before electrotransformation. The desalted De-Cre reaction mix 
should not exceed 0.1 volumes of the electrocompetent cell suspension.  
The cell/DNA mixture could be immediately used for electrotransformation without 
prior incubation on ice. 
5. Add up to 400 µl of LB media (or SOC media) per 100 µl of cell/DNA 
suspension immediately after the transformation (heat shock or 
electroporation).  
6. Incubate the suspension in a 37°C shaking incubator (recovery). 
For recovery of partially deconstructed double/triple fusions, incubate the 
suspension in a 37°C shaking incubator for at least 4 hours or overnight. 
For recovery of individual educts (after 4h Cre incubation), for example single 
ACEMBL vectors from pACKS plasmid, incubate the suspension in a 37°C shaking 
incubator for around 1h.  
7. Plate out the recovered cell suspension on agar containing the desired 
(combination of) antibiotic(s). Incubate at 37°C overnight. 
8. Colonies after overnight incubation might be verified directly by restriction 
digestion at this stage (refer to steps 12-16). 
Especially recommended in the case that only one single educt or partially 
deconstructed multifusion plasmid is desired.
For further selection by single antibiotic challenge on a 96 well microtiter 
plate, continue with step 9. 
Several different  single educts/partially deconstructed multifusion plasmids can be 
processed and selected on one 96 well microtiter plate in parallel. 
9. For 96 well analysis, inoculate four colonies each from agar plates containing 
a defined set of antibiotics into ~500 µl LB media without antibiotics. 
Incubate the cell cultures in a 37°C shaking incubator for 1-2 hours. 
10. During the incubation of colonies, fill a 96 well microtiter plate with 150 µl 
antibiotic-containing LB media or coloured dye (positional marker) in the 
corresponding wells.  
Refer to Illustrations 7 and 12 for the arrangement of the solutions in the wells, 
which are used for parallel selection of single educts or partially deconstructed 
multifusion plasmids. The concept is that every cell suspension from a single colony 
needs to be challenged by all four antibiotics separately for unambiguous 
interpretation. 
11. Add 1 µl aliquots from the pre-incubated cell cultures (Step 9) into the 
corresponding wells. Then incubate the 96 well microtiter plate in a 37°C 
shaking incubator overnight at 180-200 rpm.  
Recommended: use parafilm to wrap the plate to prevent dehydration.  
The remainder of the pre-incubated cell cultures can be kept in 4°C fridge for further 
inoculations if necessary. 
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12. Select transformants containing desired single educts or partially 
deconstructed multifusion plasmids according to the combination of dense 
(growth) and clear (no growth) cell cultures from each colony. Inoculate 10-
20 µl cell cultures into 10 ml LB media with corresponding antibiotic(s). 
Incubate in a 37°C shaking incubator overnight. 
 
13. Centrifuge the overnight cell cultures at 4000g for 5-10 minutes. Purify 
plasmid from cell pellets with common plasmid miniprep kits, according to 
manufacturers’ information.  
 
14. Determine the concentrations of purified plasmid solutions by using UV 
absorption spectroscopy (e.g. NanoDrop
TM
 1000).  
 
15. Digest 0.5~1 µg of the purified plasmid solution in a 20 µl restriction 
digestion (with 5-10 unit endonuclease). Incubate under recommended 
reaction condition for ~2 hours.  
16. Use 5-10 µl of the digestion for analytical agarose gel (0.8-1.2%) 
electrophoresis. Verify the plasmid integrity by comparing the actual 
restriction pattern to predicted restriction pattern in silico (e.g. by using 
VectorNTI, Invitrogen, or any other similar program). 
 
17. Optional: Possibly, a deconstruction reaction is not complete but yields 
partially deconstructed fusions which still retain entities to be eliminated. In 
this case, we recommend to pick these partially deconstructed fusions 
containing and perform a second round of Cre deconstruction reaction (repeat 
steps 1-8) by using this construct as starting material. 
In our hands, two sequential deconstruction reactions were always sufficient to 
recover all individual modules, for instance all four single ACEMBL vectors from a 
pACKS plasmid. Liberation of single educts from double/triple fusions were found to 
be often more efficient than from quadruples such as the pACKS plasmid of the 
system kit (Section E).  
C.3. Coexpression by Cotransformation 
Protein complexes can be expressed also from two separate vectors that were 
cotransformed in expression strains. The cotransformed vectors can have the same or 
different origins of replication, however, they must encode for different resistance 
markers. Plasmids pACE (ampicillin resistance marker) and pACE2 (tetracycline 
resistance marker) have both a ColE1 derived replicon and can therefore be used with 
all common expression strains. pACE and pACE2 derivatives (also including fused 
Donors if needed) can be cotransformed into expression strains, and double 
transformants selected for by plating on agar plates containing both ampicillin and 
tetracyclin antibiotics. 
Transformations are carried out by using standard transformation protocols. 
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D. ACEMBL multigene combination: Examples 
Examples of multiprotein expressions by ACEMBL are shown in the following 
illustrating the gene combination procedures detailed in Section C. Reactions 
presented were carried out manually following the protocols provided, and also on a 
Tecan Freedom EvoII 200 robot with adapted protocols (Section F).  
D.1. SLIC cloning into ACEMBL vectors: human TFIIF 
Genes encoding for full-length human RAP74 with a C-terminal oligo-histidine tag 
and full-length human RAP30 were amplified from pET-based plasmid template
8
 by 
using the primer pair TN7InsFor (5’-TCCCGCGAAATTAATACGACTCACTATA 
GGG-3’) and Tn7Insrev (5’-CCTCAAGACCCGTTTAGAGGCCCCAAGGGGTT 
ATGCTAG-3’) following the protocols described above. Linearized vector 
backbones were generated by PCR amplification from pACE and pDC by using 
primer pair Tn7VecFor (5’CTAGCATAACCCCTTGGGGCCTCTAAACGGGT 
CTTGAGG-3’) and Tn7VecRev (5’-CCCTATAGTGAGTCGTATTAATTTC 
GCGGGA-3’) in both cases. SLIC following Protocol 1 (Section C), resulting in 
pACE-RAP30 and pDC-RAP74his (Fig 8). These plasmids were fused by Cre-LoxP 
reaction (Section C). Results from restriction mapping by BstZ17I/BamHI double 
digestion of 11 double resistant (Cm, Ap) colonies are shown by a gel section from 
1% E-gel electrophoresis (M: NEB 1kb DNA marker). All clones tested showed the 
expected pattern (5.0 + 2.8 kb). One clone was transformed in BL21(DE3) cells. 
Expression and purification by Ni
2+
-capture and S200 chromatography resulted in 
human TFIIF complex (Fig. 3a, main text). 
Illustration 8: ACEMBLing TFIIF. 
 
                                                
8
 Gaiser, F., Tan, S. and Richmond, T.J. J. Mol. Biol. 302, 1119-1127 (2000). 
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D.2. Polycistron by SLIC: human VHL/ElonginB/ElonginC complex. 
The gene encoding for Von Hippel Lindau protein (amino acids 54-213), fused at its 
N-terminus to a six-histidine-thioredoxin fusion tag, was PCR amplified from 
plasmid pET3-HisTrxVHL by using primers Tn7InsFor (Table I) and SmaBamVHL 
(5’-GAATTCACTGGCCGTCGTTTTACAGGATCCTTAATCTCCCATCCGTTG 
ATGTGCAATG-3’). SmaBamVHL primer is a derivative of the SmaBam adaptor 
sequence (Table I) elongated at its 3’ by the insert specific sequence at the 3’ end of 
the VHL gene (including a stop codon). The gene encoding for full-length ElonginB 
was PCR amplified from pET3-ElonginB by using primers BamSmaEB (5’-
GGATCCTGTAAAACGACGGCCAGTGAATTCGCTAGCTCTAGAAATAATT
TGTTTAAC-3’) and SacHindEB (5’-GAGCTCGACTGGGAAAACCCTGGCG 
AAGCTTAGATCTGGATCCTTACTGCACGGCTTGTTCATTGG-3’), which are 
derivatives of the corresponding adaptors (Table I).  The gene for ElonginC (amino 
acids 17-112) wa amplified from pET3-ElonginC by using primers HindSacEC (5’-
AAGCTTCGCCAGGGTTTTCCCAGTCGAGCTCCAATTGGAATTCGCTAGCT
CTAG-3’) and BspEco5EC (5’GATCCGGATGTGAAATTGTTATCCGCTGG 
TACCAAGCTTAGATCTGGATCCTTAACAATCTAAGAAG-3’), which are 
derivatives of the corresponding adaptors (Table I).  Vector backbone was PCR 
amplified by using primers Tn7VecRev and Eco5Bsp, and pACE as a template 
(Illustr. 9). Multifragment SLIC was carried out according to Protocol 2 (Section C) 
resulting in pACE-VCB which contains a tricistron. Clones were plated on agar 
plates containing ampicillin. A positive clone, verified by sequencing, was used in 
the coexpression experiment described below (section D.5.) 
Illustration 9: Multifragment SLIC of pACE-VHLbc (tricistron). 
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D.3. The Homing endonuclease/BstXI module: yeast RES complex 
Plasmids pCDFDuet-Pml1p, pRSFDuet-Snu17p-NHis and pETDuet-Bud13p, 
encoding for yeast proteins (all full-length) PmI1p, Snu17p and Bud13p, respectively, 
were a kind gift from Dr. Simon Trowitzsch and Dr. Markus Wahl (MPI Göttingen). 
Snu17p contains a six-histidine tag fused to its N-terminus. The gene encoding for 
His6-tagged Snu17p was excised from pRSFDuet-Snu17p-NHis by using restriction 
enzymes NcoI and XhoI, and ligated into a NcoI/XhoI digested pACE construct 
(containing an unrelated gene between NcoI and XhoI sites) resulting in pACE-
Snu17. The gene encoding for Bud13p was liberated from pETDuet-Bud13p by 
restriction digestion with XbaI and EcoRV, and placed into XbaI/PmeI digested pDC 
resulting in pDC-Bud13. The gene encoding for Pm1Ip was liberated from 
pCDFDuet-Pml1p by restriction digestion with NdeI and XhoI, and placed into 
NdeI/XhoI digested pDC resulting in pDC-PmI1. Next, the expression cassette for 
Bud13p was liberated from pDC-Bud13 by digestion with PI-SceI and BstXI. The 
liberated fragment was inserted into PI-SceI digested and alkaline phosphatase treated 
pDC-PmI1p resulting in pDC-Bud13p-PmI1p. 
 pACE-Snu17 and pDC-BudPmI were then fused by Cre-LoxP reaction and 
selected for by plating on agar plates containing ampicillin and chloramphenicol. 
Fusion plasmids were transformed into BL21(DE3) cells. Expression and purification 
by Ni
2+
-capture and S200 size exclusion chromatography resulted in the trimeric RES 
complex (Supplementary Results, complex S12b). 
Illustration 10: The HE/BstXI multiplication module. 
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D.4. Coexpression by cotransformation: human NYB/NYC 
Genes encoding for protein NYB (amino acids 49-141) and NYC (amino acids  27-
12) were excised from vectors pACYC18411-NYB and pET15-NYC, respectively
9
. 
NdeI and BamHI where used for NFYB. XbaI and BamHI where used for NYC, thus 
importing a six-histidine tag at the N-terminus of the protein. The NYB insert was 
ligated into pACE digested with NdeI and BamHI. The NYC insert was ligated into 
pACE2 digested by XbaI and BamHI. pACE-NFYB and pACE2-NFYC were 
transformed into BL21(DE3) cells containing the pLysS plasmid. Selection on agar 
plates containing ampicillin, tetracyclin and chloramphenicol resulted in triple 
resistant colonies. The complex was expressed and purified by Ni2+ capture (IMAC) 
and S75HR (Pharmacia) size exclusion chromatography (Supplementary Results, 
complex S7a). 
D.5. Coexpression from Acceptor-Donor fusions 
Six heterologous genes encoding for a trimeric protein complex (VHLbc: VonHippel-
Lindau protein amino acids 54-213 / full-length ElonginB / ElonginC amino acids 17-
112)
10
, a gene encoding for the AAA ATPase FtsH (amino acids 147-610), and two 
genes encoding for fluorescent markers (BFP and GFP) were assembled as indicated. 
In a single Cre reaction, all combinations of one Acceptor (pACE-VHLbc) and three 
Donors (pDC-FtsH, pDK-BFP, pDS-mGFP) were obtained and selected, including a 
quadruple fusion containing all six heterologous genes (Main text, Fig. 2). Clones 
were verified by 96 well microtiter assay as described in Section C. Expression and 
Ni
2+
 affinity capture, combined with immunostaining of the untagged fluorescent 
markers, confirmed successful multiprotein expression (Main text, Figs. 2 and 3b). 
Proteins were expressed overnight in BL21(DE3) cells in 24 well deep-well plates in 
small scale using autoinduction media
11
. Restriction mapping revealed that even large 
fusion plasmids were stable over many (more than 60) generations, even if 
challenged by a single antibiotic in the medium only. 
9
 Romier, C. et al., J. Biol. Chem. 278, 1336-1345 (2003) 
10
 Stebbins, C.E., Kaelin, W.G. Jr, Pavletich, N.P. Science 284, 455-61 (1999) 
11
 Studier F.W. Protein Expr. Purif. 41, 207-34 (2005). 
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E. The ACEMBL System Kit 
Reagents to be supplied in ACEMBL system kit: 
BW23473, BW23474 cells
†
 
pACKS quadruple fusion vector* 
            made of:    pACE (Acceptor) 
                     pDC, pDK, pDS (Donors) 
pACE2 vector 
pACE-[VHLbc/BFP/mGFP] control plasmid 
            triple fusion vector 
            made of:    pACE-VHLbc 
                     pDK-BFP 
         pDS-mGFP
#
 
† 
E. coli strains expressing the pir gene for propagation of Donor 
derivatives (any other strain with pir+ background can be used). 
* This fusion vector was created by Cre-LoxP reaction of pACE, pDC, 
pDK and pDS. It is resistant to ampicillin, kanamycin, chloramphenicol 
and spectinomycin. Individual ACEMBL vectors are liberated from this 
quadruple fusion by Cre-LoxP mediated deconstruction as described in 
protocol C.2.2. Sequences for single ACEMBL vectors and pACKS 
quadruple fusion are provided in Appendix. 
# 
pDS-mGFP contains a coiled-coil  fused to the N-terminus of eGFP12. 
Reagents additionally required: 
Antibiotics: ampicillin, chloramphenicol, kanamycin, spectinomycin, tetracycline  
Enzymes: Cre recombinase 
T4 DNA polymerase (for recombination insertion of genes) 
Phusion polymerase (for PCR amplification of DNA) 
Restriction enzymes and T4 DNA ligase (for conventional cloning) 
Regular laboratory cloning strain (TOP10, HB101, DH5?) 
Expression strain(s) of choice 
                                                
12
 Berger, P. et al., Proc. Natl. Acad. Sci. USA 100, 12177-82  (2003).  
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Illustration 11: ACEMBL System Kit: Generating single vectors from pACKS. 
 
pACKS is deconstructed according to the schematic in Illustr. 11 into single vectors 
pACE, pDC, pDK and pDS. 96 well microtiter assay for identifying single vectors is 
shown in Illustr. 12. 
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Illustration 12: 96 well microtiter analysis of pACKS De-Cre reaction.
 
 
Clones containing pACE, pDC, pDK and pDS single vectors as identified by 
microtiter assay, are then used for plasmid generation. The vectors can be further 
verified by restriction digestion before use for subcloning (see Appendix for vector 
sequences). pACE2 is provided as a separate vector in the ACEMBL System Kit. 
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F. Process Automation 
 
Pipetting device: Tecan Freedom EvoII 200 
 
Equipped with: Liquid handling arm1 (LiHa1) (pos. 1) 
   4 fixed tips (steel needles), 4 disposable tips coni (Diti’s) 
   250?l syringes 
 
   Liquid handling arm2 (LiHa2) (pos. 2) 
   8 fixed tips (steel needles) 
   2.5ml syringes 
 
   Robotic manipulator arm (RoMa / transportation of plates),  
   version long (pos. 3) 
 
Integrated devices: Thermocycler PTC-200 (Biorad) (pos. 4) 
 
   Te-Shake, heatable plate shaker (Tecan) (pos. 5) 
 
   Variomag Thermoshaker, heat- and coolable plate shaker 
(Inheco) (pos. 6) 
 
 Te-Vacs, dual vacuum station for filter plates (Tecan) (pos. 7) 
 
 SafireII, UV VIS plate reader (Tecan) (pos. 8) 
 
 Cooling unit 400W (FRYKA multistar) (pos. 9) 
 
 
Tecan Freedom EvoII 200 at Paul Scherrer Institute Biomolecular Research laboratory (Ref. 8) 
1 2 3 
4 
5 
6 
7 
8 
9 
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F.1. Method I: Automated SLIC process 
 
 
Workflow
Step 1: Initial PCR
Source plate: 96 well standard microtiter plate containing the PCR templates (cDNA 
aprox. 0.2 ?g/?l) 
Reaction plate: 96 well PCR plate (Eppendorf) 
Material: Sample mix plate (96 well PCR plate; Eppendorf), 1% agarose E-Gel® 
(Invitrogen), Phusion® DNA Polymerase master mix, oligonucleotide primers at 
20?M, 2x DNA loading dye (2xDLD) (Fermentas), E-Gel® Low Range quantitative 
DNA Ladder (Invitrogen), 10x Buffer Tango® with BSA (Fermentas), DpnI 
(Fermentas) 
 
PCR program: 
 
11x [98°C for 20 sec. ? 60-50°C for 30 sec.(step down every 2nd cycle 1°C) 
? 72°C for 3 min.] 
 
19x [98°C for 20 sec. ? 50°C for 30 sec. ? 72°C for 3 min.] 
 
72°C for 3 min. 
 
Hold at 10°C 
 
DpnI digest program: 
 
37°C for 3 h 
10°C for 1 min 
Procedure:
 
Wash tips ? Pipet 89 ?l PCR master-mix into reaction plate 
Wash tips ? Pipet 1 ?l template DNA according to worklist 
Wash tips ? Pipet 5 ?l primer each to reaction plate 
Wash tips ? Run PCR program 
Wash tips ? Pipet 10 ?l 10x Buffer Tango® with BSA to reaction plate 
Wash tips ? Pipet 5 ?l DpnI to reaction plate 
Wash tips ? Run DpnI digest program 
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Wash tips ? Pipet 10 ?l 2xDLD to each well of sample mix plate 
Wash tips ? Pipet 15 ?l DNA marker each to the E-gel marker slots 
Wash tips ? Pipet 10 ?l PCR product to 2xDLD on sample mix plate 
Wash tips ? Pipet 15 ?l sample mix to the E-Gel sample slots 
Wash tips ? Run E-Gel® for 25 min. 
Assess results 
Step 2: PCR Purification
 
Source plate: 96 well PCR plate (Eppendorf) with PCR samples 
 
Target plate: 96 well microtiter elution plate (Macherey-Nagel) 
 
Material: PCR purification kit, NucleoSpin 96 Extract II Kit (Macherey-Nagel) 
 
Procedure: According to manufacturer’s information (http://www.macherey-
nagel.com/tabid/10887/default.aspx) 
Step 3: T4 DNA Polymerase Reaction
 
Source plate: 96 well microtiter elution plate (Macherey-Nagel) 
 
Reaction plate: 96 well PCR plate (Eppendorf) 
 
Material: bidest. water, 10x T4 DNA polymerase reaction buffer (Novagen),  
100mM DTT, 2M Urea, T4 DNA polymerase (Novagen LIC qualified), 
500 mM EDTA 
 
Incubation program: 23°C for 10 min. (program 1) 
    75°C for 20 min. (program 2) 
 
Procedure:
 
Wash tips ? Pipet 6 ?l water in to reaction plate 
Wash tips ? Pipet 2 ?l 10x reaction buffer into reaction plate 
Wash tips ? Pipet 1 ?l 100mM DTT into reaction plate 
Wash tips ? Pipet 2 ?l 2M Urea into reaction plate 
Wash tips ? Pipet 8 ?l DNA sample from prev. PCR into reaction plate 
Wash tips ? Pipet 0.5 ?l T4 DNA polymerase into reaction plate 
Wash tips ? Run incubation program 1 
 Wash tips ? Pipet 1 ?l 500 mM EDTA into reaction plate 
Wash tips ? Run incubation program 2 
Step 4: Annealing
 
Source plate: Reaction plate from T4 DNA polymerase reaction 
 
Reaction plate: 96 well PCR plate (Eppendorf) 
 
Material: bidest. water, 10x DNA Ligase Reaction Buffer (NEB), linearized vector 
 
Incubation program:  65°C for 8 min. ? ramp down 0.4°C/min. to 35°C               
? 10°C for 1 min. 
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Procedure:
 
Wash tips ? Pipet 150 ng T4 DNA polymerase treated insert DNA according 
to worklist into reaction plate 
Wash tips ? Pipet 150 ng linearized vector DNA according to worklist into 
reaction plate 
Wash tips ? Run incubation program 
Step 5: Transformation in E. coli
 
Source plate: Reaction plate from the annealing step 
 
Reaction plate: 96 well PCR plate (Eppendorf) 
 
Culture plate: 2 ml 96 well plate (Nunc) 
 
Target plates:  12 well cell culture plates containing 2ml of LB-agar with 
appropriate antibiotics (standard concentrations used: Ampicillin 100 ?g/ml, Kanamycin 50??g/ml, Spectinomycin 50 ?g/ml, 
Chloramphenicol 30 ?g/ml) 
 
Material: E. coli cells (Xl1blue) that are chemically competent for transformation , 
 SOC-medium  
Transformation program: Heat thermocycler to 42°C 
   Incubate at 42°C for 30sec. 
   Transfer immediately to cooled (0°C) pipetting carrier 
 
Procedure:
 
Wash tips ? Pipet 100 ?l competent E. coli cells into reaction plate 
Wash tips ? Pipet 10 ?l DNA sample from annealing step into reaction plate 
Wash tips ? Incubate at 0°C for 30 min. 
Run transformation program 
Incubate at 0°C for 5 min. 
Wash tips ? Pipet 250 ?l SOC-medium into culture plate 
Wash tips ? Transfer transformation mix into culture plate 
 Incubate at 37°C and 720 rpm. (Te-Shake Shaker) for 2 h 
 Wash tips ? Pipet 50 ?l culture into target plate (agar plate) 
Wash tips ? Shake target plate at 12 Hz for 1 min. (plating out) 
 Incubate target plates over night at 37°C 
Step 6: Picking clones and setting up over night cultures (manual step)
Source plate: 12 well cell culture plates containing E.coli colonies 
Target plate: 24 well culture plate 
Material: 2xTY culture medium, incubator which carries culture plates 
Procedure: Pick 4 colonies per reaction and transfer to 3 ml 2xTY  medium in a 24 
well culture plate. Incubate at 37°C and approx. 220 rpm over night. 
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Step 7: Plasmid Extraction (Miniprep)
 
Source plate: 24 well culture plate (usually 3 ml culture) 
 
Target plate: 96 well microtiter elution plate (Macherey-Nagel) 
 
Material: Plasmid extraction kit, NucleoSpin Robot 96 Plasmid Kit (Macherey-
 Nagel) 
 
Procedure: According to manufacturer 
(http://www.machereynagel.com/tabid/10885/default.aspx) 
 
Step 8: Assessment
Plasmid yield was quantified by measuring UV absorbance with a Thermo Scientific 
NanoDrop
TM
 1000 Spectrophotometer according to manufacturer. Plasmid integrity 
was assessed by E-gel (Invitrogen)  
The efficacy of the SLIC protocol was assessed in manual and robotics mode. The 
results of the comparison are shown in Table II. Results are based on a set of 25 
different Donor/Acceptor constructions prepared. 
Table II:
Comparison Manual versus Robotic SLIC procedure 
(based on 25 constructs each) 
 Manual EvoII
DNA used for T4 reaction: 200-400ng insert 400-800ng insert 
 200-400ng vector 400-800ng vector 
T4 reaction volume for 
transformation: 
5ul:    2.5ul (insert)  
        +2.5ul (vector) 
5ul:     2.5ul (insert)  
         +2.5ul (vector) 
Volume comp. cells 
(Xl1Blue, chem. comp): 
100ul (+300ul SOC) 100ul (+300ul SOC) 
Volume plated 200ul 
(petri dish) 
50ul/well (12well plate) 
200ul (petri dish) 
Clones obtained: 200->2000 
(petri dish) 
25-250 (12 well plate) 
70-5300 (petri dish) 
Nature Methods: doi: 10.1038/nmeth.1326
42 
F.2. Method II. Automated Cre fusion process 
 
 
 
           Workflow 
Step 1: Cre-LoxP Plasmid Fusion Reaction
 
Source plate: 96 well microtiter elution plate from the plasmid extraction process 
containing plasmids suitable for Cre-Lox fusion 
 
Reaction plate: 96 well PCR plate (Eppendorf) 
 
Material: bidest. water, 10x Cre reaction buffer (NEB), Cre recombinase (NEB) 
 
Incubation program: 37°C for 1 h ? 10°C for 1 min. 
 
Procedure:
 
Wash tips ? Pipet 6 ?l bidest. water into reaction plate 
Wash tips ? Pipet 2 ?l 10x Cre reaction buffer into reaction plate 
Wash tips ? Pipet plasmid DNA suitable for Cre recombination according to 
worklist into reaction plate 
Wash tips ? Pipet 2 ?l Cre recombinase into reaction plate 
Wash tips ? Run incubation program 
Total reaction volume: 20 ?l 
 
Step 2, 3 and 4: Transformation in E. coli and Plasmid Extraction:
Identical to Method I., with the exception that reaction plate from Cre recombination 
step is used as source plate and recovery time in SOC-medium is prolonged to a total 
of 4h. Chemically competent Mach1 cells were used for transformation. For Cre 
reaction with 3 and 4 vectors agar-plates with half of the antibiotic concentration 
(standard concentrations used: Ampicillin 100 ?g/ml, Kanamycin 50??g/ml, 
Spectinomycin 50 ?g/ml, Chloramphenicol 30 ?g/ml) were used. 
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Step 5: Assessment
 
Plasmid fusion yield was quantified by measuring UV absorbance with a Thermo 
Scientific NanoDrop
TM
 1000 Spectrophotometer according to the manufacturer's 
instructions. Plasmid integrity was assessed by E-gel (Invitrogen) of undigested and 
digested samples. Suitable restriction sites that yield a digestion pattern characteristic 
for the respective fusions were identified by using Vector NTI (Invitrogen) and used 
for restriction mapping. 
The efficacy of the Cre reaction was tested by performing a series of fusion reactions, 
each in triplicate, by using the EvoII liquid handling workstation. The results are 
summarized in Table III.   
 
Table III:
Efficiency of Cre-LoxP Reactions on EvoII 
(assessed in triplicate for each reaction) 
Volume Cre-reaction used for transformation 
(all reactions): 
10ul  
Volume chem. comp. cells (Xl1Blue, Mach1) 
per transformation (all reactions): 
 
100ul (+300ul SOC) 
Volume transformation reaction plated: 50ul/well (12well plate) 
200ul (petri dish) 
Clones obtained: 
(a) Double vector fusion reaction (AD, one Acceptor, one Donor)
>1000 fused functional AD plasmids  
plated on a standard petri dish containing the respective two antibiotics 
(b) Triple vector fusion reaction (ADD, one Acceptor, two Donors)
12-80 fused functional ADD plasmids 
plated on a standard petri dish containing the respective three antibiotics 
(c) Quadruple vector fusion reaction (ADDD, one Acceptor, three Donors) 
For quadruple vector fusions (ADDD, one Acceptor and three Donors), 
two possibilities exist.  
(1) Single reaction ADDD (four vector Cre-Lox fusion, low efficiency) 
(2) Two step reaction ADD+D: Triple fusion as in (b),  
then addition of a further Donor.  
We recommend for routine robotic use option 2 (ADD + D) as 
the  more robust approach, resulting in our experiments in  
20-100 fused functional ADDD plasmids when plated on a 
standard petri dish containing all four antibiotics. 
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F.3. Method III. High throughput micro batch IMAC 
 
Source plate: 2 ml deepwell plate (Eppendorf) 
 
Filter plate: Glas filter plate (Novagen) 
 
Target plate: standard microtiter plate (Greiner) 
Material: Ni-NTA bulk beads 50% in 20% ethanol (Ge-Healthcare), freezer at -
20°C,  tabletop centrifuge suitable for microtiter plates, sonication device with 
 microtip, IMAC binding and elution buffer suitable for the specific protein 
 (Berrow et al., Acta Cryst. (2006). D62, 1218 – 1226).  
Procedure:
 
Sample Preparation (off line) 
Harvest E. coli cells expressing the desired protein by centrifugation at 3000 g 
(4°C) directly in the source plate 
  Freeze cell pellets for 30 min. at -20°C 
Thaw cell pellets 15 min. at room temperature 
Preparation of the filter plate 
 
Wash tips ? Resuspend Ni-NTA bead suspension by pipetting up and down 
20 times 200 ?l ? Transfer 200 ?l bead suspension to filter plate 
Wash tips ? Apply vacuum 550 mbar for 30 sec. (remove 20% ethanol) 
Wash tips ? Pipet 1 ml equilibration buffer (e.g. binding buffer) to resin 
Wash tips ? Apply vacuum 300 mbar for 60 sec. (equilibration) 
IMAC purification, preparation 
 
Wash tips ? Pipet 1 ml binding buffer to the samples in the source plate 
Wash tips ? Resuspend cell pellets by pipetting up and down 10 times 750 ?l 
Wash tips 
Sonication of samples (off line) 
 Sonication of the samples to insure complete lysis of the cells 
IMAC purification, loading and elution 
 
Wash tips ? Transfer whole lysate to filter plate 
Wash tips ? Apply vacuum 300 mbar for 90 sec. (binding step) 
Wash tips ? Pipet 1 ml wash buffer to the samples 
Wash tips ? Apply vacuum 300 mbar for 90 sec. (wash step) 
Repeat wash step 3 times 
Wash tips ? Pipet 100 ?l elution buffer to the samples 
Wash tips ? Incubate 3 min. at room temperature 
Apply vacuum 650 mbar for 90 sec. (elution step) 
Assessment
Eluted samples (10 ?l - 12 ?l) were loaded manually on 12% denaturing gels using a 
Biorad Minigel System, pre-run at 135 V for 25 min, and then run for 65-70 min. at 
185 V. Gels were stained with Coomassie Brilliant Blue according to standard 
procedures. 
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G. Appendix  
G.1. DNA sequence of MIE 
Below are the sequence and map of the MIE fragment between T7/lac promoter and 
T7 terminator in ACEMBL vectors. Forward and reverse primers for sequencing can 
be standard vector primers for T7 and lac. Adaptor primer sequences (c.f. Table I) are 
indicated. DNA sequences in these homology regions contain tried-and-tested 
sequencing primers
13
. Sites of insertion (I1-I4) are shown.. The adaptor sequences, 
and probably any sequence in the homology regions, can be used as adaptors for 
multifragment insertions. The ribosome binding site present in the MIE (rbs) is boxed 
in red. 
 
 
13
 Tan S. et al. Protein Expr. Purif. 40, 385, (2005). 
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G.2. DNA sequences of ACEMBL vectors 
G.2.1. pACE 
       1 GGTACCGCGG CCGCGTAGAG GATCTGTTGA TCAGCAGTTC AACCTGTTGA 
      51 TAGTACTTCG TTAATACAGA TGTAGGTGTT GGCACCATGC ATAACTATAA 
     101 CGGTCCTAAG GTAGCGACCT AGGTATCGAT AATACGACTC ACTATAGGGG 
     151 AATTGTGAGC GGATAACAAT TCCCCTCTAG AAATAATTTT GTTTAACTTT 
     201 AAGAAGGAGA TATACATATG AGGCCTCGGA TCCTGTAAAA CGACGGCCAG 
     251 TGAATTCCCC GGGAAGCTTC GCCAGGGTTT TCCCAGTCGA GCTCGATATC 
     301 GGTACCAGCG GATAACAATT TCACATCCGG ATCGCGAACG CGTCTCGAGA 
     351 GATCCGGCTG CTAACAAAGC CCGAAAGGAA GCTGAGTTGG CTGCTGCCAC 
     401 CGCTGAGCAA TAACTAGCAT AACCCCTTGG GGCCTCTAAA CGGGTCTTGA 
     451 GGGGTTTTTT GGTTTAAACC CATCTAATTG GACTAGTAGC CCGCCTAATG 
     501 AGCGGGCTTT TTTTTAATTC CCCTATTTGT TTATTTTTCT AAATACATTC 
     551 AAATATGTAT CCGCTCATGA GACAATAACC CTGATAAATG CTTCAATAAT 
     601 ATTGAAAAAG GAAGAGTATG AGTATTCAAC ATTTCCGTGT CGCCCTTATT 
     651 CCCTTTTTTG CGGCATTTTG CCTTCCTGTT TTTGCTCACC CAGAAACGCT 
     701 CGTGAAAGTA AAAGACGCAG AGGACCAATT GGGGGCACGA GTGGGATACA 
     751 TAGAACTGGA CTTGAATAGC GGTAAAATCC TTGAGAGTTT TCGCCCTGAA 
     801 GAGCGTTTTC CAATGATGAG CACTTTCAAA GTTCTGCTAT GTGGAGCAGT 
     851 ATTATCCCGT GTAGATGCGG GGCAAGAGCA ACTCGGACGA CGAATACACT 
     901 ATTCGCAGAA TGACTTGGTT GAATACTCCC CAGTGACAGA AAAGCACCTT 
     951 ACGGACGGAA TGACGGTAAG AGAATTATGT AGTGCCGCCA TAACGATGAG 
    1001 TGATAACACT GCGGCGAACT TACTTCTGAC AACCATCGGT GGACCGAAGG 
    1051 AATTAACCGC TTTTTTGCAC AATATGGGAG ACCATGTAAC TCGCCTTGAC 
    1101 CGTTGGGAAC CAGAACTGAA TGAAGCCATA CCAAACGACG AGCGAGACAC 
    1151 CACAATGCCT GCGGCAATGG CAACAACATT ACGCAAACTA TTAACTGGCG 
    1201 AACTACTTAC TCTGGCTTCA CGGCAACAAT TAATAGACTG GCTTGAAGCG 
    1251 GATAAAGTTG CAGGACCACT ACTGCGTTCG GCACTTCCTG CTGGCTGGTT 
    1301 TATTGCTGAT AAATCTGGGG CAGGAGAGCG TGGTTCACGG GGTATCATTG 
    1351 CCGCACTTGG ACCAGATGGT AAGCCTTCCC GTATCGTAGT TATCTACACG 
    1401 ACGGGTAGTC AGGCAACTAT GGACGAACGA AATAGACAGA TTGCTGAAAT 
    1451 AGGGGCTTCA CTGATTAAGC ATTGGTAAAC CGATACAATT AAAGGCTCCT 
    1501 TTTGGAGCCT TTTTTTTTGG ACGGACCGGT AGAAAAGATC AAAGGATCTT 
    1551 CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA 
    1601 CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT 
    1651 TTTTCCGAAG GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC 
    1701 TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG 
    1751 CCTACATACC TCGCTCTGCT AATCCTGTTA CCAGTGGCTG CTGCCAGTGG 
    1801 CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG TTACCGGATA 
    1851 AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG 
    1901 GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA 
    1951 AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG 
    2001 GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC 
    2051 TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG 
    2101 ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA 
    2151 ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG 
    2201 TTCTTTCCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT 
    2251 TGAGTGAGCT GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAGT 
    2301 CAGTGAGCGA GGAAGCGGAA GAGCGCCTGA TGCGGTATTT TCTCCTTACG 
    2351 CATCTGTGCG GTATTTCACA CCGCAATGGT GCACTCTCAG TACAATCTGC 
    2401 TCTGATGCCG CATAGTTAAG CCAGTATACA CTCCGCTATC GCTACGTGAC 
    2451 TGGGTCATGG CTGCGCCCCG ACACCCGCCA ACACCCGCTG ACGCGCCCTG 
    2501 ACGGGCTTGT CTGCTCCCGG CATCCGCTTA CAGACAAGCT GTGACCGTCT 
    2551 CCGGGAGCTG CATGTGTCAG AGGTTTTCAC CGTCATCACC GAAACGCGCG 
    2601 AGGCAGGGGG AATTCCAGAT AACTTCGTAT AATGTATGCT ATACGAAGTT 
    2651 AT
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G.2.2. pACE2  
       1 ATGAAATCTA ACAATGCGCT CATCGTCATC CTCGGCACCG TCACCCTGGA 
      51 TGCTGTAGGC ATAGGCTTGG TTATGCCGGT ACTGCCGGGC CTCTTGCGGG 
     101 ATATCGTCCA TTCCGACAGC ATCGCCAGTC ACTATGGCGT GCTGCTAGCG 
     151 CTATATGCGT TGATGCAATT TCTATGCGCA CCCGTTCTCG GAGCACTGTC 
     201 CGACCGCTTT GGCCGCCGCC CAGTCCTGCT CGCTTCGCTA CTTGGAGCCA 
     251 CTATCGACTA CGCGATCATG GCGACCACAC CCGTCCTGTG GATTCTCTAC 
     301 GCCGGACGCA TCGTGGCCGG CATCACCGGC GCCACAGGTG CGGTTGCTGG 
     351 CGCCTATATC GCCGACATCA CCGATGGGGA AGATCGGGCT CGCCACTTCG 
     401 GGCTCATGAG CGCTTGTTTC GGCGTGGGTA TGGTGGCAGG CCCCGTGGCC 
     451 GGGGGACTGT TGGGCGCCAT CTCCTTACAT GCACCATTCC TTGCGGCGGC 
     501 GGTGCTCAAC GGCCTCAACC TACTACTGGG CTGCTTCCTA ATGCAGGAGT 
     551 CGCATAAGGG AGAGCGCCGA CCCATGCCCT TGAGAGCCTT CAACCCAGTC 
     601 AGCTCCTTCC GGTGGGCGCG GGGCATGACT ATCGTCGCCG CACTTATGAC 
     651 TGTCTTCTTT ATCATGCAAC TCGTAGGACA GGTGCCGGCA GCGCTCTGGG 
     701 TCATTTTCGG CGAGGACCGC TTTCGCTGGA GCGCGACGAT GATCGGCCTG 
     751 TCGCTTGCGG TATTCGGAAT CTTGCACGCC CTCGCTCAAG CCTTCGTCAC 
     801 TGGTCCCGCC ACCAAACGTT TCGGCGAGAA GCAGGCCATT ATCGCCGGCA 
     851 TGGCGGCCGA CGCGCTGGGC TACGTCTTGC TGGCGTTCGC GACGCGAGGC 
     901 TGGATGGCCT TCCCCATTAT GATTCTTCTC GCTTCCGGCG GCATCGGGAT 
     951 GCCCGCGTTG CAGGCCATGC TGTCCAGGCA GGTAGATGAC GACCATCAGG 
    1001 GACAGCTTCA AGGATCGCTC GCGGCTCTTA CCAGCCTAAC TTCGATCATT 
    1051 GGACCGCTGA TCGTCACGGC GATTTATGCC GCCTCGGCGA GCACATGGAA 
    1101 CGGGTTGGCA TGGATTGTAG GCGCCGCCCT ATACCTTGTC TGCCTCCCCG 
    1151 CGTTGCGTCG CGGTGCATGG AGCCGGGCCA CCTCGACCTG AACCGATACA 
    1201 ATTAAAGGCT CCTTTTGGAG CCTTTTTTTT TGGACGGACC GGTAGAAAAG 
    1251 ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT 
    1301 GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG CCGGATCAAG 
    1351 AGCTACCAAC TCTTTTTCCG AAGGTAACTG GCTTCAGCAG AGCGCAGATA 
    1401 CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA 
    1451 CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG 
    1501 CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA 
    1551 TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGGG GTTCGTGCAC 
    1601 ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC 
    1651 GTGAGCTATG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG 
    1701 TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC 
    1751 AGGGGGAAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT 
    1801 GACTTGAGCG TCGATTTTTG TGATGCTCGT CAGGGGGGCG GAGCCTATGG 
    1851 AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGCCT TTTGCTGGCC 
    1901 TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC 
    1951 GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGCAG CCGAACGACC 
    2001 GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC TGATGCGGTA 
    2051 TTTTCTCCTT ACGCATCTGT GCGGTATTTC ACACCGCAAT GGTGCACTCT 
    2101 CAGTACAATC TGCTCTGATG CCGCATAGTT AAGCCAGTAT ACACTCCGCT 
    2151 ATCGCTACGT GACTGGGTCA TGGCTGCGCC CCGACACCCG CCAACACCCG 
    2201 CTGACGCGCC CTGACGGGCT TGTCTGCTCC CGGCATCCGC TTACAGACAA 
    2251 GCTGTGACCG TCTCCGGGAG CTGCATGTGT CAGAGGTTTT CACCGTCATC 
    2301 ACCGAAACGC GCGAGGCAGG GGGAATTCCA GATAACTTCG TATAATGTAT 
    2351 GCTATACGAA GTTATGGTAC CGCGGCCGCG TAGAGGATCT GTTGATCAGC 
    2401 AGTTCAACCT GTTGATAGTA CTTCGTTAAT ACAGATGTAG GTGTTGGCAC 
    2451 CATGCATAAC TATAACGGTC CTAAGGTAGC GACCTAGGTA TCGATAATAC 
    2501 GACTCACTAT AGGGGAATTG TGAGCGGATA ACAATTCCCC TCTAGAAATA 
    2551 ATTTTGTTTA ACTTTAAGAA GGAGATATAC ATATGAGGCC TCGGATCCTG 
    2601 TAAAACGACG GCCAGTGAAT TCCCCGGGAA GCTTCGCCAG GGTTTTCCCA 
    2651 GTCGAGCTCG ATATCGGTAC CAGCGGATAA CAATTTCACA TCCGGATCGC 
    2701 GAACGCGTCT CGAGAGATCC GGCTGCTAAC AAAGCCCGAA AGGAAGCTGA 
    2751 GTTGGCTGCT GCCACCGCTG AGCAATAACT AGCATAACCC CTTGGGGCCT 
    2801 CTAAACGGGT CTTGAGGGGT TTTTTGGTTT AAACCCATCT AATTGGACTA 
    2851 GTAGCCCGCC TAATGAGCGG GCTTTTTTTT AATTCCCCTA TTTGTTTATT 
    2901 TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA TAACCCTGAT 
    2951 AAATGCTTCA ATAATATTGA AAAAGGAAGA GT 
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G.2.3. pDC 
 
 
1 ATCAACGTCT CATTTTCGCC AAAAGTTGGC CCAGATCTAT GTCGGGTGCG 
      51 GAGAAAGAGG TAATGAAATG GCACCTAGGT ATCGATAATA CGACTCACTA 
     101 TAGGGGAATT GTGAGCGGAT AACAATTCCC CTCTAGAAAT AATTTTGTTT 
     151 AACTTTAAGA AGGAGATATA CATATGAGGC CTCGGATCCT GTAAAACGAC 
     201 GGCCAGTGAA TTCCCCGGGA AGCTTCGCCA GGGTTTTCCC AGTCGAGCTC 
     251 GATATCGGTA CCAGCGGATA ACAATTTCAC ATCCGGATCG CGAACGCGTC 
     301 TCGAGAGATC CGGCTGCTAA CAAAGCCCGA AAGGAAGCTG AGTTGGCTGC 
     351 TGCCACCGCT GAGCAATAAC TAGCATAACC CCTTGGGGCC TCTAAACGGG 
     401 TCTTGAGGGG TTTTTTGGTT TAAACCCATG TGCCTGGCAG ATAACTTCGT 
     451 ATAATGTATG CTATACGAAG TTATGGTACC GCGGCCGCGT AGAGGATCTG 
     501 TTGATCAGCA GTTCAACCTG TTGATAGTAC GTACTAAGCT CTCATGTTTC 
     551 ACGTACTAAG CTCTCATGTT TAACGTACTA AGCTCTCATG TTTAACGAAC 
     601 TAAACCCTCA TGGCTAACGT ACTAAGCTCT CATGGCTAAC GTACTAAGCT 
     651 CTCATGTTTC ACGTACTAAG CTCTCATGTT TGAACAATAA AATTAATATA 
     701 AATCAGCAAC TTAAATAGCC TCTAAGGTTT TAAGTTTTAT AAGAAAAAAA 
     751 AGAATATATA AGGCTTTTAA AGCTTTTAAG GTTTAACGGT TGTGGACAAC 
     801 AAGCCAGGGA TGTAACGCAC TGAGAAGCCC TTAGAGCCTC TCAAAGCAAT 
     851 TTTGAGTGAC ACAGGAACAC TTAACGGCTG ACAGAATTAG CTTCACGCTG 
     901 CCGCAAGCAC TCAGGGCGCA AGGGCTGCTA AAGGAAGCGG AACACGTAGA 
     951 AAGCCAGTCC GCAGAAACGG TGCTGACCCC GGATGAATGT CAGCTGGGAG 
    1001 GCAGAATAAA TGATCATATC GTCAATTATT ACCTCCACGG GGAGAGCCTG 
    1051 AGCAAACTGG CCTCAGGCAT TTGAGAAGCA CACGGTCACA CTGCTTCCGG 
    1101 TAGTCAATAA ACCGGTAAAC CAGCAATAGA CATAAGCGGC TATTTAACGA 
    1151 CCCTGCCCTG AACCGACGAC CGGGTCGAAT TTGCTTTCGA ATTTCTGCCA 
    1201 TTCATCCGCT TATTATCACT TATTCAGGCG TAGCAACCAG GCGTTTAAGG 
    1251 GCACCAATAA CTGCCTTAAA AAAATTACGC CCCGCCCTGC CACTCATCGC 
    1301 AGTACTGTTG TAATTCATTA AGCATTCTGC CGACATGGAA GCCATCACAA 
    1351 ACGGCATGAT GAACCTGAAT CGCCAGCGGC ATCAGCACCT TGTCGCCTTG 
    1401 CGTATAATAT TTGCCCATGG TGAAAACGGG GGCGAAGAAG TTGTCCATAT 
    1451 TGGCCACGTT TAAATCAAAA CTGGTGAAAC TCACCCAGGG ATTGGCTGAG 
    1501 ACGAAAAACA TATTCTCAAT AAACCCTTTA GGGAAATAGG CCAGGTTTTC 
    1551 ACCGTAACAC GCCACATCTT GCGAATATAT GTGTAGAAAC TGCCGGAAAT 
    1601 CGTCGTGGTA TTCACTCCAG AGCGATGAAA ACGTTTCAGT TTGCTCATGG 
    1651 AAAACGGTGT AACAAGGGTG AACACTATCC CATATCACCA GCTCACCGTC 
    1701 TTTCATTGCC ATACGGAATT CCGGATGAGC ATTCATCAGG CGGGCAAGAA 
    1751 TGTGAATAAA GGCCGGATAA AACTTGTGCT TATTTTTCTT TACGGTCTTT 
    1801 AAAAAGGCCG TAATATCCAG CTGAACGGTC TGGTTATAGG TACATTGAGC 
    1851 AACTGACTGA AATGCCTCAA AATGTTCTTT ACGATGCCAT TGGGATATAT 
    1901 CAACGGTGGT ATATCCAGTG ATTTTTTTCT CCATTTTAGC TTCCTTAGCT 
    1951 CCTGAAAATC TCGATAACTC AAAAAATACG CCCGGTAGTG ATCTTATTTC 
    2001 ATTATGGTGA AAGTTGGACC CTCTTACGTG CCGATCAACG TCTCATTTTC 
    2051 GCCAAAAGTT GGCCCAG 
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G.2.4. pDK 
       1 CTATGTCGGG TGCGGAGAAA GAGGTAATGA AATGGCACCT AGGTATCGAT 
      51 GGCTTTACAC TTTATGCTTC CGGCTCGTAT GTTGTGTGGA ATTGTGAGCG 
     101 GATAACAATT TCACACAGGA AACAGCTATG ACCATGATTA CGAATTTCTA 
     151 GAAATAATTT TGTTTAACTT TAAGAAGGAG ATATACATAT GAGGCCTCGG 
     201 ATCCTGTAAA ACGACGGCCA GTGAATTCCC CGGGAAGCTT CGCCAGGGTT 
     251 TTCCCAGTCG AGCTCGATAT CGGTACCAGC GGATAACAAT TTCACATCCG 
     301 GATCGCGAAC GCGTCTCGAG ACTAGTTCCG TTTAAACCCA TGTGCCTGGC 
     351 AGATAACTTC GTATAATGTA TGCTATACGA AGTTATGGTA CGTACTAAGC 
     401 TCTCATGTTT CACGTACTAA GCTCTCATGT TTAACGTACT AAGCTCTCAT 
     451 GTTTAACGAA CTAAACCCTC ATGGCTAACG TACTAAGCTC TCATGGCTAA 
     501 CGTACTAAGC TCTCATGTTT CACGTACTAA GCTCTCATGT TTGAACAATA 
     551 AAATTAATAT AAATCAGCAA CTTAAATAGC CTCTAAGGTT TTAAGTTTTA 
     601 TAAGAAAAAA AAGAATATAT AAGGCTTTTA AAGCTTTTAA GGTTTAACGG 
     651 TTGTGGACAA CAAGCCAGGG ATGTAACGCA CTGAGAAGCC CTTAGAGCCT 
     701 CTCAAAGCAA TTTTCAGTGA CACAGGAACA CTTAACGGCT GACAGAATTA 
     751 GCTTCACGCT GCCGCAAGCA CTCAGGGCGC AAGGGCTGCT AAAGGAAGCG 
     801 GAACACGTAG AAAGCCAGTC CGCAGAAACG GTGCTGACCC CGGATGAATG 
     851 TCAGCTACTG GGCTATCTGG ACAAGGGAAA ACGCAAGCGC AAAGAGAAAG 
     901 CAGGTAGCTT GCAGTGGGCT TACATGGCGA TAGCTAGACT GGGCGGTTTT 
     951 ATGGACAGCA AGCGAACCGG AATTGCCAGC TGGGGCGCCC TCTGGTAAGG 
    1001 TTGGGAAGCC CTGCAAAGTA AACTGGATGG CTTTCTTGCC GCCAAGGATC 
    1051 TGATGGCGCA GGGGATCAAG ATCTGATCAA GAGACAGGAT GAGGATCGTT 
    1101 TCGCATGATT GAACAAGATG GATTGCACGC AGGTTCTCCG GCCGCTTGGG 
    1151 TGGAGAGGCT ATTCGGCTAT GACTGGGCAC AACAGACAAT CGGCTGCTCT 
    1201 GATGCCGCCG TGTTCCGGCT GTCAGCGCAG GGGCGCCCGG TTCTTTTTGT 
    1251 CAAGACCGAC CTGTCCGGTG CCCTGAATGA ACTGCAGGAC GAGGCAGCGC 
    1301 GGCTATCGTG GCTGGCCACG ACGGGCGTTC CTTGCGCAGC TGTGCTCGAC 
    1351 GTTGTCACTG AAGCGGGAAG GGACTGGCTG CTATTGGGCG AAGTGCCGGG 
    1401 GCAGGATCTC CTGTCATCTC ACCTTGCTCC TGCCGAGAAA GTATCCATCA 
    1451 TGGCTGATGC AATGCGGCGG CTGCATACGC TTGATCCGGC TACCTGCCCA 
    1501 TTCGACCACC AAGCGAAACA TCGCATCGAG CGAGCACGTA CTCGGATGGA 
    1551 AGCCGGTCTT GTCGATCAGG ATGATCTGGA CGAAGAGCAT CAGGGGCTCG 
    1601 CGCCAGCCGA ACTGTTCGCC AGGCTCAAGG CGCGCATGCC CGACGGCGAG 
    1651 GATCTCGTCG TGACACATGG CGATGCCTGC TTGCCGAATA TCATGGTGGA 
    1701 AAATGGCCGC TTTTCTGGAT TCATCGACTG TGGCCGGCTG GGTGTGGCGG 
    1751 ACCGCTATCA GGACATAGCG TTGGCTACCC GTGATATTGC TGAAGAGCTT 
    1801 GGCGGCGAAT GGGCTGACCG CTTCCTCGTG CTTTACGGTA TCGCCGCTCC 
    1851 CGATTCGCAG CGCATCGCCT TCTATCGCCT TCTTGACGAG TTCTTCTGAG 
    1901 CGGGACTCTG GGGTTCGAAA TGACCGACCA AGCGACGCCC AACCTGCCAT 
    1951 CACGAGATTT CGATTCCACC GCCGCCTTCT ATGAAAGGTT GGGCTTCGGA 
    2001 ATCGTTTTCC GGGACGCCGG CTGGATGATC CTCCAGCGCG GGGATCTCAT 
    2051 GCTGGAGTTC TTCGCCCACC CCGGGAT 
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G.2.5. pDS 
 
       1 CTATGTCGGG TGCGGAGAAA GAGGTAATGA AATGGCACCT AGGTATCGAT 
      51 GGCTTTACAC TTTATGCTTC CGGCTCGTAT GTTGTGTGGA ATTGTGAGCG 
     101 GATAACAATT TCACACAGGA AACAGCTATG ACCATGATTA CGAATTTCTA 
     151 GAAATAATTT TGTTTAACTT TAAGAAGGAG ATATACATAT GAGGCCTCGG 
     201 ATCCTGTAAA ACGACGGCCA GTGAATTCCC CGGGAAGCTT CGCCAGGGTT 
     251 TTCCCAGTCG AGCTCGATAT CGGTACCAGC GGATAACAAT TTCACATCCG 
     301 GATCGCGAAC GCGTCTCGAG ACTAGTTCCG TTTAAACCCA TGTGCCTGGC 
     351 AGATAACTTC GTATAATGTA TGCTATACGA AGTTATGGTA CGTACTAAGC 
     401 TCTCATGTTT CACGTACTAA GCTCTCATGT TTAACGTACT AAGCTCTCAT 
     451 GTTTAACGAA CTAAACCCTC ATGGCTAACG TACTAAGCTC TCATGGCTAA 
     501 CGTACTAAGC TCTCATGTTT CACGTACTAA GCTCTCATGT TTGAACAATA 
     551 AAATTAATAT AAATCAGCAA CTTAAATAGC CTCTAAGGTT TTAAGTTTTA 
     601 TAAGAAAAAA AAGAATATAT AAGGCTTTTA AAGCTTTTAA GGTTTAACGG 
     651 TTGTGGACAA CAAGCCAGGG ATGTAACGCA CTGAGAAGCC CTTAGAGCCT 
     701 CTCAAAGCAA TTTTGAGTGA CACAGGAACA CTTAACGGCT GACATAATTC 
     751 AGCTTCACGC TGCCGCAAGC ACTCAGGGCG CAAGGGCTGC TAAAGGAAGC 
     801 GGAACACGTA GAAAGCCAGT CCGCAGAAAC GGTGCTGACC CCGGATGAAT 
     851 GTCAGCTGGG AGGCAGAATA AATGATCATA TCGTCAATTA TTACCTCCAC 
     901 GGGGAGAGCC TGAGCAAACT GGCCTCAGGC ATTTGAGAAG CACACGGTCA 
     951 CACTGCTTCC GGTAGTCAAT AAACCGGTAA GTAGCGTATG CGCTCACGCA 
    1001 ACTGGTCCAG AACCTTGACC GAACGCAGCG GTGGTAACGG CGCAGTGGCG 
    1051 GTTTTCATGG CTTGTTATGA CTGTTTTTTT GGGGTACAGT CTATGCCTCG 
    1101 GGCATCCAAG CAGCAAGCGC GTTACGCCGT GGGTCGATGT TTGATGTTAT 
    1151 GGAGCAGCAA CGATGTTACG CAGCAGGGCA GTCGCCCTAA AACAAAGTTA 
    1201 AACATCATGA GGGAAGCGGT GATCGCCGAA GTATCGACTC AACTATCAGA 
    1251 GGTAGTTGGC GTCATCGAGC GCCATCTCGA ACCGACGTTG CTGGCCGTAC 
    1301 ATTTGTACGG CTCCGCAGTG GATGGCGGCC TGAAGCCACA CAGTGATATT 
    1351 GATTTGCTGG TTACGGTGAC CGTAAGGCTT GATGAAACAA CGCGGCGAGC 
    1401 TTTGATCAAC GACCTTTTGG AAACTTCGGC TTCCCCTGGA GAGAGCGAGA 
    1451 TTCTCCGCGC TGTAGAAGTC ACCATTGTTG TGCACGACGA CATCATTCCG 
    1501 TGGCGTTATC CAGCTAAGCG CGAACTGCAA TTTGGAGAAT GGCAGCGCAA 
    1551 TGACATTCTT GCAGGTATCT TCGAGCCAGC CACGATCGAC ATTGATCTGG 
    1601 CTATCTTGCT GACAAAAGCA AGAGAACATA GCGTTGCCTT GGTAGGTCCA 
    1651 GCGGCGGAGG AACTCTTTGA TCCGGTTCCT GAACAGGATC TATTTGAGGC 
    1701 GCTAAATGAA ACCTTAACGC TATGGAACTC GCCGCCCGAC TGGGCTGGCG 
    1751 ATGAGCGAAA TGTAGTGCTT ACGTTGTCCC GCATTTGGTA CAGCGCAGTA 
    1801 ACCGGCAAAA TCGCGCCGAA GGATGTCGCT GCCGACTGGG CAATGGAGCG 
    1851 CCTGCCGGCC CAGTATCAGC CCGTCATACT TGAAGCTAGA CAGGCTTATC 
    1901 TTGGACAAGA AGAAGATCGC TTGGCCTCGC GCGCAGATCA GTTGGAAGAA 
    1951 TTTGTCCACT ACGTGAAAGG CGAGATCACC AAGGTAGTCG GCAAATAATG 
    2001 TCTAACAATT CGTTCAAGCC GACGGAT 
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G.2.6. pACKS tetrafusion (ACEMBL kit component) 
 
       1 GGTACCGCGG CCGCGTAGAG GATCTGTTGA TCAGCAGTTC AACCTGTTGA 
      51 TAGTACTTCG TTAATACAGA TGTAGGTGTT GGCACCATGC ATAACTATAA 
     101 CGGTCCTAAG GTAGCGACCT AGGTATCGAT AATACGACTC ACTATAGGGG 
     151 AATTGTGAGC GGATAACAAT TCCCCTCTAG AAATAATTTT GTTTAACTTT 
     201 AAGAAGGAGA TATACATATG AGGCCTCGGA TCCTGTAAAA CGACGGCCAG 
     251 TGAATTCCCC GGGAAGCTTC GCCAGGGTTT TCCCAGTCGA GCTCGATATC 
     301 GGTACCAGCG GATAACAATT TCACATCCGG ATCGCGAACG CGTCTCGAGA 
     351 GATCCGGCTG CTAACAAAGC CCGAAAGGAA GCTGAGTTGG CTGCTGCCAC 
     401 CGCTGAGCAA TAACTAGCAT AACCCCTTGG GGCCTCTAAA CGGGTCTTGA 
     451 GGGGTTTTTT GGTTTAAACC CATCTAATTG GACTAGTAGC CCGCCTAATG 
     501 AGCGGGCTTT TTTTTAATTC CCCTATTTGT TTATTTTTCT AAATACATTC 
     551 AAATATGTAT CCGCTCATGA GACAATAACC CTGATAAATG CTTCAATAAT 
     601 ATTGAAAAAG GAAGAGTATG AGTATTCAAC ATTTCCGTGT CGCCCTTATT 
     651 CCCTTTTTTG CGGCATTTTG CCTTCCTGTT TTTGCTCACC CAGAAACGCT 
     701 CGTGAAAGTA AAAGACGCAG AGGACCAATT GGGGGCACGA GTGGGATACA 
     751 TAGAACTGGA CTTGAATAGC GGTAAAATCC TTGAGAGTTT TCGCCCTGAA 
     801 GAGCGTTTTC CAATGATGAG CACTTTCAAA GTTCTGCTAT GTGGAGCAGT 
     851 ATTATCCCGT GTAGATGCGG GGCAAGAGCA ACTCGGACGA CGAATACACT 
     901 ATTCGCAGAA TGACTTGGTT GAATACTCCC CAGTGACAGA AAAGCACCTT 
     951 ACGGACGGAA TGACGGTAAG AGAATTATGT AGTGCCGCCA TAACGATGAG 
    1001 TGATAACACT GCGGCGAACT TACTTCTGAC AACCATCGGT GGACCGAAGG 
    1051 AATTAACCGC TTTTTTGCAC AATATGGGAG ACCATGTAAC TCGCCTTGAC 
    1101 CGTTGGGAAC CAGAACTGAA TGAAGCCATA CCAAACGACG AGCGAGACAC 
    1151 CACAATGCCT GCGGCAATGG CAACAACATT ACGCAAACTA TTAACTGGCG 
    1201 AACTACTTAC TCTGGCTTCA CGGCAACAAT TAATAGACTG GCTTGAAGCG 
    1251 GATAAAGTTG CAGGACCACT ACTGCGTTCG GCACTTCCTG CTGGCTGGTT 
    1301 TATTGCTGAT AAATCTGGGG CAGGAGAGCG TGGTTCACGG GGTATCATTG 
    1351 CCGCACTTGG ACCAGATGGT AAGCCTTCCC GTATCGTAGT TATCTACACG 
    1401 ACGGGTAGTC AGGCAACTAT GGACGAACGA AATAGACAGA TTGCTGAAAT 
    1451 AGGGGCTTCA CTGATTAAGC ATTGGTAAAC CGATACAATT AAAGGCTCCT 
    1501 TTTGGAGCCT TTTTTTTTGG ACGGACCGGT AGAAAAGATC AAAGGATCTT 
    1551 CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA 
    1601 CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT 
    1651 TTTTCCGAAG GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC 
    1701 TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG 
    1751 CCTACATACC TCGCTCTGCT AATCCTGTTA CCAGTGGCTG CTGCCAGTGG 
    1801 CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG TTACCGGATA 
    1851 AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG 
    1901 GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA 
    1951 AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG 
    2001 GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC 
    2051 TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG 
    2101 ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA 
    2151 ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG 
    2201 TTCTTTCCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT 
    2251 TGAGTGAGCT GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAGT 
    2301 CAGTGAGCGA GGAAGCGGAA GAGCGCCTGA TGCGGTATTT TCTCCTTACG 
    2351 CATCTGTGCG GTATTTCACA CCGCAATGGT GCACTCTCAG TACAATCTGC 
    2401 TCTGATGCCG CATAGTTAAG CCAGTATACA CTCCGCTATC GCTACGTGAC 
    2451 TGGGTCATGG CTGCGCCCCG ACACCCGCCA ACACCCGCTG ACGCGCCCTG 
    2501 ACGGGCTTGT CTGCTCCCGG CATCCGCTTA CAGACAAGCT GTGACCGTCT 
    2551 CCGGGAGCTG CATGTGTCAG AGGTTTTCAC CGTCATCACC GAAACGCGCG 
    2601 AGGCAGGGGG AATTCCAGAT AACTTCGTAT AATGTATGCT ATACGAAGTT 
    2651 ATGGTACCGC GGCCGCGTAG AGGATCTGTT GATCAGCAGT TCAACCTGTT 
    2701 GATAGTACGT ACTAAGCTCT CATGTTTCAC GTACTAAGCT CTCATGTTTA 
    2751 ACGTACTAAG CTCTCATGTT TAACGAACTA AACCCTCATG GCTAACGTAC 
    2801 TAAGCTCTCA TGGCTAACGT ACTAAGCTCT CATGTTTCAC GTACTAAGCT 
    2851 CTCATGTTTG AACAATAAAA TTAATATAAA TCAGCAACTT AAATAGCCTC 
    2901 TAAGGTTTTA AGTTTTATAA GAAAAAAAAG AATATATAAG GCTTTTAAAG 
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    2951 CTTTTAAGGT TTAACGGTTG TGGACAACAA GCCAGGGATG TAACGCACTG 
    3001 AGAAGCCCTT AGAGCCTCTC AAAGCAATTT TGAGTGACAC AGGAACACTT 
    3051 AACGGCTGAC AGAATTAGCT TCACGCTGCC GCAAGCACTC AGGGCGCAAG 
    3101 GGCTGCTAAA GGAAGCGGAA CACGTAGAAA GCCAGTCCGC AGAAACGGTG 
    3151 CTGACCCCGG ATGAATGTCA GCTGGGAGGC AGAATAAATG ATCATATCGT 
    3201 CAATTATTAC CTCCACGGGG AGAGCCTGAG CAAACTGGCC TCAGGCATTT 
    3251 GAGAAGCACA CGGTCACACT GCTTCCGGTA GTCAATAAAC CGGTAAACCA 
    3301 GCAATAGACA TAAGCGGCTA TTTAACGACC CTGCCCTGAA CCGACGACCG 
    3351 GGTCGAATTT GCTTTCGAAT TTCTGCCATT CATCCGCTTA TTATCACTTA 
    3401 TTCAGGCGTA GCAACCAGGC GTTTAAGGGC ACCAATAACT GCCTTAAAAA 
    3451 AATTACGCCC CGCCCTGCCA CTCATCGCAG TACTGTTGTA ATTCATTAAG 
    3501 CATTCTGCCG ACATGGAAGC CATCACAAAC GGCATGATGA ACCTGAATCG 
    3551 CCAGCGGCAT CAGCACCTTG TCGCCTTGCG TATAATATTT GCCCATGGTG 
    3601 AAAACGGGGG CGAAGAAGTT GTCCATATTG GCCACGTTTA AATCAAAACT 
    3651 GGTGAAACTC ACCCAGGGAT TGGCTGAGAC GAAAAACATA TTCTCAATAA 
    3701 ACCCTTTAGG GAAATAGGCC AGGTTTTCAC CGTAACACGC CACATCTTGC 
    3751 GAATATATGT GTAGAAACTG CCGGAAATCG TCGTGGTATT CACTCCAGAG 
    3801 CGATGAAAAC GTTTCAGTTT GCTCATGGAA AACGGTGTAA CAAGGGTGAA 
    3851 CACTATCCCA TATCACCAGC TCACCGTCTT TCATTGCCAT ACGGAATTCC 
    3901 GGATGAGCAT TCATCAGGCG GGCAAGAATG TGAATAAAGG CCGGATAAAA 
    3951 CTTGTGCTTA TTTTTCTTTA CGGTCTTTAA AAAGGCCGTA ATATCCAGCT 
    4001 GAACGGTCTG GTTATAGGTA CATTGAGCAA CTGACTGAAA TGCCTCAAAA 
    4051 TGTTCTTTAC GATGCCATTG GGATATATCA ACGGTGGTAT ATCCAGTGAT 
    4101 TTTTTTCTCC ATTTTAGCTT CCTTAGCTCC TGAAAATCTC GATAACTCAA 
    4151 AAAATACGCC CGGTAGTGAT CTTATTTCAT TATGGTGAAA GTTGGACCCT 
    4201 CTTACGTGCC GATCAACGTC TCATTTTCGC CAAAAGTTGG CCCAGATCAA 
    4251 CGTCTCATTT TCGCCAAAAG TTGGCCCAGA TCTATGTCGG GTGCGGAGAA 
    4301 AGAGGTAATG AAATGGCACC TAGGTATCGA TAATACGACT CACTATAGGG 
    4351 GAATTGTGAG CGGATAACAA TTCCCCTCTA GAAATAATTT TGTTTAACTT 
    4401 TAAGAAGGAG ATATACATAT GAGGCCTCGG ATCCTGTAAA ACGACGGCCA 
    4451 GTGAATTCCC CGGGAAGCTT CGCCAGGGTT TTCCCAGTCG AGCTCGATAT 
    4501 CGGTACCAGC GGATAACAAT TTCACATCCG GATCGCGAAC GCGTCTCGAG 
    4551 AGATCCGGCT GCTAACAAAG CCCGAAAGGA AGCTGAGTTG GCTGCTGCCA 
    4601 CCGCTGAGCA ATAACTAGCA TAACCCCTTG GGGCCTCTAA ACGGGTCTTG 
    4651 AGGGGTTTTT TGGTTTAAAC CCATGTGCCT GGCAGATAAC TTCGTATAAT 
    4701 GTATGCTATA CGAAGTTATG GTACGTACTA AGCTCTCATG TTTCACGTAC 
    4751 TAAGCTCTCA TGTTTAACGT ACTAAGCTCT CATGTTTAAC GAACTAAACC 
    4801 CTCATGGCTA ACGTACTAAG CTCTCATGGC TAACGTACTA AGCTCTCATG 
    4851 TTTCACGTAC TAAGCTCTCA TGTTTGAACA ATAAAATTAA TATAAATCAG 
    4901 CAACTTAAAT AGCCTCTAAG GTTTTAAGTT TTATAAGAAA AAAAAGAATA 
    4951 TATAAGGCTT TTAAAGCTTT TAAGGTTTAA CGGTTGTGGA CAACAAGCCA 
    5001 GGGATGTAAC GCACTGAGAA GCCCTTAGAG CCTCTCAAAG CAATTTTCAG 
    5051 TGACACAGGA ACACTTAACG GCTGACAGAA TTAGCTTCAC GCTGCCGCAA 
    5101 GCACTCAGGG CGCAAGGGCT GCTAAAGGAA GCGGAACACG TAGAAAGCCA 
    5151 GTCCGCAGAA ACGGTGCTGA CCCCGGATGA ATGTCAGCTA CTGGGCTATC 
    5201 TGGACAAGGG AAAACGCAAG CGCAAAGAGA AAGCAGGTAG CTTGCAGTGG 
    5251 GCTTACATGG CGATAGCTAG ACTGGGCGGT TTTATGGACA GCAAGCGAAC 
    5301 CGGAATTGCC AGCTGGGGCG CCCTCTGGTA AGGTTGGGAA GCCCTGCAAA 
    5351 GTAAACTGGA TGGCTTTCTT GCCGCCAAGG ATCTGATGGC GCAGGGGATC 
    5401 AAGATCTGAT CAAGAGACAG GATGAGGATC GTTTCGCATG ATTGAACAAG 
    5451 ATGGATTGCA CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG GCTATTCGGC 
    5501 TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG CCGTGTTCCG 
    5551 GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG 
    5601 GTGCCCTGAA TGAACTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC 
    5651 ACGACGGGCG TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG 
    5701 AAGGGACTGG CTGCTATTGG GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT 
    5751 CTCACCTTGC TCCTGCCGAG AAAGTATCCA TCATGGCTGA TGCAATGCGG 
    5801 CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTCGACC ACCAAGCGAA 
    5851 ACATCGCATC GAGCGAGCAC GTACTCGGAT GGAAGCCGGT CTTGTCGATC 
    5901 AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTC 
    5951 GCCAGGCTCA AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACACA 
    6001 TGGCGATGCC TGCTTGCCGA ATATCATGGT GGAAAATGGC CGCTTTTCTG 
    6051 GATTCATCGA CTGTGGCCGG CTGGGTGTGG CGGACCGCTA TCAGGACATA 
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    6101 GCGTTGGCTA CCCGTGATAT TGCTGAAGAG CTTGGCGGCG AATGGGCTGA 
    6151 CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCGATTCG CAGCGCATCG 
    6201 CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTCG 
    6251 AAATGACCGA CCAAGCGACG CCCAACCTGC CATCACGAGA TTTCGATTCC 
    6301 ACCGCCGCCT TCTATGAAAG GTTGGGCTTC GGAATCGTTT TCCGGGACGC 
    6351 CGGCTGGATG ATCCTCCAGC GCGGGGATCT CATGCTGGAG TTCTTCGCCC 
    6401 ACCCCGGGAT CTATGTCGGG TGCGGAGAAA GAGGTAATGA AATGGCACCT 
    6451 AGGTATCGAT GGCTTTACAC TTTATGCTTC CGGCTCGTAT GTTGTGTGGA 
    6501 ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCTATG ACCATGATTA 
    6551 CGAATTTCTA GAAATAATTT TGTTTAACTT TAAGAAGGAG ATATACATAT 
    6601 GAGGCCTCGG ATCCTGTAAA ACGACGGCCA GTGAATTCCC CGGGAAGCTT 
    6651 CGCCAGGGTT TTCCCAGTCG AGCTCGATAT CGGTACCAGC GGATAACAAT 
    6701 TTCACATCCG GATCGCGAAC GCGTCTCGAG ACTAGTTCCG TTTAAACCCA 
    6751 TGTGCCTGGC AGATAACTTC GTATAATGTA TGCTATACGA AGTTATGGTA 
    6801 CGTACTAAGC TCTCATGTTT CACGTACTAA GCTCTCATGT TTAACGTACT 
    6851 AAGCTCTCAT GTTTAACGAA CTAAACCCTC ATGGCTAACG TACTAAGCTC 
    6901 TCATGGCTAA CGTACTAAGC TCTCATGTTT CACGTACTAA GCTCTCATGT 
    6951 TTGAACAATA AAATTAATAT AAATCAGCAA CTTAAATAGC CTCTAAGGTT 
    7001 TTAAGTTTTA TAAGAAAAAA AAGAATATAT AAGGCTTTTA AAGCTTTTAA 
    7051 GGTTTAACGG TTGTGGACAA CAAGCCAGGG ATGTAACGCA CTGAGAAGCC 
    7101 CTTAGAGCCT CTCAAAGCAA TTTTGAGTGA CACAGGAACA CTTAACGGCT 
    7151 GACATAATTC AGCTTCACGC TGCCGCAAGC ACTCAGGGCG CAAGGGCTGC 
    7201 TAAAGGAAGC GGAACACGTA GAAAGCCAGT CCGCAGAAAC GGTGCTGACC 
    7251 CCGGATGAAT GTCAGCTGGG AGGCAGAATA AATGATCATA TCGTCAATTA 
    7301 TTACCTCCAC GGGGAGAGCC TGAGCAAACT GGCCTCAGGC ATTTGAGAAG 
    7351 CACACGGTCA CACTGCTTCC GGTAGTCAAT AAACCGGTAA GTAGCGTATG 
    7401 CGCTCACGCA ACTGGTCCAG AACCTTGACC GAACGCAGCG GTGGTAACGG 
    7451 CGCAGTGGCG GTTTTCATGG CTTGTTATGA CTGTTTTTTT GGGGTACAGT 
    7501 CTATGCCTCG GGCATCCAAG CAGCAAGCGC GTTACGCCGT GGGTCGATGT 
    7551 TTGATGTTAT GGAGCAGCAA CGATGTTACG CAGCAGGGCA GTCGCCCTAA 
    7601 AACAAAGTTA AACATCATGA GGGAAGCGGT GATCGCCGAA GTATCGACTC 
    7651 AACTATCAGA GGTAGTTGGC GTCATCGAGC GCCATCTCGA ACCGACGTTG 
    7701 CTGGCCGTAC ATTTGTACGG CTCCGCAGTG GATGGCGGCC TGAAGCCACA 
    7751 CAGTGATATT GATTTGCTGG TTACGGTGAC CGTAAGGCTT GATGAAACAA 
    7801 CGCGGCGAGC TTTGATCAAC GACCTTTTGG AAACTTCGGC TTCCCCTGGA 
    7851 GAGAGCGAGA TTCTCCGCGC TGTAGAAGTC ACCATTGTTG TGCACGACGA 
    7901 CATCATTCCG TGGCGTTATC CAGCTAAGCG CGAACTGCAA TTTGGAGAAT 
    7951 GGCAGCGCAA TGACATTCTT GCAGGTATCT TCGAGCCAGC CACGATCGAC 
    8001 ATTGATCTGG CTATCTTGCT GACAAAAGCA AGAGAACATA GCGTTGCCTT 
    8051 GGTAGGTCCA GCGGCGGAGG AACTCTTTGA TCCGGTTCCT GAACAGGATC 
    8101 TATTTGAGGC GCTAAATGAA ACCTTAACGC TATGGAACTC GCCGCCCGAC 
    8151 TGGGCTGGCG ATGAGCGAAA TGTAGTGCTT ACGTTGTCCC GCATTTGGTA 
    8201 CAGCGCAGTA ACCGGCAAAA TCGCGCCGAA GGATGTCGCT GCCGACTGGG 
    8251 CAATGGAGCG CCTGCCGGCC CAGTATCAGC CCGTCATACT TGAAGCTAGA 
    8301 CAGGCTTATC TTGGACAAGA AGAAGATCGC TTGGCCTCGC GCGCAGATCA 
    8351 GTTGGAAGAA TTTGTCCACT ACGTGAAAGG CGAGATCACC AAGGTAGTCG 
    8401 GCAAATAATG TCTAACAATT CGTTCAAGCC GACGGATCTA TGTCGGGTGC 
    8451 GGAGAAAGAG GTAATGAAAT GGCACCTAGG TATCGATGGC TTTACACTTT 
    8501 ATGCTTCCGG CTCGTATGTT GTGTGGAATT GTGAGCGGAT AACAATTTCA 
    8551 CACAGGAAAC AGCTATGACC ATGATTACGA ATTTCTAGAA ATAATTTTGT 
    8601 TTAACTTTAA GAAGGAGATA TACATATGAG GCCTCGGATC CTGTAAAACG 
    8651 ACGGCCAGTG AATTCCCCGG GAAGCTTCGC CAGGGTTTTC CCAGTCGAGC 
    8701 TCGATATCGG TACCAGCGGA TAACAATTTC ACATCCGGAT CGCGAACGCG 
    8751 TCTCGAGACT AGTTCCGTTT AAACCCATGT GCCTGGCAGA TAACTTCGTA 
    8801 TAATGTATGC TATACGAAGT TAT 
Nature Methods: doi: 10.1038/nmeth.1326
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ACEMBL plasmid maps 
 
 
Acceptor vectors pACE and pACE2, containing a T7 promoter and terminator, are shown. 
Donor vectors pDK, pDS and pDC contain conditional origins of replication. pDS and 
pDK have a lac promoter. pDC has a T7 promoter. Resistance markers are shown in gray, 
origins of replication in yellow. LoxP imperfect inverted repeat sequences are shown as 
circles. Homing endonuclease sites and corresponding BstXI sites are boxed. The 
restriction enzyme sites in the multiple integration element (MIE) are indicated. All MIEs 
have the same DNA sequence between ClaI and PmeI. Differences in unique restriction 
site composition stem from differences in the plasmid backbone sequences. 
Methods: doi: 10.1038/nmeth.1326
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All ACEMBL vectors were analyzed by BamHI restriction digestion. The 
undigested and digested ACEMBL vectors are shown below: 
 
 
      1         2        3         4        5      M       A       B       C       D       E 
 
Restriction mapping of ACEMBL vectors. Both undigested Acceptor and 
Donor vectors are shown as well as the same vectors digested with BamHI. All 
restriction reactions yield the expected sizes. Lane 1-5 show uncut pACE, pACE2, 
pDC, pDK, and pDS vectors; lane M shows ? StyI marker; lane A-E show BamHI 
digested pACE, pACE2, pDC, pDK, and pDS vectors. 
 
Nature Methods: doi: 10.1038/nmeth.1326
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Résumé de la publication 
 
Les complexes multi protéiques constituent un domaine émergent de la recherche 
biologique contemporaine. (1). Les études moléculaires et structurales des 
assemblages multi protéiques sont souvent handicapés par la faible abondance et la 
nature hétérogène de la plupart de ces complexes dans leur hôtes natifs, empêchant 
ainsi une extraction directe. Les méthodes recombinantes qui peuvent permettre la 
surproduction de ces complexes multi protéiques sont par conséquent souvent un pré-
requis à leur étude. 
Nous avons relevé ce défi en créant ACEMBL, un système pour l’assemblage 
multi génique rapide et flexible en vue de l’expression multi protéique dans E. coli. 
ACEMBL vient en complément de MultiBac, notre technologie d’expression 
introduite précédemment pour le système baculovirus/cellules d’insecte. (2). 
ACEMBL utilise la recombinaison pour la construction de vecteurs d’expression 
multi géniques qui permet rapidement d’introduire une diversité dans chaque gène si 
le besoin se fait. Ces caractéristiques sont particulièrement importantes dans la 
biologie structurale moderne, puisque une révision rapide de l’expression du 
complexe et une diversification de chacun des composants impliqués peuvent être 
cruciales pour l’obtention de la structure. 
Le système ACEMBL peut être complètement automatisé ce qui est une priorité 
majeure dans le domaine de la science des protéines. Pour plus d’information sur 
ACEMBL comprenant les mises à jour des procédures, un manuel d’utilisateur peut 
être obtenu sur notre page web EMBL 
(http://www.embl.fr/research/services/berger/ACEMBL.pdf). Pour les réactifs du 
système ACEMBL, veuillez contacter Dr. Imre Berger (iberger@embl.fr). Les 
protocoles suivant décrivent en détail la construction/déconstruction des vecteurs 
d’expression multi géniques dans le système ACEMBL: (1) Insertion d’un gène 
unique ou d’un assemblage polycistronique par les procédures de clonage séquence et 
ligation indépendante (SLIC); (2) Insertion de gène par restriction/ligation; (3) 
Multiplication de cassette d’expression en utilisant les homing endonucleases (HE) et 
(4) la fusion de multiples plasmides d’expression en une seule construction 
d’expression multi génique par recombinaison en site spécifique utilisant la CRE 
recombinase. En plus de la construction multi génique, nous décrivons aussi comment 
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déconstruire des plasmides de fusion d’expression multi génique en utilisant l’enzyme 
CRE, dans le but par exemple de changer ou altérer uniquement une sous-unité 
particulière d’un complexe multi protéique. La combinaison des protocoles présentés 
permet, de manière simple, l’assemblage et le désassemblage de constructions multi 
géniques pour l’expression de complexes multi protéiques ainsi que la révision rapide 
et la diversification des expériences d’expression (Fig. 1). Les protocoles peuvent être 
utilisés manuellement mais également dans un environnement robotisé avec une 
station de gestion des liquides. 
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INTRODUCTION 
Multiprotein complexes are an emerging focus of contemporary biological research 
efforts (1). Molecular and structural studies of multiprotein assemblies are often 
handicapped by the low abundance and heterogeneous nature of most of these 
complexes in their native hosts, thus inhibiting direct extraction. Recombinant 
methods that can achieve overproduction of these multiprotein complexes are 
therefore often a crucial prerequisite for their study.   
We addressed several of the challenges by creating ACEMBL, a system for rapid and 
flexible multigene assembly for multiprotein expression in E.coli. ACEMBL 
complements MultiBac, our previously introduced expression technology for the 
baculovirus/insect cell system (2).  ACEMBL uses recombineering for constructing 
multigene expression vectors and to rapidly introduce diversity into each gene of 
interest if the need arises. These features are especially important in modern 
structural biology, as rapid revision of complex expression and diversification of each 
component involved can be crucial for successful structure determination. The 
ACEMBL system can be fully automated, which is a top priority in current protein 
science. For further information about ACEMBL, including updates of the procedures 
used, a User Manual can be obtained from our EMBL home page 
(http://www.embl.fr/research/services/berger/ACEMBL.pdf). For ACEMBL reagents 
please contact iberger@embl.fr. 
The protocols presented in the following describe in detail the approaches for 
(de)constructing multigene expression vectors in the ACEMBL system: (1) Single 
gene insertion  or polycistron assembly via sequence and ligation independent 
cloning (SLIC) procedures; (2) gene insertion by restriction/ligation; (3) expression 
cassette multiplication by using homing endonucleases (HE) and (4) fusion of 
multiple expression plasmids into a single multigene expression construct by site-
specific recombination using the Cre recombinase. In addition to multigene 
construction, we also describe how to deconstruct multigene expression fusion 
plasmids by using the Cre enzyme, for example to change or alter only a particular 
subunit of a multiprotein complex.  Combination of the protocols presented allows 
for simple assembly and disassembly of multigene constructs for multiprotein 
complex expression, as well as for rapid revision and diversification of expression 
experiments (Fig. 1). The protocols can be used in a manual setup and also in a 
robotic environment using a liquid handling workstation. 
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MATERIALS 
REAGENTS 
Phusion polymerase (and 5x HF Buffer), Finnzymes, Finland 
dNTP mix (10 mM), New England Biolabs (NEB), USA 
10 mM BSA, NEB 
Cre recombinase (and 10x Buffer), EMBL core facility, Germany 
Restriction endonucleases (and 10x Buffer), various suppliers 
Homing endonucleases PI-SceI, I-CeuI (and 10x Buffer), NEB 
Restriction enzyme BstXI (and 10x Buffer), NEB 
T4 DNA ligase (and 10x Buffer), NEB  
T4 DNA polymerase (and 10x Buffer), NEB 
Calf or Shrimp intestinal alkaline phosphatase, Stratagene Corp., USA 
DpnI enzyme, NEB 
E. coli competent cells (pir+ strains, pir- strains), Novagen Inc., UK 
100 mM DTT, 2 M Urea, 500 mM EDTA, Sigma-Aldrich, USA  
96well microtiter plates, Greiner GmbH, Germany 
12 well tissue-culture plates (or petri dishes), Greiner GmbH, Germany 
PCR purification kit (Qiagen, Germany) 
Gel extraction kit (Qiagen, Germany) 
NucleoSpin kit (Macherey-Nagel, France) 
Antibiotics (ampicillin, chloramphenicol, kanamycin, spectinomycin, tetracyclin) 
LB media 
Agar 
PROCEDURE 
The Multiple Integration Element (MIE) was derived from a polylinker (4) and 
allows for several approaches for multigene assembly. Single or multiple genes can 
be inserted into the MIE of any of the ACEMBL vectors by a variety of methods. For 
this, the vector needs to be linearized, which can be carried out efficiently by PCR 
reaction with appropriate primers, since the vectors are all small (2-2.6 kb). 
Alternatively, if more conventional approaches are preferred i.e. in a regular wet lab 
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setting without robotics, the vectors can also be linearized by restriction digestion, 
and a gene of interest can be pasted in by ligation. The following protocols describe 
these approaches in detail. 
Single gene insertion into the MIE by SLIC  
1. Primer design 
Design primers for the SLIC procedure containing the regions of homology which 
result in the long sticky ends upon treatment with T4 DNA polymerase in the absence 
of dNTPs (3): 
Primers for the insert contain a DNA sequence corresponding to this region of 
homology (adaptor sequence), followed by a sequence which specifically anneals to 
the insert to be amplified. Useful adaptor sequences for SLIC can be taken directly 
from the ACEMBL Manual deposited at the EMBL Grenoble homepage 
(http://www.embl.fr/research/services/berger/ACEMBL.pdf). 
In case the gene of interest is amplified from a vector already containing expression 
elements (e.g. the pET vector series), the “insert specific sequence” can be located 
upstream of a ribosome binding site (rbs). Otherwise, the forward primer needs to be 
designed such that a ribosome binding site is also provided in the final construct. 
Primers for PCR linearization of the vector backbone are simply complementary to 
the two adaptor sequences present in the primer pair chosen for insert amplification. 
2. PCR amplification of insert and vector 
Prepare PCR reactions in 100 ml volume for DNA insert to be cloned and the vector 
backbone to be linearized: 
 
ddH2O    75 ml 
5´ Phusion HF Reaction buffer    20 ml 
dNTPs (10 mM stock)      2 ml 
Template DNA (100 ng/ml)      1 ml 
5¢ SLIC primer (100 mM stock)      1 ml 
3¢ SLIC primer (100 mM stock)      1 ml 
Phusion polymerase (2 U/ml)   0.5 ml 
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Carry out PCR reactions with a standard PCR program (unless very long DNAs are 
amplified, then double the extension time or refer to the corresponding instruction of 
the polymerase to be used): 
1 x 98 °C for 2 min 
30 x [98 °C for 20 s. → 50 °C for 30 s. → 72 °C for 3 min] 
Hold at 10 °C 
Analysis of the PCR reactions by agarose gel electrophoresis and ethidium bromide 
staining is recommended. 
3. DpnI treatment of PCR products (optional) 
Supply PCR reactions with 1 ml DpnI enzyme which cleaves parental plasmids 
(methylated). For insert PCR reactions, DpnI treatment is not required if the 
resistance marker of the template plasmid differs from the destination vector. 
Carry out reactions as follows: 
 
Incubation:  37 °C for 1-4 h 
Inactivation:  80 °C for 20 min 
4. Purification of PCR products 
! PCR products must be cleaned of residual dNTPs !  
Note: Otherwise, the T4 DNA polymerase reaction (step 5) is compromised. 
Product purification is best performed by using commercial kits. It is recommended 
to perform elution in the minimal possible volume indicated by the manufacturer. 
5. T4 DNA polymerase exonuclease treatment  
Prepare identical reactions in a 20 ml volume for the insert and the corresponding 
vector it should be cloned into (both eluted in step 4): 
10x T4 DNA polymerase buffer     2 ml 
100 mM DTT     1 ml 
2 M Urea     2 ml 
DNA eluate from Step 3 (vector or insert)    14 ml 
T4 DNA polymerase       1 ml 
Carry out reactions as follows: 
Incubation:  23 °C for 20 min 
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Arrest:      Addition of 1 ml 500 mM EDTA 
Inactivation:  75 °C for 20 min 
6. Mixing and Annealing 
Mix T4 DNA polymerase treated insert and vector (step 5), followed by an (optional) 
annealing step which was found to enhance efficiency: 
T4 DNA pol treated insert:     10 ml 
T4 DNA pol treated vector:     10 ml 
Annealing:  65 °C for 10 min 
Cooling:   Slowly to RT (at least 2h) 
7. Transformation 
Transform mixture from step 6 into competent cells following standard 
transformation procedures.  
Transform reactions for pACE and pACE2 derivatives into standard E. coli cells for 
cloning (such as MACH1, TOP10, DH5a, HB101). After recovery (2-4 h) plate the 
transformed reactions on agar containing ampicillin (100 mg/ml) or tetracycline (25 
µg/ml), respectively. 
Transform reactions for Donor derivatives into E. coli cells expressing the pir gene 
(such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plate the  
transformed reactions on agar containing chloramphenicol (25 mg/ml, pDC), 
kanamycin (50 µg/ml, pDK) or spectinomycin (50 µg/ml, pDS).  
It is recommended to plate the transformed reaction on two agar plates in dilution 
series, so that one can always easily pick single colonies after the overnight 
incubation. 
8. Plasmid analysis 
Grow culture for plasmid isolation (small-scale) in media containing the 
corresponding antibiotic. The isolated plasmids should then be analyzed by 
sequencing and (optional) restriction mapping using appropriate restriction enzymes. 
 
Polycistron assembly in MIE by SLIC 
The multiple integration element (MIE) can also be used to integrate genes of interest 
by using multi-fragment SLIC recombination in order to assemble polycistrones. 
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Genes preceded by ribosome binding sites (rbs) can be assembled in this way under 
the control of one promoter. 
1. Primer design 
The multiple integration element (MIE) is composed of tried-and-tested primer 
sequences. These constitute the “adaptor sequences” that can be used for inserting 
single genes or multigene constructs. Recommended adaptor sequences for SLIC can 
be taken directly from the ACEMBL manual (http://www.embl.fr/research/ 
services/berger/ACEMBL.pdf). 
Adaptor sequences form the 5’ segments of the primers used to amplify DNA 
fragments to be inserted into the MIE. Insert specific sequences are added at 3’, and a 
DNA sequence encoding for a ribosome binding sites can be inserted optionally if not 
already present on the PCR template. 
2. PCR amplification of inserts and vector 
Prepare identical PCR reactions in 100 ml volume for all inserts to be cloned and the 
vector backbone to be linearized: 
 
ddH2O    75 ml 
5´ Phusion HF Reaction buffer    20 ml 
dNTPs (10 mM stock)      2 ml 
Template DNA (100 ng/ml)      1 ml 
5¢ SLIC primer (100 mM stock)      1 ml 
3¢ SLIC primer (100 mM stock)      1 ml 
Phusion polymerase (2 U/ml)   0.5 ml 
 
Carry out PCR reactions with a standard PCR program (unless very long DNAs are 
amplified, then double extension time or refer to the corresponding instruction of the 
polymerase to be used): 
1 x 98 °C for 2 min 
30 x [98 °C for 20 s → 50 °C for 30 s → 72 °C for 3 min] 
Hold at 10°C 
Analysis of the PCR reactions by agarose gel electrophoresis and ethidium bromide 
staining is recommended. 
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3. DpnI treatment of PCR products (optional) 
Supply PCR reactions with 1 ml DpnI enzyme which cleaves parental plasmids 
(methylated). For insert PCR reactions, DpnI treatment is not required if the 
resistance marker of the template plasmids differs from the destination vector. 
Carry out reactions as follows: 
Incubation:  37 °C for 1-4h 
Inactivation:  80 °C for 20 min 
4. Purification of PCR products 
! PCR products must be cleaned of residual dNTPs !  
Note: Otherwise, the T4 DNA polymerase reaction (step 5) is compromised. 
Product purification is best performed by using commercial kits. It is recommended 
to perform elution in the minimal possible volume indicated by the manufacturer. 
5. T4 DNA polymerase exonuclease treatment 
Prepare identical reactions in 20 ml volume for each insert and the corresponding 
vector they should be cloned into (both eluted in step 4): 
 
10x T4 DNA polymerase buffer     2 ml 
100 mM DTT     1 ml 
2M Urea     2 ml 
DNA eluate from Step 3 (vector or insert)   14 ml 
T4 DNA polymerase      1 ml 
Carry out reactions as follows: 
Incubation:  23 °C for 20 min 
Arrest:      Addition of 1 ml 500 mM EDTA 
Inactivation:  75 °C for 20 min 
6. Mixing and Annealing 
Mix T4 DNA polymerase treated inserts and vector (step 5), followed by an 
(optional) annealing step which was found to enhance efficiency1: 
 
T4 DNA pol. treated insert 1:       5 ml 
T4 DNA pol. treated insert 2:       5 ml 
T4 DNA pol. treated insert 3:       5 ml 
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T4 DNA pol. treated vector:       5 ml 
Annealing:  65 °C for 10 min 
Cooling:  Slowly (switch off heat block) to RT 
7. Transformation 
Transform mixture from step 6 into competent cells following standard 
transformation procedures.  
Transform reactions for pACE and pACE2 derivatives into standard E. coli cells for 
cloning (such as MACH1, TOP10, DH5a, HB101). After recovery, plate the 
transformed reactions on agar containing ampicillin (100 mg/ml) or tetracycline (25 
µg/ml), respectively. 
Transform reactions for Donor derivatives into E. coli cells expressing the pir gene 
(such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plate the 
transformed reactions on agar containing chloramphenicol (25 mg/ml, pDC), 
kanamycin (50 µg/ml, pDK) or spectinomycin (50 µg/ml, pDS).  
It is recommended to plate the transformed reaction on two agar plates in dilution 
series, so that one can always easily pick single colonies after the overnight 
incubation. 
8. Plasmid analysis 
Grow culture for plasmid isolation in media containing the corresponding antibiotic. 
The isolated plasmids should then be analyzed by sequencing and (optional) 
restriction mapping using appropriate restriction enzymes. 
 
 
Gene insertion by restriction/ligation 
1. Primer design 
For conventional cloning, if the gene of interest is to be PCR amplified, design PCR 
primers containing chosen restriction sites, preceded by appropriate overhangs for 
efficient restriction digestion (c.f. New England Biolabs catalogue). This region is 
followed by ≥ 20 nucleotides overlapping with the gene of interest that is to be 
inserted. 
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MIEs are identical in all the ACEMBL vectors. They contain a ribosome binding site 
preceding the NdeI site. Therefore, for single gene insertions, a ribosome binding site 
(rbs) does not need to be included in the forward primer.  
In case multigene insertions are planned, primers need to be designed such that a rbs 
is at the beginning of the gene and a stop codon at its end. Therefore, in particular for 
polycistron cloning by restriction/ligation, it is recommended to construct templates 
by custom gene synthesis. In this process, the restriction sites present in the MIE can 
be eliminated from the encoding DNAs.  
2. Insert preparation 
i) PCR of insert(s): 
Prepare identical PCR reactions in 100 ml volume for each gene of interest to be 
inserted into the MIE: 
 
ddH2O    75 ml 
5´ Phusion HF Reaction buffer    20 ml 
dNTPs (10 mM stock)      2 ml 
Template DNA (100 ng/ml)      1 ml 
5¢ primer (100 mM stock)      1 ml 
3¢ primer (100 mM stock)      1 ml 
Phusion polymerase (2 U/ml)   0.5 ml 
Carry out PCR reactions with a standard PCR program (unless very long DNAs are 
amplified, then double the extension time or refer to the corresponding instruction of 
the polymerase used): 
1 x 98 °C for 2 min 
30 x [98 °C for 20 s → 50 °C for 30 s → 72 °C for 3 min] 
Hold at 10 °C 
Analysis of the PCR reactions by agarose gel electrophoresis and ethidium bromide 
staining is recommended. 
Purification of PCR products is best performed by using commercial kits. It is 
recommended to perform elution in the minimal possible volume indicated by the 
manufacturer. 
ii) Restriction digestion of insert(s): 
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Carry out restriction reactions in 40 ml reaction volume, by using the specific 
restriction enzymes as specified by manufacturer’s recommendations. 
  
PCR Kit eluate (≥ 1 mg)   30 ml 
10x Restriction enzyme buffer     4 ml 
10 mM BSA      2 ml 
Restriction enzyme for 5’      2 ml 
Restriction enzyme for 3’  2 ml  (in case of double 
digestion, otherwise 
ddH2O) 
Perform restriction digestion in a single reaction with both enzymes (double 
digestion) or sequentially (two single digestion reactions) if the reaction conditions 
required are incompatible. 
iii) Gel extraction of insert(s): 
Purify processed inserts by agarose gel extraction using commercial kits. It is 
recommended to elute the extracted DNA in the minimal volume defined by the 
manufacturer. 
3. Vector preparation 
i) Restriction digestion of ACEMBL plasmid(s): 
Carry out restriction reactions in 40 ml reaction volume, using specific restriction 
enzymes as specified by manufacturer’s recommendations (c.f. New England Biolabs 
catalogue and others). 
  
ACEMBL plasmid (≥ 0.5 mg) in ddH2O   30 ml 
10x Restriction enzyme buffer     4 ml 
10 mM BSA     2 ml 
Restriction enzyme for 5’      2 ml 
Restriction enzyme for 3’  2 ml  (in case of double 
digestion, otherwise 
ddH2O) 
Perform restriction digestion in a single reaction with both enzymes (double 
digestion) or sequentially (two single digestion reactions) if the reaction conditions 
required are incompatible. 
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Analysis of the restriction digestion of ACEMBL vectors by agarose gel 
electrophoresis and ethidium bromide staining is recommended before gel extraction 
(ii). 
ii) Gel extraction of linearized vector(s): 
Purify processed vectors by agarose gel extraction using commercial kits. It is 
recommended to elute the extracted DNA in the minimal volume defined by the 
manufacturer. 
4. Ligation 
It is recommended to analyze the intensity and integrity of vectors and inserts from 
gel extraction by agarose gel electrophoresis and ethidium bromide staining. 
Normally the ratio between vector and insert is ranged from 1:3 to 1:6. 
Carry out ligation reactions in 20 ml reaction volume according to the 
recommendations of the supplier of T4 DNA ligase: 
 
ACEMBL plasmid (gel extracted, step 3)     8 ml 
Insert (gel extracted, step 2)   10 ml 
10x T4 DNA Ligase buffer     2 ml 
T4 DNA Ligase  0.5 ml 
Perform ligation reactions at 25 ºC (sticky end) for 1h or at 16 ºC (blunt end) 
overnight. 
5. Transformation 
Transform ligation mixtures (step 4) into E. coli competent cells following standard 
transformation procedures.  
Transform reactions for pACE and pACE2 derivatives into standard E. coli cells for 
cloning (such as TOP10, DH5a, HB101). After recovery, plate the transformed 
reactions on agar containing ampicillin (100 mg/ml) or tetracycline (25 µg/ml), 
respectively. 
Transform reactions for Donor derivatives into E. coli cells expressing the pir gene 
(such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plate the 
transformed reactions on agar containing chloramphenicol (25 mg/ml, pDC), 
kanamycin (50 µg/ml, pDK) or spectinomycin (50 µg/ml, pDS).  
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We recommend plating the transformed reaction on agar plates in a dilution series, to 
ensure optimal colony separation. 
6. Plasmid analysis 
Culture plasmids and select correct clones based on specific restriction digestion and 
DNA sequencing of the inserts. 
 
 
Multiplication by using the HE and BstXI sites 
The presence of a homing endonuclease (HE) cutting site (PI-SceI or I-CeuI) together 
with a BstXI site makes it feasible to iteratively insert further gene(s) of interest, 
which are already cloned into the MIE of an ACEMBL vector, into the expression 
cassette. The insert is being released by restriction digestion with both HE and BstXI, 
whereas the vector is being linearized by restriction digestion with HE. 
1. Insert preparation 
i) Restriction digestion of insert(s) 
Carry out restriction reactions in 40 ml reaction volume by using homing 
endonucleases PI-SceI (Donors) or I-CeuI (Acceptors) as recommended by the 
supplier (c.f. New England Biolabs catalogue and others). 
ACEMBL plasmid (≥ 0.5 mg) in ddH2O    32 ml 
10x Restriction enzyme buffer     4 ml 
10 mM BSA     2 ml 
PI-SceI (Donors) or I-CeuI (Acceptors)      2 ml 
Purify reactions using commercial kits, or acidic ethanol precipitation and perform 
the second restriction digestion by BstXI according to the recommendations of the 
supplier. 
 
HE digested DNA in ddH2O   32 ml 
10x Restriction enzyme buffer     4 ml 
10 mM BSA     2 ml 
BstXI     2 ml 
ii) Gel extraction of insert(s): 
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Purify processed insert(s) by agarose gel extraction using commercial kits. It is 
recommended to elute the extracted DNA in the minimal volume defined by the 
manufacturer. 
2. Vector preparation 
i) Restriction digestion of vector(s) 
Carry out restriction reactions in 40 ml reaction volume by using homing 
endonucleases PI-SceI (Donors) or I-CeuI (Acceptors) as recommended by the 
supplier (c.f. New England Biolabs catalogue and others). 
  
ACEMBL plasmid ( ≥ 0.5 mg) in ddH2O    33 ml 
10x Restriction enzyme buffer     4 ml 
10 mM BSA     2 ml 
PI-SceI (Donors) or I-CeuI (Acceptors)      1 ml 
Analysis of restriction digestion of ACEMBL vectors by agarose gel electrophoresis 
and ethidium bromide staining before phosphatase treatment is recommended.  
Purify reactions using commercial kits, or acidic ethanol precipitation. Next, treat the 
purified reactions with intestinal alkaline phosphatase according to the 
recommendations of the supplier. 
 
HE digested DNA in ddH2O   17 ml 
10x Alkaline phosphatase buffer     2 ml 
Alkaline phosphatase     1 ml 
 
ii) Gel extraction of vector(s): 
Purify processed vector(s) by agarose gel extraction using commercial kits. It is 
recommended to elute the extracted DNA in the minimal volume defined by the 
manufacturer. 
3. Ligation 
It is recommended to analyze the intensity and integrity of vectors and inserts from 
gel extraction by agarose gel electrophoresis and ethidium bromide staining. 
Normally the ratio between vector and insert is ranged from 1:3 to 1:6. 
Carry out ligation reactions in 20 ml reaction volume: 
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HE/Phosphatase treated vector (gel extracted)     4 ml 
HE/BstXI treated insert (gel extracted)   14 ml 
10x T4 DNA Ligase buffer     2 ml 
T4 DNA Ligase  0.5 ml 
Perform ligation reactions at 25 ºC for 1h or at 16 ºC overnight. 
4. Transformation 
Transform ligation mixtures from step 3 into E. coli competent cells following 
standard transformation procedures.  
Transform reactions for pACE and pACE2 derivatives into standard E. coli cells for 
cloning (such as TOP10, DH5a, HB101). After recovery, plate the transformed 
reactions on agar containing ampicillin (100 mg/ml) or tetracycline (25 µg/ml), 
respectively. 
Transform reactions for Donor derivatives into E. coli cells expressing the pir gene 
(such as BW23473, BW23474, or PIR1 and PIR2, Invitrogen) and plate the 
transformed reactions on agar containing chloramphenicol (25 mg/ml, pDC), 
kanamycin (50 µg/ml, pDK) or spectinomycin (50 µg/ml, pDS). 
We recommend plating the transformed reaction on two agar plates in dilution series, 
to ensure optimal colony separation. 
5. Plasmid analysis 
Culture plasmids and select correct clones based on specific restriction digestion and 
DNA sequencing of the inserts. 
Note: One can likewise perform the integration by sequence and ligation independent 
cloning (SLIC). It is recommended to carry out linearization of the vector by 
digestion with HE, if heterologous genes are already present, to avoid PCR 
amplification over encoding regions. The fragment to be inserted is generated by 
PCR amplification resulting in a PCR fragment containing a 20-25 base pair stretch at 
its 5’ end that is identical to the corresponding DNA sequence present at the HE site 
counted from the site of cleavage towards 5’ (site of cleavage is position -4). At the 
3’ end of the PCR fragment, the homology region is 20-25 base pairs counted from 
the site of cleavage towards 3’. 
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Cre-LoxP fusion of Acceptors and Donors 
Cre recombinase is a member of the integrase family catalyzing the recombination of 
a 34 bp LoxP site in the absence of accessory protein or auxiliary DNA sequence. 
The LoxP site itself is comprised of two 13 bp recombinase-binding elements 
arranged as inverted repeats flanking an 8 bp central region where cleavage and 
ligation reaction occur. As all ACEMBL plasmids contain a single LoxP site, they 
can be fused in a Cre-dependent reaction. This is possible not only for 2 plasmids 
(Acceptor-Donor fusion), but also for the fusion of several (3-4) plasmids in a single 
reaction.   
The fact that Donors contain a conditional origin of replication that depends on a pir+ 
background allows for selection of desired fusion products out of such a reaction. 
Being transformed into pir- strains (MACH1, TOP10, DH5a, HB101 or other 
common laboratory cloning strains), Donor vectors will act as suicide vectors when 
plated out on agar containing the antibiotic corresponding to the Donor encoded 
resistance marker, unless fused with an Acceptor. By properly combining antibiotics 
in the agar, all desired Acceptor-Donor fusions can be selected. 
 
1. For a 20 µl Cre reaction, mix 1-2 µg of each educt in approximately equal amounts. 
Add ddH2O to adjust the total volume to 16-17 µl, then add 2 µl 10x Cre buffer and 
1-2 µl Cre recombinase. 
CRITICAL STEP 
 
2. Incubate Cre reaction at 37 °C (or 30°C) for 1 hour. 
 
3. Optional: load 2-5 µl of Cre reaction on an analytical agarose gel for examination.  
Note: Heat inactivation at 70 °C for 10 minutes before the gel loading is strongly 
recommended. 
 
4. For chemical transformation, mix 10-15 µl Cre reaction with 200 µl chemical 
competent cells. Incubate the mixture on ice for 15-30 minutes. Then perform heat 
shock at 42 °C for 45-60 s. 
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Note: Up to 20 µl Cre reaction (max. 10% of the total volume of chemical competent 
cell suspension) can be directly transformed into 200 µl chemical competent cells.  
For electro-transformation, one could mix up to 2 µl Cre reaction with 100 µl 
electrocompetent cells and perform the transformation by using an electroporator (e.g. 
BIORAD E. coli Pulser) at 1.8-2.0 kV. 
Note: Larger volumes of Cre reaction must be desalted by ethanol precipitation or a 
PCR purification column before electrotransformation. The desalted Cre reaction mix 
should not exceed 10% of the volume of the electrocompetent cell suspension.  
The cell/DNA mixture could be immediately used for electrotransformation without 
prolonged incubation on ice. 
 
5. Add up to 400 µl of LB media (or SOC media) per 100 µl of cell/DNA suspension 
immediately after the transformation (heat shock or electroporation).  
 
6. Incubate the suspension in a 37 °C shaking incubator overnight or for at least 4 
hours (recovery period). 
Note: For recovering multifusion plasmid containing more than 2 resistance markers, 
it is strongly recommended to incubate the suspension at 37 °C overnight. 
 
7. Plate out the recovered cell suspension on agar containing the desired combination 
of antibiotics. Incubate at 37 °C overnight. 
 
TROUBLESHOOTING 
 
8. Clones from colonies present after overnight incubation can be verified by 
restriction digestion at this stage (refer to steps 12-16). 
Note: Verification is recommended especially in the case that only one multifusion 
plasmid is desired.  
For further selection by single antibiotic challenges on a 96 well microtiter plate, 
continue to step 9. 
Note: Several to many different multifusion plasmid combinations can be processed 
and selected on one 96 well microtiter plate in parallel. 
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9. For 96 well antibiotic tests, inoculate four colonies from each agar plate with 
different antibiotic combination into ~500 µl LB media without antibiotics. Incubate 
the cell cultures in a 37 °C shaking incubator for 1-2 hours. 
 
10. During the incubation of colonies, fill a 96 well microtiter plate with 150 µl 
antibiotic-containing LB media. We added coloured dye (positional marker) in 
selected wells as positional markers (Fig. 2).  
Note: A typical arrangement of the solutions, which is used for parallel selection of 
multifusion plasmids, is shown in Figure 2 as well as the ACEMBL Manual 
(http://www.embl.fr/ research/services/berger/ACEMBL.pdf). The concept behind 
the 96 well plate experiment is that every cell suspension from single colonies needs 
to be challenged by all four single antibiotics for unambiguous interpretation. 
 
11. Add 1 µl aliquots of pre-incubated cell culture (Step 9) to the corresponding wells. 
Then incubate the inoculated 96 well microtiter plate in a 37 °C shaking incubator 
overnight at 180-200 rpm.  
Recommended: Use parafilm to wrap the plate to avoid drying out.  
The remainder of the pre-incubated cell cultures could be kept at 4 °C for further 
inoculation if necessary. 
 
12. Select transformants containing desired multifusion plasmids based on antibiotic 
resistance, according to the combination of dense (positive) and clear (no growth) cell 
microcultures from each colony. Inoculate 10-20 µl cell culture into 10 ml LB media 
with corresponding antibiotics. Incubate in a 37 °C shaking incubator overnight. 
 
13. Centrifuge the overnight cell cultures at 4000 g for 5-10 minutes. Purify plasmid 
from the resulting cell pellets. It is recommended to utilize commercial kits.  
 
14. Determine the concentration of purified plasmid solutions by using UV 
absorption spectroscopy (e.g. by using a NanoDropTM 1000 machine).  
 
15. Digest 0.5-1 µg of the purified plasmid solution in a 20 µl restriction digestion 
with appropriate endonuclease(s). Incubate under recommended reaction condition 
for ~2 hours.  
Publication 4 
[19] 
 
 
16. Use 5-10 µl of the digestion for analytical agarose (0.8-1.2 %) gel electrophoresis. 
Verify plasmid integrity by comparing the experimental restriction pattern to a 
restriction pattern predicted in silico (e.g. by using program VectorNTI from 
Invitrogen or similar programs). 
 
Deconstruction of fusion vectors by Cre recombinase 
It is advantageous to release all or part of the educts composing a particular 
multifusion plasmid, for further modification and diversification. 
 
1. Incubate ~1 µg multifusion plasmid with 2 µl 10x Cre buffer and 1-2 µl Cre 
recombinase. Add ddH2O to adjust the total reaction volume to 20 µl. 
 
2. Incubate this Cre deconstruction reaction mixture at 30°C (1-4 h). 
 
3. Optional: load 2-5 µl of the reaction on an analytical agarose gel for examination.  
Note: Heat inactivation at 70°C for 10 minutes before the gel loading is strongly 
recommended. 
 
4. For chemical transformation, mix 10-15µl De-Cre reaction with 200 µl chemical 
competent cells. Incubate the mixture on ice for 15-30 minutes. Then perform heat 
shock at 42 °C for 45-60 seconds. 
Note: Up to 20 µl De-Cre reaction (10% of total volume of transformation reaction) 
can be directly transformed into 200 µl chemical competent cells.  
For electrotransformation, up to 2 µl De-Cre reaction could be directly mixed with 
100 µl electrocompetent cells, and transformed by using an electroporator (e.g. 
BIORAD E. coli Pulser) at 1.8-2.0 kV. 
Note: Larger volume of De-Cre reaction must be desalted by ethanol precipitation or 
PCR purification column before electrotransformation. The desalted De-Cre reaction 
mix should not exceed 10% of the volume of the electrocompetent cell suspension.  
The cell/DNA mixture could be immediately used for electro-transformation without 
prior incubation on ice. 
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5. Add up to 400 µl of LB media (or SOC media) per 100 µl of cell/DNA suspension 
immediately after the transformation (heat shock or electroporation).  
 
6. Incubate the suspension in a 37°C shaking incubator (recovery). 
Note: For recovery of partially deconstructed double/triple fusions, incubate the 
suspension in a 37 °C shaking incubator overnight or for at least 4 hours. 
For recovery of individual educts such as single ACEMBL vectors from pACKS 
plasmid, incubate the suspension in a 37 °C shaking incubator (1-2 h). 
 
7. Plate out the recovered cell suspension on agar containing the desired (combination 
of) antibiotic(s). Incubate at 37 °C overnight. 
TROUBLESHOOTING 
 
8. Colonies after overnight incubation might be verified directly by restriction 
digestion at this stage (refer to steps 12-16). 
Note: Especially recommended in the case that only one single educt or partially 
deconstructed multifusion plasmid is desired. 
For further selection by single antibiotic challenge on a 96 well microtiter plate, 
continue with step 9. 
Note: Several different single educts/partially deconstructed multifusion plasmids can 
be processed and selected on one 96 well microtiter plate in parallel. 
 
9. For 96 well microtiter plate analysis inoculate four colonies each from agar plates 
containing a defined set of antibiotics into ~500 µl LB media without antibiotics. 
Incubate the cell cultures in a 37 °C shaking incubator (1-2 h). 
 
10. During the incubation of colonies, fill a 96 well microtiter plate with 150 µl 
antibiotic-containing LB media or coloured dye (positional marker) in the 
corresponding wells (Fig. 2).  
Note: Compare Figure 2 as well as the ACEMBL Manual (http://www.embl.fr/ 
research/services/berger/ ACEMBL.pdf) for the arrangement of the solutions in the 
wells, which are used for parallel selection of single educts or partially deconstructed 
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multifusion plasmids. The concept is that every cell suspension from a single colony 
needs to be challenged by all four antibiotics separately for unambiguous 
interpretation. 
 
11. Add 1 µl aliquots from the pre-incubated cell cultures (step 9) into the 
corresponding wells. Then incubate the 96 well microtiter plate in a 37 °C shaking 
incubator overnight at 180-200 rpm.  
Recommended: Use parafilm to wrap the plate to prevent dehydration.  
The remainder of the pre-incubated cell cultures can be kept in 4°C fridge for further 
inoculation if necessary. 
 
12. Select transformants containing desired single educts or partially deconstructed 
multifusion plasmids according to the combination of dense (growth) and clear (no 
growth) cell cultures from each colony. Inoculate 10-20 µl cell cultures into 10 ml LB 
media with corresponding antibiotic(s). Incubate in a 37 °C shaking incubator 
overnight. 
 
13. Centrifuge the overnight cell cultures at 4000 g for 5-10 minutes. Purify plasmid 
from cell pellets.  
 
14. Determine the concentration of purified plasmid solutions by using UV 
absorption spectroscopy (e.g. NanoDropTM 1000).  
 
15. Digest 0.5-1 µg of the purified plasmid solution in a 20 µl restriction digestion 
(with 5-10 unit endonuclease). Incubate under recommended reaction condition for 
~2 hours.  
 
16. Use 5-10 µl of the digestion for analytical agarose gel (0.8-1.2 %) electrophoresis. 
Verify the plasmid integrity by comparing the actual restriction pattern to predicted 
restriction pattern in silico (e.g. by using VectorNTI, Invitrogen, or any other similar 
program). 
 
17. Optional: Possibly, a deconstruction reaction is not complete but yields partially 
deconstructed fusions which still retain entities to be eliminated. In this case, we 
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recommend to pick these partially deconstructed fusions containing and perform a 
second round of Cre deconstruction reaction (repeat steps 1-8) by using this construct 
as starting material. 
Note: In our hands, two sequential deconstruction reactions were always sufficient to 
recover all individual modules. 
 
 
TROUBLESHOOTING 
 
1 Problem: There is no colony on the plate from the Cre-LoxP fusion of 
Acceptors and Donors. 
Solution: Increase the amount of each educt of the Cre-LoxP fusion; use chemical 
competent cell with higher competence; desalt and transform more Cre-reaction into 
electrocompetent cells; recover the transformed cell suspension at 37 ºC overnight. 
 
2 Problem: There is no single educts from deconstruction of fusion vectors by 
Cre recombinase. 
Solution: increase the incubation time with Cre recombinase to 4 hours; test more 
colonies on 96 well microtiter plate. 
 
Critical Steps: 
Depending on plasmid purity and size, it may be necessary to use up to µg amounts 
of each educt plasmid for assembling multifusion plasmids in a Cre-LoxP reaction. 
Competent cells that are used for subsequent transformation should be of high-
quality, possibly commercial grade (108-9 colony forming units (cfu)). 
 
ANTICIPATED RESULTS 
This protocol describes a number of methods, mostly based on recombination 
reactions, that can be applied, also in combination, to rapidly assemble, disassemble 
and alter multigene expression plasmids for the production of protein complexes. 
Experienced users will be able to produce numerous versions of their protein 
complexes of choice, in parallel, within 2 weeks when working manually. Further, the 
reactions can be implemented on a liquid handling workstation, thereby maximizing 
throughput. 
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FIGURE 1. A. The ACEMBL system. Acceptor and Donor vectors contain a LoxP sequence and an 
identical multiple integration element (MIE). Promoters (T7 or lac), corresponding terminators and 
homing endonuclease (HE) sites (blue strike-through box, Acceptors: I-CeuI; Donors: PI-SceI) and 
matching BstXI sites (small blue squares) are indicated. Origins of replication (Acceptors: BR322; 
Donors: R6Kg) are shown. Ap: Ampicillin, Cm: Chloramphenicol, Kn: Kanamycin, Sp: 
Spectinomycin. B. Outline of the method.  
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FIGURE 2. Cre reaction and 96 well microtiter plate selection. A schematic Cre reaction pyramid is 
shown on the left for three educt plasmids (pACE, pDK, pDS). A fourth Donor (pDC) can be 
accommodated in this reaction, but is not shown for matters of clarity. Cre mediated plasmid assembly 
(Cre) and disassembly (De-Cre) reaches equilibrium with all plasmids shown in the pyramid present in 
the reaction tube. Transformation and plating of the Cre reaction yields educt plasmids and fusion 
plasmids. The plate drawn on the right displays a typical arrangement of media aliquots containing 
antibiotics as indicated, which is used for parallel selection of multifusion plasmids. Every cell 
suspension from single colonies on single- or multi-resistance agar plates needs to be challenged by all 
antibiotics for unambiguous identification of the expected plasmid architecture. A fusion reaction 
involving four plasmids (one Acceptor, three Donors, resulting in pACE-pDS-pDK-pDC) is marked 
with asterisk, but was not included in the pyramid on the left for matters of clarity. Four colonies from 
each single- or multi-resistance agar plate with two (Ap/Kn; Ap/Sp), three (Ap/Kn/Sp) or even four 
(Ap/Kn/Sp/Cm) antibiotics, are counter-selected in such a 96 well plate in parallel. denote antibiotics 
contained in the media aliquots (acronyms as in Fig. 1). Wells in the right two rows are charged 
differently. Those inoculated with four colonies each from one agar plate are boxed in black. Red dye 
is used as positional marker. Deconstruction of fusion plasmids can be carried out likewise in the 
reverse approach. 
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Discussion and perspective 
 
The ACEMBL system enables the recombinant production of challenging 
multiprotein complexes in bacteria cells in a rapid, flexible and automatable manner, 
which is indispensable for accelerating multiprotein complex research. One notable 
example is the holotranslocon from E. coli, a large prokaryotic translocation complex 
consisting of six transmembrane proteins, which was produced for the first time by 
using ACEMBL from a 16 kbp multigene plasmid. 
The logic of the ACEMBL high-throughput pipeline has then been extended to 
eukaryotic production systems MultiMam (mammalian cells) and MultiBac (insect 
cells) to facilitate multiprotein complex overproduction in eukaryotic hosts. We 
foresee that more recombinant expression systems including yeast expression and 
others will be adapted and fine-tuned for multiprotein complex research in the near 
future, based on the ACEMBL concept we developed. 
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Chapter 3: Decipher TAF3’s role in TFIID assembly 
 
Abstract 
 
It has been proposed that TAF3 is an essential subunit for assembling holo-TFIID 
(chapter 3.1). Here I describe my efforts in elucidating its structural and functional 
roles in TFIID assembly. First, I present the 3D reconstruction of 9TAF (a 1.3 MDa 
TFIID subcomplex composed of TAF2, 3, 4, 5, 6, 8, 9, 10, 12) by single-particle EM 
analysis. The structure of this recombinant complex is setting the stage for mapping 
TAF3’s location (chapter 3.2). Second, I discuss the design and production of TAF3 
truncation variants, which will be used for localizing individual TAF3 domains and 
identifying the TAF3 fragment crucial for TFIID assembly (chapter 3.3). 
 
Résumé 
 
Il est proposé que TAF3 peut être considéré comme une sous unité essentielle pour 
l’assemblage de TFIID complet (chapitre 3.1). Les efforts fournis pour élucider son 
rôle structural et fonctionnel lors de l’assemblage de TFIID sont exposés. 
Premièrement, une reconstruction 3D de 9TAF (un sous-complexe de TFIID de 1.3 
MDa composé de TAF2, 3, 4, 5, 6, 8, 9, 10, 12) obtenue par microscopie électronique 
est présentée. La structure de ce complexe recombinant est primordiale pour établir la 
localisation de TAF3. Deuxièmement, sont décrits le design et la production de 
diverses versions tronquées de TAF3 qui seront utilisées pour localiser les différents 
domaines de TAF3 et identifier les fragments cruciaux de TAF3 dans l’assemblage de 
TFIID (chapitre 3.3). 
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3.1 Significance of TAF3 in TFIID assembly 
 
The proposition that the TFIID component TAF3 may serve as an essential “linker” for 
assembling the holo-TFIID complex was put forward (personal communication, Laszlo 
Tora, IGBMC). Without TAF3, it appears to be impossible to produce complete 
TFIID. Instead, TFIID assembly is thought to stall at a subcomplex formed by seven or 
eight TAFs (Demény et al., 2007; Berger and Tora labs, unpublished). The Berger 
laboratory has produced a series of recombinant subcomplexes of human TFIID and 
purified them to homogeneity (Table 3.1). The EM structures are determined in 
collaboration with the Schaffitzel lab (EMBL) and Schultz lab (IGBMC). 
The structure determination of 3TAF, 5TAF and 7TAF complexes has allowed 
assigning the locations of TAF4, 5, 6, 8, 9, 10 and 12 (Fig. 1.22 in Introduction). 8TAF 
contains in addition also TAF2 (Table 3.1). The structure determination of 8TAF, once 
completed, should therefore allow unambiguously assigning the position of TAF2 
within this TFIID subcomplex. 
The next larger complex in the assembly of recombinant holo TFIID is 9TAF. 
TAF4, 5, 6, 9, and 12 are expected to be present in two copies in this complex (based 
on the core-TFIID work, Table 3.1), whereas TAF2, 3, and 8 are present in one copy. 
TAF10, which forms one pair with TA9 and a separate pair with TAF3, is present in 
two chemically different copies. Therefore 9TAF is expected to contain altogether 15 
proteins. My aim here is to determine the structure of 9TAF by single-particle EM 
analysis, ultimately by cryo-EM, to the highest possible resolution and interpret the 
structure by hybrid methods (combining cryo-EM and available crystal coordinates and 
homology models). By comparing the structures of 8TAF and 9TAF, and integrating 
the structural information of all other TFIID subcomplexes, we will then be able to 
pinpoint the location of TAF3 in the context of 9TAF, and to decipher its structural and 
functional role in holo-TFIID assembly. 
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Table 3.1: TFIID subcomplexes produced, purified, and analyzed by single-
particle EM methods. 
Name Subunits Molecular 
weight 
Structures ( resolution) 
3TAF 2×[TAF5,6,9] 400 kDa 3D cryo-EM (12 Å) 
5TAF 2× [TAF4,5,6,9,12] 700 kDa 3D cryo-EM (10 Å) 
7TAF 2× [TAF4,5,6,9,12]+1×[TAF8,10] 800 kDa 3D cryo-EM (14 Å) 
8TAF 2× [TAF4,5,6,9,12]+1×[TAF2,8,10] 1.0 MDa 
In progress 
(Gabor Papai, Schultz lab) 
9TAF 2× [TAF3,4,5,6,9,10,12] + 1× [TAF2,8,10] 1.3 MDa My work 
 
 
3.2 Single-particle EM analysis of 9TAF complex 
 
3.2.1 Purification and negative-stain EM analysis of 9TAF 
 
I have produced and purified the human 9TAF complex to homogeneity by utilizing 
the procedure shown schematically in Figure 3.1. 
 
 
Figure 3.1: A 1.3 MDa 9TAF complex reconstituted and purified from several 
chromatographic steps. 9TAF complex is shown schematically (left, 9TAF 
subunits colored in green). The purification procedure is shown in a diagram 
(right). The fractions corresponding to a single peak from size exclusion 
chromatography (SEC) are shown by the corresponding gel sections from SDS-
PAGE (middle). Positions of TAFs are indicated by their numbers. TAF12 (in 
bracket) ran out of the gel during electrophoresis. ‘TALON’ stands for an IMAC 
purification step using TALON metal affinity resin (Clontech). ‘IEX’ stands for 
ion exchange chromatography. 
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After size exclusion chromatography (SEC), the peak fractions was used as input 
for GraFix (Kastner et al., 2008), a density gradient centrifugation method specialized 
for single-particle EM sample preparation (a detailed protocol can be found in 
‘Materials and Methods’ chapter). Two glycerol gradients (10-40%, 4 mL) were 
prepared in parallel: a control gradient (without glutaraldehyde) and a fixed gradient 
(glutaraldehyde gradient: 0-0.15%). After centrifugation (37,000 rpm for 14 hours in a 
Beckman SW 60 Ti rotor), both gradients were fractionated from bottom to top (22 
fractions were collected for each gradient, ~180 µL (4 drops)/fraction) by a Bio-Rad 
Biological 2110 Fraction collector. Fractions #1 to #14 of both gradients were analyzed 
by SDS-PAGE (Fig. 3.2) and fraction #11 of GraFix fixed gradient was chosen for 
negative-stain EM analysis (carbon sandwich method, 1-2 min for absorption, Ohi et 
al., 2004). The negatively-stained 9TAF particles are homogeneous (Fig. 3.3); 
therefore suitable for 2D processing and 3D structure determination. 
 
Figure 3.2: GraFix analysis of 9TAF. (a) SDS-PAGE analysis (12%) of fractions 
#1-14 from GraFix control gradient. (b) SDS-PAGE analysis (6%) of fractions #1-
14 from GraFix fixed gradient. Glutaraldehyde and glycerol concentrations 
decrease from fraction #1 to #14 linearly, as indicated by the colored bars on top 
of gel images. Lane M shows annotated protein molecular weight marker (unit: 
kDa). Positions of individual TAFs are indicated by their numbers (numbers of 
TAFs, which are not well visible, were bracketed). 
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Figure 3.3: Negative-stain EM analysis of GraFix fixed 9TAF. (a) Negative-
stain EM analysis of fraction #11 of GraFix fixed gradient with 25,000 times of 
magnification and (b) 50,000 times of magnification. 
 
3.2.2 3D reconstruction of 9TAF by random conical tilt (RCT) method 
 
Random conical tilt (RCT) is a 3D reconstruction method by combining two sets of 2D 
projections of the same particles, while the angle between the two projection axes 
remains constant (Radermacher et al., 1987). This method is used for generating a 
primary 9TAF 3D model of lower resolution from a negative-stain EM dataset. This 
resulting primary 9TAF 3D model is then used as a reference model for subsequent 
structural determination from a cry-EM dataset in order to generate a 9TAF 3D model 
with higher resolution (a detailed workflow of the RCT method can be found in 
‘Materials and Methods’ chapter). 
From each area of interest on a 9TAF EM grid (prepared by the carbon sandwich 
method), two EM micrographs were taken: a tilted view (when the grid is tilted by 55°) 
and an untilted view (when the grid is not tilted). Altogether, 200 micrographs (from 
100 areas of interest) were recorded (Biotwin Ice CM120 Philips, EMBL-Heidelberg). 
The micrographs were first preprocessed by IMOD (bio3d.colorado.edu/imod/) and 
Bsoft (Heymann and Belnap, 2007) in order to remove bad image points (from X-ray) 
and lines (from camera imperfection), and then binned by a factor of 2 by Bsoft. Then, 
the preprocessed micrographs were evaluated by CTF (contrast transfer function) 
estimation with XMIPP software packages (Sorzano et al., 2004) before manual 
particle selection. Altogether 6,364 particle pairs were manually picked with TiltPicker 
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(Voss et al., 2009). The coordinates of the particle pairs were used by XMIPP to 
extract and preprocess (particle normalization, ramping background correction, and 
band-pass filtering) boxed particle pairs from micrographs. After visual inspection, 203 
boxed particle pairs of poor quality were removed from the dataset. The untilted views 
of remaining 6,161 particle pairs were analyzed by CL2D classification protocol of 
XMIPP, and also 2D MSA (multivariate statistical analysis) classification protocol of 
IMAGIC (Van Heel et al., 1996). These two independent 2D classifications both 
revealed classes resembling a horseshoe with three lobes (Fig. 3.4), which is also a 
typical structural feature of endogenous holo-TFIID (Grob et al., 2006; Elmlund et al., 
2009; Liu et al., 2009; Papai et al., 2009). 
 
Figure 3.4: 3D reconstruction of 9TAF from negative-stain EM dataset. The 
overall workflow is shown schematically with corresponding programs in 
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brackets. Representative 2D classes from two independent 2D classification 
analyses were shown for comparison. 
 
In order to perform 3D reconstruction of 9TAF by RCT method, 9TAF particle 
pairs (only untilted views) were classified by ML2D classification protocol of XMIPP 
(256 classes from 6,161 particles) and RCT 3D models were reconstructed from tilted 
views of particles in 66 selected classes, whose class averages showed distinct 
structural features. Common structural features have been found among some 9TAF 
RCT 3D models, in which two bulky lobes are connected by a thinner linker. Two 
9TAF RCT 3D models, reconstructed from classes representing putative bottom view 
and front view, were averaged by using the ‘ml_moto’ script of XMIPP (Scheres et al., 
2009), resulting an averaged 9TAF 3D model with a distinct horseshoe-like structural 
feature (Fig. 3.5). Since its reprojections generated by SPIDER (Shaikh et al., 2008) 
indicate significant missing wedge effect (some particles are smeared and no distinct 
structural features), more 9TAF RCT 3D models from classes representing various 
views (front, bottom, and side) were used for 3D averaging tests in order to find an 
optimal combination of input models (normally 5-10) to minimize the missing wedge 
effect. 
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Figure 3.5: Generation of a primary averaged 9TAF 3D model from two input 
models. Two 9TAF RCT 3D models from classes representing putative bottom and 
front views were used as input models to generate an averaged 9TAF 3D model. 
Subsequently, 83 reprojections were generated by SPIDER in order to evaluate the 
level of missing wedge effect. 
 
After a few 3D averaging trails, six 9TAF RCT 3D models from classes 
representing front, bottom, and side views were chosen as inputs for 3D averaging. The 
missing wedge effect of this averaged 9TAF 3D model has been significantly 
improved comparing to the previous model (Fig. 3.6). 
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Figure 3.6: Generating an improved 9TAF 3D model by averaging six RCT 3D 
models. Six 9TAF RCT 3D models from classes representing front, bottom and side 
views were combined to generate an averaged 3D model. The missing wedge effect 
has been significantly improved comparing to the primary averaged 9TAF 3D 
model (Fig. 3.5) as indicated by its reprojections. 
 
This improved 9TAF 3D model was then used as a reference model to generate 
reprojections for refining the alignment of untilted views of 9TAF particle pairs by 
SPIDER. A threshold (no more than 20 particles/reprojection) was used to remove 
particles in overrepresented reprojections.  Afterwards, a refined 9TAF 3D model was 
reconstructed from 1,404 9TAF particles (only untilted view) by backprojection with 
SPIDER. Comparing to the reference 9TAF 3D model, the refined 9TAF 3D model has 
the same overall shape and enhanced structural details. The authenticity of the refined 
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9TAF model has been further confirmed by the similarities between its reprojections 
and the 2D MSA classums of the original 9TAF RCT dataset (Fig. 3.7). 
 
Figure 3.7: Generation of a refined 9TAF 3D model by multireference 
alignment and backprojection with SPIDER. Significant similarities have been 
observed between reprojections (SPIDER) of the refined 9TAF 3D model and 2D 
MSA classums (IMAGIC) of the original 9TAF negative-stain dataset. 
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Excitingly, this refined 9TAF 3D model shares very similar structural features 
with previous TFIID 3D models generated from endogenously purified human and 
yeast TFIID (Liu et al., 2009; Papai et al., 2009) (Fig. 3.8).  
 
Figure 3.8: Comparing the refined 9TAF 3D model with TFIID 3D models 
generated from endogenous human and yeast TFIID. Three views (front, 
bottom, and back) of the 3D models are shown as indicated at the bottom. The 
scale bar represents 10 nm. 
 
This refined 9TAF 3D model will be used as a reference model for 
reconstructing a 9TAF cryo-EM model to the highest possible resolution (in 
collaboration with Schultz lab, IGBMC), which can then be used to localize TAF3 by 
structural comparison with the 8TAF cryo-EM model (Table 3.1). 
 
3.2.3 Generate 9TAF 3D model from cryo-EM dataset 
 
The 9TAF sample for cryo-EM dataset collection was prepared in the same way as for 
the 9TAF RCT dataset (see chapter 3.2.1). The cryo-EM grid preparation and 
automatic micrograph collection was done by Gabor Papai (Schultz lab, IGBMC) with 
a Tecnai F30 Polara platform (FEI). In total 3,880 micrographs (pixel size: 1.86 Å; 
spherical aberration (Cs): 2.0; voltage: 100 kV; amplitude contrast: 0.07) were 
collected. 
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Qualities of the micrographs were evaluated by both visual inspection and CTF 
estimation with Bsoft. Only 20% of the examined micrographs were kept for further 
processing, while the rest were excluded (Fig. 3.9). 
 
 
Figure 3.9: Preprocessing and sorting micrographs of 9TAF cryo-EM dataset. 
Altogether 1,200 micrographs have been evaluated by both visual inspection and 
CTF estimation. The micrographs of poor qualities were excluded for further 
processing. Representative examples are shown at the right side with both original 
micrographs and their corresponding CTF spectra side by side. The causes of poor 
imaging quality are indicated in brackets. Only 20% of the examined micrographs 
were chosen for further analysis. A representative micrograph and its CTF are 
shown at the bottom. 
 
Particles from the micrographs of good quality were picked with the EMAN2 
boxer program (http://blake.bcm.edu/emanwiki/EMAN2). In total 15,295 particles 
were picked from 240 micrographs and their coordinates were used for particle 
extraction from the corresponding micrographs, which have been treated by CTF 
correction, with the batchboxer script (EMAN) and bsplit script (Bsoft). Afterwards, 
the extracted particles were preprocessed by contrast inverting, binning with a factor of 
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2, normalizing, and then band-pass filtering (12 Å as high resolution threshold) with 
Bsoft before 2D MSA analysis by IMAGIC (Fig. 3.10). 
 
 
Figure 3.10: Preprocessing extracted particles from 9TAF cryo-EM dataset. A 
representative particle has been preprocessed stepwise as indicated by the arrows. 
Important parameters for certain steps are indicated in brackets: 180 × 180 and 90 
× 90 indicate the dimensions (in pixel) of the corresponding images. 12 Å is the 
high resolution threshold for the band-pass filtering. 
 
To evaluate the overall quality of the extracted and preprocessed particles, a 
primary 2D MSA analysis (IMAGIC) has been done and the resulted classums (200 
classums from 15,295 particles) show distinct structural features, some of which are 
very similar comparing to the classums from 9TAF RCT dataset (Fig. 3.11). 
 
Figure 3.11: Comparing IMAGIC classums from 9TAF cryo-EM dataset and 
RCT dataset. Only the first 100 classums (200 in total) are shown for both 
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datasets. Five representative classums from each dataset are magnified for showing 
their similarities (bottom). 
 
3.3 TAF3 truncation variants 
 
In order to localize TAF3 domains in 9TAF and to elucidate if a certain TAF3 
fragment is essential for TFIID assembly; three TAF3 truncation variants were 
designed based on domain prediction (SMART and UniProt) and multi-species 
alignment (Clustal Omega & ESPript).  
 
3.3.1 Design of TAF3 truncation variants 
 
An N-terminal HFD, a C-terminal PHD finger, and a lysine-rich region have been 
predicted in human TAF3 by using the web interfaces of SMART and UniProt (Fig. 
3.12). 
 
 
Figure 3.12: Three domains have been predicted in human TAF3. An N-
terminal HFD (annotated by SMART as a ‘BTP’ domain) and a C-terminal PHD 
finger have been predicted by using the web interface of SMART, while a lysine-
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rich region has been predicted by the UniProt web server (top panel). The 
predicted domains are combined and shown at the bottom. The N-terminal CBP-
tag and Strep-tag are also shown. The locations of each domain are indicated by 
their amino acid numbers (in black). The length of this human TAF3 protein is 
also indicated (numbers in grey). 
 
In order to determine the exact domain boundaries for designing TAF3 
truncation variants, multi-species alignment has been performed by using the web 
interfaces of Clustal Omega. The alignment results were visualized by using ESPript 
web server and two domain boundaries were defined: one locates near the C-terminus 
of the HFD and the other at the N-terminus of the lysine-rich region (Fig. 3.13). 
 
Figure 3.13: Two domain boundaries are defined in human TAF3. The multi-
species alignment was performed among: the full-length human TAF construct 
used in Berger lab (TAF3_hs_Berger), the human (TAF3_hs_929aa), M. musculus 
(TAF3_mm_932aa), G. gallus (TAF3_gg), and D. rerio (TAF3_dr) TAF3 
sequences obtained from NCBI protein database. The locations of the two defined 
domain boundaries (A, B), HFD, and lysine-rich region are also indicated. 
 
Based on these two domain boundaries, three TAF3 truncation variants were 
designed (Fig. 3.14). The first and the third TAF3 truncation variants, which contain 
the intact HFD, will be produced by co-expressing with a his-tagged TAF10 construct. 
In contrast, the second TAF3 truncation variant, which lacks the HFD, will be 
produced by itself, with an additional cleavable C-terminal MBP (maltose-binding 
protein) tag to increase its solubility. 
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Figure 3.14: A schematic view of the three TAF3 truncation variants. 
Locations of the domains and domain boundaries in TAF3 are indicated by their 
amino acid numbers. The functional elements (domains, purification tags, and 
protease cutting site) are annotated at the bottom. 
 
 
3.3.2 Production of TAF3 truncation variants 
 
All the three TAF3 truncation variants were subcloned. The inserts containing 
truncated TAF3 encoding sequences were PCR amplified from a full-length TAF3 
expression construct (obtained from Simon Trowitzsch, Berger lab), with a 5’ BstEII 
site and a 3’ RsrII site introduced by PCR primers. These PCR fragments were then 
inserted into a pUCDM derivative (a donor vector) via BstEII and RsrII sites. For the 
second TAF3 truncation variant, the additional PreScission protease site (GE 
Healthcare Life Sciences) and a MBP-tag was PCR amplified from a pMAL derivative 
(obtained from Matthias Haffke, Berger lab) and then inserted via the RsrII site. All the 
DNA constructs have been verified by DNA sequencing (Macrogen). 
The DNA constructs encoding the first and the third TAF3 truncation variants 
were fused with a TAF10 expressing construct (obtained from Simon Trowitzsch, 
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Berger lab) via Cre-LoxP reaction, whereas the DNA construct encoding the second 
TAF3 truncation variant was fused with pKDummy (a pKL derivative). Strong 
expression level has been observed for the first and the third TAF3 truncation variants 
co-expressed with TAF10 (Fig. 3.15). The expression test of the further TAF3 
truncation variants is in progress. 
 
 
Figure 3.15: Co-expressing TAF3 truncation variants with TAF10. 
‘TAF3_Trunc1/3+T10’ indicate the first and the third TAF3 truncation variants 
co-expressed with TAF10. Transfer plasmids (pFL-
TAF10CHis_×_pUCSTAF3_Trunc1/3-YFP) were integrated into MultiBac BAC 
via Tn7 transposition (left). Expression probes taken from two independent 
expressions of the same construct (1 and 2) at the date of proliferation arrest (dpa) 
and 72 hours after dpa (+72) were analyzed by SDS-PAGE together with an 
uninfected cell control sample (CC). The overexpressed TAF3/TAF10 bands are 
indicated by the yellow asterisks in the gel image and also on the side. Lane M 
shows annotated protein molecular weight marker (unit: kDa). ‘SNP’ stands for 
supernatant and pellet. The molecular weights of recombinant proteins are shown 
in the list at bottom right. 
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Discussion and Perspective 
 
In order to accurately localize TAF3 in the context of 9TAF, it is crucial to determine 
the structure of 9TAF to the highest possible resolution from the cryo-EM dataset. 
Although comparison of the IMAGIC classums from the 9TAF cryo-EM and RCT 
datasets revealed their similarities, the granular patterns in the background of IMAGIC 
classums from 9TAF cryo-EM dataset (Fig. 3.11) indicate that the filtering parameters 
should be further optimized by keeping more low frequency information. In addition, 
more particles (~30,000 in total) are probably required for high-quality 3D 
reconstruction. I am therefore picking more particles and will carry out the structure 
determination based on this larger dataset. 
Once purified to homogeneity, the TAF3 truncation variants will be incorporated 
into 8TAF to generate 9TAF complex with truncated TAF3. Therefore individual 
TAF3 domains can be accurately localized by comparing the EM structures of 9TAF 
complexes with truncated and full-length TAF3. The 9TAF complexes with truncated 
TAF3 will also be subjected to reconstitution tests to elucidate if they could still be 
incorporated by other TFIID subunits to form holo-TFIID. 
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Chapter 4: Production and characterization of 
recombinant human TFIID complexes 
 
Abstract 
 
TAF1 (250 kDa) is the largest subunit of human TFIID and it interacts with many other 
TAFs and TBP. It contains epigenetic reader and writer domains and is an essential 
component for assembling holo-TFIID. However, recombinant TAF1 expressed in 
insect cells was difficult or even impossible to purify previously, even though it was 
well expressed with the MultiBac system (Imre Berger, personal communication) due 
to its low solubility and tendency to aggregate. 
In chapter 4.1, I describe how I solved the solubility problem of TAF1 by adding 
N-terminal maltose-binding protein (MBP) tags. This approach led to well behaved 
TAF1 and allowed us to then work with this protein. In chapter 4.2, I describe the 
reconstitution and characterization of an array of TFIID subcomplexes containing the 
MBP-tagged TAF1. In chapter 4.3, I present the reconstitution and single-EM analysis 
of the ~1.5 MDa human holo-TFIID, containing a full complement of TAFs and TBP. 
 
Résumé 
 
TAF1 (250 kDa) est la sous unité la plus grande de TFIID humain, elle interagit avec 
de nombreux autres TAFs et TBP. TAF1 contient des domaines pouvant induire et 
reconnaître des modifications épigénétiques et constitue également un élément 
essentiel à la formation de TFIID. Toutefois, TAF1 exprimée de manière recombinante 
en cellules d’insecte était difficile voire même impossible à purifier compte tenu de sa 
faible solubilité et de sa tendance à s’agréger, bien que cette sous unité ait été bien 
exprimée avec le système MultiBac (Imre Berger, communication personnelle). 
Dans le chapitre 4.1 est décrite la résolution des problèmes de solubilité de 
TAF1, par ajout en N-terminal de tags maltose-binding-protein (MBP). Cette approche 
a conduit au bon comportement de TAF1 et nous a donc permis de travailler avec cette 
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protéine. Dans le chapitre 4.2 sont exposées les reconstitutions et caractérisations de 
toute une gamme de sous-complexes de TFIID contenant TAF1 additionnée de MBP-
tags. Dans le chapitre 4.3 sont présentées la reconstitution et l’analyse en microscopie 
électronique de TFIID (~1.5 MDa) composé de tous les TAFs et TBP. 
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4.1 Production and characterization of MBP-tagged TAF1 and 
TAF1-containing complexes 
 
4.1.1 TAF1: A bottleneck for holo-TFIID production and purification 
 
The production of fully recombinant human holo-TFIID for high-resolution structural 
and functional studies is a preeminent focus of the Berger laboratory. Highly purified 
9TAF (composed of TAF2, 3, 4, 5, 6, 8, 9, 10, 12) became available following the 
procedures described earlier in this thesis (chapter 3.2.1). At this stage, the TAFs still 
missing from holo-TFIID are: TAF1, TAF7, TAF11 and TAF13 (these two TAFs form 
a dimeric complex, TAF11/13), and TBP. TAF7, TAF11/13 and TBP are being studied 
by members of the Berger laboratory and are available in highly purified form. TAF1 
has been from the start of the TFIID project, and since then remained, an impeding 
‘bottleneck’ towards production of holo-TFIID (Fig. 4.1). 
 
Figure 4.1: TAF1 is a bottleneck for holo-TFIID production and 
purification. TAFs in 9TAF are colored in green. TAF7, TAF11/13 complex, 
and TBP, which are available in high purity, are colored in purple. TAF1 is 
colored in blue. 
 
TAF1 was “problematic” to produce and purify in many attempts in our 
laboratory over the years, either when expressed in isolation or when co-expressed 
with other TAFs. TAF1 is a 250 kDa protein and the biggest subunit of hTFIID. 
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Previous studies (Berger lab, unpublished) in our laboratory showed that TAF1 can be 
expressed in insect cells and purified as a single protein, however not to homogeneity 
and with very poor solubility, which is probably due to its propensity to aggregation 
and high DNA/chromatin binding affinity. Full-length human TAF1 thus cannot be 
purified in isolation in a form for reconstitution experiments with preassembled, 
purified TFIID subcomplexes. When TAF1 was co-expressed with other TAFs, the 
expression level of TAF1 dropped markedly due to reasons we do not understand at the 
moment, prohibiting complex purification with reasonable yields. A further 
complication became evident when our laboratory analyzed a co-expression 
experiment of close to all TAFs and TBP by MultiBac in insect cells - fluorescence 
microscopy using specific antibodies revealed that human TAF1 rapidly enters the 
nucleus of insect cells after being synthesized, in contrast to other TAFs which are 
apparently translocated at later times (Fig. 4.2). TAF1 or holo-TFIID could not be 
successfully purified from these experiments. The question thus came up whether 
human TAF1 and the other components of TFIID actually had at all a chance in the 
heterologous overexpression experiments to “meet” each other for efficient complex 
formation, and we are not able to answer this question to date. 
 
Figure 4.2: Expression of holo-TFIID from three polyproteins. The composite 
MultiBac virus is shown schematically on top. CFP and YFP proteins within the 
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polyproteins were used to monitor expression levels. Immunostaining with 
specific antibodies is shown below at times intervals post infection indicated. 
TAF1 is found immediately into the nucleus, whereas TAF9 is found first both in 
cytosol and nucleus and only at 60-72 h mostly in the nucleus. TAF13 remains 
cytosolic entirely until 72 hours, and then it is also found in the nucleus. 
 
We therefore considered a different approach to produce and purify TAF1 and 
also holo-TFIID. Interestingly, a roughly 80 kDa TAF1 C-terminal part, supposedly 
containing a kinase activity, has been purified successfully previously by Matthias 
Haffke and Anika Altenfeld in the Berger laboratory, and showed excellent stability 
and solubility. This construct comprises amino acids 1293-1872 of TAF1, which 
amounts to approximately the C-terminal one-third of TAF1. Consequently, we 
speculated that the part of TAF1 which causes the difficulties in previous purifications 
when TAF1 was expressed in isolation, may possibly locate to the N-terminal two-
thirds of TAF1. We further speculated that stabilizing this N-terminal part of TAF1 by 
providing a powerful solubility tag and possibly a subselection of other TAFs may 
result in a “well-behaved” TAF1 bound to these partners. We hypothesized that such 
modified TAF1 containing TFIID subcomplexes can then be used for holo-TFIID 
reconstitution. 
 
4.1.2 Improve TAF1 solubility by adding N-terminal MBP tag(s) 
 
The MBP tag (~40 kDa) is well-known for its remarkable ability of enhancing the 
expression level and solubility of its fusion partners (Kapust and Waugh, 1999). A 
recent study (Jensen et al., 2010) showed that the full-length human BRCA2 protein 
(3,418 amino acids) can be purified to near homogeneity by adding two MBP tags in 
tandem at its N-terminus (resulting in a 470 kDa fusion protein). Inspired by this 
encouraging example, I subcloned two TAF1 encoding constructs tagged at the N-
terminus with TEV cleavable MBP: one construct with one MBP tag (MBP-TAF1) and 
the other with three tandem MBP tags (MBP3-TAF1) (Fig. 4.3). Both constructs 
showed excellent expression and solubility in insect cells (Sf21) by using the MultiBac 
system. 
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Figure 4.3: Expression of MBP-TAF1 and MBP3-TAF1 in insect cells. A 300 
kDa MBP-TAF1 fusion protein and a 380 kDa MBP3-TAF1 fusion protein were 
expressed in insect cells (Sf21) and showed excellent expression and solubility. 
The plasmid maps and corresponding SDS-PAGE (6%) analyses of cell probes 
taken during expressions were shown for both (a) MBP-TAF1 and (b) MBP3-
TAF1. In the annotated SDS gel images: ‘CC’ stands for uninfected cell probe as 
negative control. ‘MBP-1 CC’ stands for MBP-TAF1 expressing cell probe. Lane 
M shows annotated protein molecular weight marker (unit: kDa). ‘dpa’ stands for 
‘date of proliferation arrest’ and ‘dpa-/+n’ stands for cell probes taken n hours 
before/after dpa; ‘SNP’ stands for supernatant and pellet; ‘SN’ stands for 
supernatant; ‘MBP-1’ and ‘MBP3-1’ indicate positions of MBP-TAF1 and 
MBP3-TAF1 bands. 
 
After extensive purification trials, I established a protocol (a detailed protocol 
can be found in ‘Materials and Methods’ chapter) to purify MBP-TAF1 and MBP3-
TAF1 from nuclear soaking supernatant fraction by using amylose resin batch 
purification, to very good amounts and high purity. 
In brief, insect cell pellet expressing MBP/MBP3-TAF1 is first lysed by 
resuspending in lysis buffer of low ionic strength (100 mM KCl) containing 0.1% NP-
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40, in order to break the cell membrane but keep the nuclei intact. The nuclei are 
washed extensively by lysis buffer to remove the cytosolic fraction and then 
resuspended in nuclear soaking buffer of higher ionic strength (400 mM KCl), so that 
MBP/MBP3-TAF1 in nuclei can be soaked out by gentle agitation (on a roller). After 
soaking, the soaked nuclei are removed by centrifugation and the MBP/MBP3-TAF1 
containing supernatant fraction is used as input for amylose resin batch purification 
(Fig. 4.4). 
 
Figure 4.4: Purification of MBP-TAF1 by Nuclear soaking protocol. The 
nuclear soaking procedure is shown schematically in the top diagram, with major 
steps indicated in the boxed texts. Nuclear soaking fractions are annotated at the 
bottom of the top diagram and connected with the corresponding sample lines on 
the SDS gel image (6%, bottom) by arrows. ‘SNP’ stands for supernatant and 
pellet. Lane M shows annotated protein molecular weight marker (unit: kDa). 
‘Washes’ stands for samples from five consecutive washes. ‘B’ stands for nuclear 
soaking mixture before rolling incubation. ‘A’ stands for nuclear soaking mixture 
after rolling incubation. ‘SN’ stands for supernatant. ‘MBP-1’ indicates the 
position of MBP-TAF1 bands. 
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During amylose resin batch purification, the MBP/MBP3-TAF1 containing 
supernatant was mixed with equilibrated amylose resin and incubated under gentle 
agitation. Contaminating proteins and nucleic acids are removed by extensive washes 
with binding buffer (nuclear soaking buffer) and high salt buffer (2M KCl). 
Afterwards, MBP/MBP3-TAF1 is eluted by elution buffer (nuclear soaking buffer 
supplied with 10 mM maltose) under gentle agitation.  
SDS-PAGE analysis showed that MBP3-TAF1 elutions contain three protein 
species (three Coomassie stained bands of similar intensities). Subsequent western blot 
analysis (against his-tag) showed that all the three protein species are his-tagged, which 
indicates that they are MBP3-TAF1, MBP2-TAF1 (TAF1 with two tandem N-terminal 
MBP tags) and MBP-TAF1 (Fig. 4.5c). The reason for this is probably degradation by 
proteolysis in the linker amino acids between the MBPs. No difference in behaviour, 
notably solubility, between the species was observed. Therefore, MBP-TAF1 was then 
chosen for further biophysical characterizations and reconstitution tests with its 
binding partners. 
 
Figure 4.5: Amylose resin batch purification of MBP/MBP3-TAF1 and 
western blot analysis of MBP3-TAF1 elutions. SDS-PAGE (6%) analyses of (a) 
MBP-TAF1 and (b) MBP3-TAF1 amylose resin batch purifications. Lane M 
shows annotated protein molecular weight marker (unit: kDa). ‘IN’ stands for 
input sample. ‘FT’ stands for flow through sample. ‘Washes’ stands for samples 
from four consecutive washes. ‘E1/2’ stands for the first/second elution samples, 
among which ‘E’ stands for elution samples as it is; ‘LS’ stands for elution 
samples after low-speed centrifugation (~16,000 g); ‘HS’ stands for elution 
samples after high-speed centrifugation (~98,000 g). ‘RS’ stands for resin 
samples. (c) Western blot analysis (against his-tag) of MBP3-TAF1 elutions. Lane 
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M shows annotated protein molecular weight marker (unit: kDa). ‘E1’ and ‘E2’ 
stand for two MBP3-TAF1 elutions. 
 
4.1.3 GraFix and negative-stain EM analysis of MBP-TAF1 
 
The addition of N-terminal MBP tag(s) improves TAF1’s solubility and greatly 
facilitates its purification. MBP-TAF1 was analyzed by GraFix (glycerol gradient: 10-
40%; glutaraldehyde gradient: 0-0.15%; 22 fractions were collected for each gradient) 
under three buffer conditions (Table 4.1). The tested additives (Mg2+, NP-40) have 
been used previously for in vitro assembly of TAF-TBP complexes, in which TAF1 
serves as a scaffold for recruiting other TAFs and TBP (Chen et al., 1994; Chen and 
Tjian, 1996): 
Table 4.1: The compositions of TAF1 GraFix buffers 1, 2, and 3. 
Buffer 1  50 mM HEPES/pH 8.0; 400 mM KCl. 
Buffer 2  50 mM HEPES/pH 8.0; 400 mM KCl; 10 mM MgCl2; 0.1 % NP-40. 
Buffer 3  50 mM HEPES/pH 8.0; 100 mM KCl; 10 mM MgCl2; 0.1 % NP-40. 
 
The GraFix results (control gradients) showed that MBP-TAF1 probably exists 
as a series of oligomers of various molecular weights, since it spans from bottom to 
middle of the glycerol gradient under all three buffer conditions (Fig. 4.6). The results 
also showed that this observed MBP-TAF1 oligomerization is neither influenced by 
addition of Mg2+ (10 mM) and NP-40 (0.1%), nor by decreasing the ionic strength of 
buffers (from 400 mM KCl to 100 mM KCl). 
 
Figure 4.6: GraFix analysis of MBP-TAF1 under three buffer conditions. 
Glycerol concentration decreases from fraction #1 to #14 linearly, as indicated by 
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the blue bar on top of each gel image. Lane M shows annotated protein molecular 
weight marker (unit: kDa). Red arrows indicate the locations of MBP-TAF1 
bands. (a) SDS-PAGE (12%) analyses of fractions #1 to #14 from GraFix control 
gradient under buffer condition 1, (b) buffer condition 2, and (c) buffer condition 
3. 
 
Fractions from GraFix gradient of MBP-TAF1 under buffer condition 1 (50 mM 
HEPES/pH 8.0; 400 mM KCl) were further analyzed by negative-stain EM. The MBP-
TAF1 particles are homogeneous (Fig. 4.7), which encouraged us to proceed further 
with this protein towards reconstituting holo-TFIID. 
 
Figure 4.7: GraFix and negative-stain EM analysis of MBP-TAF1 under 
buffer condition 1. (a) SDS-PAGE analysis (6%) of fractions #1 to #14 from 
GraFix fixed gradient. Lane M shows annotated protein molecular weight marker 
(unit: kDa). Glutaraldehyde and glycerol concentrations decrease from fraction #1 
to #14 linearly, as indicated by the colored bar on top the gel image. Red arrow 
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indicates the position of fixed MBP-TAF1. (b) Negative-stain EM analysis of 
fraction #2, (c) fraction #5, and (d) fraction #8. 
 
4.2 MBP-TAF1 as a platform for TAF/TBP interaction assays 
 
9TAF complex (TAF2, 3, 4, 5, 6, 8, 9, 10, and 12) is available in a highly-purified 
form. The still missing subunits to complete holo-TFIID are: TAF1, TAF7, TAF11, 
TAF13, and TBP, which have been identified as “peripheral” and single-copy subunits 
in endogenously purified yeast TFIID by EM coupled to immunolabelling (Leurent et 
al., 2002, 2004). TAF11 and TAF13 form a dimeric complex, TAF11/13. TAF1 has 
been shown to physically interact with TAF7 with its central region (Chiang and 
Roeder, 1995) and TBP with its N-terminal domains (Kokubo et al., 1994; Kotani et 
al., 1998), whereas TBP has been shown to form a stoichiometric complex with 
TAF11/13 in vitro (Berger lab, unpublished). These evidence strongly suggest that 
TAF1, TAF7, TAF11/13, and TBP can form a TFIID subcomplex (Cler et al., 2009; 
Papai et al., 2011) which then may bind to 9TAF to give rise to complete holo-TFIID 
containing a full complement of TAFs and TBP. 
We were interested to find out if our MBP-TAF1 protein can be used as a 
platform to assemble complexes containing some or all the TFIID subunits. A generic 
reconstitution protocol has been established as outlined below (Fig. 4.8) (a detailed 
protocol can be found in ‘Materials and Methods’ chapter). 
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Figure 4.8: TAF interaction assay with MBP-TAF1 bound amylose resin. The 
MBP-TAF1 bound amylose resin is used as a platform for testing the ability of 
MBP-TAF1 to incorporate other TFIID subunits. The major experimental steps 
are described in the boxed texts. 
 
4.2.1 The ‘MBP-TAF1/TAF7’ complex 
 
TAF1 was proposed to serve as a scaffold, which incorporates other TAFs and TBP 
into holo-TFIID (Chen et al., 1994; Wassarman and Sauer, 2001). We wanted to test if 
our MBP-TAF1 can also incorporate other TAFs and TBP, despite its N-terminal MBP 
tag. TAF7 was chosen for the first reconstitution test, since it has been shown to 
directly interact with TAF1 in previous studies (Chiang and Roeder, 1995; Gegonne et 
al., 2001). 
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This reconstitution test was done by mixing purified TAF7 (in molar excess) 
with MBP-TAF1 bound on amylose resin in buffer of high ionic strength (400 mM 
KCl), and incubating under gentle agitation. Excess of TAF7 was removed by 
extensive washes. The reconstituted ‘MBP-TAF1/TAF7’ complex was eluted by 
binding buffer supplied with 10 mM maltose under gentle agitation. In parallel with the 
reconstitution test, a resin control test was also performed by mixing equilibrated 
amylose resin with purified TAF7. This reconstitution test showed that MBP-TAF1 
forms a complex with TAF7 (Fig. 4.9). No unspecific binding of TAF7 to the resin was 
observed. 
 
Figure 4.9: MBP-TAF1 forms a complex with TAF7. Positions of individual 
TAFs and TBP are indicated aside of each gel image. (a) SDS-PAGE (12%) 
analysis of resin control test, and (b) ‘MBP-TAF1/TAF7’ reconstitution test. In 
both (a) and (b): ‘IN’ stands for input sample (purified TAF7). Lane M shows 
annotated protein molecular weight marker (unit: kDa). ‘FT’ stands for flow 
through sample. ‘Washes’ stands for five consecutive binding buffer washes. 
‘E1/2’ stands for the first/second elution samples, among which ‘E’ stands for 
elution samples as it is; ‘LS’ stands for elution samples after low-speed 
centrifugation (~16,000 g); ‘HS’ stands for elution samples after high-speed 
centrifugation (~98,000 g). ‘RS’ stands for resin samples. 
 
4.2.2 The ‘MBP-TAF1/TAF11-13/TBP’ complex 
 
Encouraged by the successful reconstitution of ‘MBP-TAF1/TAF7’ complex, another 
reconstitution test was performed with MBP-TAF1 bound on amylose resin, 
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TAF11/13, and TBP by using the same reconstitution protocol as for ‘MBP-
TAF1/TAF7’ complex. SDS-PAGE analysis showed that MBP-TAF1 also form a 
complex with TAF11/13 and TBP, though it appears that TAF11/13 may be present in 
substoichiometric ratio (Fig. 4.10). 
 
Figure 4.10: MBP-TAF1 forms a complex with TAF11/13 and TBP. Positions 
of individual TAFs and TBP are indicated aside of each gel image. (a) SDS-
PAGE (12%) analysis of resin control test, and (b) ‘MBP-TAF1/TAF11-13/TBP’ 
reconstitution test. In both (a) and (b): ‘IN’ stands for input sample (purified 
TAF11/13, and TBP). Lane M shows annotated protein molecular weight marker 
(unit: kDa). ‘FT’ stands for flow through sample. ‘Washes’ stands for five 
consecutive binding buffer washes. ‘E1/2’ stands for the first/second elution 
samples, among which ‘E’ stands for elution samples as it is; ‘LS’ stands for 
elution samples after low-speed centrifugation (~16,000 g); ‘HS’ stands for 
elution samples after high-speed centrifugation (~98,000 g). ‘RS’ stands for resin 
samples. 
 
Since this reconstitution experiment was done in small batch, the amount of 
eluted complex is not sufficient for GraFix analysis, which generally requires ~100 µg 
protein as input for each gradient. Instead, the eluted complex was fixed by mixing 
with glutaraldehyde solution directly: all elution samples were first combined and 
dialyzed against a HEPES-based dialysis buffer (50 mM HEPES/8.0, 400 mM KCl, 3 
mM β-Mercaptoethanol) overnight in a Thermo dialysis cassette (MWCO: 10 kDa) in 
order to remove Tris, leupeptin, and pepstain; afterwards, 1% glutaraldehyde solution 
was mixed directly with the dialyzed elution samples to bring the final glutaraldehyde 
concentration to 0.15%. The mixture was incubated on ice for ~1 hour before negative-
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stain EM analysis (Fig. 4.11), suggesting that ‘MBP-TAF1/TAF11-13/TBP’ complex 
is more homogeneous that MBP-TAF1 (Fig. 4.7). 
 
Figure 4.11: Negative-stain EM analysis of fixed ‘MBP-TAF1/TAF11-
13/TBP’ complex. (a) EM micrograph of lower magnification, in which the scale 
bar represents 100 nm. (b) EM micrograph of higher magnification, in which the 
scale bar represents 20 nm. 
 
4.2.3 The ‘MBP-TAF1/TAF7/TAF11-13/TBP’ complex 
 
In parallel with the reconstitution test of ‘MBP-TAF1/TAF11-13/TBP’ complex, 
MBP-TAF1, TAF7, TAF11/13, and TBP were also mixed for reconstitution test by 
using the same protocol to see if they can form a ‘MBP-TAF’ module, which can then 
be reacted with 9TAF to form complete holo-TFIID. SDS-PAGE analysis showed that 
these TFIID subunits form a complex, in which TAF11/13 is present in 
substoichiometric ratio similar to the case of ‘MBP-TAF1/TAF11-13/TBP’ 
reconstitution test (Fig. 4.12). 
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Figure 4.12: MBP-TAF1 forms a complex with TAF7, TAF11/13 and TBP. 
Positions of individual TAFs and TBP are indicated aside of each gel image. (a) 
SDS-PAGE (12%) analysis of resin control test, and (b) ‘MBP-
TAF1/TAF7/TAF11-13/TBP’ reconstitution test. In both (a) and (b): ‘IN’ stands 
for input sample (purified TAF7, TAF11/13, and TBP). Lane M shows annotated 
protein molecular weight marker (unit: kDa). ‘FT’ stands for flow through 
sample. ‘W’ and ‘Washes’ stand for five consecutive binding buffer washes. 
‘E1/2’ stands for the first/second elution samples, among which ‘E’ stands for 
elution samples as it is; ‘LS’ stands for elution samples after low-speed 
centrifugation (~16,000 g); ‘HS’ stands for elution samples after high-speed 
centrifugation (~98,000 g). ‘RS’ stands for resin samples. 
 
The elution samples were combined, dialyzed, and fixed in the same way as for 
‘MBP-TAF1/TAF11-13/TBP’ complex before negative-stain EM analysis (Fig. 4.13), 
which showed that this ‘MBP-TAF’ module is as homogeneous as ‘MBP-
TAF1/TAF11-13/TBP’ complex (Fig. 4.11). 
 
Figure 4.13: Negative-stain EM analysis of fixed ‘MBP-TAF1/TAF7/TAF11-
13/TBP’ complex. (a) EM micrograph of lower magnification, in which the scale 
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bar represents 200 nm. (b) EM micrograph of higher magnification, in which the 
scale bar represents 20 nm. 
 
4.2.4 The ‘MBP-TAF1/TAF7/TBP’ complex 
 
Since TAF11/13 appears to be present in a substoichiometric ratio in both reconstituted 
‘MBP-TAF1/TAF11-13/TBP’ and ‘MBP-TAF1/TAF7/TAF11-13/TBP’ complexes, I 
performed another reconstitution test with only MBP-TAF1 bound on amylose resin, 
TAF7, and TBP. The SDS-PAGE analysis showed that MBP-TAF1 probably forms a 
stoichiometric complex with TAF7 and TBP (Fig. 4.14). 
 
Figure 4.14: MBP-TAF1 incorporates and forms complex with TAF7 and 
TBP. Positions of individual TAFs and TBP are indicated on the right side of the 
gel image. ‘IN’ stands for input sample (purified TAF7 and TBP). Lane M shows 
annotated protein molecular weight marker (unit: kDa). ‘FT’ stands for flow 
through sample. ‘Washes’ stands for five consecutive binding buffer washes. 
‘Elutes’ stands for four consecutive elution samples. ‘RS’ stands for resin sample. 
 
The eluted ‘MBP-TAF1/TAF7/TBP’ complex was then analyzed by GraFix 
(glycerol gradient: 10-30%; glutaraldehyde gradient: 0-0.15%, 22 fractions were 
collected for each gradient) and negative-stain EM (Fig. 4.15). 
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Figure 4.15: GraFix and negative-stain EM analysis of ‘MBP-
TAF1/TAF7/TBP’ complex. (a) SDS-PAGE (12%) analysis of fractions #1-14 
from GraFix control gradient. Positions of individual TAFs and TBP are indicated 
on the right side of the gel image. (b) SDS-PAGE (6%) analysis of fractions #1-
14 from GraFix fixed gradient. Red arrow indicates the position of fixed ‘MBP-
TAF1/TAF7/TBP’ bands. In both (a) and (b): glutaraldehyde and glycerol 
concentrations decrease from fraction #1 to #14 linearly, as indicated by the 
colored bars on top of both gel images. Lane M shows annotated protein 
molecular weight marker (unit: kDa). (c) Negative-stain EM analysis of fraction 
#1, (d) fraction #2, and (e) fraction #8. The scale bars (white bars at bottom left of 
each micrograph) represent 50 nm. 
 
SDS-PAGE analysis of GraFix control gradient (Fig. 4. 15a) showed that MBP-
TAF1, TAF7 and TBP co-migrate across the gradient. Fractions #1, #2, and #8 from 
GraFix fixed gradient were analyzed by negative-stain EM (Fig. 4. 15c-e), which 
showed that the ‘MBP-TAF1/TAF7/TBP’ particles are possibly even more 
homogeneous than all the previous MBP-TAF1 containing complexes. 
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In order to see if ‘MBP-TAF1/TAF7/TBP’ particles have any distinct structural 
feature, 5,029 manually-picked particle pairs (from fraction #2 of GraFix fixed 
gradient) were analyzed by CL2D classification protocol of XMIPP and 2D MSA 
classification protocol of IMAGIC (Kevin Knoops, Schaffitzel lab, EMBL). These two 
independent 2D classifications compellingly confirmed homogeneity of the sample 
(Fig. 4.16). 
 
Figure 4.16: 2D processing of ‘MBP-TAF1/TAF7/TBP’ negative-stain EM 
dataset. The workflow is shown schematically with corresponding programs in 
brackets. Class averages/classums from two independent 2D classifications are 
shown at the bottom. 
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4.3 Production and single-particle EM analysis of holo-TFIID 
 
4.3.1 Fully recombinant human holo-TFIID 
 
Encouraged by the success of assembling a set of MBP-TAF1 containing TFIID 
subcomplexes, we pursued the reconstitution of holo-TFIID with a full complement of 
TAFs and TBP. With highly purified TAFs and TBP supplied from other members of 
the Berger laboratory, Christoph Bieniossek and I established a robust reconstitution 
protocol to produce complete holo-TFIID as described below (a  detailed protocol can 
be found in ‘Materials and Methods’ chapter): 
The ‘MBP-TAF1/TAF7/TBP’ complex was prepared by binding MBP-TAF1 to 
amylose resin, with subsequent additions of TAF7 and TBP. Highly purified TAF11/13 
and 9TAF were then provided in binding buffer of low ionic strength (150 mM KCl). 
The excess of unbound TAFs and TBP were removed by extensive washes with 
binding buffer. Reconstituted holo-TFIID is then eluted by first adding elution buffer 
of low ionic strength (150 mM KCl) and then elution buffer of high ionic strength (400 
mM KCl) with gentle agitation. SDS-PAGE analysis of the concentrated eluates 
revealed a full complement of TAFs and TBP (Fig. 4.17). 
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Figure 4.17: Reconstitution of holo-TFIID with a full complement of TAFs 
and TBP. Lane M shows annotated protein molecular weight marker (unit: kDa). 
Positions of individual TAFs and TBP bands on SDS gels are indicated by their 
numbers. Asterisk in 9TAF sample line indicates a contaminating protein co-
purified with 9TAF. 
 
The TFIID samples eluted at low ionic strength contain excess of ‘MBP-
TAF1/TAF7/TBP’ complex, whereas the stoichiometry of TFIID sample from 
subsequent elutions (with elution buffer of high ionic strength) is more balanced (Fig. 
4.18). Consequently, the TFIID samples eluted with elution buffer of high ionic 
strength are combined and concentrated as input for GraFix and single-particle EM 
analysis. 
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Figure 4.18: Stepwise elution improves TFIID stoichiometry. In both (a), (b) 
and (c): Lane M shows annotated protein molecular weight marker (unit: kDa). 
Positions of MBP-TAF1, TAF7, and TBP are indicated either on the side of SDS 
gel images or by yellow asterisks inside SDS gel images (a) SDS-PAGE analysis 
of washing and elution samples of a typical TFIID reconstitution experiment. 
‘A1’, ‘A3’, and ‘A5’ indicate the first, third, and fifth binding buffer washes (in 
total five consecutive washes). ‘E1-5’ indicate five consecutive elutions, in which 
‘E1’ and ‘E2’ samples were eluted with elution buffer of low ionic strength (LS) 
and ‘E3-5’ samples were eluted with elution buffer of high ionic strength (HS). 
(b) and (c) ‘E1’, ‘E2’, and ‘E3-5’ (combined) samples before and after 
concentration. ‘B. Con.’ stands for before concentration. ‘A. Con.’ stands for after 
concentration. 
 
Interestingly, the reconstituted TFIID has been found to remain intact when 
washed with buffers of very high ionic strength (up to 1 M KCl), once assembled in 
buffer of low ionic strength (Fig. 4.19). Consistently, endogenously purified TFIID is 
also resistant to high salt washes as indicated by the well-established purification 
protocol, in which  endogenous TFIID from nuclear extract was first bound onto an ion 
exchange column (a Whatman P11 phosphocellulose ion exchange column) and then 
eluted with buffer containing  0.85 (or 1.0) M KCl before further fractionation 
(Thomas and Chiang, 2006; also see Fig. 1.15). 
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Figure 4.19: Recombinant holo-TFIID is resistant to high-salt washes. 
Positions of TFIID subunits are indicated on the side of SDS gel image (number 
of TAF10, which is not well visible, was bracketed). Lane M shows annotated 
protein molecular weight marker (unit: kDa). TFIID assembled and bound on the 
amylose resin was washed extensively with buffers containing increasing KCl 
concentrations (150 mM, 400 mM, and 1M) as indicated on top of the SDS gel 
image. The washed TFIID bound resin samples were eluted by mixing directly 
with SDS gel loading buffer and then analyzed by SDS-PAGE (12%). 
 
4.3.2 3D reconstruction of holo-TFIID by RCT method 
 
4.3.2.1 Optimizing TFIID EM grid preparation 
 
Only TFIID samples displaying good stoichiometry were used to prepare EM sample 
by using GraFix (glycerol gradient: 10-50%; glutaraldehyde gradient: 0-0.15%; 22 
fractions were collected for each gradient). Fractions #1-10 were checked by negative-
stain EM (carbon sandwich grids), which showed that fractions from bottom of the 
gradient (especially fractions #1-4) contain more large particles, whose size (~50-100 
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nm) are much larger than the size of a single TFIID complex (~25-30 nm). These large 
particles are probably either from remnant ‘MBP-TAF1/TAF7/TBP’ complex in the 
TFIID sample, or maybe TFIID oligomers generated by the fixing procedure. Particles 
from fractions close to the middle of the gradient (#8-10) are more heterogeneous and 
the particle density is also lower for those fractions. Consequently, fraction #6 was 
chosen for preparing EM grids for RCT dataset collection (Fig. 4.20). 
 
 
Figure 4.20: Negative-stain EM analysis of TFIID GraFix fractions. Fractions 
#1-10 from TFIID GraFix gradient were analyzed by negative-stain EM. The 
fraction numbers are indicated under the corresponding EM micrographs. The 
scale bars represent 100 nm. 
 
Since the particle density of the initial EM grid (from fraction #6) was not 
sufficient for RCT dataset collection, the sample absorption time was extended to 1-2 
hours and the sample volume was increased to 5 µL; this extended sample absorption 
was performed once or twice before the grid was stained with 2% uranyl acetate and 
covered with another layer of thin carbon. Comparing to grid prepared by standard 
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procedure with short absorption time (1-2 minutes), the particle density has increased 
significantly (up to five times) with the extended absorption procedure (Fig. 4.21). 
 
 
Figure 4.21: Optimizing TFIID EM grid preparation to increase particle 
density. Fractions #6 from TFIID GraFix gradient was used for optimizing TFIID 
EM grid preparation with extended absorption time. The grid preparation 
procedures are indicated on top of the corresponding EM micrographs, while the 
numbers of particles are indicated below the corresponding EM micrographs. The 
scale bars represent 100 nm. 
 
4.3.2.2 Generate TFIID 3D model by RCT method 
 
The TFIID RCT dataset was collected and processed by a similar workflow as for the 
9TAF RCT dataset: 
Altogether 220 EM micrographs (from 110 areas of interest; tilt angle: 45°) were 
recorded (Biotwin Ice CM120 Philips, EMBL-Heidelberg). The micrographs were first 
preprocessed by IMOD and Bsoft in order to remove bad image points (from X-ray) 
and lines (from camera imperfection), and then binned by a factor of 2 by Bsoft. Then, 
the preprocessed micrographs were evaluated by CTF (contrast transfer function) 
estimation with XMIPP software packages before manual particle selection. Altogether 
9,649 particle pairs were manually picked with TiltPicker. The coordinates of the 
particle pairs were used by XMIPP to extract and preprocess (particle normalization, 
ramping background correction, and band-pass filtering) boxed particle pairs from 
micrographs. The untilted views of the particle pairs were analyzed by CL2D 
classification protocol of XMIPP, and also 2D MSA classification protocol of 
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IMAGIC. These two independent 2D classifications both revealed class 
averages/classums resembling a horseshoe (Fig. 4.22), which is a typical structural 
feature of endogenous holo-TFIID (Grob et al., 2006; Elmlund et al., 2009; Liu et al., 
2009; Papai et al., 2009). 
 
Figure 4.22: 3D reconstruction of TFIID from negative-stain EM dataset. The 
overall workflow is shown schematically with corresponding programs in 
brackets. Representative class averages/classums from two independent 2D 
classification analyses were shown for comparison. 
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As we have already observed during the analysis of 9TAF RCT dataset, the 2D 
MSA classification protocol of IMAGIC generally gives better classification results 
comparing to the ML2D classification protocol of XMIPP (more distinct structural 
features and the classified particles are more evenly distributed among classes). As a 
result, an improved XMIPP ML2D classification protocol was used for TFIID RCT 
dataset, in which IMAGIC 2D MSA classums were used as references for XMIPP 
ML2D classification. This improved XMIPP ML2D classification protocol gave good 
classification results, which are very similar to the results from IMAGIC 2D MSA 
protocol (Fig. 4.23). 
 
 
Figure 4.23: ML2D classification of TFIID RCT dataset by using IMAGIC 
classums as references. (a) The ML2D classification results of TFIID RCT 
dataset are basically the same as their references, which is the IMAGIC 2D MSA 
classums (10th iteration). (b) The similarity between the classification results is 
further confirmed by comparing the classified particles of a representative class 
(#108). 
 
RCT 3D models were reconstructed from all the XMIPP ML2D classes. After 
visual examination, 19 out of 250 TFIID RCT 3D models, with typical horseshoe-like 
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structural features, were selected and filtered to 70 Å as inputs for 3D averaging tests 
(Fig. 4.24). 
 
Figure 4.24: Selected TFIID RCT 3D models as inputs for 3D averaging tests. 
The class numbers are indicated under the corresponding RCT 3D models. The 
scale bar (bottom right) represents 10 nm. 
 
An initial 3D averaging test with two TFIID RCT 3D models generated an 
averaged TFIID 3D model, which is already very similar to the endogenous TFIID 3D 
models. Encouraged by this result, more TFIID RCT 3D models were subjected to 3D 
averaging tests, which generated averaged TFIID 3D models with the same overall 
shape and improved structural features (Fig. 4.25). 
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Figure 4.25: Averaged TFIID 3D models. Averaged TFIID 3D models from (a) 
2, (b) 5, and (c) 14 input TFIID RCT 3D models. Each model is shown in three 
different views as indicated at bottom of panel c (front, bottom, and back). The 
input TFIID RCT 3D models for each averaged TFIID 3D models are listed in the 
table at the bottom. 
 
Reprojections generated by SPIDER showed the missing wedge effect in all the 
three averaged TFIID 3D models. This missing wedge effect was not improved with 
additional input TFIID RCT 3D models. Actually, averaged TFIID 3D model b (from 5 
input models) have more distinct structural features than model c (from 14 input 
models), as evidenced by a careful comparison between their reprojections (Fig. 4.26). 
The missing wedge effect and deterioration of structural features in model c are 
probably due to the fact that most input TFIID RCT 3D models are from classes 
representing only front or back views. 
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Figure 4.26: Comparing averaged TFIID 3D models. In both (a) averaged 
TFIID 3D model b (from 5 input models), and (b) model c (from 14 input models), 
a front view of the 3D model is shown on top. The reprojections (83 in total) are 
show below the corresponding 3D model. Magnified views of four representative 
reprojections (squared in red boxes) from each reprojection series are shown at the 
bottom. 
 
Despite the missing wedge effect, our averaged TFIID 3D models already share 
structural features with previous TFIID 3D models generated from endogenous 
purified TFIID samples. Also, the A and B lobes in our averaged TFIID 3D models are 
enlarged comparing to our refined 9TAF 3D model, suggesting that some of the TFIID 
subunits (MBP-TAF1, TAF7, TAF11/13, TBP) that are incorporated into 9TAF to 
assemble holo-TFIID, are likely to locate in these two lobes (Fig. 4.27) in our 
recombinant holo-TFIID, which is consistent with the proposed subunit architecture in 
endogenous TFIID (Leurent et al., 2004). 
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Figure 4.27: Comparing 3D models of recombinant TFIID complexes with 
endogenous TFIID. Three views (front, bottom, back) of the 3D models are 
shown as indicated at the bottom. The scale bar (bottom right) represents 10 nm. 
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Discussion and perspective 
 
The 2D classification results of TFIID showed that there are still a portion of large 
particles in the TFIID RCT dataset (Fig. 4.23), which are too large for a single TFIID 
complex. Those large particles resulted in class averages/classums of poor quality (no 
distinct structural features). Indeed, RCT 3D models reconstructed from those large 
particles generally contain either a single lobe without any distinct structural feature, or 
scattered small fragments. Those large particles are probably either MBP-TAF1 or 
MBP-TAF1 containing complexes, which did not incorporate all the other TAFs and 
TBP during the TFIID reconstitution, for example the remaining ‘MBP-
TAF1/TAF7/TBP’ complex in TFIID eluates (Fig. 4.18). Also, similar particles and 
class averages/classums have been observed during the negative-stain and single-
particle EM analysis of MBP-TAF1 and MBP-TAF1 containing complexes (see 
chapters 4.2.1-4.2.4). Those MBP-TAF1 containing complexes can be removed by an 
additional purification step by using the N-terminal CBP-tag on TAF5. For that 
purpose, a new MBP-TAF1 construct, with its N-terminal CBP tag removed, has been 
produced in the Berger laboratory and will be used for further improving the purity of 
our TFIID preparation, which is essential for acquiring EM structure of high resolution 
by cryo-EM. 
Besides optimizing the purification of our recombinant TFIID, I will also 
improve the 3D reconstruction of TFIID RCT 3D models with more particles (~10,000, 
untilted view only) and refined backprojection (SPIDER), so as to have a high-quality 
reference model (no missing wedge effect) for reconstructing a TFIID cryo-EM model. 
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Summary and outlook 
 
The ACEMBL system. We have created the ACEMBL system which is the first fully 
automated pipeline for protein complex production that is compatible with robotics. 
Standard protocols and operating procedures have been implemented for multiprotein 
complex expression. This was done first using E. coli as an expression host to develop 
the protocols. Then, the ACEMBL concept was successfully extended to automatable 
HT complex expression in mammalian and insect cells. The availability of its full 
automation routine gives the ACEMBL concept unparallel advantage when processing 
a large number of constructs expressing multiprotein complex variants, which is often 
a crucial prerequisite for analyzing structure and function at high-resolution. For E. 
coli and also eukaryotic expression, the ACEMBL pipeline can already be used in 
automated HT mode not only for multigene cloning and transfer but also for protein 
complex expression and purification, using metal affinity resin in 48 or 96 well format 
and automated sample loading on micro-scale purifiers such as the ÄKTAmicro. For 
baculovirus/insect cell expression, we still need in the near future to miniaturize and 
parallelize the recombinant baculovirus generation and infection of insect cell cultures 
in small but sufficient volumes for meaningful down-stream processing (functional 
tests, analytics, EM). We anticipate that structural and functional analysis of 
multiprotein complexes including X-ray crystallography will greatly benefit from these 
developments in the future. 
The 9TAF complex and TAF3’s role in holo-TFIID assembly. The 3D EM 
reconstructions of 9TAF (with TAF3) and 8TAF (without TAF3) are currently being 
pursued myself (9TAF) and by our collaborator Gabor Papai (Schultz lab, IGBMC) 
(8TAF), respectively. Primary 3D models of both complexes have already been 
reconstructed from RCT datasets (personal communication, Gabor Papai, Schultz lab, 
IGBMC). The localization of TAF3 in the context of 9TAF will be unambiguously 
assigned once the high resolution cryo-EM models are available for both 8TAF and 
9TAF. Meanwhile, I have cloned and expressed various TAF3 truncation variants in 
insect cells and will purify them to homogeneity.  Those TAF3 truncation variants will 
then be incorporated into 9TAF complex variants replacing full-length TAF3 to 
identify the location of the individual subdomains of TAF3 in the context of multi-TAF 
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complexes. I plan to analyze the role of TAF3 in stabilizing TFIID by reconstituting 
TFIID from the MBP-TAF module (TAF1, 7, 11, 13, TBP) and 8TAF, 9TAF or 9TAF 
variants with partial TAF3 protein. The unbound proteins will be removed by extensive 
washes, and the bound proteins will be eluted and analyzed by SDS-PAGE. If TAF3 is 
indeed essential for TFIID assembly, we will observe that 8TAF (lacking TAF3) 
cannot be used to reconstitute a TFIID lacking TAF3. Similarly, if only a certain 
domain of TAF3 is essential for TFIID assembly, we will observe that 9TAF with a 
deletion variant of TAF3 lacking this putative essential TAF3 domain cannot form 
TFIID efficiently. This study will lead to a more comprehensive understanding of the 
assembling mechanism of holo-TFIID and the role of TAF3 in this vital process. 
The complete recombinant human holo-TFIID with a full complement of TAFs 
and TBP. The production of recombinant human holo-TFIID with a full complement 
of TAFs and TBP is the prominent achievement of my thesis work, and compellingly 
validates the remarkable potential of our MultiBac system in producing very 
challenging protein targets. Very recently, our recombinant TFIID has been shown by 
our collaborators, Elisabeth Scheer and Laszlo Tora (IGBMC), to be active in an in 
vitro transcription assay. With fully recombinant, high-quality TFIID in our hands, the 
stage is set for deciphering the structural and functional assembly of this essential GTF. 
Since modifications, truncations and tagging of all TAFs and TBP can be easily 
introduced in our recombinant production platform; we can now study the function of 
individual TAFs, TAF domains and TBP even at single amino acid level in TFIID 
assembly and activity. 
Clearly, the 3D EM reconstruction of the recombinant human holo-TFIID still needs to 
be further optimized for generating a high-quality 3D model from the RCT dataset. 
Also, the current TFIID reconstitution and purification protocol should also be further 
optimized by introducing an additional affinity resin purification step in order to have 
the best possible sample for collecting a cryo-EM dataset, notably to remove excess 
MBP-TAF module which we observed on our current grids. Since the quantity and 
quality of our recombinant TFIID sample are significantly improved comparing to the 
endogenously purified TFIID samples, I am proceeding with confidence to reconstruct 
a TFIID cryo-EM model which is likely to reach much higher resolution and structural 
definition than any previous TFIID 3D models available to date. Together with the 
high-resolution EM models of TFIID subcomplexes, and by using hybrid methods 
including X-ray structures and homology models, the complete subunit architecture of 
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human TFIID will be fully revealed. TFIID has been shown to interact with many 
factors including activators (p53, Sp1, VP-16, ER, ATF7, etc) and, importantly, also 
epigenetically modified chromatin. Our work sets the stage to address these 
interactions by using highly purified TFIID, activators and modified nucleosomes, to 
acquire, by using the methods described in this thesis, unprecedented insight into the 
intricate machinery regulating gene transcription in humans. 
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Résumé et perspectives 
 
Le system ACEMBL. Nous avons créé le system ACEMBL, premier protocole 
compatible pour la production de complexes protéiques. Des procédures d’opération 
standard ont été spécifiquement mises en place pour permettre l’expression de ces 
complexes multi-proteiques. L’utilisation d’E. coli a tout d’abord permis de développer 
ces protocoles, puis ils ont été étendus à l’expression haut-débit et automatisée en 
cellules mammifères et en cellules d’insectes. Cette automatisation offre l’avantage 
considérable de pouvoir traiter en parallèle un grand nombre de construits codant pour 
des variants de complexes multi-protéiques. Or cette démarche est souvent cruciale 
pour l’analyse structurale et fonctionnelle haute-résolution. Cette plateforme peut 
d’ores et déjà être utilisée dans un mode haut débit, pour E. coli et les organismes 
eucaryotes, non seulement pour le clonage et la manipulation multi-génique, mais 
également pour l’expression et la purification de complexes protéiques, en utilisant par 
exemple une résine d’affinité par immobilisation de métal dans un format 48 ou 96 
puits, et un chargement automatisé sur des instruments de purification tels que 
l’ÄKTAmicro. S’agissant de l’expression en cellules d’insectes (via le baculovirus), 
une miniaturisation du procédé de préparation du baculovirus, ainsi que de la 
transfection et de l’infection des cellules doit être mise en place dans des volumes 
permettant d’effectuer tous les tests voulus jusqu’à la microscopie électronique. Nous 
pressentons que l’analyse fonctionnelle et structurale par cristallographie aux rayons X 
de complexes multi-protéiques profitera grandement à ces projets de développement. 
Le complexe 9TAF et le rôle de TAF3 dans l’assemblage de holo-TFIID. Les 
reconstructions tridimensionnelles par microscopie électronique des complexes 8TAF 
(sans TAF3) et 9TAF (comprenant TAF3) sont actuellement en cours de réalisation et 
respectivement traitées par notre collaborateur Gabor Papai (équipe Schultz, IGBMC) 
et moi-même. Des modèles primaires tridimensionnels ont déjà été établis d’après un 
ensemble de données RCT (communication personnelle, Gabor Papai, équipe Schultz, 
IGBMC). La localisation de TAF3 au sein du complexe 9TAF sera clairement établie 
dès lors que des modèles de cryo-microscopie électronique haute résolution seront 
disponibles pour 8TAF et 9TAF. J’ai, en parallèle, cloné et exprimé en cellules 
d’insectes une multitude de variants tronqués de TAF3 que je purifierai bientôt. Ces 
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variants tronqués de TAF3 seront ensuite incorporés dans des variants du complexe 
9TAF ou ils remplaceront le TAF3 originel et permettront de déterminer la localisation 
de chaque sous-domaine de TAF3 au sein de complexes multi-TAFs. J’ai prévu 
d’analyser le rôle de TAF3 dans la stabilisation de TFIID en reconstruisant TFIID à 
partir du module MBP-TAF (TAF1, 7, 11, 13, TBP) et 8TAF, 9TAF ou des variants de 
9TAF comprenant une version tronquée de TAF3. Les protéines non fixées seront 
éliminées par des étapes de lavages, et les protéines fixées seront éluées et analysées 
par SDS-PAGE. Si TAF3 est effectivement essentiel pour l’assemblage de TFIID, il 
apparaitra que 8TAF (sans TAF3) ne pourra pas être utilisé pour reconstituer un 
complexe TFIID dépourvu de TAF3. Suivant le même raisonnement, si seul un certain 
domaine de TAF3 est essentiel pour l’assemblage de TFIID, alors cet assemblage ne 
pourra pas être réalise par un 9TAF à qui l’on aura associé le variant tronqué de TAF3, 
délestée dudit domaine. Cette étude conduira à une meilleure compréhension du 
mécanisme assemblage de holo-TFIID et du rôle de TAF3 dans ce processus vital. 
L’holo-TFIID humain recombinant à partir de TAFs et TBP. La production du 
complexe recombinant holo-TFIID humain à partir des TAFs et de TBP individuels est  
indéniablement la réalisation la plus importante de ma thèse, et valide de ce fait le 
remarquable potentiel du system MultiBac à produire des candidats protéiques d’un 
abord difficile. Encore récemment, nos collaborateurs Elisabeth Scheer et Laszlo Tora 
(IGBMC) ont montré que notre TFIID recombinant était actif lors d’un test de 
transcription in vitro. Fort de ce TFIID recombinant, nous allons pouvoir commencer à 
déchiffrer le processus d’assemblage de ce facteur de transcription général. 
L’introduction de modifications telles que des troncations et des marquages sur les 
TAFs et TBP va nous permettre d’étudier l’implication de chaque protagoniste et de 
ses domaines dans l’assemblage et l’activité de TFIID, et ce à l’échelle de l’acide 
aminé. Bien entendu, la reconstruction tridimensionnelle du holo-TFIID humain 
recombinant doit encore être optimisée de façon à générer un modèle de haute qualité 
d’après l’ensemble de données RCT. De même, le protocole actuel de reconstitution et 
de purification devrait également être optimisé en ajoutant une étape supplémentaire de 
purification par résine d’affinité. Ceci devrait permettre d’éliminer l’excès de module 
MBP-TAF observé sur nos dernières grilles, et ainsi d’obtenir une meilleure qualité 
d’échantillon pour collecter des données de cryo-microscopie électronique. Par ailleurs, 
étant donné que la qualité et la quantité de notre TFIID recombinant sont bien 
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meilleures que celles obtenues après purification du TFIID endogène, il est raisonnable 
de penser que la résolution du modèle de TFIID que je suis en train d’établir par cryo-
microscopie sera meilleure qu’aucune autre jamais atteinte pour un modèle 
tridimensionnel de TFIID. En combinant les modèles haute résolution des sous-
complexes de TFIID, et l’utilisation des structures aux rayons X et des modèles 
d’homologie, nous parviendrons à définir l’architecture détaillée du TFIID humain. Il a 
été démontré que TFIID interagit avec de nombreux facteurs, parmi lesquels des 
activateurs (p53, Sp1, VP-16, ER, ATF7, etc.) et de la chromatine ayant subi des 
modifications épigénétiques. L’identification de ces interactions sera rendue possible 
en utilisant notre TFIID hautement purifié, ces activateurs, ainsi que des nucléosomes 
modifiés. L’application des méthodes décrites ici nous permettra ainsi d’avoir un 
aperçu inédit du fonctionnement de la de machinerie de régulation de la transcription 
chez l’homme. 
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Chapter 5: Materials and methods 
 
5.1 DNA methods 
 
DNA constructs used in this work were subcloned by using the methods described in 
Publication 5 below (in press, manuscript format), and also in Publication 3 
(Supplementary Material) and 4 (chapter 1). 
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Tandem recombineering by SLIC cloning and Cre-LoxP fusion to generate multigene 
expression constructs for protein complex research. 
 
Matthias Haffke, Cristina Viola, Yan Nie and Imre Berger. 
 
Methods in Molecular Biology, in press. 
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Résumé de la publication 
 
Un protocole robuste pout générer de l’ADN recombinant contenant l’expression de 
plusieurs gènes en utilisant SLIC (sequence and ligation independent cloning) suivit 
par une recombinaison en tandem via Cre-LoxP de plusieurs plasmides pour 
l’expression et l’étude multi protéique de complexe est décrite. Le protocole 
comprends l’amplification par PCR (polymerase chain reaction) des gènes désires, 
l’insertion immédiate dans le vector cible via SLIC et recombinaison Cre-LoxP du 
plasmide accepteur et donneur, avec option robotisée. Cette procédure, appelée 
«recombinaison en tandem», a été implémente pour l’expression de plusieurs multi 
protéines chez E. coli et cellules mammifères, et également pour les cellules d’insecte 
en utilisant un baculovirus recombinant. 
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Summary 
A robust protocol to generate recombinant DNA containing multigene expression cassettes by using 
sequence and ligation independent cloning (SLIC) followed by multiplasmid Cre-LoxP recombination 
in tandem for multiprotein complex research is described. The protocol includes polymerase chain 
reaction (PCR) amplification of the desired genes, seamless insertion into the target vector via SLIC 
and Cre-LoxP recombination of specific donor and acceptor plasmid molecules, optionally in a robotic 
setup. This procedure, called tandem recombineering, has been implemented for multiprotein 
expression in E.coli and mammalian cells, and also for insect cells using a recombinant baculovirus. 
1. Introduction 
High flexibility and diversity in cloning techniques are essential aspects for the creation of multigene 
constructs and multiprotein assemblies in synthetic biology (1). Common techniques used to insert 
PCR products into vectors for gene expression are restriction enzyme dependent cloning (2), blunt end 
cloning (3) and Gateway cloning (4). However, such cloning techniques possess limitations due to the 
requirements for specific DNA sequences and/or restriction enzyme sites and are therefore not feasible 
for high-throughput applications or automation. Since SLIC removes the requirement for specific 
DNA sequences and furthermore does not require restriction enzyme sites, it is more suitable for 
integration in an automated setup (5, 6). 
In a typical SLIC reaction, the gene of interest (GOI) is amplified using primers which provide a 
homology sequence to the vector on their 5’ sites, followed by a GOI specific sequence (Fig. 1). 
Primers for the creation of multigene constructs are designed in a similar way, providing a 
complementary sequence to the 5’ adjacent GOI or to the homology sequence of the vector (Fig. 2). 
Primers for linearization of the vector are complementary to the homology sequences chosen in the 
GOI primers. The PCR products and the linearized vector are treated with T4 DNA polymerase, which 
exhibits 3’ exonuclease activity in the absence of dNTPs to generate 5’ overhangs. In vitro 
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recombination is achieved by annealing of the T4 DNA polymerase treated fragments and 
transformation of competent E.coli cells with the reaction mix. 
The combination of SLIC with Cre-LoxP recombination of specific acceptor and donor plasmids in 
vitro, called tandem recombineering, further increases versatility and flexibility of the generation of 
multigene constructs for multiprotein expression. The ACEMBL technology is available for E.coli 
(MultiColi) (6, 8), mammalian cells (MultiMam) (9) and insect cells via a recombinant baculovirus 
(MultiBac) (7, 10) (Tab. 1). Both acceptor and donor plasmids contain LoxP sites for recombination 
via Cre recombinase in vitro. Acceptor plasmids can be recombined with multiple donors to create 
fused plasmids for multiprotein expression (Fig. 3). Since donor plasmids carry a conditional origin of 
replication (R6Kg), they are only propagated in pir positive E.coli strains or after fusion with 
one/multiple acceptor plasmids in conventional cloning (pir negative) strains (6, 8). This, in 
combination with different antibiotic resistances, (Tab. 1) allows for specific selection of the desired 
Cre-LoxP recombined multiplasmid constructs. The methods described here were optimized to be 
integrated in an automated robotic setup with a liquid handling system (6). 
2. Materials 
All solutions should be prepared using ultrapure water (Millipore Milli-Q system or equivalent; 
conductivity of 18.2 MΩ·cm at 25°C) and analytical grade reagents. Store all buffers, antibiotics and 
enzymes at -20°C. 
2.1 Preparation of vector  
1. LB Broth (Miller, cat. no. 0103) 
2. Purified Agar Agar (Euromedex, ref. 1329-D) 
3. Sterile polystyrene Falcon tube (15 ml) 
4. QIAprep Spin Miniprep Kit (Qiagen, cat. no. 27104) 
5. Antibiotics: Ampicillin, Chloramphenicol, Spectinomycin, Tetracycline, Gentamycin, 
Kanamicin (see Note 1) 
2.2 PCR and linearization of vector 
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1. Phusion High-Fidelity DNA Polymerase (Thermo Scientific, kit cat. no. F-530S) 
2.  5xPhusion HF Buffer (included in kit) 
3. 10 mM dNTP mix (New England Biolabs Inc., cat. no. N0447S) 
4. Thermocycler (e.g. Biometra GmbH, Thermocycler T3000) 
2.3 Dpn1 digest 
1. Dpn1 (New England Biolabs Inc., cat. no. R0176S) 
2. 10x NEBuffer 4 (included in kit) 
3. 37°C water bath 
4. Qiagen spin column (QIAquick Gel Extraction Kit, cat. no. 28704) 
5. Qiagen buffers (included in kit) 
6. Agarose gel electrophoresis system (e.g. BioRad, Mini-Sub Cell GT System) 
7. 5x TBE Buffer: 0.89 M Tris base, 0.89 M boric acid, 20 mM EDTA (pH 8.0) (see Note 2) 
8. Agarose Type D-5 DNA-grade (Euromedex, ref. D5-D) 
9. 6x DNA Loading Dye: 30% (v/v) glycerol, 0.125% (w/v) bromophenol blue, 0.125% (w/v) 
Xylene cyanol FF (see Note 3) 
10. 1 kb DNA Ladder (New England Biolabs Inc., cat. no. N3232S) (see Note 4) 
2.4 T4 DNA Polymerase treatment 
1. T4 DNA Polymerase (New England Biolabs Inc., cat. no. M0203S) 
2. NEBuffer 2 (included in kit) 
3. 2M Urea 
4. 500 mM EDTA (see Note 5) 
5. 75°C Heat Block 
2.5 SLIC annealing 
1. 65°C heat block 
2.6 Transformation of chemical competent cells 
1. BW23474 chemical competent cells or equivalent 
2. 42°C waterbath 
3. LB Broth (Miller, cat. no. 0103) 
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4. 37°C shaking incubator 
2.7 Cre-LoxP recombination 
1. Cre Recombinase (New England Biolabs Inc., cat. no. M0298S) 
2. 10x Cre Recombinase Reaction Buffer (New England Biolabs Inc., cat. no. B0298S) 
3. 37°C water bath 
 
3. Methods 
3.1 Preparation of vector 
1. Inoculate 5 ml of LB broth containing appropriate antibiotics in a 15 ml Falcon tube from a 
glycerol stock of E.coli cells containing the desired vector. Incubate at 37°C, agitating at 
150 rpm for 12 h. Concentrations for antibiotics: Ampicillin 50 µg/ml, Chloramphenicol 
34 µg/ml, Spectinomycin 100 µg/ml Tetracycline 12.5 µg/ml, Gentamycin 10 µg/ml, 
Kanamicin 30 µg/ml. 
2. Centrifuge the Falcon tubes for 10 min at 5,000 x g at 4°C. Take off the supernatant and invert 
the Falcon tubes to drain.  
3. Perform a plasmid prep using the QIAprep Spin Miniprep Kit and follow the instructions in 
the product’s manual.  
4. Determine the concentration of the extracted DNA spectrophotometrically (e.g. Thermo 
Scientific NanoDrop 2000). 
3.2 PCR and linearization of vector 
1. Identical PCR reactions are set up for amplification of the desired insert and linearization of 
the vector. 
2. Set up a 100 µl PCR reaction in a 0.5 ml PCR tube: Mix 1 µl template DNA (approximately 
10 ng) with 20 µl 5x Phusion HF Buffer (see Note 6), 2 µl 10 mM dNTP mix, 1 µl of forward 
primer (concentration 100 µM), 1 µl of reverse primer (concentration 100 µM) and 74.5 µl 
water. 
3. Add 0.5 µl Phusion High-Fidelity DNA Polymerase and mix (see Note 7). 
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4. Choose appropriate annealing temperatures for the specific primers chosen to perform the 
PCR (see Note 8). Typically, templates are initially denatured at 98°C for 60 s; followed by 30 
cycles at 98°C for 20 s, the specific annealing temperature for 30 s, 72°C for 30 s (for 1 kb 
product size); and a single final step at 72°C for 10 min. 
3.3 Dpn1 digest and purification of PCR product and linearized vector 
1. Add 20 U of Dpn1 directly to the 100 µl PCR product and incubate at 37°C for 2 h (see 
Note 9). This step is not required for insert PCR reactions if the resistance marker of the 
template plasmid differs from the destination vector. 
2. Mix with 20 µl 6x DNA loading dye, load on 1% TBE agarose gel and run the gel at 100 V 
(see Note 10) for around 1.5 h until the 1 kb DNA ladder is well resolved.  
3. Excise the band corresponding to the PCR product using a UV light box and transfer to a 2 ml 
sterile Eppendorf tube (see Note 11).  
4. Extract the DNA from the gel slices using the QIAquick Gel Extraction Kit following the 
instructions in the product’s manual. 
5. Determine the concentration of the extracted DNA spectrophotometrically (e.g. Thermo 
Scientific NanoDrop 2000). 
3.4 T4 DNA Polymerase treatment of PCR product and linearized vector 
1. Set up the reaction in a 0.5 ml PCR tube: Mix 2 µl 10x NEBuffer 2, 1 µl 100mM DTT, 2 µL 
2M Urea, 0.5 U T4 DNA Polymerase and 1 µg of the purified PCR product (see Note 12) in a 
total volume of 20 µl. For a 20 bp overhang between PCR product and vector, incubate for 
30 min at room temperature (see Note 13).  
2. Stop the reaction by adding 1 µL of 500 mM EDTA. 
3. Inactivate T4 DNA Polymerase by heating to 75°C for 20 min. 
3.5 SLIC annealing 
1. Set up the reaction in a 0.5 ml PCR tube: Mix 10 µL of the T4 DNA polymerase treated vector 
with 10 µL of T4 DNA polymerase treated insert. 
2. Incubate at 65°C for 10 min and let cool down slowly in the heat block at RT. 
3.6 Transformation of chemical competent cells 
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1. Mix 5 µl of the annealing reaction with 50 µl of BW23474 chemical competent cells on ice 
and incubate for 30 min, heat shock at 42°C for 60 s, incubate on ice for 2 min, add 400 µl of 
LB Broth and incubate in a 37°C shaker for 1 h. 
2. Plate 100 µl of the cells on a selective LB agar plate with appropriate antibiotic(s), pellet the 
remaining cells by centrifugation at 4,000 x g for 1 min, take off 250 µl supernatant and 
resuspend the pellet in the remaining 100 µl. Plate this concentrated cell suspension cells on a 
second LB agar plate. 
3.7 Cre-LoxP recombination of Acceptor and Donor vectors 
1. Set up a 10 µl Cre-LoxP recombination reaction in a 0.5 ml PCR tube: Mix 1 µg of Donor 
vector with a 1:1 molar ratio of Acceptor, 1 µl 10x Cre Recombinase Reaction Buffer and 
0.5 µl Cre Recombinase in a 10 µl total reaction volume.  
2. Incubate the reaction at 37°C for 1 h (see Note 14). 
3.8 Transformation of chemical competent cells 
1. Mix 5 µl of the Cre-LoxP recombination reaction with 50 µl of BW23474 chemical competent 
cells on ice and incubate for 30 min, heat shock at 42°C for 60 s, incubate on ice for 2 min, 
add 400 µl of LB Broth and incubate at 37°C for overnight (see Note 15). 
2. Plate 100 µl of the cells on a selective LB agar plate with appropriate antibiotic(s), pellet the 
remaining cells by centrifugation at 4,000 x g for 1 min, take off 250 µl supernatant and 
resuspend the pellet in the remaining 100 µl. Plate the remaining cells on a second LB agar 
plate. 
 
4. Notes 
1. Carbenicillin can be used as a substitute for Ampicillin (at the same concentration) to reduce 
presence of satellite colonies. Concentration of stock solutions (1000x): Ampicillin 50 mg/ml 
in water, Carbenicillin 50 mg/ml in 50% ethanol, Chloramphenicol 34 mg/ml in ethanol, 
Spectinomycin 10 mg/ml in water, Tetracycline 12.5 mg/ml in 70% ethanol, Gentamycin 
10 mg/ml in water, Kanamicin 30 mg/ml in water. 
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2. Weigh 108 g Tris base (MW: 121.10 g/mol) and 55 g boric acid (MW: 61.83 g/mol) and add 
40 ml of 0.5 M EDTA, pH 8.0 in a 2-L graduated cylinder. Having water on the bottom of the 
cylinder (~400 ml) and stirring while adding Tris base and boric acid helps to dissolve these 
components. Fill up to a total volume of 2 L with water. Filter through 0.22 µm filter and 
autoclave to prevent precipitation during long-term storage. Store at room temperature. 
3. Add 0.125% Orange G to the 6x DNA Loading Dye if working with small PCR products. 
Orange G migrates at about 50 bp in 1% TBE agarose gels and helps to determine the time 
needed for electrophoresis. 
4. For smaller PCR products use a 100 bp DNA ladder (New England Biolabs Inc., cat. no. 
N3231S) to identify fragments in the range of 100 bp to 1 kbp more easily.  
5. Weigh 73.06 g EDTA (MW: 292.24 g/mol), add 400 mL of water and adjust pH to 8.0. EDTA 
will not dissolve until the pH is adjusted to 8.0. Top up to a total volume of 500 mL. Filter 
through a 0.22 µm filter and store at room temperature. 
6. When using the Phusion High-Fidelity DNA Polymerase kit, the 5x GC buffer can help to 
increase the performance of Phusion High-Fidelity DNA Polymerase on long or GC rich 
templates. When working with GC rich templates, add 3%DMSO as a PCR additive to aid 
denaturing of templates with high GC content. It is practical to run two PCR reactions with 
HF and GC buffer in parallel and compare yield and PCR product specificity for both 
reactions. 
7. Mix by pipetting or flipping the tube. Centrifuge for 10 s at 4,000 x g to collect the mix on the 
bottom of the PCR tube. No bubbles should remain in the tube. 
8. When using the Phusion High-Fidelity DNA Polymerase kit, calculate the annealing 
temperature with the manufacturer’s Tm calculator tool on the website: 
http://www.finnzymes.fi/tm_determination.html 
9. This is a critical step to reduce background colonies after transformation. The Dpn1 digest can 
be incubated longer than 2 h (e.g. overnight) to reduce background colonies. 
10. Depending on the gel system used the voltage might be increased up to 120 V to reduce 
separation time. Increasing the voltage can result in heating up and melting the agarose gel. 
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11. 1.5 ml Eppendorf tubes can be used in this step as well, depending on size of the gel slice. 
When excising the desired band from the agarose gel, use longer wavelength (e.g. 365 nm or 
equivalent) and reduced intensity on the UV lightbox to avoid any modifications to your PCR 
product. 
12. It is important to purify the desired PCR products as described before the T4 DNA Polymerase 
treatment as residual dNTPs from the PCR reaction inhibit the 3’ exonuclease activity of the 
T4 DNA Polymerase.  
13. The incubation time is a critical step for T4 DNA Polymerase treatment. A too short 
incubation time will result in non-overlapping overhangs between PCR product and vector and 
impede correct annealing. 
14. Longer incubation times will likely lead to undesired higher molecular weight recombination 
products.  
15. Long recovering times are essential to obtain positive transformants, especially when creating 
multiple acceptor-donor fusions due to the high selective pressure from the combination of 
antibiotics used. 
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Figures: 
 
 
Fig. 1. Schematic overview of single- and multigene SLIC reactions. Genes of interest (A, B, C) are 
shown as colored boxes. 5’ sites in primers and T4 DNA polymerase treated PCR products are 
indicated. Regions of homology are indicated by different grayscales. Inset: schematic representation 
of the primer design for SLIC reactions. The homology sequence should be 20 bp long, a similar 
length should be chosen for the GOI specific sequence. 
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Fig. 2. Examples for primer design for single- and multigene SLIC reactions. Complementary 
sequences to GOIs and vectors are indicated by lines, as well as 5’ and 3’ sites. Homology regions for 
multi SLIC reactions are shown in different grayscales. The sequences shown do not refer to a specific 
vectors or GOIs and need to be changed accordingly. 
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Fig. 3. Schematic representation of the Cre-LoxP recombination process. The Cre recombination 
process is an equilibrium reaction and gives rise to all combinations of the acceptor (A) and donor (D) 
fusions. One acceptor can be fused with multiple donors. Desired acceptor-donor fusions (A-D1 / A-
D2 / A-D1-D2) are selected via specific antibiotics (colored boxes). The process of Cre-LoxP 
recombination is reversible (De-Cre reaction). LoxP sites are shown as red balls. Adapted from (11). 
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Tab 1. Overview of available ACEMBL systems showing all acceptor and donor plasmids for 
prokaryotic (MultiColi), mammalian (MultiMam) and baculovirus expression (MultiBac). 1 For 
reagents contact: iberger@embl.fr  
 
                                                          
1
 Reprinted from: Robots, pipelines, polyproteins: enabling multiprotein expression in prokaryotic and 
eukaryotic cells, 175(2), Vijayachandran, L.S., Viola, C., Garzoni, F., Trowitzsch, S., Bieniossek, C., Chaillet, 
M., Schaffitzel, C., Busso, D., Romier, C., Poterszman, A., Richmond, T.J. and Berger, I., pages 198-208, 
Copyright 2011, with permission from Elsevier. 
Thesis  Chapter 5 
Yan NIE  Materials and methods 
     114 
5.2 Insect cell expression methods 
 
Proteins that I purified for this work were all expressed in Sf21 cells, an insect cell line 
originally cloned from pupal ovarian tissue of the Fall Armyworm Spodoptera 
frugiperda (Vaughn et al., 1977).  
The insect cell expression methods used for this work are briefly outlined below 
and further details can be found in methods published by the Berger laboratory 
(Fitzgerald et al., 2006; Bieniossek et al., 2008).  
All insect cell culture handling was carried out in sterile hoods in EMBL’s 
Eukaryotic Expression Facility (EEF), a fully equipped insect cell culture room with 
constant temperature kept at 27°C. 
 
5.2.1 Maintain insect cell cultures in suspension 
 
Sf21 cells were maintained in screw-capped Erlenmeyer ﬂasks (250 mL to 2 L volume, 
Pyrex) on table-top shakers at the cell densities between 0.5 × 106 and 2 × 106 cells/mL 
(ideally around 1 × 106 cells/mL). Densities below 0.5 × 106 cells/mL are not 
recommended because cells divide more slowly, and densities above 2 × 106 cells/mL 
were avoided since cells in this case are too dense to receive good aeration. 
The cell density was counted manually with a Neubauer counting chamber and a 
light microscope. Since the cell doubling time is approximately 18-20 hours, the cells 
were diluted using the Hyclone SFM4Insect media (Thermo Scientific) or SF900 II 
SFM serum free media (Gibco Life Technologies, Invitrogen) every 24-48 hours. The 
volume of the cell culture was usually between 1/20 and 1/5 of the shaker flask volume, 
to avoid drying-out (with smaller volumes) or poor aeration (with larger volumes), 
respectively (Fitzgerald et al., 2006). 
Cells from one initial stock were cultured and propagated for approximately 3 
months, since then the cell viability started to decrease, as seen from the visual 
examination using the light microscope. Healthy, viable cells have a round and regular 
shape, while old cultures exhibit cells that tend to increase in size (polyploidy cells) or 
develop different irregular shapes with a lot of cell debris present in the culture. 
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5.2.2 Production of recombinant bacmid 
 
The transfer vectors were generated by subcloning gene(s) of interest into individual 
MultiBac vectors by a variety of methods (restriction/ligation or ligation independent 
cloning such as SLIC), which were then fused by in vitro Cre-LoxP reactions, using 
the DNA handling methods described above. The resulting constructs were then used 
for the transformation of competent DH10MultiBac E. coli cells, which contain the 
bacmid and a helper plasmid that encodes for Tn7 transposase complex. The Tn7 
transposase complex catalyzes the Tn7 transposition reaction of the expression 
cassette(s) together with a gentamicin resistance marker (present between Tn7L and 
Tn7R sites) from the transfer vector into the Tn7 attachment site on the bacmid to 
generate recombinant bacmids. DH10MultiBac E. coli cells contain the original 
MultiBac virus as a BAC, (Berger et al., 2004). DH10EMBacY E. coli cells contain the 
MultiBac virus with a YFP (as a marker protein) encoding gene, inserted in the 
backbone (Trowitzsch et al., 2010). The cell/DNA mixture treated by heat shock (or 
electroporation) was incubated in a 37°C shaking incubator overnight (12-16 hours) to 
allow efficient transposition to occur. After the incubation, four serial dilutions of the 
cell/DNA mixture were streaked out on two LB/agar plates containing gentamicin, 
kanamycin, tetracycline, IPTG and Bluo-gal. The plates were incubated at 37°C for 24 
to 48 hours till the blue and white colonies can be clearly differentiated by eyes. 
Four to eight white colonies were picked and restreaked on the same type of 
LB/agar plates to confirm they are positive. Four confirmed white colonies were 
inoculated in 2 mL of LB medium supplemented with gentamicin, kanamycin, and 
tetracycline. After overnight incubation, two to four of the cell cultures were used for 
bacmid purification by alkaline lysis followed by isopropanol precipitation. Each 
bacmid pellet was washed and kept in 70% ethanol solution before being used for 
transfecting Sf21 cells. 
 
5.2.3 Transfection of Sf21 cells 
 
Under a sterile hood, the 70% ethanol supernatant was removed from the bacmid 
pellets by pipetting with care. The bacmid pellets were then air-dried for 10 minutes 
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and resuspended with 30 µL sterile Milli-Q water by gentle tapping (no pipetting since 
bacmid might be disrupted by shear force) and then incubated for 10 minutes, during 
which each 35 mm well (on a BD Falcon 6-well plate) was seeded with 0.7-1.0 × 106 
Sf21 cells and diluted to a final volume of 2.5-3.0 mL with fresh medium. The cells 
were allowed to attach to the plate by incubating for 15-30 minutes, during which 
transfection mixture for each bacmid solution was prepared by first diluting 10 µL 
transfection reagent (X-tremeGENE HP DNA Transfection Reagent, Roche) in 100 µL 
fresh medium and then adding 20 µL bacmid solution and 200 µL fresh medium. This 
transfection mixture was then incubated for 15-30 minutes and used to transfect two 
wells of insect cells by adding 150 µL aliquot to each. 
Normally on a 6-well plate, four wells were used for transfections with two 
bacmid solutions (from two different white colonies). For the remaining two wells, one 
was used for the non-transfected cells (as a negative transfection control) and the other 
was filled with 3 mL fresh medium (as a medium control in case of contamination). 
The cells were then incubated in the dark for 48-60 hours before the supernatant was 
harvested as the initial virus stock (V0 virus) for further amplifications (Trowitzsch et 
al., 2010). 
To evaluate progression of cell infection and confirm successful heterologous 
protein expression in the transfected cells, 3 mL of fresh medium was added to each 
well immediately after removal of V0. After 3-4 additional days of incubation, cells 
were lysed and assayed for protein expressions by SDS-PAGE and/or Western blot 
analysis. 
 
5.2.4 Virus amplification and protein expression 
 
Since the amount of infective viral particles in V0 is not sufficient for large-scale 
protein expression, ~3 mL of the harvested V0 was used immediately to infecting 25-
50 mL Sf21 cell suspension freshly diluted to a density of ~0.7 × 106 cells/mL in a 
250/500 mL Erlenmeyer ﬂask. To avoid accumulation of defective viruses, a low MOI 
was ascertained by allowing at least one doubling of the infected cells after addition of 
V0, otherwise the V0 infection step was repeated with less V0 virus. The cell density of 
the infected cell culture was maintained between 0.5-1.0 × 106 cells/mL by counting 
and diluting, if necessary, every 24 hours. After cell proliferation arrest, cell probes 
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containing 1.0 × 106 cells were taken every 24 hours and used for following and 
estimating the protein expression level by measuring YFP ﬂuorescence signal(s). 
Concomitantly, this amplified virus (V1) was harvested 48-60 hours after cell 
proliferation arrest and fresh medium was supplemented to the cells. Finally, cells were 
harvested when YFP signal reached a plateau (typically after 3–4 days), and protein 
production was analyzed by SDS-PAGE and pilot purifications in small batches. 
The V1 (25-50 mL) is generally sufficient to infect ~10-50 L of cell cultures at 
the density of ~0.7 × 106 cells/mL by repeating the procedures outlined above for 
generating V1. Typically, 1-100 mg of purified recombinant protein/protein complex 
can be obtained from 1L infected cell culture. When larger production scale and/or 
longer virus storage time (V1 can be stored up to 1 year when kept at 4°C in the dark) 
were desired, V1 was further amplified by infecting 400 mL cell cultures at the density 
of ~0.7 × 106 cells/mL in 2L Erlenmeyer flasks, before which the optimal V1/cell 
culture ratio for infection was roughly estimated by infecting three 25 mL cell cultures 
with 2.5 µL (1:10,000), 25 µL (1:1,000), and 250 µL (1:100) V1. This infected cell 
culture (V2) was then harvested at ~24 hours after cell proliferation arrest and used for 
preparing baculovirus-infected insect cell (BIIC) aliquots stored in liquid nitrogen 
(Wasilko et al., 2009). By applying the BIIC method for virus storage, uncompromised 
infectivity of the recombinant baculovirus can be preserved for years. 
 
5.3 Protein methods 
 
Proteins that I purified for this work were all expressed in insect cells (Sf21). Therefore, 
only insect cell-relevant preparation procedures are described below. 
 
5.3.1 Preparation of insect cell cytosolic and nuclear soaking fraction 
 
Insect cell cytosolic or nuclear fraction was prepared for subsequent protein 
purification steps depending on the localization (cytosol or nucleus) of the protein of 
interest. 
The cell pellets (stored in 15/50 mL Falcon tubes in a -80°C freezer) were thawed 
at room temperature and resuspended in 5-10 cell pellet volumes of lysis buffer of low 
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ionic strength (100-150 mM KCl). The resuspended cells were pipetted up and down 
till homogeneity and then frozen again in liquid nitrogen. This freeze-thaw procedure 
was repeated once or twice to ensure complete disruption of the cell membrane but 
keep the nuclei intact. 
Afterwards, the cell resuspension was centrifuged at top speed in a cooling table-
top centrifuge (4°C, 10 minutes) to separate pellet contained the nuclei and supernatant 
represented the crude cytosolic fraction. According to the localization of the protein of 
interest, purification was either continued with the cytosolic fraction, or the nuclear 
soaking fraction, which was prepared as outlined below: 
The nuclei were washed with 10 nuclei volumes of lysis buffer for four times 
before resuspended in 10 nuclei volumes of nuclear soak buffer, which is of high ionic 
strength (400 mM KCl). This nuclei resuspension was then incubated under gentle 
agitation for 3-5 hours to allow nuclear proteins to be soaked out. Afterwards, the 
nuclei resuspension was centrifuged at top speed in a cooling table-top centrifuge (4°C, 
10 minutes) to separate pellet contained the soaked nuclei and supernatant represented 
the crude nuclear soaking fraction containing soaked-out protein of interest (a detailed 
nuclear soaking protocol can be found in chapter 5.3.4 below). 
Both the crude cytosolic fraction and crude nuclear soaking fraction were further 
centrifuged using a 70 Ti rotor (Beckman Coulter) in a Beckman ultracentrifuge at 
20,000 rpm (~40,000 g) for 45-60 minutes before subsequent purification steps. 
 
5.3.2 Batch protein purification 
 
Batch purification method was generally used for establishing optimal purification 
protocols for protein/protein complex of interest, since it requires less samples (a  cell 
pellet from a 50 mL V1 amplification is normally sufficient for two or more batch 
purifications in Eppendorf tubes) and is more practical for handling multiple 
purifications in parallel (testing different buffer conditions). 
The chosen chromatography resin was placed into a 1.5 mL Eppendorf tube in 
the volume of 50-200 µL (15/50 mL Falcon tubes were used for larger resin volumes). 
The resin was equilibrated with the binding buffer by mixing and centrifuging in a 
table-top centrifuge (1-2,000 g, 1-2 minutes, 4°C or room temperature). The 
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supernatant was carefully removed without disturbing the resin. Cytosolic or nuclear 
soaking fraction (input sample) was mixed with the resin and then incubated under 
gentle agitation from several hours to overnight for efficient binding. The unbound 
sample was separated by centrifugation and stored separately on ice (flow through 
sample), whereas the resin was washed five times by 5-10 resin volumes of binding 
buffer and/or high salt buffer (washing samples). The bound protein was then eluted 
two to four times with 1-2 resin volumes of elution buffer (elution samples). After the 
elution, the resin was resuspended with 2 resin volumes of elution buffer and mixed 
with SDS gel loading buffer (resin sample), which was analyzed together with other 
SDS gel samples representing various batch purification fractions (input sample, flow 
through sample, washing samples, elution samples, and resin sample) by SDS-PAGE. 
Our holo-TFIID was reconstituted and purified by batch purification using 
amylose resin (New England Biolabs), which is described in details in chapter 5.3.4. 
 
5.3.3 High-performance liquid chromatography (HPLC) method 
 
Once an optimal purification protocol was established for protein/protein complex of 
interest, HPLC experiments were carried out with ÄKTA HPLC systems (GE 
Healthcare Life Sciences) for stepwise large-scale protein purification. The purity of 
protein samples generally reached crystallography grade (>90% purity judged by SDS-
PAGE) after a three-step HPLC purification routine: IMAC (with an ÄKTAprime) 
followed by IEX and SEC (with an ÄKTAbasic or ÄKTApurifier). 
The protein solution to be purified by IMAC was generally the cytosolic fraction 
from a pellet of ~1L insect cell culture, which was prepared as described in chapter 
5.3.1 before loading onto 1-2 mL equilibrated TALON resin packed in a GE XK16/20 
column (GE Healthcare Life Sciences) to allow sample binding. The TALON was then 
washed first by 10-20 resin volumes of binding buffer, followed by 10-20 resin 
volumes of high salt buffer (1M NaCl), and finally 10-20 resin volumes of binding 
buffer. The bound protein/protein complex was eluted with 50-100 resin volumes of 
binding buffer supplied with a linear imidazole gradient (0-200 mM). Except the flow 
through sample, all the purification fractions (washing and elution samples) were 
collected in 2 mL aliquots. The peak fractions as detected by UV absorption spectrum 
at 280 nm were analyzed by SDS-PAGE and pooled. 
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The IMAC purification step was generally followed by an IEX purification step. 
The pooled protein sample from IMAC experiment was dialyzed in Spectra/Por 
dialysis membrane (molecular weight cut off (MWCO) was at least twice smaller than 
the predicted molecular weight of protein of interest) against >20 sample volumes of 
dialysis buffer at 4°C for a few hours to overnight. Optionally, TEV protease can be 
mixed with the pooled protein sample before dialysis in 1:10-20 mass ratio for 
removing the cleavable his-tag, if desired. After dialysis, the cleaved his-tag and uncut 
protein can be removed with an additional IMAC purification step using 1-2 mL 
equilibrated TALON resin in a gravity-flow column. The flow through was collected 
and analyzed by SDS-PAGE before further processing. 
The protein sample was then filtered (with a 0.2 µm Gilson sterile syringe filter) 
and loaded on to an equilibrated MonoQ 5/50 GL (or 5 mL HiTrap SP HP column) 
(GE Healthcare Life Sciences) depending on the charge of the protein of interest in the 
IEX binding buffer. Afterwards, the IEX column was washed with 5-10 column 
volumes of binding buffer and the bound protein sample was eluted with 20-50 column 
volumes of elution buffer with a linear NaCl gradient (0.1-1.0 M). The peak fractions 
as detected by UV absorption spectrum at 280 nm were analyzed by SDS-PAGE and 
pooled. 
The IEX purification was then followed by SEC as a final purification step. The 
concentration and also buffer exchange of the pooled protein sample was performed in 
an Amicon Ultra-4 Centrifugal Filter Unit (Merck Millipore) by concentrating and 
diluting (at least 10-fold) for two or three rounds. Protein concentration was monitored 
spectrophotometrically with a Thermo Scientific NanoDrop 2000 to prevent protein 
precipitation caused by exceeding its concentration limit. The protein sample was 
concentrated to the recommended sample volume and centrifuged for 5-10 minutes at 
top speed at 4°C in a cooling table-top centrifuge before being injected on to a 
Superdex 75/200 or Superose 6 column (GE Healthcare Life Sciences) depending on 
the predicted molecular weight of protein of interest. The peak fractions as detected by 
UV absorption spectrum at 280 nm were analyzed by SDS-PAGE, pooled, 
concentrated, aliquoted, and quickly frozen in liquid nitrogen for long-term storage in -
80°C freezer. To find out if the quick frozen process was detrimental for the protein 
stability, a small aliquot of the frozen protein sample (0.5-1 mg) was thawed on ice and 
then injected on to the same SEC column. A protein peak eluted at the same elution 
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volume as before indicated that the protein sample remained stable during the quick 
freezing process. 
 
5.3.4 Holo-TFIID reconstitution method 
 
Holo-TFIID was reconstituted by mixing preassembled ‘MBP-TAF1/TAF7/TBP’ 
complex bound on amylose resin, TAF11/13, and 9TAF complex (TAF2, 3, 4, 5, 6, 8, 
9, 10, 12) in binding buffer of low ionic strength (150 mM KCl). Excess of TAFs and 
TBP were removed by extensive washes using binding buffer. Afterwards, the holo-
TFIID bound on amylose resin was eluted stepwise by first adding elution buffer of 
low ionic strength (150 mM KCl) and then elution buffer of high ionic strength (400 
mM KCl). Buffer recipe can be found in chapter 5.3.4.5. 
One round of holo-TFIID reconstitution and purification procedure (preparative), 
which generally took 3-4 days (Fig. 5.1), is described in details below: 
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Figure 5.1: Reconstitution of recombinant holo-TFIID. The workflow of 
TFIID reconstitution is summarized schematically. Reagents are annotated in 
boxed texts. The molar concentrations of KCl in purification buffers and protein 
samples are indicated in brackets. 
 
5.3.4.1 MBP-TAF1 bound amylose resin preparation (day 1-2) 
 
SDS gel sample preparation: 50 µL probe + 20 µL 4x protein gel loading buffer 
(PGLB) unless otherwise stated. 
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1. Take one MBP-TAF1 expressing insect cell pellet (from 400 mL Sf21 culture, 
the pellet volume was normally 5-10 mL) from the -80°C freezer and thaw it on 
ice (or at room temperature). Resuspend the thawed cell pellet with 40 mL lysis 
buffer by pipetting up and down with a 10/25 mL pipette. Transfer the cell 
resuspension to a 50 mL Falcon tube. 
2. Pipette the cell resuspension up and down gently with a 25 mL pipette for 2 
minutes. 
→ Take a probe, this is your ‘SNP (supernatant and pellet)’ sample (optional: 
sonicate 5 seconds before adding PGLB). 
3. Centrifuge the cell resuspension for 5 minutes at 4,000 g in a 4°C table-top 
centrifuge. Supernatant should contain proteins that are NOT in the nucleus. 
4. Carefully decant supernatant (pellet is not hard initially) and keep it in a 50 mL 
Falcon tube. 
→ Take a probe, this is your ‘1
st
 cyt (cytosolic)’ sample. 
5. Repeat steps 2 through 4 a total of 5 times (keep all the supernatants in 50 mL 
Falcon tubes). 
→ Take probes, they are your ‘2
nd
-5
th
 cyt’ samples.  
The pellet should become whitish and more solid at this stage since only nuclei 
are left. 
6. Resuspend the pellet with 40 mL KCl soak buffer by pipetting up and down 
gently for 2 minutes. Remove the foam if there is any. 
→ Take a probe, this is your ‘Nucl. Res. B.I. (Nuclear resuspension before 
incubation)’ sample. 
7. Optional: Analyze all the probes by running a 6% SDS gel to evaluate the 
amount of nuclear MBP-TAF1. 
8. Place the resuspension on a roller in cold room for 3-5 hours (protein extraction 
takes place gradually; appearance of the pellet is going to be gel-like and the 
color will change from whitish to slightly grey). 
→ Take a probe, this is your ‘Nucl. Res. A.I. (Nuclear resuspension after 
incubation)’ sample. 
9. Centrifuge the resuspension for 10 minutes at 4,000 g in a 4° C table-top 
centrifuge (pellet size might increase after soaking). Transfer the supernatant to 
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a 50 mL Falcon tube (if the pellet is not compact, repeat the centrifugation step 
once). 
→ Take a probe, this is your ‘Nucl. Soak SN 4000 (supernatant after 4,000 g 
spin)’ sample. 
10. Dilute the ‘Nucl. Soak SN 4000’ sample from step 9 to 2 × 30 mL aliquots 
using KCl soak buffer, so as to fit into two centrifugation tubes for the 
Beckman 70 Ti rotor. 
→ Take a probe, this is your ‘Nucl. Soak SN A.D. (after dilution)’ sample. 
11. Centrifuge the ‘Nucl. Soak SN A.D.’ sample from step 10 using a Beckman 70 
Ti rotor in a 4°C Beckman ultracentrifuge at 20,000 rpm (~40,000 g) for 45-60 
minutes. 
→ Take a probe, this is your ‘Nucl. Soak SN A.D. HSSN (high-spin 
supernatant)’ sample (also the input sample for amylose batch purification). 
12. During the centrifugation in step 11, equilibrate 1 mL amylose resin (Amylose 
Resin High Flow, E8022L/S, New England Biolabs) by washing with 2 × 10 
mL Milli-Q water and 2 × 10 mL KCl soak buffer in a 15 mL Falcon tube 
(centrifuge the resin resuspension at 3,000 g for 1-2 minutes in a 4°C table-top 
centrifuge). 
13. Incubate the 2 × 30 mL ‘Nucl. Soak SN A.D. HSSN’ sample from step 11 with 
2 × 0.5 mL equilibrated amylose resin in 50 mL Falcon tubes on a roller in cold 
room overnight (it is recommended to wrap the tube with Parafilm to avoid 
possible sample leaking). 
14. Centrifuge the ‘Nucl. Soak SN A.D. HSSN’ sample/resin mixtures at 3,000 g 
for 10 minutes in a 4°C table-top centrifuge. Decant the supernatants into fresh 
50 mL falcon tubes and keep on ice. 
→ Take a probe, this is your ‘MBP-TAF1 Amy (amylose) FT (flow through)’ 
sample, which can be used as input for preparing another batch of MBP-TAF1 
bound amylose resin by repeating steps 12 and 13. 
15. Resuspend the 1 mL MBP-TAF1 bound amylose resin with 10 mL KCl soak 
buffer and transfer the resuspension to an equilibrated gravity-flow column 
(10/20 mL). Wash the MBP-TAF1 bound amylose resin with 20 mL 2M KCl 
wash buffer and then 20 mL KCl soak buffer. 
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16. Resuspend the washed MBP-TAF1 bound amylose resin with 10 mL KCl 
buffer and transfer the resuspension to a 15 mL Falcon tube. 
→ Take a probe, this is your ‘MBP-TAF1 Amy RS (resin)’ sample. 
Centrifuge the MBP-TAF1 bound amylose resin resuspension at 3,000 g for 1-2 
minutes in a 4°C table-top centrifuge. Remove the supernatant by decanting and 
keep the resin pellet on ice. 
 
5.3.4.2 ‘MBP-TAF1/TAF7/TBP’ bound amylose resin preparation (day 2) 
 
1. Input sample preparation (purified TAF7 and TBP). 
Mix and dilute both purified TAF7 and TBP to a final concentration of ~0.5 
mg/mL and a final volume of ~1 mL, by first adding X µL TAF7 (0.5 mg) and 
then Y µL of  TBP (0.5 mg) to (1000-X-Y) µL of KCl soak buffer. 
The mixture might become cloudy upon TBP addition. In such case, incubate 
the mixture on a roller in cold room for 10 minutes, and then centrifuge the 
mixture in a 4°C table-top centrifuge at top speed for 2-3 minutes. Afterwards 
the mixture should become clear and ready for reconstituting ‘MBP-
TAF1/TAF7/TBP’ complex. 
→ Take a probe (4 µL probe + 16 µL PGLB), this is your ‘IN (input)’ sample 
(load 10 µL/well). 
2. Mix the input sample (1 mL TAF7/TBP mixture) with MBP-TAF1 bound 
amylose resin (1 mL) and split to 2 × 1 mL aliquots in two 1.5 mL Eppendorf 
tubes. Incubate on a roller in cold room for at least 2 hours. 
During the rolling incubation, analyze the probes from ‘MBP-TAF1 bound 
amylose resin preparation’ by SDS-PAGE to confirm the MBP-TAF1 binding. 
3. After the rolling incubation, centrifuge the mixtures at 3,000 g for 2 minutes in 
a 4°C table-top centrifuge. Combine and transfer the supernatants to a 2 mL 
Eppendorf tube. 
→ Take a probe (4 µL probe + 16 µL PGLB), this is your ‘FT (flow through)’ 
sample (load 10 µL/well). 
4. Combine and transfer the resin pellets to a 15 mL Falcon tube. Wash the resin 
first with 2 × 10 mL KCl soak buffer and then 3 × 10 mL 150 mM KCl buffer 
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(centrifuge the resin resuspension at 3,000 g for 2-3 minutes in a 4°C table-top 
centrifuge). 
→ Take probes (12 µL probe + 4 µL PGLB), they are your ‘A1-A5 (1
st
-5
th
 
washes)’ samples. 
5. Resuspend the resin with 2.0 mL 150 mM KCl buffer. 
→ Take a probe (50 µL probe + 20 µL PGLB), this is your ‘RS (resin) IN 
(input)’ sample. 
6. Analyze the probes by SDS-PAGE (12%) to confirm the formation of ‘MBP-
TAF1/TAF7/TBP’ complex. 
 
5.3.4.3 9TAF preparation by SEC (day 2) 
 
The 9TAF was prepared by first mixing and diluting all its subunits in molar ratios 
according to their copy numbers with the SEC buffer, to a final volume of 500-800 µL 
in a 1.5 mL Eppendorf tube. A typical mixing recipe is listed below: 
 
Table 5.1: a standard recipe for preparing 9TAF complex by SEC. 
9TAF subunits Amount Subunit copy number 
3TAF (TAF5, 6, 9) 2.4 mg 2 
TAF4/12 1.8 mg 2 
TAF8/10 0.78 mg 1 
TAF2 1.0 mg 1 
TAF3/10 0.84 mg 1 
 
The mixture was incubated on a roller in cold room for 1 hour, after which the 
mixture was split in two identical aliquots and resolved on a Superose 6 column (GE 
Healthcare Life Sciences) in two independent SEC experiments.  The peak fractions as 
detected by UV absorption spectrum at 280 nm were analyzed by SDS-PAGE and 
pooled (~ 8 mL in total). 
→ Take a probe (50 µL probe + 20 µL PGLB), this is your ‘9TAF IN (input)’ 
sample. 
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5.3.4.4 Holo-TFIID reconstitution and purification (day 2-4) 
 
1. Mix ‘MBP-TAF1/TAF7/TBP’ bound amylose resin (~1 mL), TAF11/13 (0.5 
mg diluted by 150 mM KCl buffer to a final volume of 1 mL), and 9TAF 
complex (~8 mL) in a 15 mL Falcon tube. 
→ Take a probe of TAF11/13 (8 µL probe + 12 µL PGLB), this is your ‘11/13 
(TAF11/13) IN (input)’ sample (load 10 µL/well). 
2. Incubate the mixture on a roller in cold room overnight. Afterwards, centrifuge 
the mixture at 3,000 g for 5 minutes in a 4°C table-top centrifuge. Decant the 
supernatant to a fresh 15 mL Falcon tube. 
→ Take a probe (50 µL probe + 20 µL PGLB), this is your ‘FT (flow through)’ 
sample. 
3. Wash the resin with 5 × 10 mL 150 mM KCl buffer (centrifuge the resin 
resuspension at 3,000 g for 2-3 minutes in a 4°C table-top centrifuge). 
→ Take probes (18 µL probe + 6 µL PGLB), they are your ‘A1-A5 (1
st
-5
th
 
washes)’ samples. 
4. Resuspend the resin pellet with 1 mL 150 mM KCl buffer and split evenly to 
two 1.5 mL Eppendorf tubes. Centrifuge the resuspensions at 3,000 g for 30 
seconds in a 4°C table-top centrifuge. Remove the supernatant. 
→ Take a probe before centrifugation (18 µL probe + 6 µL PGLB), this is your 
‘IID (TFIID) RS (resin)’ sample. 
5. Elute the holo-TFIID bound on amylose resin by adding elution buffer and 
incubating on a roller in cold room as following: 
Elution 1: 2 × 1 mL 150 mM KCl elution buffer, 30 minutes; 
Elution 2: 2 × 1 mL 150 mM KCl elution buffer, 30 minutes; 
Elution 3: 2 × 1 mL 400 mM KCl elution buffer, 30 minutes; 
Elution 4: 2 × 1 mL 400 mM KCl elution buffer, 30 minutes; 
Elution 5: 2 × 1 mL 400 mM KCl elution buffer, overnight. 
After each elution, centrifuge the resin resuspension at 3,000 g for 1-2 minutes 
in a 4°C table-top centrifuge. Combine and transfer the supernatants to 2 mL 
Eppendorf tubes. 
→ Take probes (18 µL probe + 6 µL PGLB), they are your ‘E1-E5 (1
st
-5
th
 
elution)’ samples. 
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6. Resuspend the resin pellets with 2 × 1 mL 400 mM KCl elution buffer. 
→ Take a probe (18 µL probe + 6 µL PGLB), this is your ‘E5 (5
th
 Elution) RS 
(resin)’ sample. 
7. Analyze the probes by SDS-PAGE (12%). If higher TFIID sample 
concentration is desired, concentrate the elution samples in an Amicon Ultra-4 
Centrifugal Filter Unit (MWCO: 30 kDa) by centrifuging at 1-2,000 g at 3-5 
minute intervals in a 4°C table-top centrifuge. 
 
5.3.4.5 Important remarks 
 
The first and second TFIID elutions (E1 and E2, eluted by elution buffer of low ionic 
strength) might contains excess of ‘MBP-TAF1/TAF7/TBP’ complex. If so, they 
cannot be used for preparing EM grids for single-particle analysis. 
Avoid centrifuging the resin at more than 3,000 g for extended time, otherwise 
they might stick tightly in the inside surface of Falcon tubes and become difficult to be 
resuspended and recovered. 
A certain amount of resin might be lost during the reconstitution and purification. 
In such case, decrease the volume of elution buffer used for each elution 
correspondingly. 
It is strongly recommended to use the flow through samples to perform at least 
an additional round of TFIID reconstitution and purification. 
 
5.3.4.6 Recipe of Buffers 
 
Note: pH of the buffers should be adjusted with 10M KOH or 2M HCl. 
 
Lysis Buffer 300 (mL)  
50 mM Tris/8.0 (4°C) 15 1 M Tris/8.0 (4°C) 
100 mM KCl 10 3 M KCl 
0.1%  NP-40 3 10% NP-40 
Supply with leupeptin and pepstatin. 
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KCl Soak Buffer 200 (mL)  
50 mM Tris/8.0 (4°C) 10 1 M Tris/8.0 (4°C) 
400 mM KCl 26.7 3 M KCl 
Supply with leupeptin, pepstatin and ~3 mM β-mercaptoethanol (1 µL/5 mL buffer). 
 
150 mM KCl Buffer 400 (mL)  
50 mM Tris/8.0 (4°C) 20 1 M Tris/8.0 (4°C) 
150 mM KCl 20 3 M KCl 
Supply with leupeptin, pepstatin and ~3 mM β-mercaptoethanol (1 µL/5 mL buffer). 
 
2M KCl Wash Buffer 50 (mL)  
50 mM Tris/8.0 (4°C) 2.5 1 M Tris/8.0 (4°C) 
2 M KCl 33.3 3 M KCl 
Supply with leupeptin, pepstatin and ~3 mM β-mercaptoethanol (1 µL/5 mL buffer). 
 
9TAF SEC buffer (pH 8.0@4ºC) 1L  
25 mM Tris/8.0 (4°C) 25 mL 1 M Tris/8.0 (4ºC) 
150 mM KCl 50 mL 3 M NaCl 
1 mM Dithiothreitol (DTT) 1 mL 1 M Dithiothreitol (DTT) 
1 mM EDTA/8.0 2 mL 0.5 M EDTA/8.0 
 
150 mM KCl Elution Buffer 20 (mL)  
50 mM Tris/8.0 (4°C) 1 1 M Tris/8.0 (4°C) 
150 mM KCl 1 3 M KCl 
10 mM  Maltose 2 100 mM Maltose 
  16 Milli-Q water 
Supply with leupeptin, pepstatin and ~3 mM β-mercaptoethanol (1 µL/5 mL buffer). 
 
400 mM KCl Elution Buffer 20 (mL)  
50 mM Tris/8.0 (4°C) 1 1 M Tris/8.0 (4°C) 
400 mM KCl 2.67 3 M KCl 
10 mM  Maltose 2 100 mM Maltose 
  14.33 Milli-Q water 
Supply with leupeptin, pepstatin and ~3 mM β-mercaptoethanol (1 µL/5 mL buffer). 
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5.4 GraFix method 
 
Material: 
 
· 100 % glycerol 
· 25% glutaraldehyde aqueous solution (10 × 10 mL, ref. 16216, EMS; store in -
20°C freezer) 
· Beckman ultracentrifuge and SW60Ti rotor 
· Biocomp Gradient Master system 
· 4 mL polyallomer Beckman tube (ref. 328874) 
· Bio-Rad Biologic 2110 Fraction collector/Needle 20G (0.9 × 40 mm) 
· 10 mg/mL lysine solution (4°C for short-term storage, -20°C for long-term 
storage) 
 
Procedure: 
 
1. Determine GraFix conditions (buffer composition, gradient range, 
centrifugation parameters): 
Choose the gradient range and centrifugation parameters based the molecular 
weight of the protein complex of interest by referring to the table below. 
Generally, glycerol gradients of 10-30/40% are used. 
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Table 5.2 Ultracentrifugation guidelines for GraFix, based on a selection of 
various complexes (Holger, 2010). 
 
 
2. Prepare 2 times concentrated sample buffer stock/buffer 2X (without Tris, 
detergent, or β-mercaptoethanol). 
IMPORTANT: DO NOT use Tris based buffer as glutaraldehyde crosslinks 
primary amino group. Tris could be replaced by HEPES at the same pH and 
molar concentration.  
 
Standard buffer 2X recipe (100 mL stock solution): 
 
High salt buffer 2X: 100 mM HEPES/pH 8.0, 800 mM KCl. 
§ Mix 26.7 mL 3M KCl and 2.38 g HEPES in a beaker. 
IMPORTANT: add HEPES powder bit by bit on top of the buffer. Mix 
with a rotating magnet. 
§ Water up to ~90 mL, adjust pH to 8.0 with 10M KOH drop by drop, and 
then water up to 100 mL. 
§ Filter by a 0.2 µm filter and keep in a fridge or cold room. 
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Low salt buffer 2X: 100 mM HEPES/pH 8.0, 300 mM KCl. 
§ Mix 10 mL 3M KCl and 2.38 g HEPES in a beaker. 
IMPORTANT: add HEPES powder bit by bit on top of the buffer. Mix 
with a rotating magnet. 
§ Water up to ~90 mL, adjust pH to 8.0 with 10M KOH drop by drop, and 
then water up to 100 mL. 
§ Filter by a 0.2 µm filter and keep in a fridge or cold room. 
 
3. Prepare glycerol solutions by using the recipe below: 
· 10% glycerol solution:  
1.26 g 100% glycerol (1 mL) 
5 mL buffer 2X 
Fill up to 10 mL with Milli-Q 
 
· 30% glycerol solutions: 
Control: 
3.78 g 100% glycerol (3 mL) 
5 mL buffer 2X 
Fill up to 10 mL with Milli-Q 
Fixed: 
3.78 g 100% glycerol (3 mL) 
5 mL buffer 2X 
Fill up to 10 mL with Milli-Q 
Add 60 µL glutaraldehyde stock (25 
%) prior to use 
 
· 40% glycerol solutions: 
Control: 
5.04 g 100% glycerol (4 mL) 
5 mL buffer 2X 
Fill up to 10 mL with Milli-Q 
Fixed: 
5.04 g 100% glycerol (4 mL) 
5 mL buffer 2X 
Fill up to 10 mL with Milli-Q 
Add 60 µL glutaraldehyde stock (25 
%) prior to use 
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· 50% glycerol solutions: 
Control: 
6.3 g 100% glycerol (5 mL) 
5 mL buffer 2X 
 
Fixed: 
6.3 g 100% glycerol (5 mL) 
5 mL buffer 2X 
Add 60 µL glutaraldehyde stock (25 
%) prior to use 
 
Optional: keep all buffers at 4°C if not to use immediately. 
 
4. Prepare continuous glycerol gradient as described below: 
 
· Put magnetic base holder on the Gradient master and adjust the holder till 
flat. 
· Assign the middle of tube with the supplied marker block (use the upper 
part). 
· For each sample, fill two 4 mL polyallomer tubes with 10% glycerol 
solution up to the mark. 
· Fill one tube with 30% (or higher percentage) glycerol solution below the 
10% glycerol solution up to the mark (use a syringe with a long needle 
20G). 
→ This is your control gradient. 
· Fill the other tube with 30% (or higher percentage) glycerol solution with 
glutaraldehyde below the 10% glycerol solution up to the mark (use a 
syringe with a long needle 20G). 
→ This is your fixed gradient. 
· Seal the tube with a black lid, avoid forming air bubbles. Remove extra 
liquid in the lid with a 200 µL tip. 
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IMPORTANT: from this point, one needs to be very careful when 
handling gradients, in order not to disturb them by external 
mechanical force (vibration, etc).  
· Carefully put those two tubes on a magnetic base holder and mix the 
gradient on the Gradient master with following settings: 
Setting of Gradient master: 
10-30%: 
S01/01 1:10 m 83° 22 rpm 
10-40%: 
S01/01 1:16 m 82.5° 18 rpm 
10-50%: 
S01/01 0:53 m 86° 18 rpm 
Let the newly-made gradients stay in 4°C fridge for 0.5-1 hour. 
· Remove the lid carefully and remove 200 µL solution from the top of the 
gradient. 
· Slowly add a cushion of 200 µL 5% glycerol solution (dilute 1 volume of 
10% glycerol solution with 1 volume of buffer 1X). 
500 µL buffer 1X (250 µL Milli-Q + 250 µL buffer 2X) 
500 µL 10% glycerol solution 
 
· Carefully and slowly load 50-200 µL of protein sample (~100 µg protein in 
total, concentration: 0.5-2.0 mg/mL) onto the 5% glycerol cushion. 
 
Figure 5.2: Schematic summary of the continuous gradient establishment 
and sample loading. The preparation of 10-30% glycerol gradient is used as an 
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example, which also applies to the preparation of 10-40% and 10-50% glycerol 
gradients. 
Optional: Balance the gradients in rotor bucket. 
5. Centrifuge the gradients using a SW60Ti rotor in a Beckman ultracentrifuge. 
IMPORTANT: mount all the buckets even some of them are empty. This is 
for the correct alignment of the rotor. 
 
10-30%: 
18 hours; 34, 000 rpm; 4°C. 
10-40% (10-50%): 
14 hours; 37,000 rpm; 4°C. 
 
6. Perform Gradient fractionation: 
Option 1 –fraction collector (Bio-Rad Biologic 2110 Fraction collector): 
· Wash the plastic tubes with water and make a test fractionation with a 
spare 4 mL polyallomer Beckman tube filled with water (Flow rate: 0.6 
mL/minute. Writing rate: 3 cm/minute). 
· Fractionate control run first, and then fixation run. Collect the drops in 
1.5 mL Eppendorf tubes (4 drops≈180 µL, resulting 22 fractions; 5 
drops≈220 µL, resulting 18 fractions). 
· Clean the plastic tubes with water between each fractionation. 
Option 2 – needling: 
· Fix the tube with a clamp on a stand. 
· Drill a hole by inserting a needle at an angle of ~45° (to horizontal) in 
the bottom of the tube. 
· Collect the fractions from the bottom of the gradient in 1.5 mL 
Eppendorf tubes (5 drop≈180 µL). 
 
7. Analysis fractions as follows:  
· To each fraction, add 2 µL of 10 mg/mL lysine and incubate at RT for ~10 
minutes (or longer on ice) to neutralize the remaining glutaraldehyde. 
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· Use 12% SDS gel to analyze fractions from control gradients; 6% SDS gel 
to analyze fractions from fixed gradients. 
· One can prepare negative-stain EM grids directly with fractions of interest 
based on SDS-PAGE results. 
· For preparing cryo-EM grids, perform buffer exchange (to remove glycerol) 
with desalting columns (Zeba™ Desalt Spin Columns, Thermo Scientific). 
 
5.5 RCT methods 
 
The workflow for generating 3D EM models of holo-TFIID or TFIID subcomplexes 
from a RCT dataset is outlined below, with detailed discussions and suggestions for 
critical steps.  
 
5.5.1 EM grid preparation and RCT dataset collection 
 
1. Identify the best fraction for RCT dataset collection. 
The protein sample used for preparing EM grids for RCT dataset collection 
should be taken from a peak fraction from a GraFix fixed gradient. It is 
recommended to check and compare a few peak fractions by negative-stain EM 
analysis in order to identify the fraction with the best homogeneity. 
2. Grid preparation: carbon sandwich versus single layer. 
Prepare EM grids using carbon sandwich technique first, since large protein 
complexes are generally stained better this way. On the other hand, carbon 
sandwich technique might cause more particle deformation comparing to single 
layer technique. 
It is recommended to prepare EM grids of a specific protein sample 
using both techniques so as to choose the better one by comparison. 
3. Optimize the particle density on EM grids. 
The particle density on an EM grid for RCT dataset collection should be dense 
enough so that less EM micrographs are required for having enough particle 
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pairs, but not too dense in order to avoid ‘crowded’ particles especially when 
collecting micrographs of tilted views. Dilute the protein sample or decrease 
sample absorption time if the particle density is too high. Increase the sample 
absorption time when the particle density is too low. 
IMPORTANT: DO NOT concentrate GraFix fixed fractions with a protein 
concentrator (e. g. Amicon Ultra-4 Centrifugal Filter Unit, Merck Millipore) 
since it might lead to aggregation. 
Prepare two to four EM grids by using the optimized grid preparation 
procedure for subsequent RCT dataset collection. 
4. RCT dataset collection. 
Normally it requires ~5,000 particle pairs for 3D reconstruction. More particle 
pairs are required if the sample is heterogeneous. If the particle binds to carbon 
film with preferred orientation, additional micrographs of only untilted views 
should be collected in order to compensate the missing wedge effect during 
multireference alignment and backprojection with SPIDER (chapter 5.5.4). 
The tilt angles are between 45-60°. Larger tilt angle gives more 
structural information of the side views but might lead to stronger staining 
artifacts, especially for EM grids prepared by single layer technique. 
During dataset collection, it is highly recommended to monitor the CTF 
of recorded micrographs in real time. A good CTF resembles a series of 
concentric ripples called Thon rings, without distortion and other patterns. 
Those micrographs with bad CTF should be discarded immediately. 
 
5.5.2 Preprocessing micrographs and particles 
 
1. Preprocess the micrographs. 
Preprocess the recorded micrographs using a script performing the following 
steps: 
§ Transform the micrograph format from 16-bit TIFF (Tagged Image File 
Format) to 16-bit integer MRC with the ‘tif2mrc’ program of IMOD. 
§ Remove X-rays and correct for bad camera lines with the ‘ccderaser’ 
program of IMOD. 
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§ Recount and split the micrographs to untilted and tilted groups. 
§ Bin the micrographs by a factor of 2 to improve contrast, reduce noise 
and the file size (faster data processing) with the ‘bint’ program of 
Bsoft. 
§ Transform the micrograph format from 16-bit integer MRC to Spider 
with the ‘bimg’ program of Bsoft. 
2. Evaluate the quality of preprocessed micrographs. 
Evaluate the quality of preprocessed micrographs by CTF estimation using the 
‘Preprocess micrographs’ protocol of XMIPP. This step is not compulsory if 
CTFs of the micrographs have been examined during the RCT dataset 
collection (see chapter 5.5.1, step 4). 
3. Manual particle selection. 
Select particles on the preprocessed and CTF estimated micrograph pairs with 
TiltPicker. For each micrograph pair, pick the particles in the micrograph 
representing tilted view first; and then pick the particles in the micrograph 
representing the untilted view. Avoid picking particles that are too large/small, 
too close to each other, and too close to the micrograph borders. 
4. Extract and preprocess selected particles. 
The coordinates of selected particles were extracted and relocated to 
corresponding XMIPP directories for particle extraction using the ‘Preprocess 
particles’ protocol of XMIPP, while the particle box dimension is normally 1.5-
2 times of the particle’s longest diameter. Concomitantly, the extracted 
particles are also preprocessed to minimize the imaging imperfections with the 
‘particle normalization’ and ‘ramping background correction’ protocols of 
XMIPP. 
 
5.5.3 2D classifications 
 
Only particles representing untilted views are subjected to 2D classifications. CL2D 
protocol of XMIPP requires less computing power and is used first to have a brief 
estimation of the overall particle shape and structural features. In contrast, XMIPP 
ML2D protocol generates better classification results but requires more computing 
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power. IMAGIC 2D MSA protocol normally gives the best classification results but 
also requires longer processing time since it needs to be used in an interactive manner.  
For CL2D and ML2D classifications, it is highly recommended to initiate the 
calculation using command lines instead of the XMIPP GUI (graphical user interface) 
panel. 
The resulting aligning parameters (in-plane rotation angles) from ML2D 
classification are used to assign Euler angles of the corresponding particles 
representing tilted views for reconstructing RCT 3D models by backprojection. 
 
1. 2D classification with CL2D protocol of XMIPP. 
CL2D algorithm features in subdividing a collection of images into many 
classes. It therefore has the advantage of creating very homogeneous classes. 
Normally 200-250 classes are generated from 5-10,000 particles after 25 
iterations.  
Normally a CL2D classification is done within one day: for example, 
9,649 TFIID particles were subdivided to 250 classes in ~11 hours by CL2D 
program calculated on one computing node (12 CPUs). 
 
2. 2D classification with ML2D protocol of XMIPP. 
ML2D classification is the prerequisite step for subsequent reconstruction of 
RCT 3D models. The ML2D algorithm performs a maximum-likelihood multi-
reference refinement, which requires a considerable amount of CPU time. 
Similar as CL2D protocol, 200-250 classes are normally generated from 5-
10,000 particles after 25 iterations. However the particles are distributed less 
evenly among classes. 
3. 2D classification with 2D MSA protocol of IMAGIC. 
IMAGIC 2D MSA protocol requires interactive selection of a number of 
representative classums (10-15), which are used as references for the next 
round of alignment and classification. In the first few rounds, a larger number 
(5-600) of classes is commonly used to avoid overaveraging, since the particle 
orientations are randomly distributed at the very beginning. Once the particles 
are better aligned in the later rounds, a smaller number (2-300) of classes is 
used in order to improve signal-to-noise ratio of the classums. This process is 
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normally iterated for 5-10 rounds until the structural features of the classums 
become stable. 
4. Perform XMIPP ML2D classification by using IMAGIC 2D MSA classums 
as references. 
Based on our observation, the IMAGIC 2D MSA classification generally gave 
better classification results than XMIPP ML2D classification. A protocol has 
been established to perform referenced XMIPP ML2D classification by using 
the IMAGIC 2D MSA classums as references, which resulted in very similar 
classification results and actually took much less CPU time than XMIPP ML2D 
classification without references: 9,649 TFIID particles were subdivided to 250 
classes in ~9 hours calculated on three nodes (36 CPUs). This protocol was 
used when the ML2D classification without references didn’t give satisfactory 
results. 
 
5.5.4 3D reconstruction and structure refinement 
 
1. RCT reconstruction. 
RCT 3D models are reconstructed based on the output of the ML2D 
classification, which are the aligning parameters (in-plane rotation angles), 
stored in .doc file. Those parameters are extracted and used to align the tilt 
particle pairs so as to assign Euler angles to the tilted particles, which are then 
used for reconstructing RCT 3D model by backprojection with XMIPP 
programs. The generated RCT 3D models are generally filtered with a 
resolution threshold of 40-70 Å before further examination. 
All filtered RCT 3D models are checked visually with the Chimera 
software. Those with the distinct structural features are grouped based on their 
resemblance to front, bottom, or side views and used as input models for the 
subsequent 3D averaging steps. 
2. 3D averaging. 
Two or three RCT 3D models are normally used for initial 3D averaging tests 
using the ‘ml_tomo’ program of XMIPP (angular sampling rate: 15°; maximum 
resolution: 0.45 pix^-1; 25 iterations) to find an optimal combination, which 
generally consists of 5-10 RCT 3D models from ML2D classes representing 
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various views (front, bottom, side). Reprojections (83 in total, generated using 
15° as angular sampling rate) generated by SPIDER are used to estimate the 
level of missing wedge effect in averaged 3D models. 
Once an optimal combination is identified, all the input models are 
subjected to 3D averaging with increasingly fine angular samplings in a 
stepwise manner (15°→10°→5°; all with 25 iterations). 
IMPORTANT: it has been observed from time to time that the 3D averaging 
results from the same input 3D models might be very different in two 
independent averaging sessions, which is probably due to the 3D averaging 
algorithm of XMIPP. Since the initial averaged 3D model is generated by 
averaging input 3D models at random orientations. Consequently, when the 
program is searching for the optimal 3D model aligning parameters, it might be 
‘trapped’ in a local minimum and then stop exhaustive searching. 
In practice, when the first 3D averaging result shows no reasonable 
structural similarities with the input models, it is strongly recommended to run 
the 3D averaging algorithm for a second time and check whether the result is 
improved. 
3. 3D structure refinement. 
Once a good averaged 3D model is generated (from tilted particles), it is used 
as a reference model for generating reprojections (normally 83) with SPIDER, 
which are then used as references for refining the alignment of untilted particles. 
A new 3D model is generated from the realigned untilted particles and can 
again be used as a reference model for another round of structural refinement, 
until the structural features of the 3D model become stable or start to 
deteriorate. Reprojections must be carefully monitored to prevent 
overrefinement. 
The resulting refined 3D model can then be used as a reference model 
for reconstructing a 3D cryo-EM model in order to acquire more detailed 
structural information of the protein complex of interest. 
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Appendix 
 
Here I present Publication 6, which summarizes the structure and function analysis on 
components of essential eukaryotic basal and activated transcription complexes 
including TFIID, TFIIH and other important transcription regulators. Results presented 
in this work were parts of research projects supported by the European Commission 
Framework Programme 7 initiative for structural proteomics in Europe, SPINE2-
COMPLEXES. 
 
Cette partie concerne une sixième publication qui résume les analyses structurales et 
fonctionnelles faites sur les composants de complexes eucaryotes essentiels la 
transcription, comprenant TFIID, TFIIH et d’autres importants régulateurs de la 
transcription. Les résultats présentés dans le cadre de ce travail font partie de projets de 
recherche qui ont été financés par le European Commission Framework Programme 7 
pour promouvoir la protéomique structurale en Europe, SPINE2-COMPLEXES. 
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Publication 6 
 
 
 
 
 
Structural insights into transcription complexes. 
 
Imre Berger, Alexandre G. Blanco, Rolf Boelens, Jean Cavarelli, Miquel Coll, Gert E. 
Folkers, Yan Nie, Vivian Pogenberg, Patrick Schultz, Matthias Wilmanns, Dino 
Moras, Arnaud Poterszman. 
 
Journal of Structural Biology. 2011;175(2):135-46. 
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Résumé de la publication 
 
Le contrôle de la transcription permet la régulation de l’activité cellulaire en réponse à 
un stimuli externe et la recherche dans ce domaine a grandement bénéficiée des efforts 
de la biologie structurale. Dans cette exposée, en se basant sur les exemples spécifiques 
de l’initiative européennes SPINE2-COMPLEXES, nous avons illustres l’impact de la 
protonique structurale sur notre compréhension des bases moléculaires de l’expression 
de gènes. Si la plupart des structures atomiques ont été obtenues par la cristallographie 
des rayons X, l’impact des solutions apportées par la résonance magnétique nucléaire 
(RMN) ainsi que par la cryo-microscopie électronique est loin d’être négligeable. Ici, 
nous résumons quelques exemples marquants et illustrons l’importance de ces 
technologies en biologie structurale sur le complexe de transcription de proteine-
proteine ou de protéine-ADN: l’analyse structure/fonction des composants de la 
machinerie transcriptionelle activée et basale avec un intérêt particulier sur le 
complexe de multi-sous-unités TFIID et également les régulateurs de transcription 
comme membre de la famille de récepteurs hormonales nucléaire. Nous présentons 
également les aspects moléculaires du contrôle epigenetiques de l’expression des gènes 
et de la reconnaissance du promoteur. 
 
Review
Structural insights into transcription complexes
Imre Berger a, Alexandre G. Blanco b,c, Rolf Boelens d, Jean Cavarelli e,f,g,h, Miquel Coll b,c, Gert E. Folkers b,
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a b s t r a c t
Control of transcription allows the regulation of cell activity in response to external stimuli and research
in the field has greatly benefited from efforts in structural biology. In this review, based on specific exam-
ples from the European SPINE2-COMPLEXES initiative, we illustrate the impact of structural proteomics
on our understanding of the molecular basis of gene expression. While most atomic structures were
obtained by X-ray crystallography, the impact of solution NMR and cryo-electron microscopy is far from
being negligible. Here, we summarize some highlights and illustrate the importance of specific technol-
ogies on the structural biology of protein–protein or protein/DNA transcription complexes: structure/
function analysis of components the eukaryotic basal and activated transcription machinery with focus
on the TFIID and TFIIH multi-subunit complexes as well as transcription regulators such as members
of the nuclear hormone receptor families. We also discuss molecular aspects of promoter recognition
and epigenetic control of gene expression.
Ó 2011 Elsevier Inc. All rights reserved.
1. Introduction
The ultimate goal of research on transcription is an understand-
ing of transcriptional control and of the capacity of living cells to
respond to environmental changes. In the human body, modula-
tion of gene expression is a very complex process as given physio-
logical response involves different stimuli in a time-dependent
manner. Complexity stems from multiple interactions between
the molecules involved in distinct pathways. The molecular mech-
anisms governing transcription regulation are of primordial impor-
tance and have major biomedical relevance. Although
inappropriate regulation or execution of apoptosis leads to disease,
such as cancer, there is now evidence for their great therapeutic
potential especially if apoptosis could be targeted at defined or-
gans, rather than acting ubiquitously like chemotherapy.
The SPINE2-COMPLEXES consortium whose aim was to develop
new methods and technologies for structural analysis of multi-
component complexes was driven by the choice of ‘high-value hu-
man health targets’ and number of them targets are associated
with transcription initiation and regulation. We have investigated
components the eukaryotic basal and activated transcription
machinery with focus on (i) the TFIID and TFIIH general transcrip-
tion factors as well as (ii) transcription regulators including mem-
bers of the nuclear hormone receptor family, and have addressed
(iii) molecular aspects of promoter recognition and (iv) epigenetic
control of gene expression.
This work has benefited from HTP technologies for the struc-
tural genomic implemented in the context of SPINE I and has re-
quired development of new technologies adapted for the
production, characterization and structural analysis of multi-
component assemblies. It has led to methodological developments
to cope with technical challenges and to the determination of more
than 50 three-dimensional structures of proteins and complexes
directly involved in transcription and its control. While most atom-
ic structures were obtained by X-ray crystallography (Table 1), the
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impact of solution NMR and cryo-electron microscopy is far from
being negligible. Here, we summarize some highlights and illus-
trate the importance of specific technologies on the structural biol-
ogy of protein–protein or protein/DNA transcription complexes.
2. Challenges for sample preparation: New methods for protein
complex production
Many important protein complexes such as multicomponent
transcription factors exist in very low quantities in their natural
hosts, which renders their extraction from endogenous source dif-
ficult. Purification techniques such as tandem-affinity purification
(TAP) of tagged open reading frames (Rigaut et al., 1999) are now
widely used to isolate native complexes for analysis of protein sub-
unit stoichiometry, interactions, post-translational modifications,
and in some cases, for structural studies by cryo-electron micros-
copy (see below) or exceptionally by X-ray crystallography
(Kornberg, 2007). Yet, preparation of complexes in the quality
and quantity required for high-resolution structural studies from
endogenous source, particularly for human targets is often virtu-
ally impossible, or requires very large culture volumes. Heteroge-
neity of the complexes purified from endogenous source further
complicates their study. Often, transcription factor complexes are
highly regulated and can exist as mixtures of isoforms differing
in subunit composition and/or containing differential post-transla-
tional modifications, representing the kaleidoscope of states the
specimens were in at the moment of cell disruption for purifica-
tion. For example, in-depth profiling of endogenously purified hu-
man general transcription factor TFIID by high-resolution mass
spectrometry revealed 118 unique phosphorylation sites and 54
unique lysine acetylation sites, distributed over the ensemble of
the TFIID molecules purified, giving insights into interesting func-
tional details (Mousson et al., 2008; Pijnappel et al., 2009).
Overproduction of recombinant proteins had a decisive impact
on biological research and in particular in structural biology.
Producing proteins in a heterologous host can furthermore over-
come a number of the above outlined impediments. High-level
production of proteins of interest can result in several milligrams
of high quality sample from comparatively small culture volumes.
Thus, recombinant sample production techniques, in particular using
Escherichia coli as a prokaryotic expression host organism, have be-
come commonplace for the production of proteins of interest in
virtually every molecular biology laboratory. Many plasmid-based
systems exist for overexpressing proteins in Escherichia coli each
with their own merit, several are distributed by commercial
Table 1
List of representative structure solved.
Complex Protein (s) Ligand Access number Method Resolution Reference
PhoB complex PhoB,o4, RNAP (3-fiap DNA X-ray 4.3 Å Submitted
Transcription factor IID (TFIID) 15 subunits none EMD-5026 Cryo-
EM
22 Å Papai et al. (2009)
15 subunits DNA EMD-5075, EMD-5076,
EMD-5077, EMD-5078
Cryo-
EM
29 Å, 24 Å,
19 Å, 31 Å
Papai et al. (2010)
TAF3 module H3K4me3
peptide, Zn2+
2K16, 2K17 NMR rmsd 0.9 Å,
0.8 Å
van Ingen et al. (2008)
TAF5 modules none 2J4B, 2J49 X-ray 2.2, 2.3 Å Romier et al. (2007)
Transcription factor IIH (TFIIH) p8-TTD-A none 2JNJ NMR rmsd 0.9 Å Vitorino et al. (2007)
Tfb2, Tfb5 (p52 and p8-TTD-A) none 3DGP, 3DOM X-ray 2.9, 1.9 Å Kainov et al. (2008)
Coactivator-Associated
arginine methyl transferase
I (CARM1)
CARM1 modules none 3B3F, 3B3G, 3B3 J,
2OQB
X-ray 2.2 Å, 2.4 Å,
2.5 Å, 1.7 Å
Troeffer et al. (2007b)
CARM1 catalytic domains SFG, ligands
analogues
10 structures X-ray 2,2–2,7A To be published
Transcription elelongation
complexes
Spt6 C-terminal domain none 2XP1 X-ray 2,20 Å Diebold et al. (2010a,b)
Iws1/Spt6 complexes none 2XPL, 2XPN, 2XPO,
2XPP
X-ray 2.2 Å, 1.9 Å,
2.1 Å, 1.7 Å
Diebold et al. (2010a,b)
SAGA complex ATXN7L3 SCA7 Zn2+ 2KKT, 2KKR NMR rmsd 0.5 Å,
0.6 Å
Bonnet et al. (2010)
Lac repressor/Lac DNA
complexes
Lac repressor DNA 2KEI, 2KEJ, 2KEK NMR rmsd 0.9 Å,
1.0 Å, 1.7 Å
Romanuka et al. (2009)
Ets-1 dimer DNA complex Ets-1 DNA 2NNY X-ray 2.8 Å Lamber et al. (2008)
MafB DNA complexes MAfB, c-Fos DNA 2WT7, 2WTY X-ray 2.3 Å To be published
Nuclear Hormone receptors RXR/RAR heterodimer (LBDs) atRA/LG100754 3A9E X-ray 2.7 Å Sato et al. (2010)
Tribolium castaneum
heterodimer EcR/USP ecysone
receptor
ponasterone A 2NXX X-ray 2.7 Å Iwema et al. (2007)
Heliothis virescens
heterodimer EcR/USP
ecdysone receptor
20-
hydroxyecdysone
2R40 X-ray 2.4 Å Browning et al. (2007)
Amphioxus RXR tetramer none 3EYB 2HC4, 2HCD X-ray 2.8 Å, 2.2 Å,
2.6 Å
Tocchini-Valentini et al.
(2009), Ciesielski et al.
(2007)
Vitamin D receptor (LBD) Vit D synthetic
ligands
3A32, 3A40 3CS4, 3CS6 X-ray 1.7 Å, 1.4 Å,
2.0 Å, 1.8 Å
Antony et al. (2010), Rochel
et al. (2011)
ERR ligand binding domain PGC-alpha
peptide
3D24 X-ray 2.1 Å Greschik et al. (2008)
RXR/VDR heterodimer
(DBDs + LBDs)
DNA, Vit D,
retinoid
– cryo-
EM
12 Å Submitted
heterodimer (DBDs + LBDs) DNA – cryo-
EM
12 Å To be published
AR DBD WT and T575A
mutant
none – NMR rmsd 0.8 Å To be published
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suppliers. Eukaryotic proteins may impose particular requirements
on the expression host, such as requiring post-translational modi-
fications for activity. Consequently, eukaryotic expression systems
have begun to complement prokaryotic expression systems most
commonly used are expression systems using mammalian cells
or baculovirus systems that infect insect cell cultures (Jarvis,
2009; Nettleship et al., 2010).
Recombinant production of protein complexes with many sub-
units, in particular for high-resolution structural studies, has its
own challenges and intricacies. Many protein subunits in a com-
plex require cloning and combination of many genes for co-expres-
sion. In structural biology, especially for crystallization, proteins
often need to be modified by truncation, mutation or deletion of
low complexity regions to achieve a sample which can form a
well-ordered three-dimensional crystal lattice that diffracts the
incident X-ray radiation to high resolution. This necessitates a flex-
ible system of gene assembly into multigene expression vectors,
which allows for replacement and manipulation of genes encoding
for individual subunits in a rapid and uncomplicated fashion.
Within the SPINE2-COMPLEXES consortium a wide panel of
cloning strategies and vector sets have been developed to stream-
line construct design for expression/co-expression screening in
Escherichia coli (Busso et al., 2005; de Jong et al., 2006; Berrow
et al., 2007; Scheich et al., 2007; Fogg and Wilkinson, 2008;
Bieniossek et al., 2009; Unger et al., 2010; Diebold et al., 2011)
(Luna-Vargas et al., 2011) as well as in insect and mammalian cells
(Aricescu et al., 2006; Berrow et al., 2007; Abdulrahman et al.,
2009; Pradeau-Aubreton et al., 2010; Trowitzsch et al., 2010). A
variety of new technologies for DNA manipulation including
ligation independent or restriction free procedures, in-fusion or
gateway approaches are now being used in addition to classical
restriction-based strategies (see Busso et al., 2011 for examples and
test cases). Partner Grenoble has developed a system for combinatorial
gene assembly into multigene expression vectors called ACEMBL.
This system (Bieniossek et al., 2009; Nie et al., 2009) uses a single
multigene plasmid which is rapidly built from custom-designed,
tiny progenitor DNA molecules by a method termed ‘‘tandem rec-
ombineering’’ (TR) (Nie et al., 2009). Tandem recombineering ex-
ploits the exonuclease activity of T4 DNA polymerase in the
absence of nucleotides to create long (20–30 bases) overhangs on
double stranded DNA molecules such as PCR fragments or linear-
ized plasmids. By properly designing these long stick ends, genes,
regulatory elements or entire expression cassettes can be concate-
nated and inserted into small plasmids by sequence and ligation
independent cloning methods (SLIC). An array of plasmids, called
donor and acceptor plasmids, can be conveniently charged with re-
combinant DNA cargo in this way (Fig. 1). The main specificity of
the ACEMBL approach lies in the use of donor and acceptor plasmid
molecules that can easily be assembled into multigene constructs
containing all desired genes encoding for subunits of a protein
complex of choice. The assembly is catalyzed by Cre recombinase,
which creates acceptor–donor fusions by joining the plasmids via a
short DNA sequence, LoxP, present on each plasmid. The Cre-LoxP
reaction is an equilibrium reaction, therefore, all combinations of
donor and acceptor plasmid molecules with their selection of
genes co-exist in the reaction vessel in which the Cre-fusion is car-
ried out. The combinations can then be selected by challenging
with combinations of antibiotic, as the acceptor and donor plas-
mids each encode for a different resistance marker.
ACEMBL has been originally designed for multigene expression
in Escherichia coli and a series of protein complexes, including fac-
tors involved in transcription and gene regulation, has been pro-
duced by this method (Bieniossek et al., 2009). Automation is a
vital prerequisite in contemporary protein complex research. A
fully automated pipeline for producing multiprotein complexes
in Escherichia coli has been achieved using the TR approach, made
possible by the implementation of robust and simple protocols for
PCR, gene insertion by SLIC and the reliance of the method on only
two enzymes (T4 DNA polymerase and Cre recombinase) for multi-
gene assembly using the TR approach.. The ACEMBL pipeline is de-
scribed in a separate contribution in this SPINE2-COMPLEXES
special issue (Vijayachandran et al., 2011). More recently, the ACE-
MBL TR pipeline has been extended successfully to include also
multigene assembly for complex expression in eukaryotic systems
(Kriz et al. 2010; Vijayachandran et al., 2011).
3. Insights into the eukaryotic basal transcription machinery
In eukaryotes, the core promoter serves as a platform for the
assembly of the transcription preinitiation complex (PIC) that in-
cludes transcription factors IIA, IIB, IID, IIE, IIF, IIH, and RNA poly-
merase II, which function collectively to specify the transcription
start site. While RNA polymerase II as well as general transcription
factors IIA, IIB and TBP are now characterized at the atomic level
(Liu et al., 2010), the structure and architecture of the multi-
subunit complexes IID (TFIID) and IIH (TFIIH) are still under
investigation.
These complexes composed of 14 and 10 subunits, respectively,
are difficult to purify to homogeneity and their crystallization is still
out of reach. On the way towards an atomic description of theses
macromolecular assemblies and to provide insight into functional
aspects, Strasbourg follows a multi-scale approach that combines
electron microscopy to obtain a global view of the architecture as
well as X-ray crystallography and NMR for atomic scale details.
3.1. X-ray and solution structures of the p8/TTD-A TFIIH subunit:
structural basis for trichothiodystrophy
The multi-protein transcription factor TFIIH is involved in the
transcription of classes I and II genes as well as in DNA repair (Egly,
2001; Mydlikova et al., 2010). Mutations in its XPB, XPD helicase
subunit as well as in its p8/Tfb5 subunit (Giglia-Mari et al., 2004;
Coin et al., 2006) have been incriminated in trichothiodystrophy
(TTD), a rare autosomal recessive multisystem disorder character-
ized by sulfur-deficient brittle hair, mental and physical retarda-
tion, ichthyosis and, in many cases, cutaneous photosensitivity
but no predisposition to cancer. To gain insights into the molecular
basis of this disease, the Strasbourg team has determined the solu-
tion and X-ray structures of the p8/Tfb5 TFIIH subunit isolated
(Vitorino et al., 2007) as well as in complex with the p52/Tfb2
(Kainov et al., 2008), another TFIIH component. The minimal complex
between Tfb5, the yeast ortholog of p8, and the carboxy-terminal
domain of Tfb2, the yeast p52 subunit of TFIIH revealed that these
two polypeptides adopt the same fold, forming a compact pseudo-
symmetric heterodimer via a b-strand addition and coiled coils
interactions between terminal a-helices. Furthermore, Tfb5 pro-
tects a hydrophobic surface in Tfb2 from solvent, providing a ratio-
nale for the influence of p8 in the stabilization of p52 (Fig. 2A) and
explaining whymutations that weaken p8–p52 interactions lead to
a reduced intracellular TFIIH concentration and a defect in nucleo-
tide-excision repair, a common feature of TTD cells.
Key to the successful structure determination of a minimal
Tfb2:Tfb5 complex was the use of limited proteolysis combined
with mass spectrometry to map the Tfb2 domain required for
interaction with Tfb5. A bottleneck in the structure determination
was the limited quality of the initial crystals which diffracted to
2.6 Å but were difficult to handle. Despite extensive efforts to con-
trol cryoprotection, only a minor proportion of crystals exhibited
reasonable diffraction and mosaicity, which hampered the possi-
bility to solve the structure using heavy atom derivatives. From
250 crystals tested, only three yielded usable datasets. Of major
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importance was the shortening of the Tfb2 construct, which affects
crystal packing along the c axis, leading to a new crystal form.
These crystals diffracted to 1.7 Å on a synchrotron beamline, which
facilitated heavy atom screening and structure determination
(Kainov et al., 2010).
3.2. Cryo-EM structures of TFIID and transcription activation
The general transcription factor TFIID is composed of the TATA
binding protein (TBP) and thirteen TBP associated factors (Tafs)
which recognize gene promoters in a activator dependant way.
The Strasbourg node has determined an improved structural model
of the TFIID complex at 23 Å (Papai et al., 2009) and determined
the 3-D organization of different TFIID-containing complexes from
cryo electron microscopy (CryoEM) images (Papai et al., 2010) to
better understand the activator-dependant promoter recruitment
of S. cerevisiae TFIID. The purification of endogenous TFIID from
affinity Tagged yeast strains was instrumental in the production
of highly homogeneous complexes. In this respect several yeast
strains were prepared in order to introduce different type of tags
and to place the tag on different Tafs subunits and to screen the
constructs were the integrity of the complex is least affected. For
example, when the 140 kDa Taf1 subunit was Tap tagged on its
carboxy-terminus, a sub stoichiometric amount of Taf2 was found
in the purified TFIID suggesting that this large 37 kDa Tag fragilizes
the interaction of Taf2 with the TFIID core. In contrast when the
same Taf1 subunit was HA tagged on its amino-terminus the
Taf2 composition was not affected. The interaction of TFIID with
DNA was studied in the presence of TFIIA and the CryoEM images
revealed that TFIIA interacts close to TBP as predicted by the
TBP–TFIIA–DNA crystal structure (Fig. 2B). To exert its coactivator
function TFIID was shown in several systems to directly contact
transactivators. The Rap1 transactivator was shown to directly
bind the TFIID complex through a network of interactions with
Taf4, -5, and -12. CryoEM revealed that Rap1 binds to lobe B away
from TBP, which is located at the junction of A and C lobes.
In order to obtain deeper insights into the activation mecha-
nism the structure of a committed activation complex formed be-
tween Rap1, TFIID and TFIIA, all assembled on a ribosomal
enhancer–promoter DNA fragment was determined. A major diffi-
culty in this analysis came from the heterogeneity of the dataset
and the use of new methods of particle separation according to de-
fined functional states was instrumental in deciphering this com-
plex mixture of functional states. The results revealed an
unexpected interaction between TFIIA and Rap1 which form a pro-
tein bridge between TBP and the lobe B-bound Rap1 thus resulting
in a large conformational change in the position of TFIIA. We spec-
ulate that these rearrangements could (i) stimulate an activator-
dependant binding of TBP to the promoter; (ii) stabilize the
TFIID–promoter interaction since the protein bridge topologically
traps the DNA; or (iii) facilitate subsequent recruitment of TFIIB,
Pol II and/or the additional components involved in PIC formation.
Fig. 1. Protein complex expression by ACEMBL. (A) Genes encoding for subunits of a protein complex are introduced into the multiple integration element (MIE) of small
(2 kb) plasmid DNA molecules called acceptor and donor. Donors contain a conditional replicon derived from R6 Kc phage. The acceptor has a regular ColE1 replicon.
Promoters (T7, Lac) are indicated. Resistance markers are Ap (ampicillin), Cm (Chloramphenicol), Kn (kanamycin), Sp (spectinomycin). All plasmids contain a LoxP sequence
(marked in red). (B) Cre recombinase generates multigene constructs by Cre-LoxP fusion. The multigene constructs are characterized by unique combinations of resistance
markers and can be selected for by challenge with the corresponding antibiotics. (C) ACEMBLing transcription factor TFIIA from three subunits (a,b,c) from a multigene fusion
constructed by recombineering. A size exclusion profile (SEC) of the purified complex is shown, with a corresponding SDS–PAGE gel section of the three polypeptides (left).
The three-dimensional structure of TFIIA (based on PDB submission 1NH2) is illustrated on the right (panels adapted from Ref. 10, Bieniossek et al., with kind permission of
the publisher).
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4. Promoter recognition
The transcription factors assemble to DNA to either activate or
inhibit transcription of their target genes. These regulatory events
are governed by cooperative protein–protein or protein–DNA
interactions in a dynamic network of multi-component complexes.
4.1. Structure of the RNAP r4-b-flap chimera/PhoB
E/pho box DNA
transcription activation sub-complex
One of the strategies that have proven to be successful for the
structural characterization of biological complexes is the formation
of sub-complexes comprising only the most relevant regions or do-
mains of each of the protein components within the whole com-
plex. The obvious advantage of this approach is that the often
difficult purification of full-length proteins can be avoided, but
then other drawbacks may arise. The absence of regions that play
critical roles in the stabilization of one of the components can be
a major problem that can be circumvented by the design and con-
struction of a chimeric protein. This strategy was followed by Bar-
celona to determine the crystal structure of a ternary
transcriptional initiation sub-complex.
PhoB, a two-component response regulator, activates transcrip-
tion by interacting with the r70 subunit of the Escherichia coli RNA
polymerase in promoters in which the pho box replaces the –35
r70-recognition sequence. Mutations and carboxy-terminal dele-
tions of r70 had shown the implication of its r4 subdomain in
the transcriptional activation mediated by PhoB (Makino et al.,
1993). Barcelona already had solved the crystal structure showing
the tandem DNA recognition by the PhoB effector domain (PhoBE)
(Blanco et al., 2002), but initial efforts to get the structure of the
PhoBE-DNA-r4 ternary complex were fruitless because all the r4
domain constructs were very poorly expressed or the protein pre-
cipitated during the purification process. An analysis of genetic
studies (Kuznedelov et al., 2002) and available RNAPH crystal
structures (Darst et al., 2001; Murakami et al., 2002; Vassylyev
et al., 2002) indicated that r4 has a hydrophobic surface that inter-
acts with a region of the RNAP b-flap. This finding inspired the
Barcelona group to design a chimera by fusing r4 with the b-flap
tip helix through an artificial flexible linker. The resulting construct
provided a soluble and stable globular domain that could be easily
overexpressed in Escherichia coli.
Once purified, the r4-b-flap chimeric construct was incubated
with the PhoBE-pho box DNA complex and the resulting ternary
complex was isolated by using size exclusion chromatography.
The stability of the complex was assessed by SDS–PAGE and the fi-
nal sample was subsequently used in crystallization trials. After
testing many crystal forms that systematically turned out to be
formed by PhoB-DNA binary complexes, a crystal form that en-
abled the determination of the ternary complex structure was
obtained.
The data revealed that r4 recognizes the upstream pho box re-
peat (Fig. 3A). As with the ÿ35 element, r4 achieves this recogni-
tion capacity through the amino-terminal portion of its DNA
recognition helix, although in this case the helix is less extended
onto the DNA groove. As a consequence, r4 establishes less direct
contacts with the DNA pho box than with the canonical ÿ35 pro-
moter sequence. However, the lost direct contacts of r4 with the
DNA are compensated by new contacts with the PhoBE activator
which is bound to the pho-box as well. This observation suggests
a simple recruitment mechanism of the polymerase to the Pho pro-
moters which occurs only in the presence of already-bound tran-
scriptional activator dimer.
4.2. DNA recognition and allosteric regulation by the Lac repressor
The expression of genes involved in the lactose metabolism of
Escherichia coli is effectively controlled by the Lac repressor
(Wilson et al., 2007). The presence of multiple Lac repressor operator
binding sites within the lac operon is responsible for the effective
down regulation of these genes. The main operator O1 overlaps
with the lac promoter and is essential for the function of the lac
operon. In addition there exist two auxiliary operators O2 and O3,
located 401 base pairs (bp) downstream of O1 and 92 bp upstream
of O1, respectively, which contribute significantly to the transcrip-
tional repression. Mutation or deletion of O1 leads to an almost
complete loss of repression even in the presence of both auxiliary
operators, and thus O1 appears indispensable (Betz et al., 1986;
Oehler et al., 1990). Inactivation of either O2 or O3 results in a
slight decrease of repression, apparently compensating each other,
while the combined loss of both O2 and O3 leads to a significant
(70-fold) decrease of repression (Oehler et al., 1990). This cooper-
ativity can be well explained, since the tetrameric Lac repressor
functions as a dimer of dimers and binds simultaneously to the
O1 operator and to either of the auxiliary O2 and O3 operators cre-
ating one of two alternative DNA loops (Kramer et al., 1987).
Mutational studies of the various operators revealed that varia-
tion of the sequences leads different affinities for the Lac repressor
and results in a distinct repression efficiency (Oehler et al., 1994).
O1 and O2 operators have similar base pair composition while
the O3 sequence differs significantly. Structural studies of DNA
complexes, including those of the Lac repressor, make often use of
Fig. 2. Insights into the basal Transcription machinery. (A) X-ray structure of the
p8/Tfb5 TFIIH subunit in complex with the carboxy-terminal domain of p52/Tfb2,
another TFIIH component. Tfb5 is shown as a ribbon lying on the surface of Tfb2C.
Hydrophobic side chains in the binding region are in yellow, and others are in green
(Kainov et al., 2008). (B) Cryo-EM structure of TFIID in complex with TFIIA and the
transactivator Rap1 which cooperate to commit TFIID for transcription initiation
(Papai et al., 2010). The analysis of different functional intermediates revealed the
mode of binding of Rap1 and TFIIA to TFIID, as well as a Rap1-induced reorgani-
zation of TFIIA.
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symmetrical operators containing two identical half-sites. However
the natural lac operators are pseudo-palindromic sequences, where
the symmetry is broken by variations in the sequence between
the two half-sites and by insertion of the central G:C base pair.
When considered separately, the two half-sites can differ signifi-
cantly in their affinity for the Lac repressor (Sasmor and Betz,
1990).
In an ongoing effort to understand specificity and recognition of
various operator sequences by the Lac repressor the Utrecht team
determined the NMR structures of the complexes of the dimeric
Lac headpiece with its auxiliary operators O2 and O3. The structure
with O2 (Fig. 3A) shows strong similarity with that of the previ-
ously determined structure of HP62 with a symmetric SymL oper-
ator (Spronk et al., 1999) and that of HP62V52C in complex with
O1 (Kalodimos et al., 2002). The Lac HP bound to a non-operator
DNA (NOD) fragment is different: a major difference is that the
hinge helices, which play an important role in the strong coopera-
tive operator binding of the Headpieces are not formed (Kalodimos
et al., 2002) and that of the Lac HP bound to a non-operator DNA
(NOD) fragment (Kalodimos et al., 2004). The analysis of these
complexes helps to understand how the Lac repressor recognizes
its operators and can explain the significant differences in operator
affinity (Romanuka et al., 2009).
The structure of the complex of HP62V52C with its auxiliary
operator O3 presents a surprise. The left monomer of the Lac
repressor in the Lac-O3 complex retains most of these specific con-
tacts, as found in the other operator complexes. However in the
right half-site of the O3 operator there is a significant loss of pro-
tein–DNA contacts, explaining the low affinity of the Lac repressor
for the O3 operator. In fact the binding mode in the right half-site
resembles that of the non-specific complex. In contrast to the Lac-
non-operator DNA complex however where no hinge helices are
formed, the stability of the hinge helices in the weak Lac-O3 com-
plex is the same as in the Lac-O1 and Lac-O2 complexes as judged
from the results of the hydrogen–deuterium experiments.
4.3. Oligomeric state and promoter recognition of the Ets-1
transcription factor
The members of the Ets family of transcription factors, which
share a common DNA binding domain called ETS domain, play
important roles in the development of metazoans and are some-
times involved in oncogenesis (Sharrocks, 2001). During the past
fifteen years, the data published on ETS domains highlight how
structural biology can provide very powerful tools to understand
the mechanisms of recognition of the DNA (Kodandapani et al.,
1996), the assembly of activator complexes and regulatory processes
like cooperative binding (Garvie et al., 2001), auto-inhibition
(Garvie et al., 2002) or post-translational modification (Pufall
et al., 2005). However, the previously established mechanism for
auto-inhibition of monomeric Ets-1 on DNA response elements
with a single ETS-binding site (EBS: 50-GGA(A/T)-30) had not been
observed for the stromelysin-1 promoter or the P53 promoter con-
taining both two palindromic EBS separated by four base pairs
(Venanzoni et al., 1996; Baillat et al., 2002; Baillat et al., 2009).
The Hamburg group has determined the X-ray structure of Ets-1
DNA binding domain on the stromelysin-1 promoter element
(S-EBS), revealing a ternary complex in which protein homo-
dimerization is mediated by the specific arrangement of the two
ETS-binding sites (Fig. 3C). In this complex, both Ets-1 protomers
recognize the two EBS via conserved residues of the DNA-recognition
helix (Arg391, Arg394 and Tyr395) similarly to the way how the
monomeric form of Ets-1 interacts with the single EBS. Additional
data demonstrated that Ets-1 does not dimerize in solution in the
absence of DNA and protein–protein interactions occur when Ets-1
binds to the S-EBS element (Lamber et al., 2008).
Several mutations of the Glycine–Proline motif (Gly333–
Pro334), situated on one of the two identified protein–protein
interfaces, impaired the recognition of the S-EBS by an Ets-1 dimer
and decreased the ability of Ets-1 to transactivate the Stromelysin-
1 promoter. The Glycine–Proline motif is not conserved in the
whole Ets-1 family and therefore these data suggest that S-EBS-like
promoters are specifically regulated by the Ets transcription factors
sharing this particular motif (Ets-1 and Ets-2).
Altogether, this work unravels the molecular basis for relief of
auto-inhibition and the ability of Ets-1 to function as a facultative
dimeric transcription factor on this site. Indeed, in the structure
Fig. 3. Promoter recognition. (A) Structure of the RNAP r4-b-flap chimera/PhoB
E/
pho box DNA transcription activation sub-Complex. Ribbon representation of the
structure of the quaternary complex showing the upstream (magenta) and
downstream (purple) PhoBE protomers and the chimera (r4 in red and the b-flap
in beige) bound to the pho box DNA (gold). (B) Structure of the DNA binding
domains (Headpiece HP62V52C) of the Lac repressor in complex with the O2
operator. The left and right Lac HP subunits are coloured dark blue and dark orange,
respectively. (C) The structure of Ets-1 homo-dimer bound to the stromelysin-1
promoter element (S-EBS). Ribbon representation of the two components of the Ets-
1 homo-dimer, Ets-1 and Ets-10 , colored in blue and green, respectively. The
residues of the Glycine-Proline motif are depicted in orange. The two palindromic
EBS elements (EBS and EBS0) are shown in magenta on the 22-base pairs DNA
duplex corresponding to a fragment of the stromelysin-1 promoter.
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presented, the amino-terminal ETS-flanking region, which is
known to be involved in inhibition of Ets-1 function, is observed
to be unfolded when the Ets-1 dimer is bound to S-EBS similarly
to what was observed in the context of monomeric Ets-1 bound
to EBS. Findings from the Hamburg group may also explain previ-
ous data of Ets-1 function in the context of heterologous transcrip-
tion factors, thus providing a molecular model that could also be
valid for Ets-1 regulation by hetero-oligomeric assembly. In this
model, the protein–protein interactions within the transcriptional
regulator complexes are mediated by DNA binding and directly
associated with the release of auto-inhibition.
5. Transcription regulation by nuclear hormone receptors
The superfamily of nuclear receptors (NRs) present in verte-
brates, arthropods and nematodes plays crucial roles in the regula-
tion of transcription, and is involved in various stages of
development, maintaining the control of homeostasis and causing
or preventing cellular proliferation, differentiation and death
(McEwan, 2009). Some 48 members have been found in the human
genome, and a smaller group in arthropoda, housing around 21 in
Drosophila melanogaster. Nuclear receptors are ligand-activated
transcription factors. Many members of the superfamily thus bind
major hormones, such as steroids, thyroid hormones, or retinoids.
These occupy a special position in gene regulation by providing a
direct link between the ligand, which they bind, and the target
gene, whose expression they regulate. Orphan nuclear receptors
for which no known ligand has yet been found represent around
half of the total number of NRs. These may have empty ligand
binding pockets as in the case of estrogen-related receptor-alpha
(ERRa). Others have structural ligands that constitutively bind to
the LBD, such as the Drosophila USP, but for which no biological
function has been established yet.
Nuclear receptors are composed of several functional domains.
The amino-terminal A/B domain is highly variable in length and se-
quence, and contains a constitutively active transactivation func-
tion AF-1. C and E correspond to the DNA-binding domain (DBD)
and the ligand-binding domain (LBD), respectively. The LBD con-
tains the ligand-dependent transactivation function AF-2. The
DBD and LBD are connected via a flexible hinge (domain D). NRs
act in vivo and in vitro as ligand-dependant transcriptional regula-
tors through binding, most often as dimers, to DNA response ele-
ments present in promoters of target genes. Activation of gene
transcription occurs after binding of ligand, leading to release of
corepressor and binding of coactivator to the LBD. To date, the
crystal structures of more than 30 different NR LBDs have been
solved but only one of full length receptors, the heterodimer
PPAR/RXR (Chandra et al., 2008).
The Strasbourg node has determined and analyzed the struc-
tures of three orphan receptors, the homodimer ERR, RXR and
USP associated to heterodimeric partners. The case of RXR (USP
in arthropods) is especially interesting since this receptor plays a
pivotal role inside the NR superfamily being required as a hetero-
dimer partner for numerous NRs such as RARs, PPARs and VDR in
human or EcR, the ecdysone receptor in insects. The molecular evo-
lution of RXR has been investigated through LBD structures of nu-
clear receptors from two arthropods (Iwema et al., 2007; Iwema
et al., 2009) and from that of a cephalochordate amphioxus (Bran-
chiostoma floridae), an invertebrate chordate (Tocchini-Valentini
et al., 2009). The crystal structure of this latter revealed an apotetr-
amer (Fig. 4A) with a peculiar conformation of helix H11 filling the
binding pocket. In contrast to the arthropods RXR/USPs, which can-
not be activated by any RXR ligands, functional data showed that
this receptor like the vertebrates/mollusk RXRs, is able to bind
and be activated by RXR ligands although less efficiently than ver-
tebrate RXRs. This suggests that amphioxus RXR is an intermediate
between arthropods RXR/USPs and vertebrate RXRs.
Strasbourg has also studied the crystal and solution structures
of several complexes (USP/EcR, RXR/RAR, RXR/VDR and RXR/PPAR)
in different functional states. The crystal structures of LBDs, homo
or heterodimers, bound to ligands and coactivator peptides provide
high resolution pictures of ligand induced conformational changes.
In addition these structures unravel the structural basis for under-
standing coactivator binding. Although structural studies on the li-
gand-binding domain (LBD) have established the general mode of
nuclear receptor (NR)/coactivator interaction, determinants of
binding specificity are only partially understood. A new crystal
structure of the ERRa LBD in complex with a PGC-1a box3 peptide
(Fig. 4B), explained why the LBD of estrogen receptor-alpha (ERa),
interacts only with a region of the (PGC)-1a coactivator, which
Fig. 4. Nuclear hormone receptor complexes. (A) Quaternary structure of the RXR LBD from an invertebrate chordate. (B) Structure of ERRa LBD in complex with a PGC-1a
box3 peptide. Residues amino-terminal of the PGC-1a LXXYL motif contact helix 4 (H4), the loop connecting helices 8 and 9 (H8-H9), and the C terminus of the ERRa LBD.
Interaction studies using wild-type and mutant PGC-1a and ERRa showed that these contacts are functionally relevant and are required for efficient ERRa/PGC-1a
interaction.
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contains the canonical LXXLL motif (NR box2), whereas the LBD of
ERRa also binds efficiently an untypical, LXXYL-containing region
(NR box3) (Greschik et al., 2008).
To address the communication between nuclear receptors, DNA
and components of the basal transcription machinery, data on full
length nuclear receptors are required. Strasbourg has worked in
this direction and the solution structures of full length receptors
in complexes with DNA direct repeat elements and the interacting
regions of coactivators such a Med1 or SRC-1 were studied using
SAXS, SANS and FRET methods (Rochel et al., 2011). The structures
revealed an extended asymmetric shape that is markedly different
from that seen in the crystal structure of PPAR/RXR, which is nei-
ther new nor extraordinary. These results pointed to the role
played by the hinge domains in establishing and maintaining the
integrity of the structure and showed two additional important
features: the conserved position of the ligand-binding domains at
the 50 ends of the target DNAs and the binding of only one coacti-
vator molecule per heterodimer, to RXR’s partner.
6. Epigenetics
It is well established that next to the presence of transcription
factors that control promoter activity, gene expression is critically
controlled by the accessibility of the gene. The higher order chro-
matins structure plays a key regulatory role in this process. Specific
modifications in the termini of the histone tails that either lead to
more or less compact chromatin structures, in turn modulates the
accessibility of transcription factors to promoter and enhancer se-
quences. These posttranslational modifications are believed to play
a key role in epigenetic gene regulation. Both the type of modifica-
tion and the position within the gene determine the transcriptional
outcome of the various modifications, generally referred to as the
‘‘histone code’’ These marks form specific interaction sites for so
called reader proteins that in turn through interactions with other
proteins promote or inhibit transcription (Kouzarides, 2007) by
opening or compacting the chromatin structure of the gene.
6.1. CARM1
Post-translational methylation of arginine is a widespread epi-
genetic modification found in eukaryotes that is catalyzed by the
protein arginine methyltransferases (PRMTs) (Bedford and Clarke,
2009). At least nine members of PRMTs have been identified and
classified into two main classes. CARM1 (also known as PRMT4
(Spannhoff et al., 2009) is a crucial protein involved in many bio-
logical processes including the regulation of chromatin structure
and transcription via methylation of histones and many transcrip-
tional cofactors. As such, understanding the detailed mechanism of
action of this protein at the structural level is important and has
implications ranging from pure structural information to potential
way of regulating gene expression via inhibitor design (Spannhoff
et al., 2009). CARM1 contains 608 amino acids in mouse (and hu-
man) is built around a catalytic core domain (residues 150–470
in mouse CARM1) that is well conserved in sequence among all
PRMTs members. CARM1 possesses two unique additional do-
mains attached, respectively, at the amino-terminal and at the car-
boxy-terminal end of the PRMT active site. Both additional
domains have been shown to be required for the coactivator func-
tion of human CARM1. As a first step of a process aimed at under-
standing at the atomic level the cooperative mechanism by which
CARM1 plays its biological functions, we have reported the struc-
ture determination and the structural analysis of several crystal
structures corresponding to three isolated modules of mouse
CARM1: CARM128–140, CARM1140–480 and CARM128–507 (Troffer-
Charlier et al., 2007a,b).
The 1.7 Å crystal structure of the amino-terminal domain of
CARM1 (CARM128–140) reveals an unexpected PH domain, a scaffold
frequently found to regulate protein–protein interactions in a large
variety of biological processes. The structure of CARM1140–480 has
been determined in two different biological states: an apo form
and a SAH-CARM1140–480 form (both at 2.2 Å resolution) with the
SAHmolecule bound in the catalytic active site (Fig. 5A). The crystal
structures of the CARM1 isolated modules reveal large structural
modifications including disorder to order transition, helix to strand
transition and active sitemodifications. The amino-terminal and the
carboxy-terminal end of CARM1catalyticmodule containmolecular
switches thatmay inspire how CARM1 regulates its biological activ-
ities by protein–protein interactions.
Keys to the successful structure determination was to benefit
from HTP technologies and as a first step the ability to screen a
large numbers of constructions using insect cells infected by re-
combinant baculovirus (Troffer-Charlier et al., 2007a,b). CARM1
is a bad candidate for structural studies as full length protein be-
haves in solution as large polydisperse oligomers. From sequences
analysis, the first 25 amino acids and the last 120 amino acids are
Fig. 5. Epigenetics. (A) The structure of SAH-CARM1_140–480. Overview of one
monomer with the SAH/SAM binding domain in yellow, the amino-terminal helices
in pink, the b-barrel in green, the dimerization arm in blue. The bound SAH
molecule is shown in a stick model. Ribbon representations of SAH-CARM1_140–
480 dimer formed by interactions between the dimerization arm of monomer 1
with the outer surface of the Rossmann fold moiety of monomer 2 (insert). (B)
Solution structure of the PHD domain of TAF3 in surface representation, the bound
Histone H3 peptide is shown in stick representation, the carboxy-terminus is
indicated. The binding pockets of TAF3 for Histone H3 R2 and 3methylated K4 are
presented in red and yellow, respectively, with the key residues indicated.
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predicted to be highly disordered. Despite extensive efforts, it has
not been possible to over-express, obtain in a soluble state, and
purify in quantities or concentrations compatible with structural
studies any constructs encompassing those disordered regions.
Moreover, constructs containing the carboxy-terminal domain of
mCARM1 are prone to proteolysis. All those data prompted us to
hypothesize that the carboxy-terminal domain of mCARM1 is
mainly unfolded in a free state and that a disorder to order transi-
tion will take place upon binding to one or several adapted part-
ners. CARM1 is another example of partly natively disordered
protein build around a wobbly PH domain linked to a PRMT cata-
lytic platform.
6.2. The PHD domain of TAF3
While dimethylated H3R2 correlates with inactive genes, trime-
thylation of lysine K4 of histone H3 within the promoter region is
generally accompanied with RNA polymerase II transcription. The
latter modification is recognized by Chromo, Tudor or PHD do-
mains. The observation that the TFIID factor TAF3 contains a PHD
domain argues that TAF3 is contributing to the recruitment of
TFIID to promoters, thereby promoting transcription initiation.
This is underscored by the observation that selective loss of
H3K4 trimethylation leads to loss of binding of TFIID to the pro-
moter region and that the TAF3 PhD domain selectively binds to
trimethylated but not to non or mono methylated H3K4 peptides
(Vermeulen et al., 2007).
Utrecht has determined the solution structure of the PHD do-
main of TAF3 in the absence or presence trimethylated H3K4 pep-
tides (van Ingen et al., 2008). A quantitative biochemical
characterization of potential Histone H3 peptides that could bind
to PHD domain combined with sample condition optimization per-
mitted structural analysis of this complex by NMR. The binding
pocket for trimethylated K4 clearly explains the preference for
methylated histone tails (Fig. 5B). These results further provide a
structural explanation for the observation that H3R2me2 prevents
binding of H3K4 trimethylated peptides (Vermeulen et al., 2007).
These data underscore the importance of the ability to read the
modification signal and through this recognition control gene
expression. The presence or absence of these modifications at posi-
tion R2 and K4 act as a regulatory methyl-methyl switch that can
be specifically read by the PHD domain of TAF3.
6.3. Plus3 domain of RTF1
While the structural details on the recognition of post-transla-
tionally modified histone proteins is significant, the molecular
mechanism underlying the addition or removal of certain modifi-
cations is poorly understood. The Set1 protein present in the COM-
PASS complex is needed for methylation of H3K4. The underlying
regulatory mechanism is largely unknown but the PAF complex
composed of Paf1, Cdc73, Ctr9, Leo1, and Rtf1, plays an essential
role. This complex is thought to interact with elongating RNA poly-
merase II and is required for cotranscriptional ubiquitination of
H2B. Depletion of RTF1 results in loss of H3K4 methylation and
transcriptional defects. The Plus3 domain, one of the conserved re-
gions of RTF1 was, using chromatin immuno precipitation, shown
to be essential for binding to open reading frames and influencing
most of the other RTF1 functions, including transcription (Warner
et al., 2007).
The availability of a procedure for effective optimization of
expression, solubility and biophysical behavior (Folkers et al.,
2004) permitted the optimization of domain boundaries showing
that the domain identified by bioinformatics lacked essential
Fig. 6. Towards integrative structural biology studies of transcription complexes.
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part of the structured domain. 15N HSQC screening clearly estab-
lished that these terminal residues were crucial for folding. Utr-
echt determined the solution structure of the Plus3 domain of
RTF1 revealing a novel fold with a beta stranded subdomain
structurally resembling Tudor domains and the Dicer/Argonaute
PAZ domains (de Jong et al., 2008). Biochemical analysis revealed
no evidence for specific interaction with H3 tails either methyl-
ated or non-methylated arguing that this domain is not a reader
of chromatin modifications. The structural homology with a siR-
NA domain suggested a potential role for mRNA binding, which
would agree with the proposed role for RTF1 in mRNA process-
ing but no RNA interaction could be observed. Importantly using
EMSA, NMR binding studies and site directed mutagenesis we
identified an ssDNA binding surface on the RTF Plus3 domain.
The ability to bind preferentially to ssDNA containing sequences
suggests a role for RTF1 in binding to the transcription elonga-
tion bubble.
7. Conclusion and future directions: Imaging of transcription,
integrated structural biology
Transcription and its regulation depends on the structures of
the protein complexes that are its building blocks, and correct cel-
lular function requires the dynamic association of protein com-
plexes with regulatory elements and a myriad of macro- and
small molecules. Transcription factors and their complexes can
be relatively stable and a wealth of structural data at atomic reso-
lution has been accumulated on a few well characterized com-
plexes, such as Escherichia coli or yeast RNA polymerase
transcription complexes. We are however still in the early stages
of understanding how both general and gene-specific transcription
is regulated in eukaryotes, particularly in Human. One reason for
this is that the eukaryotic transcription machinery is extremely
complex and that many components are multi-subunit assemblies,
often poorly characterized. As discussed above, the identification of
targets suitable for structural analysis is often challenging and
sample preparation often constitutes a major bottleneck. Another
difficulty lies in the nature of the complexes, in part because regu-
lation often involves the formation of transient complexes with
poor binding constants and in part because their composition is
not fixed and can change depending upon the promoter context.
Recent years have seen intensive activities world-wide in func-
tional genomics based around the exploitation of the ever increas-
ing databases of sequence information from genome sequencing
projects and the result of structural proteomics initiatives that pio-
neered high-throughput (HTP) technologies to streamline X-ray
and NMR structure determination (Terwilliger et al., 2009). The
SPINE2-COMPLEXES program has targeted the development and
application of methodologies to address structural studies of mul-
ti-protein, protein-nucleic acid and protein–ligand complexes (see
the Methods section of this issue). Data summarized above have
widely benefited from these technological innovations, resulting
in new and/or improved HTP procedures at all stages, from expres-
sion screening, large scale production and purification through bio-
physical and biochemical characterization of individual proteins
and complexes, to crystallization, data collection, and solution
of structures, as well as solution of smaller macromolecular
structures by NMR. Data produced in the frame of the SPINE2-
COMPLEXES program not only provided detailed structural
information but also paved the ways towards the description of
higher order structures using an integrative multi-scale approach
that relies on a set of complementary technologies, both in vitro
and in situ (Fig. 6). The understanding of transcription regulation
that such an endeavor will produce for native and pathogenic sys-
tems, is not only an end in itself, but is also a prerequisite for the
effective design of new drugs and vaccines impacting the health
and quality of life.
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